<SEC-DOCUMENT>0001641172-25-010089.txt : 20250514
<SEC-HEADER>0001641172-25-010089.hdr.sgml : 20250514
<ACCEPTANCE-DATETIME>20250514063420
ACCESSION NUMBER:		0001641172-25-010089
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		52
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250514
DATE AS OF CHANGE:		20250514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Kairos Pharma, LTD.
		CENTRAL INDEX KEY:			0001962011
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				462993314
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42275
		FILM NUMBER:		25942550

	BUSINESS ADDRESS:	
		STREET 1:		2355 WESTWOOD BLVD. #139
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90064
		BUSINESS PHONE:		818-404-5541

	MAIL ADDRESS:	
		STREET 1:		2355 WESTWOOD BLVD. #139
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90064
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:KAPA="http://kairospharma.com/20250331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_021_US%2DGAAP%2D2024%2D(with%2DECD) -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_KAPA_kairospharma.com_20250331 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20250101_20250331 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001962011 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000006" name="dei:EntityCentralIndexKey">0001962011</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2025-03-31" id="xdx2ixbrl0083" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0084" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-03-31" id="xdx2ixbrl0089" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0090" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="KAPA:CommonStockToBeIssuedValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0128" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0144" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0145" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0165" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0168" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0172" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0200" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0207" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="KAPA:AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0209" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="KAPA:AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2025-01-012025-03-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0210" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="KAPA:AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0212" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="KAPA:StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" contextRef="From2025-01-012025-03-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0216" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="KAPA:StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0217" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="KAPA:StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="KAPA:StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0223" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="KAPA:StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="KAPA:StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0226" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0231" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-01-012025-03-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0234" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0240" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0273" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="KAPA:IncreaseDecreaseInVendorAdvances" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="KAPA:IssuanceOfCommonSharesForDeferredOfferingCosts" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="KAPA:IssuanceOfCommonSharesForVendorAdvances" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl0422" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046" id="xdx2ixbrl0615" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="KAPA:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046" id="xdx2ixbrl0617" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046" id="xdx2ixbrl0619" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember" id="xdx2ixbrl0679" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="KAPA:ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled" contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember" id="xdx2ixbrl0681" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember" id="xdx2ixbrl0683" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_us-gaap_OperatingSegmentsMember" id="xdx2ixbrl0863" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-03-31_us-gaap_OperatingSegmentsMember" id="xdx2ixbrl0864" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-01-012024-03-31_us-gaap_OperatingSegmentsMember" id="xdx2ixbrl0870" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-03-31_us-gaap_OperatingSegmentsMember" id="xdx2ixbrl0876" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="kapa-20250331.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-01-01to2025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_EnviroThreapeuticsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">KAPA:EnviroThreapeuticsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_EquityLineOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:EquityLineOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_EquityLineOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:EquityLineOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">KAPA:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">KAPA:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-08-31_custom_MasterServiceAndTechnologyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:MasterServiceAndTechnologyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-202024-09-20_custom_BioassayServicesAgreementMember_custom_PreCheckHealthServicesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:BioassayServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:PreCheckHealthServicesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-20</xbrli:startDate>
        <xbrli:endDate>2024-09-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BioassayServicesAgreementMember_custom_PreCheckHealthServicesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:BioassayServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:PreCheckHealthServicesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_BioassayServicesAgreementMember_custom_PreCheckHealthServicesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:BioassayServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:PreCheckHealthServicesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-232024-09-23_custom_AdvisoryAndConsultingServicesAgreementMember_custom_CEOCATechnologiesLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:AdvisoryAndConsultingServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:CEOCATechnologiesLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-23</xbrli:startDate>
        <xbrli:endDate>2024-09-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_AdvisoryAndConsultingServicesAgreementMember_custom_CEOCATechnologiesLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:AdvisoryAndConsultingServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:CEOCATechnologiesLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AdvisoryAndConsultingServicesAgreementMember_custom_CEOCATechnologiesLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:AdvisoryAndConsultingServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:CEOCATechnologiesLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-232024-09-23_custom_StrategicAdvisoryAgreementMember_custom_BelairCapitalAdvisorsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:StrategicAdvisoryAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:BelairCapitalAdvisorsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-23</xbrli:startDate>
        <xbrli:endDate>2024-09-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_StrategicAdvisoryAgreementMember_custom_BelairCapitalAdvisorsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:StrategicAdvisoryAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:BelairCapitalAdvisorsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_StrategicAdvisoryAgreementMember_custom_BelairCapitalAdvisorsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:StrategicAdvisoryAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:BelairCapitalAdvisorsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-10-01_custom_ConsultingAgreementMember_custom_CurrentCapitalLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:CurrentCapitalLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-10-01_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-04-01_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-04-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-04-01_custom_ConsultingAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-04-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-122024-11-12_custom_HelenaGlobalInvestmentOpportunitiesILTDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:HelenaGlobalInvestmentOpportunitiesILTDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-12</xbrli:startDate>
        <xbrli:endDate>2024-11-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-122024-11-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-12</xbrli:startDate>
        <xbrli:endDate>2024-11-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-242025-04-24_us-gaap_CommonStockMember_custom_HelenaGlobalInvestmentOpportunitiesILTDMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:HelenaGlobalInvestmentOpportunitiesILTDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-24</xbrli:startDate>
        <xbrli:endDate>2025-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PrevailInfoworksIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:PrevailInfoworksIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PrevailInfoworksIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:PrevailInfoworksIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PreCheckHealthServicesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:PreCheckHealthServicesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PreCheckHealthServicesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:PreCheckHealthServicesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_CEOCATechnologiesLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:CEOCATechnologiesLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CEOCATechnologiesLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:CEOCATechnologiesLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_BelairCapitalAdvisorsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:BelairCapitalAdvisorsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_BelairCapitalAdvisorsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:BelairCapitalAdvisorsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_CrossCurrentCapitalLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:CrossCurrentCapitalLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CrossCurrentCapitalLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:CrossCurrentCapitalLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-142025-01-14_custom_SecurityPurchaseAgreementMember_custom_PreFundedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:PreFundedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-14</xbrli:startDate>
        <xbrli:endDate>2025-01-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-14_custom_SecurityPurchaseAgreementMember_custom_PreFundedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:PreFundedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-14_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-162025-01-16_custom_SecurityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-16</xbrli:startDate>
        <xbrli:endDate>2025-01-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-14_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-14_custom_CommonWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:CommonWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-142025-01-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-14</xbrli:startDate>
        <xbrli:endDate>2025-01-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-31_custom_TwentyTwentyThreeEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">KAPA:TwentyTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_TwentyTwentyThreeEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">KAPA:TwentyTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwentyTwentyThreeEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">KAPA:TwentyTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-232024-09-23_us-gaap_RestrictedStockUnitsRSUMember_custom_StrategicAdvisoryAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:StrategicAdvisoryAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-23</xbrli:startDate>
        <xbrli:endDate>2024-09-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-232024-09-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-23</xbrli:startDate>
        <xbrli:endDate>2024-09-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_StrategicAdvisoryAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:StrategicAdvisoryAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember_custom_StrategicAdvisoryAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:StrategicAdvisoryAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember_custom_FourOfficersAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:FourOfficersAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-012024-09-30_custom_FourOfficersAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:FourOfficersAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_FourOfficersAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:FourOfficersAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_FourOfficersAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:FourOfficersAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_ThreeIndependentDirectorsMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">KAPA:ThreeIndependentDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_DirectorAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:DirectorAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DirectorAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:DirectorAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember_custom_PreFundedWarrantMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:PreFundedWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember_custom_UnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">KAPA:UnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-14_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember_custom_UnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">KAPA:UnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-142025-01-14_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember_custom_UnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">KAPA:UnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-14</xbrli:startDate>
        <xbrli:endDate>2025-01-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_ExercisePriceRangeOneMember_custom_WarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">KAPA:ExercisePriceRangeOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:WarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_WarrantOneMember_custom_ExercisePriceRangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:WarrantOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">KAPA:ExercisePriceRangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_ExercisePriceRangeTwoMember_custom_WarrantTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">KAPA:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:WarrantTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_WarrantTwoMember_custom_ExercisePriceRangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:WarrantTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">KAPA:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_ExercisePriceRangeThreeMember_custom_WarrantThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">KAPA:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:WarrantThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_WarrantThreeMember_custom_ExercisePriceRangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:WarrantThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">KAPA:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_PhaseOneClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:PhaseOneClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_ItemOneAndTwoMember_custom_PhaseTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemOneAndTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">KAPA:PhaseTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_ItemThreeMember_custom_PhaseTwoClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">KAPA:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_ItemOneAndTwoMember_us-gaap_NonUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemOneAndTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_ItemOneAndTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemOneAndTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_custom_ItemFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_ExclusiveLicenseAgreementMember_custom_ItemFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_ItemFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MinimumMember_custom_ItemFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MaximumMember_custom_ItemFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_ItemFourMember_custom_PhaseTwoClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">KAPA:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ItemFourMember_custom_FoodAndDrugAdministrationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:FoodAndDrugAdministrationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_PhaseThreeClinicalTrialMember_custom_EnviroCedarsLicenseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:EnviroCedarsLicenseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_ItemOneAndTwoMember_custom_PhaseThreeMember_custom_EnviroCedarsLicenseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemOneAndTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">KAPA:PhaseThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:EnviroCedarsLicenseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_OperatingSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_OperatingSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-04-01_custom_CrossCurrentCapitalLLCMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:CrossCurrentCapitalLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-04-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-242025-04-24_custom_HelenaGlobalInvestmentOpportunitiesILTDMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001962011</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:HelenaGlobalInvestmentOpportunitiesILTDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-24</xbrli:startDate>
        <xbrli:endDate>2025-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>KAPA:Integer</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>



<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->



<p style="font: bold 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>UNITED STATES</b></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90F_edei--DocumentType_c20250101__20250331_za7o72nuxCBd"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000013" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Segoe UI Symbol,sans-serif"><b><span id="xdx_907_edei--DocumentQuarterlyReport_c20250101__20250331_z5i2b2sKZz49"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:booleantrue" id="Fact000014" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>
</b></span><b>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>For the quarterly period ended <span id="xdx_90C_edei--DocumentPeriodEndDate_c20250101__20250331_zgE6EfV3nhhf"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:datemonthdayyearen" id="Fact000015" name="dei:DocumentPeriodEndDate">March 31, <span id="xdx_904_edei--DocumentFiscalYearFocus_c20250101__20250331_zKRSCp6bMKla"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000016" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric></span></ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>or</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Segoe UI Symbol,sans-serif"><b><span id="xdx_900_edei--DocumentTransitionReport_c20250101__20250331_zP9T3kaFHoi7"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:booleanfalse" id="Fact000017" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
</b></span><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>For the transition period from ___________ to ___________</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Commission File Number: <span id="xdx_90C_edei--EntityFileNumber_c20250101__20250331_zZB9NHgsz1Uf"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000018" name="dei:EntityFileNumber">001-42275</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_901_edei--EntityRegistrantName_c20250101__20250331_zg4d0Hu8kjve"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000019" name="dei:EntityRegistrantName">KAIROS
PHARMA, LTD.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-size: 10pt"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20250101__20250331_zxevadV2n4Rj"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt-sec:stateprovnameen" id="Fact000020" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-size: 10pt"><b><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20250101__20250331_z74dWOlc0LU4"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000021" name="dei:EntityTaxIdentificationNumber">46-2993314</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">(State or other jurisdiction of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">incorporation or organization)</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">(I.R.S Employer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Identification No.)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b><span id="xdx_900_edei--EntityAddressAddressLine1_c20250101__20250331_zPxDyu70Gz7b"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000022" name="dei:EntityAddressAddressLine1">2355 Westwood Blvd.</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressAddressLine2_c20250101__20250331_z0YfdnSGQGd3"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000023" name="dei:EntityAddressAddressLine2">#139</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressCityOrTown_c20250101__20250331_zKoGZuN6N1pd"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000024" name="dei:EntityAddressCityOrTown">Los Angeles</ix:nonNumeric></span> <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20250101__20250331_zttaCDnJLS34"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000025" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span> <span id="xdx_90C_edei--EntityAddressPostalZipCode_c20250101__20250331_zu7SRjLgExCl"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000026" name="dei:EntityAddressPostalZipCode">90064</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">(Address of principal executive offices) (Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b><span id="xdx_900_edei--CityAreaCode_c20250101__20250331_zNeqHnChrRCg"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000027" name="dei:CityAreaCode">(310)</ix:nonNumeric></span> <span id="xdx_902_edei--LocalPhoneNumber_c20250101__20250331_zl8gdKkvMVCb"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000028" name="dei:LocalPhoneNumber">948-2356</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">(Registrant&#8217;s telephone number, including area
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">(Former name, former address and former fiscal year,
if changed since last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Securities registered pursuant to Section 12(b) of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%"><span style="font-size: 10pt"><b>Trading symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><span id="xdx_901_edei--Security12bTitle_c20250101__20250331_zbqsJopecDa3"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000029" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20250101__20250331_zrJHrCExRrE9"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000030" name="dei:TradingSymbol">KAPA</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_901_edei--SecurityExchangeName_c20250101__20250331_zBk2lUnuW7Sf"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_902_edei--EntityCurrentReportingStatus_c20250101__20250331_z7ToTSK8zLt9"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000032" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> <span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span>
No &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Indicate by check mark whether the registrant has
submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of
this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <span id="xdx_906_edei--EntityInteractiveDataCurrent_c20250101__20250331_zmGWCqxYfQwl"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000033" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> <span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span>
No <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Indicate by check mark whether the registrant is a
large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See
the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and
&#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Large accelerated filer <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">Accelerated filer <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><span id="xdx_907_edei--EntityFilerCategory_c20250101__20250331_z1yDxgSMUNL3"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt-sec:entityfilercategoryen" id="Fact000034" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> <span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">Smaller reporting company <span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_909_edei--EntitySmallBusiness_c20250101__20250331_z7yZ6E0fjwR9"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:booleantrue" id="Fact000035" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">Emerging growth company <span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_905_edei--EntityEmergingGrowthCompany_c20250101__20250331_z4XWAKka5KAi"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:booleantrue" id="Fact000036" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_90B_edei--EntityExTransitionPeriod_c20250101__20250331_zDcmoHUAQCF3"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:booleanfalse" id="Fact000037" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes &#9744; No <span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_90C_edei--EntityShellCompany_dbF_c20250101__20250331_ztY7GZcbGvjd"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:booleanfalse" id="Fact000038" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The
number of shares issued and outstanding of the registrant&#8217;s common stock on May 13, 2025 was <span id="xdx_90A_edei--EntityCommonStockSharesOutstanding_iI_c20250513_zQoxChND6KSi"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-05-13" id="Fact000039" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,849,306</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>KAIROS PHARMA, LTD.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt"><b><a href="#a_001">PART I - FINANCIAL INFORMATION</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">3<span style="font-size: 10pt"></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top; width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt"><a href="#a_002">Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">3<span style="font-size: 10pt"></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#a_003">Unaudited Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">3</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#a_004">Unaudited Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2025 and 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">4<span style="font-size: 10pt"></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#a_005">Unaudited Condensed Consolidated Statements of Shareholders&#8217; Equity (Deficit) for the Three Months Ended March 31, 2025 and 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">5<span style="font-size: 10pt"></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#a_006">Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2025 and 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">6</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#a_007">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">7</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt"><a href="#a_008">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">18<span style="font-size: 10pt"></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt"><a href="#a_009">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">26<span style="font-size: 10pt"></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt"><a href="#a_010">Control and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">27<span style="font-size: 10pt"></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt"><b><a href="#a_011">PART II - OTHER INFORMATION</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">28<span style="font-size: 10pt"></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top"><span style="font-size: 10pt"></span>&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt"><a href="#a_012">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">28</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 1A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt"><a href="#a_013">Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">28<span style="font-size: 10pt"></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt"><a href="#a_014">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">28<span style="font-size: 10pt"></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt"><a href="#a_015">Defaults Upon Senior Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">28<span style="font-size: 10pt"></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt"><a href="#a_016">Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">28<span style="font-size: 10pt"></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt"><a href="#a_017">Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">28<span style="font-size: 10pt"></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt"><a href="#a_018">Exhibits</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">29<span style="font-size: 10pt"></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt"><b><a href="#a_019">SIGNATURES</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">30<span style="font-size: 10pt"></span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b><span id="a_001"></span>PART I-FINANCIAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="a_002"></span><b>Item 1: Financial Statements.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Kairos
Pharma, Ltd.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>Condensed
Consolidated Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
thousands, except for share amounts and par value data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_111_pn3n3_zqQ2dgnSWLo5" summary="xdx: Statement - Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250331_zRYG4h45h6ta" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20241231_zGgwmGn2QDOf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzZrj_zBSjfSNFo6e9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-03-31" id="Fact000047" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,616</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000048" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,272</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--VendorAdvancesNet_i02I_maACzZrj_zhMT5kDFfX9g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vendor advances, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:VendorAdvancesNet" contextRef="AsOf2025-03-31" id="Fact000050" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,379</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:VendorAdvancesNet" contextRef="AsOf2024-12-31" id="Fact000051" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,859</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzZrj_zrZTT4CYOGPf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-03-31" id="Fact000053" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000054" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsCurrent_i02TI_maAz7iz_mtACzZrj_zaWpY53pZEE3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Current Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-03-31" id="Fact000056" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,050</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000057" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,169</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredCosts_i01I_maANz3xA_z3yLPL22WoO7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2025-03-31" id="Fact000059" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,705</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2024-12-31" id="Fact000060" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,377</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_maANz3xA_zwXNXxGZVvva" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Intangible assets, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2025-03-31" id="Fact000062" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">182</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-12-31" id="Fact000063" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">222</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsNoncurrent_i01TI_maAz7iz_mtANz3xA_zuCsel4gYoQ3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Other Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2025-03-31" id="Fact000065" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,887</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000066" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,599</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Assets_i01TI_mtAz7iz_z9OMqSjR1Gb6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-03-31" id="Fact000068" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,937</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000069" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,768</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maLCzA5l_zfw11rgrpjx4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accounts payable and accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2025-03-31" id="Fact000077" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">805</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000078" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">992</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzA5l_maLASEzlBI_zK1Pu3BmIKOh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Current Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-03-31" id="Fact000080" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">805</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">992</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CommitmentsAndContingencies_iI_maLASEzlBI_zd80ON2gIzrb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0083">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0084">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquityAbstract_iB_zi8cPhNB5aVl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Shareholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PreferredStockValue_i01I_maSEzOrV_zcSus7vY1Lni" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Preferred stock, par value $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250331_zr7Y90nhddi1" title="Preferred stock, par value"><span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231_zY1ASEmU3lG5" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-03-31" id="Fact000092" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000094" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250331_zc1iDwaOGjMa" title="Preferred stock, shares authorized"><span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zviynD7Go2R5" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-03-31" id="Fact000096" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20250331_zktub23hDxq6" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20250331_zcO4stWKuo5l" title="Preferred stock, shares outstanding"><span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20241231_z2BsvTsBeYYa" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20241231_z9ae8dAawwyg" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-03-31" id="Fact000100" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-03-31" id="Fact000102" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000104" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000106" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding,
    respectively;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0089">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0090">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CommonStockValue_i01I_maSEzOrV_z4sYeMQkkxZb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Common stock, par value $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250331_z5M1jbmaHrs9" title="Common stock, par value"><span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_z87hFTZsit05" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-03-31" id="Fact000111" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000113" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250331_z2Jefg1yWSre" title="Common stock, shares authorized"><span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zefibsgS2xdb" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-03-31" id="Fact000115" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000117" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pid_c20250331_zwPiobm7IBih" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20250331_zSSMVDwKCpG8" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-03-31" id="Fact000119" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-03-31" id="Fact000121" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,825,118</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zJv96SXIdUv1" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zHWsmGzDZCPe" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000123" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000125" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,736,597</ix:nonFraction></ix:nonFraction></span></span> shares
    issued and outstanding, respectively;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-03-31" id="Fact000108" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000109" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--CommonStockToBeIssuedValue_i01I_maSEzOrV_zNUBDVLU7fs5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Common stock to be issued, <span id="xdx_900_ecustom--CommonStockToBeIssuedSharesOutstanding_iI_pid_c20250331_zs5PTKKOekXa" title="Common stock to be issued, shares outstanding"><ix:nonFraction name="KAPA:CommonStockToBeIssuedSharesOutstanding" contextRef="AsOf2025-03-31" id="Fact000130" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">551,000</ix:nonFraction></span> shares outstanding at March 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:CommonStockToBeIssuedValue" contextRef="AsOf2025-03-31" id="Fact000127" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">484</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0128">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AdditionalPaidInCapital_i01I_maSEzOrV_ztjcYwUPunNb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-03-31" id="Fact000132" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,709</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000133" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,577</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maSEzOrV_zxAWm7kYXGT2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-03-31" id="Fact000135" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,077</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000136" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,815</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--StockholdersEquity_i01TI_mtSEzOrV_maLASEzlBI_zz7aYAjUQX53" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Shareholders&#8217; Equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000138" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,132</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,776</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzlBI_zdKsZzrCSGFh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000141" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,937</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000142" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,768</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">The accompanying notes are an integral part of these
condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>Kairos Pharma, Ltd.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b><span id="a_004"></span>Condensed Consolidated Statements of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">(in thousands, except for share amounts and per share
data)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_113_pn3n3_zWbvH2fIxkuh" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250101__20250331_zALdc5MTR8ll" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20240331_zYMUFvvyeL5l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Revenues_maOILzddv_zh7pQrTEQdde" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Revenues</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0144">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0145">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB_zd5PzCJUH5S7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzY9t_zbVyiILdrgl7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-03-31" id="Fact000150" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">493</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-03-31" id="Fact000151" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">165</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEzY9t_zjCJwq6PkD1k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-03-31" id="Fact000153" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">773</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-03-31" id="Fact000154" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">122</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingExpenses_i01T_mtOEzY9t_msOILzddv_z7bh1rp3hOL7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-01to2025-03-31" id="Fact000156" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,266</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-03-31" id="Fact000157" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">287</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingIncomeLoss_iT_mtOILzddv_maNILzERs_zx5yps5Ryzw8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-03-31" id="Fact000159" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,266</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000160" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">287</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_z4tYdubMItve" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Other income (expenses):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestExpenseNonoperating_i01N_di_msNIEzjku_msNIEzROl_zZq7iAddqbtg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0165">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-012024-03-31" id="Fact000166" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AmortizationOfDebtDiscountPremium_i01N_di_msNIEzjku_msNIEzROl_zJmQMR3w3Ccb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Debt discount amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0168">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-01-012024-03-31" id="Fact000169" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--InvestmentIncomeNet_i01_msNIEzjku_maNIEzROl_zdxAZBgKoB23" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Interest income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="From2025-01-01to2025-03-31" id="Fact000171" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0172">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NonoperatingIncomeExpense_i01T_maNILzERs_mtNIEzROl_zoVLhq1x4Em6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total other income (expenses)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-01to2025-03-31" id="Fact000174" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-03-31" id="Fact000175" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">36</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_iT_mtNILzERs_zIOAn6kBSFaf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">NET LOSS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31" id="Fact000177" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,262</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000178" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">323</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">BASIC AND DILUTED LOSS PER COMMON SHARE</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_pid_c20250101__20250331_zlrdlVIP8Tn3" title="BASIC LOSS PER COMMON SHARE" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_pid_c20250101__20250331_zOJjo0LRJeBf" title="DILUTED LOSS PER COMMON SHARE" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-01to2025-03-31" id="Fact000180" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-01to2025-03-31" id="Fact000182" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.08</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_pid_c20240101__20240331_zIUewiHPq6" title="BASIC LOSS PER COMMON SHARE" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20240331_zdqMEJdC0gX" title="DILUTED LOSS PER COMMON SHARE" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-03-31" id="Fact000184" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-03-31" id="Fact000186" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.03</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_zU1zT24q9T0a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">BASIC AND DILUTED</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_c20250101__20250331_zBmU6I7jCK9g" title="BASIC" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_pid_c20250101__20250331_zPTjHEVu01x8" title="DILUTED" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-01to2025-03-31" id="Fact000191" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-01to2025-03-31" id="Fact000193" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,875,485</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_c20240101__20240331_zrLcPFHF9N6e" title="BASIC" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_pid_c20240101__20240331_zmFi7DAGQXE3" title="DILUTED" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-03-31" id="Fact000195" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-03-31" id="Fact000197" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,562,640</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">The accompanying notes are an integral part of these
condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>Kairos Pharma, Ltd.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span id="a_005"></span><b>Condensed Consolidated Statements of Shareholders&#8217;
Equity (Deficit) (Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">(in thousands, except share amounts)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_114_pn3n3_zIjng07ui6B5" summary="xdx: Statement - Condensed Consolidated Statements of Shareholders' Equity (Deficit) (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z99SdsxJYPIj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_custom--CommonStockToBeIssuedMember_zYPO9E5kMc4i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zN9UIYokzgQb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Paid-in Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zORwSNSZPoZg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_ziycsWyHh8Ql" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock to be Issued</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Paid-in Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_43D_c20250101__20250331_eus-gaap--StockholdersEquity_iS_z5l42cBM3199" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; font-weight: bold">Balance, December 31, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqudYhbPR0si" title="Balance, shares" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000205" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,736,597</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000199" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_zh3TSNLmOb43" title="Balance, shares" style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0207">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0200">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000201" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,577</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000202" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,815</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,776</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts_zhHlDk4mDkg6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from the sale of pre-funded warrants, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0209">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0210">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000211" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,056</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0212">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2025-01-01to2025-03-31" id="Fact000213" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,056</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_zjpxly1R9eog" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common shares upon the exercise of pre-funded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTzmS6a0Q523" title="Issuance of common shares upon the exercise of pre-funded warrants, shares" style="text-align: right"><ix:nonFraction name="KAPA:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000221" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,010,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000215" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0216">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0217">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0218">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" contextRef="From2025-01-01to2025-03-31" id="Fact000219" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts_zAfX7Qs9XSOl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair value of common shares to be issued for vendor advance and deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0223">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_fWzFd_zPFPWYKODMag" title="Fair value of common shares to be issued for vendor advance and deferred offering costs, shares" style="text-align: right"><ix:nonFraction name="KAPA:StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" contextRef="From2025-01-012025-03-31_custom_CommonStockToBeIssuedMember" id="Fact000229" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">551,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" contextRef="From2025-01-012025-03-31_custom_CommonStockToBeIssuedMember" id="Fact000224" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">484</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0225">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0226">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" contextRef="From2025-01-01to2025-03-31" id="Fact000227" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">484</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_z3I3An0EoVqd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair value of vested restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHXZJaRrKZF3" title="Fair value of vested restricted stock units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000237" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,521</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0231">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0232">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000233" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0234">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-01-01to2025-03-31" id="Fact000235" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">76</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zi3YDQqG7Au" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Net loss for the three months ended March 31, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0239">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0240">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0241">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="Fact000242" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,262</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31" id="Fact000243" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,262</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_439_c20250101__20250331_eus-gaap--StockholdersEquity_iE_zC2fJkYAQD9a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance, March 31, 2025 (unaudited)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWkKDZUtgwbl" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000251" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,825,118</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000245" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockToBeIssuedMember_z4OmCtbMY8Mb" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_custom_CommonStockToBeIssuedMember" id="Fact000253" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">551,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_custom_CommonStockToBeIssuedMember" id="Fact000246" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">484</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000247" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,709</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember" id="Fact000248" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,077</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000249" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,132</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_431_c20240101__20240331_eus-gaap--StockholdersEquity_iS_zrN14mCKunK4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance, December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWqHTYtv6NAe" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000261" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,562,640</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000255" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0256">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000257" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000258" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,212</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000259" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,078</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_433_c20240101__20240331_eus-gaap--StockholdersEquity_iS_zzONmmvd1Mgk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPMTxwXXaEWd" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000269" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,562,640</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000263" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0264">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000265" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000266" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,212</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000267" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,078</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zd987Dh7zyqh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Net loss for the three months ended March 31, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0271">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0272">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0273">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="Fact000274" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">323</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000275" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">323</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_z7UxLX6sgJYd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0278">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="Fact000280" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">323</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000281" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">323</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20240101__20240331_eus-gaap--StockholdersEquity_iE_zBSgWPxSH0qj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance, March 31, 2024 (unaudited)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zc3Gy4CQq7G6" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000289" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,562,640</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000283" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0284">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000285" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,123</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000286" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,535</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000287" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,401</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_439_c20240101__20240331_eus-gaap--StockholdersEquity_iE_zGsDLlzgUcTj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx6frZhiYLRh" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000297" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,562,640</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000291" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0292">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000293" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,123</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000294" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,535</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000295" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,401</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">The accompanying notes are an integral part of these
condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>Kairos
Pharma, Ltd.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span id="a_006"></span><b>Condensed Consolidated Statements of Cash Flows</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">(In thousands)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_112_pn3n3_zPONovj74aUi" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20250101__20250331_z52EtC8IHuea" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20240331_z4Azei0vO5Gb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zG3tKIhe7Am5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-weight: bold; text-align: left">Cash Flows from Operating Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_i01_maNCPBUz5qI_z0nWS8v6a2S" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31" id="Fact000302" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,262</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000303" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">323</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zsRpnzC7wUrb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AmortizationOfIntangibleAssets_i02_maNCPBUz5qI_zxz3bzZSffXk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Amortization expense - intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2025-01-01to2025-03-31" id="Fact000308" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-03-31" id="Fact000309" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--FairValueOfVestedRestrictedStockUnits_i02_maNCPBUz5qI_zu5pcsa5IKe7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Fair value of vested restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:FairValueOfVestedRestrictedStockUnits" contextRef="From2025-01-01to2025-03-31" id="Fact000311" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:FairValueOfVestedRestrictedStockUnits" contextRef="From2024-01-012024-03-31" id="Fact000312" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zQf3NVp8xJX8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--IncreaseDecreaseInVendorAdvances_i03_maNCPBUz5qI_zUhG9p4eaMe9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Vendor advances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:IncreaseDecreaseInVendorAdvances" contextRef="From2025-01-01to2025-03-31" id="Fact000317" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">636</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUz5qI_zuXKzFrhyR7j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2025-01-01to2025-03-31" id="Fact000320" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-012024-03-31" id="Fact000321" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i03_maNCPBUz5qI_zgmoaPuspYih" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2025-01-01to2025-03-31" id="Fact000323" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">187</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-012024-03-31" id="Fact000324" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">310</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_maCCERCzNVo_mtNCPBUz5qI_z3xMzUkwN3t8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net cash provided by (used in) operating activities</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-03-31" id="Fact000326" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">714</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-03-31" id="Fact000327" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zayjer2eI6N" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-weight: bold; text-align: left">Cash Flows from Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProceedsFromIssuanceOfWarrants_i01_maNCPBUzszx_zhnlkpXE08rk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sale and exercise of  prefunded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2025-01-01to2025-03-31" id="Fact000332" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,058</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PaymentsOfFinancingCosts_i01N_di_msNCPBUzszx_zezQPNAlUDh5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Payment of deferred offering costs</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2024-01-012024-03-31" id="Fact000336" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">89</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzszx_maCCERCzNVo_zbQwNHIggi3f" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net cash provided by (used in) financing activities</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-01-01to2025-03-31" id="Fact000338" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,058</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-03-31" id="Fact000339" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">89</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzNVo_z79OqgpwCJm7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net increase (decrease) in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-01-01to2025-03-31" id="Fact000341" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,344</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-012024-03-31" id="Fact000342" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">53</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zILN40zJ4Bfj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash and cash equivalents beginning of period</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000344" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,272</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000345" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">93</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zywMaHuxNOl9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash and cash equivalents end of period</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-03-31" id="Fact000347" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,616</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-03-31" id="Fact000348" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--SupplementalCashFlowElementsAbstract_iB_zcGh4WjDP39b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-weight: bold; text-align: left">Supplemental cash flows disclosures:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestPaidNet_i01_ztAQGa9QiDd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest paid</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxesPaidNet_i01_zumTyAfx9ot9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Taxes paid</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zGzQ5Hsd12nj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-weight: bold; text-align: left">Supplemental non-cash financing disclosures:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--IssuanceOfCommonSharesForDeferredOfferingCosts_i01_zQDSpSWHzPU8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common shares issued for deferred offering costs</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="KAPA:IssuanceOfCommonSharesForDeferredOfferingCosts" contextRef="From2025-01-01to2025-03-31" id="Fact000362" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">328</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--IssuanceOfCommonSharesForVendorAdvances_i01_zY1Jo7VE6CRe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common shares issued for vendor advance</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="KAPA:IssuanceOfCommonSharesForVendorAdvances" contextRef="From2025-01-01to2025-03-31" id="Fact000365" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">156</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">The accompanying notes are an integral part of these
condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>KAIROS
PHARMA, LTD.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b><span id="a_007"></span>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>(In thousands, except for share amounts and per
share data)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000368" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_80A_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zeNelbWjJVki" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>NOTE 1 &#8211; <span id="xdx_82B_zFS9CXK2zAq7">BASIS OF PRESENTATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>Organization and Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Kairos Pharma, Ltd. (the &#8220;Company&#8221; or
&#8220;Kairos&#8221;) was incorporated on June 17, 2013 under the laws of the state of California as NanoGB13, Inc. The Company changed
its name to Kairos Pharma, Ltd. on July 15, 2016 and subsequently converted into a Delaware corporation under the same name, Kairos Pharma,
Ltd., on May 10, 2023. The Company is an early-stage biotechnology company focused on the development of immunotherapy and cell therapy
treatments for oncology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b>Basis of Presentation
of Unaudited Financial Information </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">The
accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles
generally accepted in the United States for interim financial information and the instructions to Form 10-Q and Rule 10-01 of
Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting
principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary
for a fair presentation have been included. Operating results for the three months ended March 31, 2025, are not necessarily
indicative of the results that may be expected for the year ending December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization
of assets and the settlement of liabilities and commitments in the normal course of business.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2025, the Company incurred a net loss of $<span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20250101__20250331_ztt2sJYsJd6l" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31" id="Fact000370" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,262</ix:nonFraction></span>&#160;and used cash in operations of $<span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20250101__20250331_zs7bN1jDJTP7" title="Cash in operations"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-03-31" id="Fact000372" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">714</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, the Company closed a private financing in which the Company received net proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20250101__20250131_zpBuO4rEE97h" title="Net proceeds from offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2025-01-012025-01-31" id="Fact000374" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,145</ix:nonFraction></span>, and at March 31, 2025,
the Company had cash and cash equivalents totaling $<span id="xdx_90F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20250331_zb8TldjEhKXe" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-03-31" id="Fact000376" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,616</ix:nonFraction></span>&#160;and shareholders&#8217; equity of $<span id="xdx_905_eus-gaap--StockholdersEquity_iI_pn3n3_c20250331_zcd23idEH5P1" title="Shareholders' equity"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000378" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,132</ix:nonFraction></span>. The Company expects its
current cash reserves to fund the Company&#8217;s operations for at least 12 months from the date of this filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in
the future, which will primarily be accomplished by raising additional capital to meet its operating needs and repay its liabilities
arising from normal business operations when they come due. Since inception, the Company has funded its operations primarily through
equity and debt financings and it expects to continue to rely on these sources of capital in the future until it is able to generate
revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to
the Company. Even if the Company is able to obtain additional financing, such financing may contain undue restrictions on our operations,
in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000380" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zIAdKQ2HwWO1" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="background-color: white"><b>NOTE 2 -
<span id="xdx_826_zf0OtYmGdAJi">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000382" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zOkRiq0UKjP9" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="background-color: white"><b><span id="xdx_864_zYxatAsNGs2h">Basis of
Consolidation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The
accompanying condensed consolidated financial statements and accompanying notes have been prepared in accordance with accounting
principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying condensed consolidated
financial statements include the accounts of the Company and its wholly owned subsidiary, Enviro Therapeutics, Inc.
(&#8220;Enviro&#8221;). All intercompany balances and transactions have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000384" name="us-gaap:UseOfEstimates"><p id="xdx_84E_eus-gaap--UseOfEstimates_zDiSjzzSHV3h" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_860_zJyaYE3qESYe">Use of Estimates</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The preparation of the financial statements in conformity
with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts
of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accruals for potential liabilities,
valuations of stock-based compensation, the realization of deferred tax assets, and impairment analysis and useful life for intangible
assets among others. Actual results could differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000386" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zhq94cFuVsZ8" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_86C_z4sbsgETDg8a">Concentration of Credit Risk</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Financial instruments, which potentially subject the
Company to concentration of credit risk, consist primarily of cash deposits. The Company maintains deposits in federally insured financial
institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due
to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses
on deposits since its inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000388" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQVxrqcLBLh7" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_86B_zC44RJl7CIr4">Cash Equivalents</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Company considers all highly liquid investments
with original maturities of three months or less on the date of purchase to be cash equivalents. Cash equivalents consisted of money market
funds as of March 31, 2025. There were <span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20241231_zdo5haAu0w6g" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000390" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> cash equivalents as of December 31, 2024. As of March 31, 2025, the amount of cash equivalents
included in cash and cash equivalents totaled $<span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20250331_zBdf2sxHleOj" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2025-03-31" id="Fact000392" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,504</ix:nonFraction></span>. The underlying securities in the money market funds held by the Company are all
government backed securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000394" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"><p id="xdx_844_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zQYCNnpXR7eb" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_86D_zSDuiKUe9A82">Intangible Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Company&#8217;s intangible assets are stated at
fair value as of the date acquired, less accumulated amortization. Amortization is calculated based on the estimated useful lives of the
assets, which were determined to be <span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dc_c20250331_zTbXG9AR5Lll" title="Intangible assets useful life"><ix:nonNumeric contextRef="AsOf2025-03-31" format="ixt-sec:durwordsen" id="Fact000396" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">five years</ix:nonNumeric></span>, using the straight-line method. The intangible asset consists of a licensing agreement
that the Company acquired through its acquisition of Enviro during the year ended December 31, 2021, with an acquisition
cost of $<span id="xdx_90D_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_pn3n3_c20211231__us-gaap--BusinessAcquisitionAxis__custom--EnviroThreapeuticsIncMember_zHpRYAmvGkFi" title="Acquisition cost"><ix:nonFraction name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" contextRef="AsOf2021-12-31_custom_EnviroThreapeuticsIncMember" id="Fact000398" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">800</ix:nonFraction></span>. Amortization expense relating to the intangible asset during the three months ended March 31, 2025 and 2024 was $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20250101__20250331_zunLGsSr22Q9" title="Amortization expenses"><span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240101__20240331_zfqPWqgpJ6i9" title="Amortization expenses"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2025-01-01to2025-03-31" id="Fact000400" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-03-31" id="Fact000402" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></ix:nonFraction></span></span>, respectively,
with an unamortized balance of $<span id="xdx_90B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20250331_z4ulo3hNsNr7" title="Intangible assets unamortized balance"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2025-03-31" id="Fact000404" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">182</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20241231_zwUj3ulbgYVf" title="Intangible assets unamortized balance"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-12-31" id="Fact000406" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">222</ix:nonFraction></span> at March 31, 2025 and December 31, 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000408" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zdkZtWrXr199" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><b><span><span id="xdx_862_zzgt8VHN0Ug7">Impairment of Long-Lived
Assets</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Company applies the provisions of ASC Topic 360,
<i>Property, Plant, and Equipment</i>, which addresses financial accounting and reporting for the impairment of long-lived assets. A long-lived
asset that is held and used should be tested for recoverability whenever events or changes in circumstances indicate that the carrying
amount of the asset group may not be recoverable. If the estimated undiscounted
future cash flows are less than the carrying value, an impairment determination is required. In that event, a loss is recognized based
on the amount by which the carrying amount exceeds the fair value of the long-lived assets. <span id="xdx_90A_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pn3n3_do_c20250101__20250331_zmYqEVsxlK6b" title="Impairment of intangible assets"><span id="xdx_90A_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pn3n3_do_c20240101__20240331_zuftzu83Acma" title="Impairment of intangible assets"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2025-01-01to2025-03-31" id="Fact000410" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2024-01-012024-03-31" id="Fact000412" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USD">No</ix:nonFraction></ix:nonFraction></span></span> impairment was recorded relating to the
Company&#8217;s intangible asset during the three months ended March 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000414" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zSNqSpNPsyxl" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_86C_ztQC0cp5KIS8">Income (Loss) Per Share</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Basic loss per share is computed by dividing net loss
applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share
is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus
the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000416" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zEr8aWBQ0z0l" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">For the three months ended March 31, 2025 and 2024,
the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. The potentially
dilutive securities consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="xdx_8B0_zX66bhEgul26" style="display: none">SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20250101__20250331_zTIhOkr4S1xl" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20240331_zWHWDvfZ4Qpl" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2024</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zJlzlViCK8J9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Warrants to purchase common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-03-31_custom_WarrantsToPurchaseCommonStockMember" id="Fact000418" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,543,188</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31_custom_WarrantsToPurchaseCommonStockMember" id="Fact000419" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zNxS3XyLOHVh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000421" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">113,599</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zhQVSBZIkIth" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-01to2025-03-31" id="Fact000424" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,656,787</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31" id="Fact000425" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zoYQPGs7Sij" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000427" name="us-gaap:DeferredChargesPolicyTextBlock"><p id="xdx_845_eus-gaap--DeferredChargesPolicyTextBlock_z1yrQvKC7rKh" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><span id="xdx_863_zzoCf4kSJiNe">Deferred Offering Costs</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The
Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity
issuances as deferred offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs
are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be delayed or abandoned,
the deferred offering costs will be expensed immediately as a charge to operating expenses in the Statement of Operations. As of December
31, 2024, the Company incurred $<span id="xdx_902_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--EquityLineOfCreditMember_zWXIMHUyHEk7"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2024-12-31_custom_EquityLineOfCreditMember" id="Fact000428" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,377</ix:nonFraction>
</span>of deferred offering costs related to the Company&#8217;s pending Equity Line of Credit (ELOC) offering. During the three months
ended March 31, 2025, the Company incurred $<span id="xdx_90D_ecustom--DeferredOfferingAdditionalCosts_iI_pn3n3_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--EquityLineofCreditMember_zaTIoYRuDcW5" title="Deferred offering additional cost"><ix:nonFraction name="KAPA:DeferredOfferingAdditionalCosts" contextRef="AsOf2025-03-31_custom_EquityLineOfCreditMember" id="Fact000430" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">328</ix:nonFraction>
</span>of additional costs related to the ELOC, and as of March 31, 2025, total deferred offering costs were $<span id="xdx_907_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--EquityLineofCreditMember_zK0Ol2liMitg"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2025-03-31_custom_EquityLineOfCreditMember" id="Fact000431" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,705</ix:nonFraction></span> related to the ELOC. The ELOC was declared effective on April 24, 2025, and the Company will amortize these costs as cost of capital as
the funds are raised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000433" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z36aILlhLgRj" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_866_zjflgjo1cuYd">Fair Value Measurements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; text-indent: 0.2pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Company determines the fair value of its assets
and liabilities based on the exchange price in U.S. dollars that would be received to sell an asset or paid to transfer a liability (an
exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of
unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable
and the last unobservable, to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><i>Level 1 &#8212;</i> Quoted prices in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><i>Level 2 &#8212;</i> Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><i>Level 3 &#8212;</i> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The
carrying amounts of financial instruments such as cash, and accounts payable and accrued liabilities, approximate the related fair values
due to the short-term maturities of these instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Cash equivalents consisted of money market funds at
March 31, 2025. Money market funds were valued by the Company using quoted prices in active markets for identical securities, which represent
a Level 1 measurement within the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000435" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zs1TfzBwDLZ" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_868_z8xjIVgzQhaj">Recent Accounting Pronouncements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">In November 2024, FASB issued ASU 2024-03 Income Statement&#8212;Reporting
Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses. The guidance
in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information
about certain costs and expenses including purchases of inventory; employee compensation; and depreciation and amortization expense for
each caption on the income statement where such expenses are included. The update is effective for annual reporting periods beginning
after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments
may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial
statements. We are currently evaluating the provisions of this guidance and assessing the potential impact on our financial statement
disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Other recent accounting pronouncements issued by the
FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange
Commission did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated financial
statements.</p>

</ix:nonNumeric><p id="xdx_859_zVmeNxeIMm97" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000437" name="KAPA:DisclosureOfVendorAgreementsTextBlock"><p id="xdx_807_ecustom--DisclosureOfVendorAgreementsTextBlock_zQJpXCyjjeek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8211; <span id="xdx_821_zT9jWaEcGprl">VENDOR AGREEMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000439" name="KAPA:VendorAdvancesPolicyTextBlock"><p id="xdx_84A_ecustom--VendorAdvancesPolicyTextBlock_zOtuPccDdpK8" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_86F_z3UKkIMW4u24">Vendor Advances</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The
Company has entered into various contracts with service providers pursuant to which the Company pays the vendor an advance at the
beginning of the contractual period. These vendor advances could be paid by the Company either in cash or in shares of common stock,
depending on the terms of the contract. The advances are reduced by the accumulated value of the services performed by the vendor or
are amortized on a straight-line basis over the service period, whichever is shorter. As of December 31, 2024, advances to vendors
totaled $<span id="xdx_90C_eus-gaap--CustomerAdvancesAndDeposits_iI_pn3n3_c20241231_zugSftaZDSWc" title="Advances to vendor amount"><ix:nonFraction name="us-gaap:CustomerAdvancesAndDeposits" contextRef="AsOf2024-12-31" id="Fact000441" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,115</ix:nonFraction></span>, with $<span id="xdx_90C_ecustom--VendorAdvancesInCash_iNI_pn3n3_di_c20241231_zNSTeIrdLhXb" title="Vendor advances in cash"><ix:nonFraction name="KAPA:VendorAdvancesInCash" contextRef="AsOf2024-12-31" id="Fact000443" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,615</ix:nonFraction></span> being paid in cash and $<span id="xdx_902_ecustom--IssuanceOfCommonSharesPaidForVendorsAdvances_pn3n3_c20240101__20241231_zswPgID777F7" title="Issuance of common shares paid for vendors advances"><ix:nonFraction name="KAPA:IssuanceOfCommonSharesPaidForVendorsAdvances" contextRef="From2024-01-012024-12-31" id="Fact000445" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></span> being paid with shares of the Company&#8217;s common stock (see Note 4).
Amortization expense relating to the vendor advances during the year ended December 31, 2024 was $<span id="xdx_901_ecustom--AmortizationExpenseVendorAdvances_pn3n3_c20240101__20241231_zG0xS9taYI12" title="Amortization expense relating to vendor advances"><ix:nonFraction name="KAPA:AmortizationExpenseVendorAdvances" contextRef="From2024-01-012024-12-31" id="Fact000447" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">256</ix:nonFraction></span>, with an unamortized balance
of $<span id="xdx_900_ecustom--VendorAdvancesCurrent_iI_pn3n3_c20241231_zNdSyV9ug8A7" title="Vendor advances"><ix:nonFraction name="KAPA:VendorAdvancesCurrent" contextRef="AsOf2024-12-31" id="Fact000449" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,859</ix:nonFraction></span> as of December 31, 2024. During the three months ended March 31, 2025, additional advances to vendors totaled $<span id="xdx_905_ecustom--IssuanceOfCommonSharesPaidForVendorsAdvances_pn3n3_c20250101__20250331_zGHRqulU2S7e" title="Issuance of common shares paid for vendors advances"><ix:nonFraction name="KAPA:IssuanceOfCommonSharesPaidForVendorsAdvances" contextRef="From2025-01-01to2025-03-31" id="Fact000451" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">156</ix:nonFraction></span>, with
the advance being paid with shares of the Company&#8217;s common stock (see Notes 3 and 4). Amortization expense relating to the
vendor advances was $<span id="xdx_90A_ecustom--AmortizationExpenseVendorAdvances_pn3n3_c20250101__20250331_zUHuliREq3Tl" title="Amortization expense relating to vendor advances"><ix:nonFraction name="KAPA:AmortizationExpenseVendorAdvances" contextRef="From2025-01-01to2025-03-31" id="Fact000453" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">636</ix:nonFraction></span>, with an unamortized balance of $<span id="xdx_903_ecustom--VendorAdvancesCurrent_iI_pn3n3_c20250331_znuraBHHDmT4" title="Vendor advances"><ix:nonFraction name="KAPA:VendorAdvancesCurrent" contextRef="AsOf2025-03-31" id="Fact000455" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,379</ix:nonFraction></span> as of March 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000457" name="KAPA:ScheduleOfVendorAdvancesTableTextBlock"><p id="xdx_897_ecustom--ScheduleOfVendorAdvancesTableTextBlock_zBHJpnMELoPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vendor
advances consisted of the following at March 31, 2025, and December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zPEy2vznLef8" style="display: none">SCHEDULE
OF VENDOR ADVANCES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250331_zMBMKTy3m0M7" style="border-bottom: Black 1pt solid; text-align: center">March 31,<br/> 2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_zWgJyV0SPHV3" style="border-bottom: Black 1pt solid; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_409_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--PrevailInfoworksIncMember_zYsH4hFTQDu" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F4F_zIlElyXVuLjf" style="width: 64%; text-align: justify; text-indent: -12pt; padding-left: 12pt">Prevail Infoworks (a)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="KAPA:VendorAdvancesGross" contextRef="AsOf2025-03-31_custom_PrevailInfoworksIncMember" id="Fact000459" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">900</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="KAPA:VendorAdvancesGross" contextRef="AsOf2024-12-31_custom_PrevailInfoworksIncMember" id="Fact000460" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">900</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zu0l7EtIN1j4" style="vertical-align: bottom; background-color: White">
    <td id="xdx_F42_z2mPBU0QOL15" style="text-align: justify; text-indent: -12pt; padding-left: 12pt">PreCheck Health Services (b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:VendorAdvancesGross" contextRef="AsOf2025-03-31_custom_PreCheckHealthServicesIncMember" id="Fact000462" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:VendorAdvancesGross" contextRef="AsOf2024-12-31_custom_PreCheckHealthServicesIncMember" id="Fact000463" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">900</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zEW5CuxIuXF3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F45_z27GEf7cW9mh" style="text-align: justify; text-indent: -12pt; padding-left: 12pt">CEO.CA Technologies (c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:VendorAdvancesGross" contextRef="AsOf2025-03-31_custom_CEOCATechnologiesLtdMember" id="Fact000465" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:VendorAdvancesGross" contextRef="AsOf2024-12-31_custom_CEOCATechnologiesLtdMember" id="Fact000466" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zaYjFvFN5kvk" style="vertical-align: bottom; background-color: White">
    <td id="xdx_F48_zhHNaFSHYl53" style="text-align: justify; text-indent: -12pt; padding-left: 12pt">Belair Capital Advisors (d)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:VendorAdvancesGross" contextRef="AsOf2025-03-31_custom_BelairCapitalAdvisorsIncMember" id="Fact000468" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:VendorAdvancesGross" contextRef="AsOf2024-12-31_custom_BelairCapitalAdvisorsIncMember" id="Fact000469" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">365</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--CrossCurrentCapitalLLCMember_z9WNeQNhcHRf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F46_zp8WQRJ4lTFf" style="text-align: justify; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Cross Current Capital (e)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="KAPA:VendorAdvancesGross" contextRef="AsOf2025-03-31_custom_CrossCurrentCapitalLLCMember" id="Fact000471" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">856</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="KAPA:VendorAdvancesGross" contextRef="AsOf2024-12-31_custom_CrossCurrentCapitalLLCMember" id="Fact000472" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">700</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--VendorAdvancesGross_iI_maVANzSvy_zniJYtW0OSve" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Vendor advances, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:VendorAdvancesGross" contextRef="AsOf2025-03-31" id="Fact000474" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,271</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="KAPA:VendorAdvancesGross" contextRef="AsOf2024-12-31" id="Fact000475" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,115</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--VendorAdvancesAccumulatedAmortization_iNI_di_msVANzSvy_zjnKmRDVplX8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="KAPA:VendorAdvancesAccumulatedAmortization" contextRef="AsOf2025-03-31" id="Fact000477" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">892</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="KAPA:VendorAdvancesAccumulatedAmortization" contextRef="AsOf2024-12-31" id="Fact000478" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">256</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--VendorAdvancesNet_iTI_mtVANzSvy_zmvZB94q6Je4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: justify; text-indent: -12pt; padding-left: 12pt">Vendor advances, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="KAPA:VendorAdvancesNet" contextRef="AsOf2025-03-31" id="Fact000480" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,379</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="KAPA:VendorAdvancesNet" contextRef="AsOf2024-12-31" id="Fact000481" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,859</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(a)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with Prevail Infoworks, Inc.</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2024, the Company entered into a master service and technology agreement with Prevail Infoworks, Inc. (&#8220;Prevail&#8221;),
pursuant to which Prevail agreed to provide certain clinical research services to the Company. As part of the agreement, the Company
was required to make an advance payment of $<span id="xdx_905_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_zprPoAiaebDh" title="Advance payment"><ix:nonFraction name="us-gaap:PaymentsForAdvanceToAffiliate" contextRef="From2024-08-012024-08-31_custom_MasterServiceAndTechnologyAgreementMember" id="Fact000483" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">900</ix:nonFraction></span> to Prevail before commencement of services and, at such time as we notify Prevail to
engage their services related to the relevant clinical trial, or six months from the date of the agreement, pay approximately $<span id="xdx_90A_ecustom--MonthlyPayment_pn3n3_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_z5ccsCCqpfnh" title="Monthly payment"><ix:nonFraction name="KAPA:MonthlyPayment" contextRef="From2024-08-012024-08-31_custom_MasterServiceAndTechnologyAgreementMember" id="Fact000485" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80</ix:nonFraction></span> per
month during the time Prevail performs clinical research services for the Company&#8217;s Phase 2 ENV 105 prostate and Phase 1 ENV 105
lung clinical trials. The agreement with Prevail is subject to cancellation at any time upon 30 days&#8217; written notice to the other
party. The Company made the advance payment to Prevail in October 2024 and it is included in vendor advances on the accompanying balance
sheet as of March 31, 2025 and December 31, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(b)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with PreCheck Health Services, Inc.</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2024, the Company entered into a bioassay services agreement (the &#8220;Bioassay Services Agreement&#8221;) with PreCheck
Health Services, Inc., a Florida-based corporation (&#8220;PreCheck&#8221;). Pursuant to the Bioassay Services Agreement, PreCheck will
provide certain biomarker screening services for the Company&#8217;s ongoing carotuximab (ENV105) clinical trials in order to assist
the Company in identifying lung and prostate cancer patients suitable to the Company&#8217;s ongoing Phase 1 clinical trials for lung
cancer patients and Phase 2 clinical trials for patients with castrate resistant prostate cancer. In exchange for PreCheck&#8217;s services,
and according to the terms of the Bioassay Services Agreement, the Company paid $<span id="xdx_904_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240920__20240920__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zduXccqjwVB3" title="Payments for services"><ix:nonFraction name="us-gaap:PaymentsForAdvanceToAffiliate" contextRef="From2024-09-202024-09-20_custom_BioassayServicesAgreementMember_custom_PreCheckHealthServicesIncMember" id="Fact000487" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">900</ix:nonFraction></span> to PreCheck as an advance for the future laboratory
services to be performed. The payment of $<span id="xdx_90D_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zwLbkpGeqLZc" title="Payments for vendor advance"><span id="xdx_90F_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zjW07xt7c818" title="Payments for vendor advance"><ix:nonFraction name="us-gaap:PaymentsForAdvanceToAffiliate" contextRef="From2024-01-012024-12-31_custom_BioassayServicesAgreementMember_custom_PreCheckHealthServicesIncMember" id="Fact000489" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:PaymentsForAdvanceToAffiliate" contextRef="From2025-01-012025-03-31_custom_BioassayServicesAgreementMember_custom_PreCheckHealthServicesIncMember" id="Fact000491" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">900</ix:nonFraction></ix:nonFraction></span></span> is included in vendor advances on the accompanying balance sheet as of March 31, 2025 and
December 31, 2024 (see Note 2). The term of the agreement is one year from the effective date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(c)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with CEO.CA Technologies Ltd.</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2024, the Company entered into an advisory and consulting services agreement (the &#8220;CEO.CA Agreement&#8221;) with
CEO.CA Technologies Ltd., a Canadian company (&#8220;CEO.CA&#8221;), pursuant to which CEO.CA will provide certain internet-based financial
information and communications services for a period of one year for a services fee of $<span id="xdx_90B_eus-gaap--ManagementFeeExpense_pn3n3_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zdwOjkCdY2mk" title="Service fee"><ix:nonFraction name="us-gaap:ManagementFeeExpense" contextRef="From2024-09-232024-09-23_custom_AdvisoryAndConsultingServicesAgreementMember_custom_CEOCATechnologiesLtdMember" id="Fact000493" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></span>. The service fee is an advance on future
services to be performed. The CEO.CA Agreement includes such services as strategic news placement, news releases, interviews, monthly
analytics and a video launch. The CEO.CA Agreement contains other customary clauses, including representations and warranties, indemnification
clauses and governing law clauses. The payment of $<span id="xdx_907_eus-gaap--ManagementFeeExpense_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zCcYQ0z44iD2" title="Service fee"><span id="xdx_90E_eus-gaap--ManagementFeeExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zQ4vCZ1jJsAd" title="Service fee"><ix:nonFraction name="us-gaap:ManagementFeeExpense" contextRef="From2025-01-012025-03-31_custom_AdvisoryAndConsultingServicesAgreementMember_custom_CEOCATechnologiesLtdMember" id="Fact000495" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ManagementFeeExpense" contextRef="From2024-01-012024-12-31_custom_AdvisoryAndConsultingServicesAgreementMember_custom_CEOCATechnologiesLtdMember" id="Fact000497" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></ix:nonFraction></span></span> is included in vendor advances on the accompanying balance sheet as of March 31,
2025, and December 31, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(d)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with Belair Capital Advisors Inc.</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2024, the Company entered into a strategic advisory agreement (the &#8220;Strategic Advisory Agreement&#8221;) with Belair
Capital Advisors Inc. (&#8220;BCA&#8221;). BCA, a venture capital and corporate finance advisory firm, has been a long-term investor
and advisor to the Company and frequently works with early-stage pharmaceutical companies. The strategic advisory services provided by
BCA consist of corporate strategy, market positioning and long-term growth plans within the pharmaceutical sector, digital marketing
and engagement, market research analysis and business development assistance, among other things. During the one-year term of the Strategic
Advisory Agreement, in exchange for its services, the Company will pay BCA a $<span id="xdx_90B_eus-gaap--ManagementFeeExpense_pn3n3_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zWK09mzIVjcf" title="Service fee"><ix:nonFraction name="us-gaap:ManagementFeeExpense" contextRef="From2024-09-232024-09-23_custom_StrategicAdvisoryAgreementMember_custom_BelairCapitalAdvisorsIncMember" id="Fact000499" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">365</ix:nonFraction></span> fee and will issue BCA <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zH4wUeKY4gce" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-09-232024-09-23_custom_StrategicAdvisoryAgreementMember_custom_BelairCapitalAdvisorsIncMember" id="Fact000501" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> RSUs, which will vest
at the end of six months following the date of issuance. The payment of $<span id="xdx_904_eus-gaap--ManagementFeeExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_z5u2qaE8GJ13" title="Service fee"><span id="xdx_90E_eus-gaap--ManagementFeeExpense_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zqWNwT1AmMp2" title="Service fee"><ix:nonFraction name="us-gaap:ManagementFeeExpense" contextRef="From2024-01-012024-12-31_custom_StrategicAdvisoryAgreementMember_custom_BelairCapitalAdvisorsIncMember" id="Fact000503" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ManagementFeeExpense" contextRef="From2025-01-012025-03-31_custom_StrategicAdvisoryAgreementMember_custom_BelairCapitalAdvisorsIncMember" id="Fact000505" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">365</ix:nonFraction></ix:nonFraction></span></span> is included in vendor advances on the accompanying balance
sheet as of March 31, 2025, and December 31, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(e)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with Cross Current Capital LLC</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2024, the Company entered into a consulting agreement (the &#8220;Consulting Agreement&#8221;) with Cross Current Capital
LLC, a limited liability company organized under the laws of Puerto Rico (&#8220;Cross Current&#8221;), and Alan Masley (the &#8220;Advisor&#8221;),
pursuant to which Cross Current agreed to provide certain financial and business consulting services to the Company including, but not
limited, to (a) help drafting a public company competitive overview, (b) help preparing and/or reviewing a valuation analysis, (c) help
in drafting marketing materials and presentations, (d) reviewing the Company&#8217;s business requirements and discuss financing and
businesses opportunities, (e) investor marketing, (f) investor relations introductions, (g) legal counsel introductions, (h) auditor
introductions, (i) investment banking and research introductions, (j) M&amp;A canvassing and ways to grow the business organically, and
(k) stand by capital markets advisory services. For the services rendered thereunder, the Company agreed to pay Cross Current $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zs967aIjw35a" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-10-012024-10-01_custom_ConsultingAgreementMember_custom_CurrentCapitalLLCMember" id="Fact000507" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000</ix:nonFraction></span>
in cash and agreed to issue to the Advisor $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zg32SQq41PFa" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-10-012024-10-01_custom_ConsultingAgreementMember_custom_CurrentCapitalLLCMember" id="Fact000509" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></span> of restricted shares of the Company&#8217;s common stock under the Company&#8217;s 2023
Plan , calculated at <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zwdhN9xZw456" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-10-012024-10-01_custom_ConsultingAgreementMember_custom_CurrentCapitalLLCMember" id="Fact000511" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">367,647</ix:nonFraction></span> shares (the &#8220;Shares&#8221;) as of the date of the agreement. The term of the Consulting Agreement
is 24 months and can be extended for another 12 months with the written consent of both parties. The Company made the $<span id="xdx_900_ecustom--SettlementAgreementAmount_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z06niaGMIAY" title="Settlement agreement amount"><ix:nonFraction name="KAPA:SettlementAgreementAmount" contextRef="From2024-10-012024-10-01_custom_ConsultingAgreementMember" id="Fact000513" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></span> payment in
October 2024. The payment of $<span id="xdx_903_ecustom--VendorPaymentAdvances_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zuE1Up2Yf3Oc" title="Vendor payment advances"><ix:nonFraction name="KAPA:VendorPaymentAdvances" contextRef="AsOf2024-12-31_custom_ConsultingAgreementMember" id="Fact000515" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></span> and the value of the shares issued of $<span id="xdx_90B_eus-gaap--AdditionalCollateralAggregateFairValue_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z6yCdjjdyhR4" title="Aggregate fair value of the common stock"><span id="xdx_904_eus-gaap--AdditionalCollateralAggregateFairValue_iI_pn3n3_c20250331__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zdHaZRYlUKB9" title="Aggregate fair value of the common stock"><ix:nonFraction name="us-gaap:AdditionalCollateralAggregateFairValue" contextRef="AsOf2024-12-31_custom_ConsultingAgreementMember" id="Fact000517" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:AdditionalCollateralAggregateFairValue" contextRef="AsOf2025-03-31_custom_ConsultingAgreementMember" id="Fact000519" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></ix:nonFraction></span></span> are included in vendor advances on the accompanying balance
sheet as of March 31, 2025, and December 31, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTfiiSp4Yj82" title="Stock issued shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-04-012025-04-01_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember" id="Fact000521" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">367,647</ix:nonFraction></span> shares issued in 2024 were subject to a &#8220;true up&#8221; on April 1, 2025, at which time additional shares will be issued
to the Advisor (or returned by the Advisor to the Company) in order to ensure the shares are valued at $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIZpvH8zT7f" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-012025-04-01_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember" id="Fact000523" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></span> as of April 1, 2025. On April
1, 2025, the Company issued an additional<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z30ZJg7BXA84" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-04-012025-04-01_custom_ConsultingAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact000525" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">166,541</ix:nonFraction></span> shares of its common stock to the Advisor. The fair value of the additional shares on
the date of grant was $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgBbAS3MRlag" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-012025-04-01_custom_ConsultingAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact000527" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">156</ix:nonFraction></span>. The Company recorded the shares as common stock to be issued as of March 31, 2025, and recorded the fair
value of the shares as a vendor advance as of the same date (see Notes 2 and 4).</span></p>

</ix:nonNumeric><p id="xdx_8A1_zKXzBpgYIBPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Agreement
with Helena Global Investment Opportunities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2024, the Company entered into an agreement with Helena Global Investment Opportunities I LTD (&#8220;Helena&#8221;) pursuant
to which the Company will have the right to issue and sell to Helena, from time to time, and Helena shall purchase from the Company,
up to $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20241112__20241112__us-gaap--TypeOfArrangementAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember_zX8ZODczRail" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-11-122024-11-12_custom_HelenaGlobalInvestmentOpportunitiesILTDMember" id="Fact000529" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,000</ix:nonFraction></span> of the Company&#8217;s shares of common stock (the &#8220;Equity Line of Credit&#8221;). The Equity Line of Credit will
become available to the Company at such time as it files a registration statement on Form S-1 registering the shares issuable under the
Equity Line of Credit. In exchange for the Equity Line of Credit, the Company is obligated to issue Helena a certain number of shares
of common stock, calculated using $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20241112__20241112_zOkFyaO9FIBl" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-11-122024-11-12" id="Fact000531" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">900</ix:nonFraction></span> divided by the lowest one-day VWAP during the five trading days prior to entry into the agreement.
As a result, the Company issued Helena <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241112__20241112__us-gaap--TypeOfArrangementAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember_zoIsXhxdEUKl" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-11-122024-11-12_custom_HelenaGlobalInvestmentOpportunitiesILTDMember" id="Fact000533" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">670,641</ix:nonFraction></span> shares of its common stock valued at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueOther_pn3n3_c20241112__20241112__us-gaap--TypeOfArrangementAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember_zENKFjeTkvdl" title="Stock issued  value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-11-122024-11-12_custom_HelenaGlobalInvestmentOpportunitiesILTDMember" id="Fact000535" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,377</ix:nonFraction></span> on the date of issuance. The Company accounted
for the value of the shares issued as deferred offering costs (see Note 2). The shares vested on the date of the agreement, were issued
to Helena, and are subject to a &#8220;true up&#8221; based upon the value of the stock at the time the company files and obtains effectiveness
of a registration statement registering the shares for resale. In addition, the Company agreed to register such shares for resale pursuant
to a registration statement on Form S-1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 24, 2025, the Company issued another <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250424__20250424__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkWtQCztnWb7" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-04-242025-04-24_us-gaap_CommonStockMember_custom_HelenaGlobalInvestmentOpportunitiesILTDMember_us-gaap_SubsequentEventMember" id="Fact000537" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">384,459</ix:nonFraction></span> shares of its common stock to Helena. The fair value of the shares on the date of
grant was $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250424__20250424__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9lasvQbcC87" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-242025-04-24_us-gaap_CommonStockMember_custom_HelenaGlobalInvestmentOpportunitiesILTDMember_us-gaap_SubsequentEventMember" id="Fact000539" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">328</ix:nonFraction></span>. The Company recorded the shares as common stock to be issued as of March 31, 2025, and recorded the fair value of the
shares as deferred offering costs as of the same date (see Notes 2 and 4).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000541" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zqWGd9INJv04" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>NOTE 4 &#8211; <span id="xdx_828_zDtkd8Qtsvn8">SHAREHOLDERS&#8217; EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><span style="text-decoration: underline">Common Stock</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><i><span style="text-decoration: underline">Authorized Shares</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">The Company&#8217;s Certificate
of Incorporation, as filed with the State of Delaware on May 10, 2023, following the Company&#8217;s conversion from a California corporation
into a Delaware corporation, authorizes the Company to issue up to <span id="xdx_90F_ecustom--SharesAuthorized_iI_pid_c20230510_zVuRxtV3P1T5" title="Shares authorized"><ix:nonFraction name="KAPA:SharesAuthorized" contextRef="AsOf2023-05-10" id="Fact000543" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000,000</ix:nonFraction></span> shares, consisting of <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230510_zerZJjFwF7aj" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-05-10" id="Fact000545" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></span> shares of common stock,
par value of $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230510_zeJcxOJO54t4" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-05-10" id="Fact000547" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share, and <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230510_zhx6sbUePF2g" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-05-10" id="Fact000549" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></span> shares of preferred stock, par value $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230510_zabv1cM2QXPe" title="Preferred stock par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-05-10" id="Fact000551" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share. Holders of shares of common stock
have full voting rights, one vote for each share held of record. Shareholders are entitled to receive dividends as may be declared by
the board of directors out of funds legally available and share pro rata in any distributions with shareholders upon liquidation. Shareholders
have no conversion, pre-emptive or subscription rights. All outstanding shares of common stock are fully paid and non-assessable. As of
March 31, 2025 and December 31, 2024 there were <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pid_c20250331_zgju3NGCas83" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20250331_z5xf7gWD7cL7" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-03-31" id="Fact000553" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-03-31" id="Fact000555" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,825,118</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zmY8yK5eKIjl" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zK0shRWPUan2" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000557" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000559" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,736,597</ix:nonFraction></ix:nonFraction></span></span> shares of common stock issued and outstanding, respectively,
and <span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20250331_zwac76Gpjpra" title="Preferred stock, shares outstanding"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20241231_z21CK91DRuaj" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-03-31" id="Fact000561" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000563" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> shares of preferred stock outstanding, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><i><span style="text-decoration: underline">Common Stock Issued
for Cash Upon Closing of the Company&#8217;s Private Financing</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">On
January 14, 2025, the Company entered into a securities purchase agreement (&#8220;SPA&#8221;) and registration rights agreement
with an investor for the sale and issuance of <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250114__20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_z9qSKWCISLid" title="Sale of stock, number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-01-142025-01-14_custom_SecurityPurchaseAgreementMember_custom_PreFundedWarrantMember" id="Fact000565" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></span> units (the &#8220;Pre-Funded Units&#8221;), with each Pre-Funded Unit
consisting of a pre-funded warrant to purchase one share of common stock, exercisable for $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_z36o49zonGr8" title="Exercisable price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-01-14_custom_SecurityPurchaseAgreementMember_custom_PreFundedWarrantMember" id="Fact000567" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share, and a common warrant to
purchase one and one half shares of common stock (an aggregate of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pp0p0_c20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zE8QburIr3qg" title="Warrants to purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-14_custom_SecurityPurchaseAgreementMember_custom_PreFundedWarrantMember" id="Fact000569" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">3,750,000</ix:nonFraction></span>), exercisable at $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQ7rERlMaaEb" title="Exercisable price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-01-14_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember" id="Fact000571" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.399</ix:nonFraction></span> per share. On January 16, 2025, the
Company closed on the sale of the Pre-Funded Units for a total purchase price of $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn3n3_c20250116__20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember_zcFWsRsjX6Xk" title="Purchase price of pre-funded unit"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2025-01-162025-01-16_custom_SecurityPurchaseAgreementMember" id="Fact000573" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,500</ix:nonFraction></span> (or $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember_zzoT0Wrr1w2b" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember" id="Fact000575" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.40</ix:nonFraction></span> per Pre-Funded Unit). Net proceeds
received by the Company relating to the financing, and subsequent exercise of prefunded warrants was $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3n3_c20250116__20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember_zWh4D7F7V9kk" title="Net proceeds received from financing"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2025-01-162025-01-16_custom_SecurityPurchaseAgreementMember" id="Fact000577" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,058</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">The pre-funded warrants have
an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250114__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zsS1eMWJ75nl" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-01-14_custom_PrefundedWarrantsMember" id="Fact000579" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share and are immediately exercisable and will expire when exercised in full. The common warrants have
an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250114__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember_z8w3gUancoX2" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-01-14_custom_CommonWarrantsMember" id="Fact000581" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.40</ix:nonFraction></span> per share, <span id="xdx_904_ecustom--ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_c20250114__20250114_z9WWjrlP8b9e" title="Warrants exercisable description"><ix:nonNumeric contextRef="From2025-01-142025-01-14" id="Fact000583" name="KAPA:ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription">will be exercisable six months from issuance and will expire five and a half years from the issuance
date.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">During
the three months ended March 31, 2025, the investor exercised <span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z92sb2DPyc3l" title="Warrants exercised"><ix:nonFraction name="KAPA:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" contextRef="From2025-01-012025-03-31_custom_PrefundedWarrantsMember" id="Fact000585" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,010,000</ix:nonFraction></span>
shares of the pre-funded warrants and as of March 31, 2025, there were <span id="xdx_90C_ecustom--WarrantsUnexercised_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zAca6jILQrF9" title="Warrants unexercised"><ix:nonFraction name="KAPA:WarrantsUnexercised" contextRef="AsOf2025-03-31_custom_PrefundedWarrantsMember" id="Fact000587" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">490,000</ix:nonFraction></span>
pre-funded shares remaining unexercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><i><span style="text-decoration: underline">Adoption of the
2023 Equity Incentive Plan</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">In
July 2023, the Company&#8217;s board of directors and stockholders adopted the 2023 Equity Incentive Plan (the &#8220;2023
Plan&#8221;). Under the 2023 Plan, the Company may grant incentive stock options to employees, including employees of any parent or
subsidiary, and nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards and
other forms of stock compensation to employees, directors and consultants, including employees and consultants of the
Company&#8217;s affiliates. As approved, a total of <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230731__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeEquityIncentivePlanMember_zJKlaYqX7lQi" title="Common stock reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-07-31_custom_TwentyTwentyThreeEquityIncentivePlanMember" id="Fact000589" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,650,000</ix:nonFraction></span>
shares of common stock were initially reserved for issuance under the 2023 Plan. As of March 31, 2025 and December 31, 2024, a total
of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20250331__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeEquityIncentivePlanMember_zd0lN1yAEhm9" title="Shares available for grant"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeEquityIncentivePlanMember_zDw46Pp9xELa" title="Shares available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-03-31_custom_TwentyTwentyThreeEquityIncentivePlanMember" id="Fact000591" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-12-31_custom_TwentyTwentyThreeEquityIncentivePlanMember" id="Fact000593" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,457,880</ix:nonFraction></ix:nonFraction></span></span>
shares remained available for issuance under the 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><i><span style="text-decoration: underline">Grant of Restricted
Stock Units (RSUs)</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000595" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_znOl1UY3MWR5" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="background-color: white">The following
table summarizes restricted common stock activity during the three months ended March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="xdx_8B2_zro0G2YkumV7" style="display: none">SCHEDULE
OF RESTRICTED COMMON STOCK ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>Number of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>Restricted Shares</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted Average Grant Date Fair</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Value</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: justify">Unvested, December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zo4J5tjWOVG6" title="Number of Restricted Shares, Unvested Beginning balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000597" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">172,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zACBeqUT19tj" title="Fair Value, Unvested, Beginning balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000599" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">314</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5euLO2mchWa" title="Weighted Average Grant Date Fair Value, Beginning balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000601" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.83</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyYJ5CNyaCOb" title="Number of Restricted shares Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046" id="Fact000603" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,120</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztjSGHgO3D82" title="Fair Value, Granted" style="text-align: right"><ix:nonFraction name="KAPA:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046" id="Fact000605" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGJWSKYxQbW9" title="Weighted Average Grant Date Fair Value, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046" id="Fact000607" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.49</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkN7GfUl4ntc" title="Number of Restricted shares Vested" style="text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046" id="Fact000609" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,521</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_iN_pn3n3_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrxA1bTiYca6" title="Fair Value, Vested" style="text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046" id="Fact000611" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">76</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD6xx18OPh1j" title="Weighted Average Grant Date Fair Value, Vested" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046" id="Fact000613" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.97</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNz4dFXhXYUa" title="Number of Restricted shares Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0615">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z333fYfpkiI5" title="Fair Value, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0617">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEKJ7p9cuqpg" title="Weighted Average Grant Date Fair Value, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0619">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Unvested, March 31, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFYmZdchnf48" title="Number of Restricted Shares, Unvested Ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2025-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000621" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">113,599</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzKw5fFxyMs2" title="Fair Value, Unvested, Ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000623" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">288</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpM4dMoxwrqh" title="Weighted Average Grant Date Fair Value, Ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2025-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000625" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.54</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zJVGc2waC3yg" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On September 23, 2024, the Company entered into a
strategic advisory agreement with Belair Capital Advisors Inc. (&#8220;Belair&#8221;). During the one-year term of the agreement, in exchange
for its services, the Company issued Belair <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240923__20240923__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember_zcz9Ohyp3V0h" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-09-232024-09-23_us-gaap_RestrictedStockUnitsRSUMember_custom_StrategicAdvisoryAgreementMember" id="Fact000627" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> RSUs, which vest six months from the date of issuance. The fair value of the shares
on the date of grant was $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20240923__20240923_zXr8MdCRYdU4" title="Fair value of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-09-232024-09-23" id="Fact000629" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></span>, which value will be amortized over the one-year service period of the agreement. <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_dn_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember_z2zxdkYdRpZi" title="Number of shares vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-01-012024-12-31_custom_StrategicAdvisoryAgreementMember" id="Fact000631" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">None</ix:nonFraction></span> of these shares vested
or were issued during the year ended December 31, 2024. During the three months ended March 31, 2025, the <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember_zbJbW6AP3Ype" title="Number of shares vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember_custom_StrategicAdvisoryAgreementMember" id="Fact000633" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> RSUs vested and the shares
were issued to Belair.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Upon
the closing of the Company&#8217;s IPO, the Company entered into agreements with each of its four officers. Such agreements provided
for annual grants of RSUs in accordance with the terms of the Company&#8217;s 2023 Equity Incentive Plan. The RSUs vest over one- or
two-year periods and are subject to full acceleration of vesting upon the sale of the Company. Upon the closing of the
Company&#8217;s IPO in September 2024, the Company granted the officers <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240901__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--FourOfficersAgreementMember_zBNejeGo5Wh8" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-09-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember_custom_FourOfficersAgreementMember" id="Fact000635" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">92,000</ix:nonFraction></span>
RSUs. The fair value of the shares on the date of grant was $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20240901__20240930__us-gaap--TypeOfArrangementAxis__custom--FourOfficersAgreementMember_zv3V5m3mMtl6" title="Fair value of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-09-012024-09-30_custom_FourOfficersAgreementMember" id="Fact000637" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">226</ix:nonFraction></span>. <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_dn_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--FourOfficersAgreementMember_z6uOZwCLZtPc" title="Number of shares vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-01-012024-12-31_custom_FourOfficersAgreementMember" id="Fact000639" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">None</ix:nonFraction></span>
of these RSUs vested during the year ended December 31, 2024. During the three months ended March 31, 2025, a total of <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--FourOfficersAgreementMember_zYiqIMoyUJVi" title="Number of shares vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2025-01-012025-03-31_custom_FourOfficersAgreementMember" id="Fact000641" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,521</ix:nonFraction></span>
RSUs vested and the shares were issued to the officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Upon the closing of the Company&#8217;s IPO, the Company
entered into agreements with each of its three independent directors. The Company&#8217;s policy provides that, upon initial election
or appointment to its board of directors, each new non-employee director will be granted a one-time grant, or Director Initial Grant,
with a value of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20250101__20250331__srt--TitleOfIndividualAxis__custom--ThreeIndependentDirectorsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQPNDjBYzN0a" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-01-012025-03-31_custom_ThreeIndependentDirectorsMember_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000643" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span> of RSUs that will vest in substantially equal annual installments over a period of three years. The Director Initial
Grant is subject to full acceleration vesting upon the sale of the Company, in accordance with the terms of the Company&#8217;s 2023 Plan.
In 2024, a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zvwlcTay1F6e" title="Number of shares granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember" id="Fact000645" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></span> RSUs were granted to the directors. The fair value of the shares on the date of grant was $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zPVmkLXW2sr" title="Fair value of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember" id="Fact000647" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">74</ix:nonFraction></span>. During the three
months ended March 31, 2025, an additional <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zlvZXs4Pkf87" title="Granted shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember" id="Fact000649" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,120</ix:nonFraction></span> RSUs was granted to the Company&#8217;s new director with a fair value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z7peKzrpAsek" title="Fair value of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember" id="Fact000651" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31</ix:nonFraction></span>. <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_dn_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--DirectorAgreementsMember_z2iIr5bevzgi" title="Number of shares vested"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_dn_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--DirectorAgreementsMember_ztKsNAPZoN4d" title="Number of shares vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2025-01-012025-03-31_custom_DirectorAgreementsMember" id="Fact000653" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-01-012024-12-31_custom_DirectorAgreementsMember" id="Fact000655" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">None</ix:nonFraction></ix:nonFraction></span></span>
of these RSUs had vested as of the three months ended March 31, 2025 or the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">During the three months ended March 31, 2025, the
Company recorded $<span id="xdx_90B_ecustom--FairValueOfRestrictedStockUnits_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zr3JfvgEROWk" title="Stock compensation-related expense for fair value vesting of restricted common stock"><ix:nonFraction name="KAPA:FairValueOfRestrictedStockUnits" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046" id="Fact000657" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">76</ix:nonFraction></span> of stock compensation-related expense for the fair value vesting of restricted common stock. As of March 31, 2025,
$<span id="xdx_900_ecustom--FairValueOfUnamortizedCompensation_iI_pn3n3_c20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm8PfokPuF3f" title="Fair value of unamortized compensation"><ix:nonFraction name="KAPA:FairValueOfUnamortizedCompensation" contextRef="AsOf2025-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000659" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">280</ix:nonFraction></span> of unamortized compensation remained.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i><span style="text-decoration: underline">Stock Warrants</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000661" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zRPh3JBqEOK9" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The table below summarizes the Company&#8217;s warrant
activities for three months ended March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="xdx_8BD_zx5peycnu1Ri" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Warrant</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Shares</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Price</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Range</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Per Share</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Balance, December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG7ExkPdZU5h" title="Warrants Shares, Beginning Balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000663" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">278,188</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_905_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zw3RnSMwO1zf" title="Exercise Price Range Per Share, Beginning Balance"><ix:nonFraction name="KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" contextRef="AsOf2024-12-31_us-gaap_WarrantMember_srt_MinimumMember" id="Fact000665" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.40</ix:nonFraction></span> - <span id="xdx_903_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zHYp8JiW4h56" title="Exercise Price Range Per Share, Beginning Balance"><ix:nonFraction name="KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" contextRef="AsOf2024-12-31_us-gaap_WarrantMember_srt_MaximumMember" id="Fact000667" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.80</ix:nonFraction></span> &#160;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhTHISzzX9v9" title="Weighted Average Exercise Price Warrant Warrant, Beginning Balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000669" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.29</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zx9rkEE2e1Pl" title="Warrants Shares, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember" id="Fact000671" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,425,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zLg00osw0D24" title="Exercise Price Range Per Share, Granted"><ix:nonFraction name="KAPA:ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted" contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember_srt_MinimumMember" id="Fact000673" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>
&#8211; <span id="xdx_905_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zYa4xrmSX0S6" title="Exercise Price Range Per Share, Granted"><ix:nonFraction name="KAPA:ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted" contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember_srt_MaximumMember" id="Fact000675" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.40</ix:nonFraction></span> &#160;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zalttfYULl4a" title="Weighted Average Exercise Price Warrant, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember" id="Fact000677" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.86</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoMomLkOoL31" title="Warrants Shares, Cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0679">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zz0Cgyu0ZGUj" title="Exercise Price Range Per Share, Cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0681">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYK9e5nbujj5" title="Weighted Average Exercise Price Warrant, Cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0683">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_iN_pid_di_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXSSmCr7kJPb" title="Warrants Shares, Exercised" style="text-align: right">(<ix:nonFraction name="KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember" id="Fact000685" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,010,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRxuISik6huc" title="Exercise Price Range Per Share, Exercised" style="text-align: right"><ix:nonFraction name="KAPA:ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised" contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember" id="Fact000687" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zicNkvsQa6yf" title="Weighted Average Exercise Price Warrant, Exercised" style="text-align: right"><ix:nonFraction name="KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember" id="Fact000689" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Forfeited/Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmI19NGAzaF9" title="Warrants Shares, Forfeited/Expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember" id="Fact000691" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">150,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIiD5R6BaEva" title="Exercise Price Range Per Share, Forfeited/Expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="KAPA:ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited" contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember" id="Fact000693" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.17</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zD9fUkg6oNae" title="Weighted Average Exercise Price Warrant, Forfeited/Expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember" id="Fact000695" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.17</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Balance, March 31, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zm2nfrTaknP" title="Warrants Shares, Ending Balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2025-03-31_us-gaap_WarrantMember" id="Fact000697" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,543,188</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_908_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zXAJuNDqIm6a" title="Exercise Price Range Per Share, Ending Balance"><ix:nonFraction name="KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" contextRef="AsOf2025-03-31_us-gaap_WarrantMember_srt_MinimumMember" id="Fact000699" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> &#8211; <span id="xdx_90B_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zOFcJpaWLmM" title="Exercise Price Range Per Share, Ending Balance"><ix:nonFraction name="KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" contextRef="AsOf2025-03-31_us-gaap_WarrantMember_srt_MaximumMember" id="Fact000701" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.80</ix:nonFraction></span> &#160;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcbNWOHZ8cHf" title="Weighted Average Exercise Price Warrant, Ending Balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2025-03-31_us-gaap_WarrantMember" id="Fact000703" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.33</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Vested and exercisable, March 31, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwbE3cf7Nrv8" title="Number of Shares Warrants, Vested and exercisable" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod" contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember" id="Fact000705" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">793,188</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zZmT94eyvOe6" title="Exercise Price Range Per Share, Vested and exercisable"><ix:nonFraction name="KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable" contextRef="AsOf2025-03-31_us-gaap_WarrantMember_srt_MinimumMember" id="Fact000707" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>
&#8211; <span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z3edkZ4ytpfg" title="Exercise Price Range Per Share, Vested and exercisable"><ix:nonFraction name="KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable" contextRef="AsOf2025-03-31_us-gaap_WarrantMember_srt_MaximumMember" id="Fact000709" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.80</ix:nonFraction></span> &#160;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyWdYxVLXWb1" title="Weighted Average Exercise Price, Vested and exercisable" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember" id="Fact000711" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.03</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A8_zVylqT4mjkTg" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000713" name="KAPA:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock"><p id="xdx_891_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zljZNQpyXmFi" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The following table summarizes information concerning
outstanding and exercisable warrants as of March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="xdx_8B7_zSVp0cQWvB86" style="display: none">SCHEDULE
OF OUTSTANDING AND EXERCISABLE WARRANTS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Warrants Outstanding</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Warrants Exercisable</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Range of</b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>Exercise Prices</b></p></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><b>Number Outstanding</b></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>Average</b></p>
                                                                                                                                                                                             <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>Remaining Contractual Life</b> <b>(in years)</b></p></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Weighted Average</b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>Exercise Price</b></p></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Number</b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>Exercisable</b></p></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Average Remaining</b></p>
                                                                                                                                                                                             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Contractual Life</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>(in years)</b></p></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Weighted Average</b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>Exercise Price</b></p></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zBsvWacU2RMg" title="Range of exercise prices"><ix:nonFraction name="KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" contextRef="AsOf2025-03-31_custom_ExercisePriceRangeOneMember_custom_WarrantOneMember" id="Fact000715" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_z3Rgrws4GxJl" title="Warrants Outstanding, Number Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2025-03-31_custom_ExercisePriceRangeOneMember_custom_WarrantOneMember" id="Fact000717" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">490,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zeNTwOUURfie" title="Warrants Outstanding, Average Remaining Contractual Life (in years)" style="display: none"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_WarrantOneMember_custom_ExercisePriceRangeOneMember" format="ixt-sec:duryear" id="Fact000719" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">0</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zj5vfy4uPEng" title="Warrants Outstanding, Weighted Average Exercise Price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-31_custom_ExercisePriceRangeOneMember_custom_WarrantOneMember" id="Fact000721" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zYPx8I5dHgi3" title="Warrants Exercisable, Number Exercisable"><ix:nonFraction name="KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber" contextRef="AsOf2025-03-31_custom_ExercisePriceRangeOneMember_custom_WarrantOneMember" id="Fact000723" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">490,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zyHT23wh2jX4" title="Warrants Exercisable, Weighted Average Exercise Price"><ix:nonFraction name="KAPA:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_custom_ExercisePriceRangeOneMember_custom_WarrantOneMember" id="Fact000725" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_904_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zqHqZmhEYfN4" title="Range of exercise prices lower range"><ix:nonFraction name="KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit" contextRef="From2025-01-012025-03-31_custom_ExercisePriceRangeTwoMember_custom_WarrantTwoMember" id="Fact000727" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.40</ix:nonFraction></span> - <span id="xdx_909_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zBEkkdCMQREd" title="Range of exercise prices upper range"><ix:nonFraction name="KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-03-31_custom_ExercisePriceRangeTwoMember_custom_WarrantTwoMember" id="Fact000729" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.40</ix:nonFraction></span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zmPfOod4vwN1" title="Warrants Outstanding, Number Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2025-03-31_custom_WarrantTwoMember_custom_ExercisePriceRangeTwoMember" id="Fact000731" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,944,688</ix:nonFraction></span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_ziS65o1YNYql" title="Warrants Outstanding, Average Remaining Contractual Life (in years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_ExercisePriceRangeTwoMember_custom_WarrantTwoMember" format="ixt-sec:duryear" id="Fact000733" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.74</ix:nonNumeric></span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zGB04cnxTQ91" title="Warrants Outstanding, Weighted Average Exercise Price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-31_custom_WarrantTwoMember_custom_ExercisePriceRangeTwoMember" id="Fact000735" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.40</ix:nonFraction></span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zLeh8lehsKc9" title="Warrants Exercisable, Number Exercisable"><ix:nonFraction name="KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber" contextRef="AsOf2025-03-31_custom_WarrantTwoMember_custom_ExercisePriceRangeTwoMember" id="Fact000737" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">194,688</ix:nonFraction></span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zFy7qWTmkTXj" title="Warrants Exercisable, Average Remaining Contractual Life (in years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_ExercisePriceRangeTwoMember_custom_WarrantTwoMember" format="ixt-sec:duryear" id="Fact000739" name="KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms">4.51</ix:nonNumeric></span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zWkh6uWUCFDi" title="Warrants Exercisable, Weighted Average Exercise Price"><ix:nonFraction name="KAPA:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_custom_WarrantTwoMember_custom_ExercisePriceRangeTwoMember" id="Fact000741" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.50</ix:nonFraction></span></p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember_zCopYuf7owIc" title="Range of exercise prices"><ix:nonFraction name="KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" contextRef="AsOf2025-03-31_custom_ExercisePriceRangeThreeMember_custom_WarrantThreeMember" id="Fact000743" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.80</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zITZqVCczLT6" title="Warrants Outstanding, Number Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2025-03-31_custom_ExercisePriceRangeThreeMember_custom_WarrantThreeMember" id="Fact000745" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">108,500</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zztv0kFlmqX3" title="Warrants Outstanding, Average Remaining Contractual Life (in years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_WarrantThreeMember_custom_ExercisePriceRangeThreeMember" format="ixt-sec:duryear" id="Fact000747" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.50</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zz6dJWbG6832" title="Warrants Outstanding, Weighted Average Exercise Price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-31_custom_ExercisePriceRangeThreeMember_custom_WarrantThreeMember" id="Fact000749" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.80</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z8AtC8v8Smag" title="Warrants Exercisable, Number Exercisable"><ix:nonFraction name="KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber" contextRef="AsOf2025-03-31_custom_ExercisePriceRangeThreeMember_custom_WarrantThreeMember" id="Fact000751" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">108,500</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z9iVFZbxptK8" title="Warrants Exercisable, Average Remaining Contractual Life (in years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_WarrantThreeMember_custom_ExercisePriceRangeThreeMember" format="ixt-sec:duryear" id="Fact000753" name="KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms">4.50</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zA4BYzGpUTV3" title="Warrants Exercisable, Weighted Average Exercise Price"><ix:nonFraction name="KAPA:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_custom_ExercisePriceRangeThreeMember_custom_WarrantThreeMember" id="Fact000755" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.17</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcPQleayNeF9" title="Range of exercise prices lower range"><ix:nonFraction name="KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit" contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember" id="Fact000757" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>&#8211; <span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhYijr2DKKNa" title="Range of exercise prices upper range"><ix:nonFraction name="KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember" id="Fact000759" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.80</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z18mFrjx5gP8" title="Warrants Outstanding, Number Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2025-03-31_us-gaap_WarrantMember" id="Fact000761" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,543,188</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmwVo1Ycqmaa" title="Warrants Outstanding, Average Remaining Contractual Life (in years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact000763" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.22</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgKuGxXlQv4k" title="Warrants Outstanding, Weighted Average Exercise Price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-31_us-gaap_WarrantMember" id="Fact000765" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.33</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8ZAoGVLPSL5" title="Warrants Exercisable, Number Exercisable"><ix:nonFraction name="KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber" contextRef="AsOf2025-03-31_us-gaap_WarrantMember" id="Fact000767" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">793,188</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsxWURbruItf" title="Warrants Exercisable, Average Remaining Contractual Life (in years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact000769" name="KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms">1.72</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zycoAar2cEA2" title="Warrants Exercisable, Weighted Average Exercise Price"><ix:nonFraction name="KAPA:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_us-gaap_WarrantMember" id="Fact000771" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.03</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A9_zrc89PTGlkuh" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"></p>


<ix:exclude><!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>Warrant Grants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">On
January 14, 2025, as amended on January 16, 2025, the Company entered into a securities purchase agreement (&#8220;SPA&#8221;) and
registration rights agreement with a select investor. In connection with the agreement, on January 16, 2025, the Company issued the
investor a pre-funded warrant to purchase up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_ztgVNiX7CVa8" title="Warants to purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember_custom_PreFundedWarrantMember_us-gaap_InvestorMember" id="Fact000773" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></span>
shares of the Company&#8217;s common stock at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zbLWTlofQhri" title="Exercisable price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember_custom_PreFundedWarrantMember_us-gaap_InvestorMember" id="Fact000775" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>
per share. The warrant is immediately exercisable and will expire when exercised in full. The investor also received a warrant to
purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zVTnO8Dz05yl" title="Warrants to purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember_us-gaap_InvestorMember" id="Fact000777" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750,000</ix:nonFraction></span>
shares of the Company&#8217;s common stock at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zaF9XPqLZssj" title="Exercisable price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember_us-gaap_InvestorMember" id="Fact000779" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.40</ix:nonFraction></span>
per share. <span id="xdx_90B_ecustom--ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_c20250114__20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zNBsOczw7Ic8" title="Warrants exercisable description"><ix:nonNumeric contextRef="From2025-01-142025-01-14_custom_SecurityPurchaseAgreementMember_custom_PreFundedWarrantMember" id="Fact000781" name="KAPA:ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription">The
warrant will be exercisable six months from the date of issuance and will expire five years from the issuance
date.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">On
January 16, 2025, the Company issued a warrant to purchase common stock to the underwriters of the SPA for the purchase of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zA8uUcE7iKkb" title="Warrant to purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember_custom_UnderwritersMember" id="Fact000783" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">175,000</ix:nonFraction></span>
shares of the Company&#8217;s common stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zx1C0yWejQql" title="Exercisable price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-01-14_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember_custom_UnderwritersMember" id="Fact000785" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.40</ix:nonFraction></span>
per share. The warrant vested upon grant. The warrant was issued to the underwriters as they were the placement agents for the SPA
noted above. <span id="xdx_90D_ecustom--ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_c20250114__20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_z8Aln3v8AWn7" title="Warrants exercisable description"><ix:nonNumeric contextRef="From2025-01-142025-01-14_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember_custom_UnderwritersMember" id="Fact000787" name="KAPA:ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription">The
warrant expires five years from the date of grant.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><i>Warrant Exercises</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">During the three months ended
March 31, 2025, the SPA investor exercised <span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zKRCDrGnU1t7" title="Warrants exercised"><ix:nonFraction name="KAPA:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" contextRef="From2025-01-012025-03-31_custom_PrefundedWarrantsMember" id="Fact000789" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,010,000</ix:nonFraction></span> shares of the pre-funded warrant, and as of March 31, 2025, there <span id="xdx_90C_ecustom--WarrantsUnexercised_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zp3x1ohmSLoe" title="Warrants unexercised"><ix:nonFraction name="KAPA:WarrantsUnexercised" contextRef="AsOf2025-03-31_custom_PrefundedWarrantsMember" id="Fact000791" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">490,000</ix:nonFraction></span> shares
remained unexercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">The intrinsic value for warrant
shares outstanding as of March 31, 2025 was $<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pn3n3_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQaYqcEIcBM4" title="Warrant shares outstanding, intrinsic value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2025-03-31_us-gaap_WarrantMember" id="Fact000793" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">458</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><span style="text-decoration: underline">Common
Stock to be Issued</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company has entered into
agreements with certain vendors as describes in Note 3 that require the issuance of additional shares of common stock based upon a
defined true calculation.&#160;&#160; As of March 31, 2025, the vendors became due an aggregate of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250331_zz5iCA03Uz5f" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-01to2025-03-31" id="Fact000795" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">551,100</ix:nonFraction></span>
shares of common stock with an aggregate fair value of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250101__20250331_zolkGKn0U2Pd" title="Number of shares issued, fair value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-01to2025-03-31" id="Fact000797" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">484</ix:nonFraction></span>.
The shares were issued in April 2025 and have been reflected as common stock issuable as of March 31, 2025.&#160; See further
discussion at Note 5.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000799" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z5LoqcZiAgz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_827_z2spAiTwEO9h">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i><span style="text-decoration: underline">Kairos Exclusive License Agreements with
Cedars-Sinai Medical Center (Cedars)</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Company has entered into four Exclusive License
Agreements with Cedars, each of which grants the Company licensing rights with respect to certain patent rights owned by Cedars as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Methods of use of compounds that bind to RelA of NFkB;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Composition and methods for treating fibrosis;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Compositions and methods for treating cancer and autoimmune diseases; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Method of generating activated T cells for cancer therapy.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">For each of the exclusive license agreement in items
1, 2 and 3, the Company was required to pay an initial license fee of $<span id="xdx_90C_ecustom--LicenseFee_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zq9YVMHPZyNj" title="License fee"><ix:nonFraction name="KAPA:LicenseFee" contextRef="From2025-01-012025-03-31_custom_LicenseAgreementMember" id="Fact000801" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></span>, reimburse Cedars for patent protection costs ranging from approximately
$<span id="xdx_90B_ecustom--PatentProtectionCosts_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zO00ZMtnBIj7" title="Patent protection costs"><ix:nonFraction name="KAPA:PatentProtectionCosts" contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MinimumMember" id="Fact000803" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></span> to $<span id="xdx_90C_ecustom--PatentProtectionCosts_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zZ6XSFEu0tn4" title="Patent protection costs"><ix:nonFraction name="KAPA:PatentProtectionCosts" contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MaximumMember" id="Fact000805" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61</ix:nonFraction></span>, pay an annual maintenance fee of $<span id="xdx_90A_eus-gaap--CostMaintenance_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zHsBuWgyXUN6" title="Annual maintenance fee"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2025-01-012025-03-31_custom_LicenseAgreementMember" id="Fact000807" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></span>, and pay royalties based on <span id="xdx_90A_ecustom--RoyaltyPercentage_pid_dp_uPure_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zTm78Hf66O35" title="Royalty percentage"><ix:nonFraction name="KAPA:RoyaltyPercentage" contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember" id="Fact000809" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.75</ix:nonFraction></span>% of net sales and pay other non-royalty sublicense fees
ranging from <span id="xdx_901_ecustom--OtherNonroyaltySublicenseFeesPercentage_pid_dp_uPure_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_ze8A7Ebqt32c" title="Other non-royalty sublicense fees percentage"><ix:nonFraction name="KAPA:OtherNonroyaltySublicenseFeesPercentage" contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MinimumMember" id="Fact000811" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% to <span id="xdx_905_ecustom--OtherNonroyaltySublicenseFeesPercentage_pid_dp_uPure_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zCJ3urpOvibi" title="Other non-royalty sublicense fees percentage"><ix:nonFraction name="KAPA:OtherNonroyaltySublicenseFeesPercentage" contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MaximumMember" id="Fact000813" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">35</ix:nonFraction></span>% of sales of products. In addition, for items 1, 2 and 3, the Company is required to pay Cedars based on the following
milestones:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">$<span id="xdx_906_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--PhaseOneClinicalTrialMember_z7QHM5phOP6e" title="Payment for milestone"><ix:nonFraction name="KAPA:PaymentForMilestones" contextRef="From2025-01-012025-03-31_custom_PhaseOneClinicalTrialMember" id="Fact000815" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></span> upon the successful completing of Phase I clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">$<span id="xdx_907_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemOneAndTwoMember__us-gaap--AwardTypeAxis__custom--PhaseTwoMember_zjVI82Unn4m7" title="Payment for milestone"><ix:nonFraction name="KAPA:PaymentForMilestones" contextRef="From2025-01-012025-03-31_custom_ItemOneAndTwoMember_custom_PhaseTwoMember" id="Fact000817" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></span> (for items 1 and 2) and $<span id="xdx_907_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemThreeMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_zm7vZWoeqq6a" title="Payment for milestone"><ix:nonFraction name="KAPA:PaymentForMilestones" contextRef="From2025-01-012025-03-31_custom_ItemThreeMember_custom_PhaseTwoClinicalTrialMember" id="Fact000819" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></span> (for item 3) upon the successful completing of Phase II clinical trial for a product and receipt of Food and Drug Administration (&#8220;FDA&#8221;) approval for a Phase III clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">$<span id="xdx_90F_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemOneAndTwoMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zvySZwFkR5ei" title="Payment for milestone"><ix:nonFraction name="KAPA:PaymentForMilestones" contextRef="From2025-01-012025-03-31_custom_ItemOneAndTwoMember_us-gaap_NonUsMember" id="Fact000821" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></span> upon receipt of FDA approval of a new drug application or equivalent foreign regulatory approval in a non-United States major commercial market; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">$<span id="xdx_904_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemOneAndTwoMember_zxmGz7iKTrQf" title="Payment for milestone"><ix:nonFraction name="KAPA:PaymentForMilestones" contextRef="From2025-01-012025-03-31_custom_ItemOneAndTwoMember" id="Fact000823" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></span> upon cumulative net sales exceeding $<span id="xdx_906_eus-gaap--Revenues_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemOneAndTwoMember_zuBk6S1wUUk9" title="Net sales"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_custom_ItemOneAndTwoMember" id="Fact000825" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,000</ix:nonFraction></span>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">For the exclusive license agreement in item 4, the
Company is required to pay an initial license fee of $<span id="xdx_907_ecustom--LicenseFee_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zStwRHN7l564" title="License fee"><ix:nonFraction name="KAPA:LicenseFee" contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_custom_ItemFourMember" id="Fact000827" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span> upon raising $<span id="xdx_90E_ecustom--MinimumRequirermentOfCapital_iI_pn3n3_c20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zEktpNNKeepl" title="Minimum requirerment of capital"><ix:nonFraction name="KAPA:MinimumRequirermentOfCapital" contextRef="AsOf2025-03-31_custom_ExclusiveLicenseAgreementMember_custom_ItemFourMember" id="Fact000829" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></span> in capital, pay an annual maintenance fee of $<span id="xdx_90E_eus-gaap--CostMaintenance_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zt1mUwE1r7mc" title="Annual maintenance fee"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_custom_ItemFourMember" id="Fact000831" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></span>, pay
royalties based on <span id="xdx_902_ecustom--RoyaltyPercentage_pid_dp_uPure_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zuxeb3PHTeej" title="Royalty percentage"><ix:nonFraction name="KAPA:RoyaltyPercentage" contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_custom_ItemFourMember" id="Fact000833" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.25</ix:nonFraction></span>% of patent product sales and <span id="xdx_903_ecustom--PatentProductSalesPercentage_pid_dp_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemFourMember_z4rbAzw48kCi" title="Patent product sales"><ix:nonFraction name="KAPA:PatentProductSalesPercentage" contextRef="From2025-01-012025-03-31_custom_ItemFourMember" id="Fact000835" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.5</ix:nonFraction></span>% of other sales and pay other non-royalty sublicense fees ranging from <span id="xdx_902_ecustom--OtherNonroyaltySublicenseFeesPercentage_pid_dp_uPure_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zCXg6uA3KWkl" title="Other non-royalty sublicense fees percentage"><ix:nonFraction name="KAPA:OtherNonroyaltySublicenseFeesPercentage" contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MinimumMember_custom_ItemFourMember" id="Fact000837" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% to
<span id="xdx_908_ecustom--OtherNonroyaltySublicenseFeesPercentage_pid_dp_uPure_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zKORXKiUKBQ6" title="Other non-royalty sublicense fees percentage"><ix:nonFraction name="KAPA:OtherNonroyaltySublicenseFeesPercentage" contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MaximumMember_custom_ItemFourMember" id="Fact000839" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">35</ix:nonFraction></span>%. In addition, the Company is required to pay Cedars based on the following milestones:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">$<span id="xdx_901_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--PhaseOneClinicalTrialMember_z9XuO3ozOqoi" title="Payment for milestone"><ix:nonFraction name="KAPA:PaymentForMilestones" contextRef="From2025-01-012025-03-31_custom_PhaseOneClinicalTrialMember" id="Fact000841" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></span> upon the successful completing of Phase I clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">$<span id="xdx_909_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemFourMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_zMvzfWAhHkea" title="Payment for milestone"><ix:nonFraction name="KAPA:PaymentForMilestones" contextRef="From2025-01-012025-03-31_custom_ItemFourMember_custom_PhaseTwoClinicalTrialMember" id="Fact000843" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></span> upon the successful completing of Phase II clinical trial and receipt of Food and Drug Administration (&#8220;FDA&#8221;) or equivalent regulatory agency in another jurisdiction approval for a Phase III clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">$<span id="xdx_90C_ecustom--PaymentForMilestones_pn3n3_c20240101__20241231__srt--ProductOrServiceAxis__custom--ItemFourMember__dei--LegalEntityAxis__custom--FoodAndDrugAdministrationMember_znidBqZg6Akc" title="Payment for milestone"><ix:nonFraction name="KAPA:PaymentForMilestones" contextRef="From2024-01-012024-12-31_custom_ItemFourMember_custom_FoodAndDrugAdministrationMember" id="Fact000845" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></span> upon receipt of FDA approval of a new drug application; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">$<span id="xdx_905_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemFourMember_zjtqcDBsC8y4" title="Payment for milestone"><ix:nonFraction name="KAPA:PaymentForMilestones" contextRef="From2025-01-012025-03-31_custom_ItemFourMember" id="Fact000847" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,500</ix:nonFraction></span> upon cumulative net sales exceeding $<span id="xdx_904_eus-gaap--Revenues_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemFourMember_zqZUiMfZ5r5i" title="Net sales"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_custom_ItemFourMember" id="Fact000849" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50,000</ix:nonFraction></span>.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i><span style="text-decoration: underline">Enviro Therapeutics</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On June 2, 2021, the Company&#8217;s wholly owned
subsidiary, Enviro,  entered into two Exclusive License Agreements with Cedars, which granted Enviro exclusive
licensing rights (which include the right to sublicense) with respect to certain patent rights owned by Cedars, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">an Exclusive License Agreement (the &#8220;Enviro-Cedars License Agreement (Mitochondrial DNA)&#8221;) for Enviro to develop, manufacture, use and sell products utilized or derived from patent rights worldwide related to the &#8220;Compositions and Methods for Treating Diseases and Conditions by Depletion of Mitochondrial DNA from Circulation and for Detection of Mitochondrial DNA&#8221; invented by Dr. Neil Bhowmick and others; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">an Exclusive License Agreement (the &#8220;Enviro-Cedars License Agreement (Endoglin Antagonism)&#8221; and, collectively with the Enviro-Cedars License Agreement (Mitochondrial DNA), the &#8220;Enviro-Cedars License Agreements&#8221;) for Enviro to develop, manufacture, use and sell products utilized or derived from the patent rights and technical information worldwide related to the &#8220;Sensitization of Tumors to Therapies Through Endoglin Antagonism&#8221; invented by Dr. Neil Bhowmick and others.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">In exchange for each of the licenses, Enviro is required
to pay an upfront license fee in the mid four-figures and low-five figures, respectively. Enviro is also required to reimburse Cedars
for the costs in the mid-to-high six figures incurred in the prosecution of the patent rights subject to the Enviro-Cedars License Agreements
prior to the date of execution of such agreements, and certain costs and fees then outstanding aggregating in the low-six figures owed
by Kairos pursuant to the Kairos-Cedars License Agreements. Pursuant to the Enviro-Cedars License Agreements, Cedars shall also receive
royalty payments of a mid-single-digit percentage of net sales of products associated with the licensed patent right and less than one
percent of net sales of other products derived from Cedars&#8217; technical information, with a minimum annual royalty fee in the low
five-digits due beginning on the third anniversary of the effective date of the Enviro-Cedars License Agreements. To the extent Enviro
derives non-royalty sublicensing revenues, a high single-digit to low double-digit percentage of such revenues would be due and payable
to Cedars, with the actual percentage of such revenues dependent on the stage of FDA authorization at the time the sublicense revenue
is generated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Enviro is also required to pay Cedars in connection
with achieving the following Payment Milestones relating to products derived from the patent rights: successful completion of a Phase
I clinical trial; successful completion of a Phase II clinical trial, receipt of FDA approval, and approval for a Phase III clinical trial;
FDA approval of an NDA or BLA; cumulative net sales exceeding $<span id="xdx_90E_eus-gaap--Revenues_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--PhaseThreeClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--EnviroCedarsLicenseAgreementsMember_zpFIc1ZuVdAa" title="Net sales"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_custom_PhaseThreeClinicalTrialMember_custom_EnviroCedarsLicenseAgreementsMember" id="Fact000851" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50,000</ix:nonFraction></span>; and cumulative net sales exceeding $<span id="xdx_907_eus-gaap--Revenues_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemOneAndTwoMember__us-gaap--AwardTypeAxis__custom--PhaseThreeMember__us-gaap--TypeOfArrangementAxis__custom--EnviroCedarsLicenseAgreementsMember_zauTHZg3VKHk" title="Net sales"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_custom_ItemOneAndTwoMember_custom_PhaseThreeMember_custom_EnviroCedarsLicenseAgreementsMember" id="Fact000853" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100,000</ix:nonFraction></span>. If all of these payment
milestones are met among both of the Enviro-Cedars License Agreements, the required milestone payments would total in the mid-to-high
seven-figures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Pursuant to the Enviro-Cedars License Agreements,
Enviro is obligated to meet the following Commercialization Milestones. Pursuant to the Enviro-Cedars License Agreement (Endoglin Antagonism),
Enviro is obligated to <span id="xdx_902_ecustom--LicenseAgreementDescription_c20250101__20250331_zOLJGelSyXYa" title="License agreement description"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000855" name="KAPA:LicenseAgreementDescription">(1) obtain an IND for a patent product within 1 year of the effective date of the agreement, (2) commence a Phase
II trial within 2 years of the effective date of the agreement, and (3) submit an NDA or BLA to the FDA or equivalent regulatory agency
in another jurisdiction within 7 years of the effective date of the agreement. Pursuant to the Enviro-Cedars License Agreement (Mitochondrial
DNA), Enviro is obligated to (1) complete preclinical studies of a patent product within 2 years of the effective date of the agreement,
(2) complete toxicology studies within 2.5 years of the effective date of the agreement, (3) obtain IND within 3 years of the effective
date of the agreement, (4) begin a Phase I trial within 4 years of the effective date of the agreement, and (5) submit an NDA or BLA to
the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. If the Commercialization
Milestones are not met or extended, Cedars may convert the exclusive licenses into non-exclusive licenses or to a co-exclusive licenses
or terminate the licenses.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Enviro-Cedars License Agreements will, unless
sooner terminated, continue in effect on a country-by-country basis until the last of the patents covering the patent rights or future
patent rights expires. Under the terms of the Enviro-Cedars License Agreements, unless waived by Cedars, the agreements would automatically
terminate: (a) if Enviro ceases, dissolves or winds up its business operations; (b) if performance by either party jeopardizes the licensure,
accreditation or tax exempt status of Cedars or the agreement is deemed illegal by a governmental body; (c) within 30 days for non-payment
of royalties or if Enviro fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (d)
within 60 days of Cedars&#8217; failure to cure any breach or default of a material obligation under the agreements; (e) within 90 days
of Enviro&#8217;s failure to cure any breach or default of a material obligation under the agreements; or (f) upon mutual written agreement
of the parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Matters</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Company&#8217;s knowledge, it is not currently the subject of any material legal proceeding. In the future, the Company may be involved
in actual and/or threatened legal proceedings, claims, investigations and government inquiries arising in the ordinary course of our
business, including legal proceedings, claims, investigations and government inquiries involving intellectual property, data privacy
and security, other torts, illegal or objectionable content, consumer protection, securities, employment, contractual rights, civil rights
infringement, false or misleading advertising, or other legal claims relating to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000857" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_809_eus-gaap--SegmentReportingDisclosureTextBlock_z8XkEY1EvlC1" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>NOTE
6 &#8211; <span id="xdx_82A_zlsq603MtRA1">SEGMENT INFORMATION</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Company operates and manages its business as <span id="xdx_906_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20250101__20250331_zFNtCtNOXoy5" title="Number of reportable segments"><ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2025-01-01to2025-03-31" id="Fact000859" format="ixt-sec:numwordsen" decimals="INF" unitRef="Integer">one</ix:nonFraction></span>
reportable segment and operates as a clinical-stage biopharmaceutical company. The Company&#8217;s current focus is on developing immunotherapy
and cell therapies for the treatment of cancer. The Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) is the Chief Executive
Officer, who reviews financial information presented and decides how to allocate resources based on net income (loss). Net income (loss)
is used for evaluating financial performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Significant segment expenses include research and
development, officer compensation, insurance, and stock-based compensation. Operating expenses include all the remaining costs necessary
to operate our business, which primarily include external professional services and other administrative expenses. The following table
presents the significant segment expenses and other segment items regularly reviewed by our CODM:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000861" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zwOoPqF4lB2d" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="xdx_8BF_zfYjnLQ59nya" style="display: none">SCHEDULE
OF SEGMENT EXPENSES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20250101__20250331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zE3wkZgjfXWe" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20240331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zFLJtujBKoZ7" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Three Months Ended</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">March 31,</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Revenues_pn3n3_zjIfQN6O33e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0863">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Less:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_zJIVhMBFVLx1" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Research and development, less officer compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-03-31_us-gaap_OperatingSegmentsMember" id="Fact000866" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">448</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-03-31_us-gaap_OperatingSegmentsMember" id="Fact000867" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">165</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OfficersCompensation_pn3n3_zBkkTeuBOPTh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Officer compensation and wages</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2025-01-012025-03-31_us-gaap_OperatingSegmentsMember" id="Fact000869" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">101</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0870">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InsuranceRecoveries_pn3n3_zmOpMxR28Ti6" style="vertical-align: bottom; background-color: White">
    <td>Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InsuranceRecoveries" contextRef="From2025-01-012025-03-31_us-gaap_OperatingSegmentsMember" id="Fact000872" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">105</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InsuranceRecoveries" contextRef="From2024-01-012024-03-31_us-gaap_OperatingSegmentsMember" id="Fact000873" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_z8UGnZMYgXXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-03-31_us-gaap_OperatingSegmentsMember" id="Fact000875" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingExpenses_pn3n3_zgPWkL9ZBq17" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-012025-03-31_us-gaap_OperatingSegmentsMember" id="Fact000878" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">536</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-03-31_us-gaap_OperatingSegmentsMember" id="Fact000879" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">114</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherOperatingIncomeExpenseNet_pn3n3_zgeUMAx9qARf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other income (expenses)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="From2025-01-012025-03-31_us-gaap_OperatingSegmentsMember" id="Fact000881" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="From2024-01-012024-03-31_us-gaap_OperatingSegmentsMember" id="Fact000882" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">36</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_pn3n3_ziiUdJ3hBZDe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_OperatingSegmentsMember" id="Fact000884" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,262</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_OperatingSegmentsMember" id="Fact000885" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">323</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A6_z6TV6oU9LaXd" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000887" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zzUq306wPoH1" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>NOTE 7 &#8211; <span id="xdx_825_zUsElv5Zo8xd">SUBSEQUENT EVENTS</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On
April 1, 2025, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__dei--LegalEntityAxis__custom--CrossCurrentCapitalLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zF0NRtAgXVFj" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-04-012025-04-01_custom_CrossCurrentCapitalLLCMember_us-gaap_SubsequentEventMember" id="Fact000889" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">166,541</ix:nonFraction></span>
shares of its common stock to Cross Current in connection with its agreement with Cross Current (see Notes 3 and 4).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On April 24, 2025, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250424__20250424__dei--LegalEntityAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znBlc2wdF5hg" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-04-242025-04-24_custom_HelenaGlobalInvestmentOpportunitiesILTDMember_us-gaap_SubsequentEventMember" id="Fact000891" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">384,459</ix:nonFraction></span>
shares of its common stock to Helena in connection with its agreement with Helena (see Notes 3 and 4).</p>

</ix:nonNumeric><p id="xdx_811_zGjj8WuN3wCh" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="a_008"></span><b>Item 2. Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">(in thousands, except for share amounts and per share
data)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"><i>You should read the following
discussion and analysis of our financial condition and results of operations (the &#8220;MD&amp;A&#8221;) together with our unaudited
consolidated financial statements and related notes appearing in Part I, Item 1 of this Quarterly Report on Form 10-Q (the &#8220;Quarterly
Report&#8221;), and with our audited financial statements and notes thereto for the year ended December 31, 2024, included in our annual
report on Form 10-K filed with the Securities Exchange Commission (the &#8220;SEC&#8221;) on April 15, 2025, as amended (the &#8220;2024
Annual Report&#8221;)</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; text-indent: 0pt; margin-bottom: 0pt"><b><i>Special
Note Regarding Forward-Looking Statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><i>In addition to historical information, some of
the statements contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect
to our plans and strategy for our business, constitute forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;). We have based these forward-looking statements on our current expectations and any projections about future events. The following
information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Quarterly Report,
along with the risks identified in the Prospectus under the title &#8220;Risk Factors&#8221; and in our other filings with the Securities
Exchange Commission (the &#8220;SEC&#8221;).</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><i>We caution you that forward-looking statements
are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development
of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report. Statements
made herein are as of the date of the filing of this Quarterly Report with the SEC and should not be relied upon as of any subsequent
date. Even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are
consistent with the forward-looking statements contained in this Quarterly Report, they may not be predictive of results or developments
in future periods. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or
revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements
may be based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">We are a clinical-stage biopharmaceutical company
advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Our mission is to advance our portfolio of innovative
therapeutics to reverse key mechanisms of therapeutic resistance and immune suppression and transform the way cancer is treated. We have
leveraged molecular insights of the mechanisms of therapeutic resistance and immune suppression to develop a new class of novel drugs
that we expect will target drug resistance and checkpoints of immune suppression. As of the date of this Annual Report, our product candidates
have not been approved as safe or effective by the FDA or any other comparable foreign regulator.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Since inception, our operations have focused on organizing
and staffing our Company, business planning, raising capital, acquiring and developing our technology, establishing our intellectual property
portfolio, identifying potential product candidates, and undertaking preclinical and clinical studies and manufacturing. We do not have
any products approved for sale and have not generated any revenue from product sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Since inception, we have incurred significant operating
losses. Our net losses were $1,262 and $2,603 for the three months ended March 31, 2025 and the year ended December 31, 2024, respectively.
As of March 31, 2025, we had an accumulated deficit of $10,077. We expect to continue to incur significant and increasing expenses and
operating losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical
development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain
and expand our intellectual property portfolio, hire additional research and development and business personnel, and operate as a public
company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">We
will not generate revenue from product sales unless and until we successfully complete our clinical trials and obtain
regulatory approval for our product candidates. In addition, if we obtain regulatory approval for our product candidates and do not
enter into a third-party commercialization partnership, we will likely incur significant expenses related to developing our
commercialization capability to support product sales, marketing, manufacturing, and distribution activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">As a result, we will need substantial additional funding
to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if
ever, we expect to finance our operations through a combination of public or private equity offerings and debt financings and other sources,
such as potential collaboration agreements, strategic alliances and licensing arrangements. We may be unable to raise additional funds
or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to raise capital or enter
into such agreements as and when needed could have a material adverse effect on our business, results of operations and financial condition.
No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory
to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the
case of debt financing, or cause substantial dilution for our stockholders, in case of equity financing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>Recent Developments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i><span style="text-decoration: underline">Equity Line of Credit Agreement (ELOC)</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On
November 12, 2024, we entered into an ELOC agreement (the &#8220;ELOC Agreement&#8221;) with Helena Global Investment Opportunities
I LTD (&#8220;Helena&#8221;), pursuant to which Helena agreed to purchase from the Company up to $30,000 of common stock (the
&#8220;ELOC Shares&#8221;). The Company issued 670,641 shares of restricted common stock (the &#8220;Commitment Fee Shares&#8221;)
to Helena as a &#8220;Commitment Fee&#8221; for the ELOC Agreement. The ELOC Agreement will be available for the Company&#8217;s
use at such time following the filing and effectiveness of a resale registration statement registering the ELOC Shares for resale.
At the time of effectiveness of the resale registration statement (the &#8220;Effective Date&#8221;), the Commitment Fee Shares will
be subject to a &#8220;true-up&#8221; pursuant to which, in the event the shares are valued at less than $900 on the Effective Date,
additional shares will be issued to Helena to bring the ELOC Shares to the full $900 value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The ELOC Agreement will terminate upon the following
events: (i) the first day of the month next following the 36-month anniversary of the date of the ELOC Agreement or (ii) the date on which
Helena has purchased the full $30,000 of ELOC Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The ELOC Agreement may be terminated by the Company
after its commencement, at the Company&#8217;s discretion, provided that there are no advance notices outstanding for which common stock
has yet to be issued, and the Company has paid all amounts owed to Helena under the ELOC Agreement, including the Commitment Fee shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i><span style="text-decoration: underline">January 2025 PIPE Offering</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On January 14, 2025, the Company entered into a securities
purchase agreement (the &#8220;Purchase Agreement&#8221;) and registration rights agreement (the &#8220;Registration Rights Agreement&#8221;)
with the investor name therein (the &#8220;Investor&#8221;) for the sale and issuance of 2,500,000 units (the &#8220;Pre-Funded Units&#8221;),
with each Pre-Funded Unit consisting of a pre-funded warrant (the &#8220;Pre-Funded Warrant&#8221;) to purchase one share of common stock,
exercisable for $0.001 per share, and a common warrant (the &#8220;Common Warrant&#8221;) to purchase one and one half shares of common
stock, exercisable at $1.40 per share (the &#8220;January 2025 PIPE Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On January
16, 2025, the Company closed the January 2025 PIPE Offering for a total purchase price of $3,498 (or $1.399 per Pre-Funded Unit), with
an additional $2 payable upon the Investor&#8217;s exercise of the Pre-Funded Warrants in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">In advance of closing, on January 16, 2025, the Company
and the Investor entered into an amendment and restatement to the Purchase Agreement (the &#8220;A&amp;R Purchase Agreement&#8221;), which
amended the terms of the Purchase Agreement to include a requirement that the Company obtain shareholder approval prior to issuing in
excess of 19.99% of the Company&#8217;s common stock and also amended the Common Warrants to make them immediately exercisable and reduce
the exercise period from 5.5 years to five years. Other terms of the Purchase Agreement and Common Warrants remained the same.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Boustead and D. Boral Capital LLC (&#8220;D. Boral&#8221;)
acted as co-placement agents for the January 2025 PIPE Offering. In conjunction therewith, on January 16, 2025, the Company entered into
a Placement Agent Agreement with Boustead (the &#8220;Placement Agent Agreement&#8221;). Under the terms of the Placement Agent Agreement,
at closing, the Company paid the Placement Agents (i) a cash commission equal to 8% of the gross proceeds (including a 1% non-accountable
expense fee) and (ii) warrants to purchase a total of 175,000 shares of common stock, exercisable at $1.40 per share, with the total cash
and warrant compensation split equally between Boustead and D. Boral.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On January 20, 2025, the Company obtained the approval
of 55.4% of the shareholders (the &#8220;Majority Shareholders&#8221;) for the issuance in excess of 19.99% of the Company&#8217;s common
stock at a price below market value, in compliance with Rule 713 of the NYSE American LLC Company Guide. On February 10, 2025, the Company
filed the definitive Schedule 14C and the shareholder approval became effective on March 1, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>Components of Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>Net Sales</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">We have not generated any sales to date. No revenue
was recorded from any sources during the three months ended March 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>Operating Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Our operating expenses consist of (i) research and
development expenses and (ii) general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>Research and Development Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Dr. Ramachandran Murali is our Vice President of Research
and Development. Dr. Murali is a doctor and scientist at Cedars-Sinai Medical Center, and is the inventor, with others, of three of the
patented technologies that are subject to the Kairos-Cedars license agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">We
are engaged in rolling out our Phase 1 and Phase 2 clinical trials for ENV 105 and a Phase 1 trial for KROS 201. In addition, we
are continuously performing preclinical research including animal models of disease, medicinal chemistry laboratory studies,
formulation, and toxicology and biodistribution studies. Our clinical development costs may vary significantly based on factors such
as: per patient trial costs; the number of trials required for approval; the number of sites included in the trials; the location
where the trials are conducted; the length of time required to enroll eligible patients; the number of patients that participate in
the trials; the number of doses that patients receive; the drop-out or discontinuation rates of patients; potential additional
safety monitoring requested by regulatory agencies; the duration of patient participation in the trials and follow-up; the cost and
timing of manufacturing our product candidates; the phase of development of our product candidates; and the efficacy and safety
profile of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The
successful development and commercialization of product candidates is highly uncertain. This is due to the numerous risks and uncertainties
associated with product development and commercialization, including the following: the timing and progress of nonclinical and clinical
development activities; the number and scope of nonclinical and clinical programs we decide to pursue; raising necessary additional funds;
the progress of the development efforts of parties with whom we may enter into collaboration arrangements; our ability to maintain our
current development program and to establish new ones; our ability to establish new licensing or collaboration arrangements; the successful
initiation and completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any
comparable foreign regulatory authority; the receipt and related terms of regulatory approvals from applicable regulatory authorities;
the availability of drug substance and drug product for use in production of our product candidate; establishing and maintaining agreements
with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidates are
approved; our ability to obtain and maintain patents, trade secret protection and regulatory exclusivity, both in the United States and
internationally; our ability to protect our rights in our intellectual property portfolio; the commercialization of our product candidates,
if and when approved; obtaining and maintaining third-party insurance coverage and adequate reimbursement; the acceptance of our product
candidate, if approved, by patients, the medical community and third-party payors; competition with other products; the impact of any
business interruptions to our operations, including the timing and enrollment of patients in our planned clinical trials, or to those
of our manufacturers, suppliers, or other vendors resulting from any pandemic or public health crisis; and a continued acceptable safety
profile of our therapies following approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">A change in the outcome of any of these variables
with respect to the development of our product candidates could significantly change the costs and timing associated with the development
of that product candidate. We may never succeed in obtaining regulatory approval for any of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>General and administrative expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">General and administrative expenses consist primarily
of salaries and related costs for personnel in executive, finance, corporate and business development, as well as administrative functions.
General and administrative expenses also include legal fees relating to patent, corporate, IPO-related matters, and reporting matters;
professional fees for accounting, auditing, tax and administrative consulting services; insurance costs; administrative travel expenses;
marketing expenses and other operating costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">We anticipate that our general and administrative
expenses will increase in the future as we increase our headcount to support our business operations. We also anticipate that we will
incur increased accounting, audit, legal, regulatory, compliance, and director and officer insurance costs, as well as investor and public
relations expenses associated with being a public company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>Comparison of the Three Months Ended March 31,
2025 and 2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The following table summarizes our results of operations
for the three months ended March 31, 2025 and 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2024</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">493</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">165</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">773</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">122</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,266</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">287</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,266</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(287</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Debt discount amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Interest income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total other expenses, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(36</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,262</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(323</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>Research and Development Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The table below summarizes our research and development
expenses for the three months ended March 31, 2025 and 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Research and Development Expenses:</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2024</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left; padding-bottom: 1pt">Clinical and related expenses</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">493</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">165</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total research and development expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">493</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">165</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Research and development expenses were $493 and $165
for the three months ended March 31, 2025 and 2024, respectively. The increase in R&amp;D expenses in 2025 primarily related to our Phase
2 trial in prostate cancer beginning in 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>General and Administrative Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The table below summarizes our general and administrative
expenses for the three months ended March 31, 2025 and 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">General and Administrative Expenses:</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2024</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Stock-related expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Officer compensation and wages</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Patent related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Legal expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounting expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other professional service expenses and fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Fees relating to license agreements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Vendor advances amortization expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">240</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Intangible amortization expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">129</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">773</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">122</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">General and administrative expenses were $773 and
$122 for the three months ended March 31, 2025 and 2024, respectively. Significant changes between periods consisted of a $132 increase
in stock-related and officer compensation expenses in 2025, relating to stock awards and cash compensation earned by our officers in 2025;
and the $240 increase in vendor advance amortization expense in 2025, relating to our vendor advances in 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>Other Income (Expenses)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Other income (expenses) were $4 and $(36) for the
three months ended March 31, 2025 and 2024, respectively. In 2025, the other income was interest income earned from our money market account.
In 2024, the other expenses were interest expense of $16 and debt discount amortization of $20.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization
of assets and the settlement of liabilities and commitments in the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2025, the Company incurred a net loss of $1,262&#160;and used cash in operations of $714.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, the Company closed a private financing in which the Company received net proceeds of $3,145, and at March 31, 2025,
the Company had cash and cash equivalents totaling $3,616&#160;and shareholders&#8217; equity of $7,132. The Company expects its
current cash reserves to fund the Company&#8217;s operations for at least 12 months from the date of this filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations
in the future, which will primarily be accomplished in the near term by raising additional capital to meet the Company&#8217;s
operating needs and repay liabilities arising from normal business operations when they come due. Since inception, the Company
has funded its operations primarily through equity and debt financings and it expects to continue to rely on these sources of
capital in the future until it is able to generate revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to
the Company. Even if the Company is able to obtain additional financing, such financing may contain undue restrictions on our operations,
in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>Cash Flows</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; text-indent: 0.25in; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The table below summarizes our cash flow activities
for the three months ended March 31, 2025 and 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; text-indent: 0.25in; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">March 31,</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">March 31,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Net cash provided by (used in):</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; padding-left: 10pt"><span style="font-size: 10pt">Operating activities</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-size: 10pt">(714</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-size: 10pt">36</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-size: 10pt">Investing activities</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt"><span style="font-size: 10pt">Financing activities</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">3,058</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(89)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">Net increase (decrease) in cash</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2,344</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(53)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>Operating Activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; text-indent: 0.25in; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">During the three months ended March 31, 2025, we used
cash from operating activities of $714, compared to $36 provided during the three months ended March 31, 2024. During the three months
ended March 31, 2025, we incurred a net loss of $1,262 and had non-cash expenses of $116, compared to a net loss of $323 and non-cash
expenses of $60 during the three months ended March 31, 2024. The primary non-cash expense during both periods was stock-related expenses
totaling $76 and $20 during the three months ended March 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The net change in operating assets and liabilities
during the three months ended March 31, 2025, provided cash of $432, compared to $299 provided during the three months ended March 31,
2024. The primary source of cash relating to operating assets and liabilities during the three months ended March 31, 2025 was the decrease
in vendor advances of $636. The primary source of cash during the three months ended March 31, 2024 was the increase in accounts payable
and accrued expenses of $310.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>Financing Activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; text-indent: 0.25in; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">During the three months ended March 31, 2025, we provided
cash from financing activities of $3,058, compared to $89 used during the three months ended March 31, 2024. For the three months ended
March 31, 2025, cash provided by financing activities consisted of gross proceeds from our private financing of $3,500. Net cash used
in 2025 and 2024 consisted of the payment of deferred offering costs of $442 and $89, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span style="text-decoration: underline">Funding
Requirements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">We expect our expenses to increase substantially in
connection with our ongoing research activities, particularly as we pursue the advancement of our product candidates through clinical
trials. In addition, we expect to incur additional costs associated with operating as a public company. The timing and amount of our operating
expenditures will depend on numerous variables, including: the initiation, progress, timing, costs and results of the clinical trials
for our product candidates or any future product candidates we may develop; the initiation, progress, timing, costs and results of nonclinical
studies for our product candidates or any future product candidates we may develop; our ability to maintain our relationships with key
collaborators; the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and comparable foreign regulatory
authorities, including the potential for such authorities to require that we perform more nonclinical studies or clinical trials than
those that we currently expect or change their requirements on studies that had previously been agreed to; the cost to establish, maintain,
expand, enforce and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be
required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing any patents
or other intellectual property rights; the effect of competing technological and market developments; the costs of continuing to grow
our business, including hiring key personnel and maintain or acquiring operating space; market acceptance of any approved product candidates,
including product pricing, as well as product coverage and the adequacy of reimbursement by third-party payors; the cost of acquiring,
licensing or investing in additional businesses, products, product candidates and technologies; the cost and timing of selecting, auditing
and potentially validating a manufacturing site for commercial-scale manufacturing; the cost of establishing sales, marketing and distribution
capabilities for any product candidates for which we may receive regulatory approval and that we determine to commercialize; and our need
to implement additional internal systems and infrastructure, including financial and reporting systems.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">We
believe that our existing cash, including the net proceeds we received from the IPO and the January 2025 PIPE Offering, will enable
us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. We have based this estimate
on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. We expect
that we will continue to require additional funding to complete the clinical development and commercialization of our product
candidates, if we receive regulatory approval, and pursue in-licenses or acquisitions of other product candidates. If we receive
regulatory approval for our product candidates, we expect to incur significant commercialization expenses related to product
manufacturing, sales, marketing and distribution, depending on where we choose to commercialize ourselves.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Until such time, if ever, as we can generate substantial
product revenue, we expect to finance our cash needs through a combination of equity and debt financings, collaborations, strategic alliances,
and marketing, distribution or licensing arrangements with third parties. To the extent that we raise additional capital through the sale
of equity or convertible debt securities, ownership interest may be materially diluted, and the terms of such securities could include
liquidation or other preferences that adversely affect the rights of our current common stockholder. Debt financing and preferred equity
financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such
as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, strategic
alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies,
future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are
unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, reduce
or eliminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that
we would otherwise prefer to develop and market ourselves.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>Contractual Obligations and Commitments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>Kairos Agreement with Prevail Infoworks, Inc.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">In
August 2024, the Company entered into a master service and technology agreement with Prevail Infoworks, Inc.
(&#8220;Prevail&#8221;), pursuant to which Prevail agreed to provide certain clinical research services to the Company. As part of
the agreement, the Company was required to make an advance payment of $900 to Prevail before they begin their services. At such time
as we notify Prevail to engage their services related to the relevant clinical trial, or six months from the date of the agreement,
we will be required to pay approximately $80 per month during the time Prevail performs such clinical research services. The agreement with Prevail is subject to
cancellation at any time upon 30 days&#8217; written notice to the other party. The Company made the advance payment to Prevail in
October 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>Kairos Agreement with PreCheck Health Services,
Inc.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On
September 20, 2024, the Company entered into a bioassay services agreement (the &#8220;Bioassay Services Agreement&#8221;) with
PreCheck Health Services, Inc., a Florida-based corporation (&#8220;PreCheck&#8221;). Pursuant to the Bioassay Services Agreement,
PreCheck will provide certain biomarker screening services for the Company&#8217;s ongoing carotuximab (ENV 105) clinical trials in
order to assist the Company in identifying lung and prostate cancer patients suitable to the Company&#8217;s ongoing Phase 1
clinical trials for lung cancer patients and Phase 2 trials for patients with castrate resistant prostate cancer. In order to
identify biomarkers for patient screening and therapy monitoring using carotuximab (ENV 105), PreCheck will utilize its
SolidTumorCheck+ platform for the somatic gene expression analysis of biopsy tissue samples derived from patients with lung and
prostate cancer, as part of the Company&#8217;s ongoing clinical trials. In furtherance of these efforts, PreCheck will develop a
companion diagnostic to support its identification of such patients with a three gene PCR analysis or other genetic analysis, which
diagnostic test will then be developed and submitted to the FDA for castrate-resistant prostate cancer patients and for lung cancer
patients on Tagrisso. In exchange for PreCheck&#8217;s services, and according to the terms of the Bioassay Services Agreement, the
Company paid $900 to PreCheck as an advance for the future laboratory services to be performed. The term of the agreement is one
year from the effective date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>Kairos Agreement with CEO.CA Technologies Ltd.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On September 23, 2024, the Company entered into an
advisory and consulting services agreement (the &#8220;CEO.CA Agreement&#8221;) with CEO.CA Technologies Ltd., a Canadian company (&#8220;CEO.CA&#8221;),
pursuant to which CEO.CA will provide certain internet-based financial information and communications services for a period of one year
for a services fee of $250. The service fee is an advance on future services to be performed. The CEO.CA Agreement includes such services
as strategic news placement, news releases, interviews, monthly analytics and a video launch. The CEO.CA Agreement contains other customary
clauses, including representations and warranties, indemnification clauses and governing law clauses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>Kairos Agreement with Belair Capital Advisors
Inc.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On September 23, 2024, the Company entered into a
strategic advisory agreement (the &#8220;Strategic Advisory Agreement&#8221;) with Belair Capital Advisors Inc. (&#8220;BCA&#8221;). BCA,
a venture capital and corporate finance advisory firm, has been a long-term investor and advisor to the Company and frequently works with
early-stage pharmaceutical companies. The strategic advisory services consist of corporate strategy, market positioning and long-term
growth plans within the pharmaceutical sector, digital marketing and engagement, market research analysis and business development assistance,
among other things. During the one-year term of the Strategic Advisory Agreement, in exchange for its services, the Company will pay BCA
$365 fee and will issue BCA 50,000 RSUs, which will vest at the end of six months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>Kairos
Agreement with Cross Current Capital LLC</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On October 1, 2024, the Company entered into a consulting
agreement (the &#8220;Consulting Agreement&#8221;) with Cross Current Capital LLC, a limited liability company organized under the laws
of Puerto Rico (&#8220;Cross Current&#8221;), and Alan Masley (the &#8220;Advisor&#8221;), pursuant to which Cross Current agreed to provide
certain financial and business consulting services to the Company including, but not limited, to (a) help drafting a public company competitive
overview, (b) help preparing and/or reviewing a valuation analysis, (c) help in drafting marketing materials and presentations, (d) reviewing
the Company&#8217;s business requirements and discuss financing and businesses opportunities, (e) investor marketing, (f) investor relations
introductions, (g) legal counsel introductions, (h) auditor introductions, (i) investment banking and research introductions, (j) M&amp;A
canvassing and ways to grow the business organically, and (k) stand by capital markets advisory services. For the services rendered thereunder,
the Company agreed to pay Cross Current $200,000 in cash and agreed to issue to the Advisor restricted shares of the Company&#8217;s common
stock, issuable under the Company&#8217;s 2023 Equity Inventive Plan, in an amount equal to $500,000 (the &#8220;Shares&#8221;), which
Shares shall vest at the end of six months after issuance. The term of the Consulting Agreement is 24 months and can be extended for another
12 months upon the written consent of both parties. The Company made the $200 payment in October 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span style="text-decoration: underline">Exclusive License Agreements with Cedars</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">We have entered into four Exclusive License Agreements
with Cedars which grants us licensing rights with respect to certain patent rights owned by Cedars as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Methods of use of compounds that bind to RelA of NFkB;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Composition and methods for treating fibrosis;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Compositions and methods for treating cancer and autoimmune diseases; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Method of generating activated T cells for cancer therapy.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On June 2, 2021, our wholly owned subsidiary, Enviro,
entered into two Exclusive License Agreements with Cedars, which granted Enviro exclusive licensing rights (which include the right to
sublicense) with respect to certain patent rights owned by Cedars, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">an Exclusive License Agreement (the &#8220;Enviro-Cedars License Agreement (Mitochondrial DNA)&#8221;) for Enviro to develop, manufacture, use and sell products utilized or derived from patent rights worldwide related to the &#8220;Compositions and Methods for Treating Diseases and Conditions by Depletion of Mitochondrial DNA from Circulation and for Detection of Mitochondrial DNA&#8221; invented by Dr. Neil Bhowmick and others; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">an Exclusive License Agreement, (the &#8220;Enviro-Cedars License Agreement (Endoglin Antagonism)&#8221; and, collectively with the Enviro-Cedars License Agreement (Mitochondrial DNA), the &#8220;Enviro-Cedars License Agreements&#8221;) for Enviro to develop, manufacture, use and sell products utilized or derived from the patent rights and technical information worldwide related to the &#8220;Sensitization of Tumors to Therapies Through Endoglin Antagonism&#8221; invented by Dr. Neil Bhowmick and others.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="a_009"></span><b><span style="text-decoration: underline">Item 3. Quantitative and Qualitative Disclosures
about Market Risks.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">As a &#8220;smaller reporting company,&#8221; we are
not required to provide the information required by this Item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="a_010"></span><b><span style="text-decoration: underline">Item
4. Controls and Procedures.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span style="text-decoration: underline">Evaluation of Disclosure Controls and Procedures</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The term &#8220;disclosure controls and procedures,&#8221;
as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, refers to controls and procedures that are designed to ensure that
information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed,
summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include,
without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to a company&#8217;s
management, including its principal executive and principal financial officers, as appropriate to allow for timely decisions regarding
required disclosure. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief
Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of March 31, 2025. Based
on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were
not effective at a reasonable assurance level as of March 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">In designing and evaluating our disclosure controls
and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide
only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing
disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship
of possible disclosure controls and procedures. The design of any system of controls is also based in part upon certain assumptions about
the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential
future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies
or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur
and not be detected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span style="text-decoration: underline">Status of Previously Disclosed Material Weakness</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">As
previously disclosed in our Annual Report on Form 10-K for the period ended December 31, 2024, we identified the below material weakness in our internal controls over financial reporting:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Due to our size and stage of development, segregation of all conflicting duties is not always possible
or economically feasible. As of March 31, 2025, we continue to lack sufficient review procedures and segregation of duties such that proper review had
not been performed by someone other than the preparer, including manual journal entries, and that process documentation is lacking for
review</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">There
have been no changes in the Company&#8217;s internal control over financial reporting during the three months ended March 31, 2025
that has materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.
Management will continue to monitor and evaluate the effectiveness of our internal controls and procedures over financial reporting as
necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span style="text-decoration: underline">Changes in Internal Control over Financial Reporting</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">There have been no changes in our internal control
over financial reporting (as defined in Rules 13a-15(f) or 15d-15(f) of the Exchange Act) that occurred during the period covered by this
Quarterly Report that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
However, the Company will continue to monitor and work to address the underlying causes of material weaknesses and control deficiencies.
Such material weaknesses and control deficiencies will not be fully remediated until the Company has concluded that its internal controls
are operating effectively for a sufficient period of time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="a_011"></span><b>PART II - OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="a_012"></span><b>Item 1. Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">We are not presently party to any pending or other
threatened legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating
results, although from time to time, we may become involved in legal proceedings in the ordinary course of business. We maintain insurance
policies in amounts and with the coverage and deductibles we believe are adequate, based on the nature and risks of our business, historical
experience and industry standards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="a_013"></span><b>Item 1A. Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">As a smaller reporting company, we are not required
to provide the information required by this item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="a_014"></span><b>Item 2. Unregistered Sales of Equity Securities
and Use of Proceeds.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On September 16, 2024, our registration statement
on Form S-1 registering our common stock was declared effective by the SEC. On September 17, 2024, the Company completed the IPO of 1,550,000
shares of common stock at a price of $4.00 per share. The Company received gross proceeds of $6,200,000, before deducting underwriting
discounts and commissions and offering expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">There has been no material change in the planned use
of proceeds from our IPO as described in our final prospectus filed with the SEC on September 17, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Company issued a total of 1,055,100 shares to
Helena Global Investment Opportunities I Ltd., a Cayman Islands entity (&#8220;Helena&#8221;), in conjunction with entry into an up to
$30 million equity line of credit agreement (the &#8220;ELOC&#8221;). The 1,055,100 shares were issued in two batches, with 670,641 shares
issued at the time of entry into the ELOC and 384,459 shares issued in April 2025 upon effectiveness of the registration statement on
Form S-1 (File No. 333-286662) registering the shares issued and issuable to Helena, with such shares being issued in reliance on an exemption
from registration pursuant to Section 4(a)(2) of the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="a_015"></span>Item 3. Defaults Upon Senior Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="a_016"></span><b>Item 4. Mine Safety Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="a_017"></span><b>Item 5. Other Information.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">During the period ended March 31, 2025, none of our
directors or executive officers <span id="xdx_902_eecd--Rule10b51ArrAdoptedFlag_dbF_c20250101__20250331_zN82dF3oJZ77" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90A_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20250101__20250331_zk6HHfDS5Tzi" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:booleanfalse" id="Fact000892" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:booleanfalse" id="Fact000893" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span> or <span id="xdx_906_eecd--Rule10b51ArrTrmntdFlag_dbF_c20250101__20250331_z1Ztj9SuxzH7" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90F_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20250101__20250331_zpgiBslwVyI1" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:booleanfalse" id="Fact000894" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:booleanfalse" id="Fact000895" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> any &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading
arrangement&#8221; (as each item is defined Item 408(a) of Regulation S-K).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><b><span id="a_018"></span>Item 6. Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: bold 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></p>
                                                                                <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 1pt; width: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex3-5.htm" style="-sec-extract: exhibit">Certificate of Incorporation of Kairos Pharma, Ltd. filed with the Secretary of State of the State of Delaware, dated May 10, 2023 (incorporated by reference to Exhibit 3.5 to the Company&#8217;s Registration Statement on Form S-1, filed on August 16, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex3-6.htm" style="-sec-extract: exhibit">Bylaws of Kairos Pharma, Ltd. (Delaware) (incorporated by reference to Exhibit 3.6 to the Company&#8217;s Registration Statement on Form S-1, filed on August 16, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1962011/000149315224017318/ex4-1.htm" style="-sec-extract: exhibit">Form of Representative&#8217;s Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-1, filed on August 16, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="ex31-1.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="ex31-2.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">32.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="ex32-1.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">32.2**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="ex32-2.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">101.INS**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Inline XBRL Instance Document-the
    instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">101.SCH**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension
    Schema.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension
    Calculation Linkbase.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension
    Definition Linkbase.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension
    Label Linkbase.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension
    Presentation Linkbase.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">104*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data
    File (embedded within the Inline XBRL document and contained in Exhibit 101).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">* Filed herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">** Furnished herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span id="a_019"></span><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Date: May 14, 2025</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>KAIROS PHARMA, LTD.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><i>/s/ John S. Yu</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">John S. Yu</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Chief Executive Officer and Chairman of the Board of Directors (principal
    executive officer)</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><i>/s/ Douglas Samuelson</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Douglas Samuelson</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(Principal Financial and Accounting Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 30; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->



<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--   -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
John S. Yu, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Quarterly Report on Form 10-Q of Kairos Pharma, Ltd.;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(r) and 15d-15(r)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
May 14, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    John S. Yu</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    S. Yu</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman of the Board of Directors (principal executive officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31-2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT</B></FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Douglas Samuelson, certify that:</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Quarterly Report on Form 10-Q of Kairos Pharma, Ltd.:</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(r) and 15d-15(r) for the registrant and have:</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
May 14, 2025</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Douglas Samuelson</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Douglas
    Samuelson</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<I>Principal
    Financial and Accounting Officer</I>)</FONT></TD></TR>
  </TABLE>
<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32-1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Quarterly Report of Kairos Pharma, Ltd. (the &ldquo;Company&rdquo;) on Form 10-Q pursuant to Rule 15d-2 under the
Securities Exchange Act of 1934, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;),
I, John S. Yu, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
May 14, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    John S. Yu</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    S. Yu</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman of the Board of Directors (principal executive officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex32-2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Quarterly Report of Kairos Pharma, Ltd. (the &ldquo;Company&rdquo;) on Form 10-Q pursuant to Rule 15d-2 under the
Securities Exchange Act of 1934, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;),
I, Douglas Samuelson, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
May 14, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Douglas Samuelson</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Douglas
    Samuelson</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Financial and Accounting Officer)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>kapa-20250331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaKN+bP9z5Z8aekhvWB/bXnafyMrz56zdyMotm0WESQH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:KAPA="http://kairospharma.com/20250331" elementFormDefault="qualified" targetNamespace="http://kairospharma.com/20250331">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://kairospharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit" id="StatementsOfShareholdersEquityDeficit">
          <link:definition>00000005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Deficit) (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/BasisOfPresentation" id="BasisOfPresentation">
          <link:definition>999012 - Disclosure - BASIS OF PRESENTATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/VendorAgreements" id="VendorAgreements">
          <link:definition>999014 - Disclosure - VENDOR AGREEMENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/ShareholdersEquity" id="ShareholdersEquity">
          <link:definition>999015 - Disclosure - SHAREHOLDERS&#8217; EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999016 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/SegmentInformation" id="SegmentInformation">
          <link:definition>999017 - Disclosure - SEGMENT INFORMATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999018 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/VendorAgreementsPolicies" id="VendorAgreementsPolicies">
          <link:definition>999020 - Disclosure - VENDOR AGREEMENTS (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/VendorAgreementsTables" id="VendorAgreementsTables">
          <link:definition>999022 - Disclosure - VENDOR AGREEMENTS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/ShareholdersEquityTables" id="ShareholdersEquityTables">
          <link:definition>999023 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/SegmentInformationTables" id="SegmentInformationTables">
          <link:definition>999024 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/BasisOfPresentationDetailsNarrative" id="BasisOfPresentationDetailsNarrative">
          <link:definition>999025 - Disclosure - BASIS OF PRESENTATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" id="ScheduleOfPotentiallyDilutiveSecuritiesDetails">
          <link:definition>999026 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails" id="ScheduleOfVendorAdvancesDetails">
          <link:definition>999028 - Disclosure - SCHEDULE OF VENDOR ADVANCES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/VendorAgreementsDetailsNarrative" id="VendorAgreementsDetailsNarrative">
          <link:definition>999029 - Disclosure - VENDOR AGREEMENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails" id="ScheduleOfRestrictedCommonStockActivityDetails">
          <link:definition>999030 - Disclosure - SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/ScheduleOfWarrantActivityDetails" id="ScheduleOfWarrantActivityDetails">
          <link:definition>999031 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails" id="ScheduleOfOutstandingAndExercisableWarrantsDetails">
          <link:definition>999032 - Disclosure - SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/ShareholdersEquityDetailsNarrative" id="ShareholdersEquityDetailsNarrative">
          <link:definition>999033 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails" id="ScheduleOfSegmentExpensesDetails">
          <link:definition>999035 - Disclosure - SCHEDULE OF SEGMENT EXPENSES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/SegmentInformationDetailsNarrative" id="SegmentInformationDetailsNarrative">
          <link:definition>999036 - Disclosure - SEGMENT INFORMATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://kairospharma.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="kapa-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="kapa-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="kapa-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="kapa-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="KAPA_CommonStockToBeIssuedMember" name="CommonStockToBeIssuedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_EnviroThreapeuticsIncMember" name="EnviroThreapeuticsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_EquityLineOfCreditMember" name="EquityLineOfCreditMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_WarrantsToPurchaseCommonStockMember" name="WarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_MasterServiceAndTechnologyAgreementMember" name="MasterServiceAndTechnologyAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_BioassayServicesAgreementMember" name="BioassayServicesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_PreCheckHealthServicesIncMember" name="PreCheckHealthServicesIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_AdvisoryAndConsultingServicesAgreementMember" name="AdvisoryAndConsultingServicesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_CEOCATechnologiesLtdMember" name="CEOCATechnologiesLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_StrategicAdvisoryAgreementMember" name="StrategicAdvisoryAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_BelairCapitalAdvisorsIncMember" name="BelairCapitalAdvisorsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ConsultingAgreementMember" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_CurrentCapitalLLCMember" name="CurrentCapitalLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember" name="HelenaGlobalInvestmentOpportunitiesILTDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_PrevailInfoworksIncMember" name="PrevailInfoworksIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_CrossCurrentCapitalLLCMember" name="CrossCurrentCapitalLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_SecurityPurchaseAgreementMember" name="SecurityPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_PreFundedWarrantMember" name="PreFundedWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_PrefundedWarrantsMember" name="PrefundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_CommonWarrantsMember" name="CommonWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_TwentyTwentyThreeEquityIncentivePlanMember" name="TwentyTwentyThreeEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_FourOfficersAgreementMember" name="FourOfficersAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ThreeIndependentDirectorsMember" name="ThreeIndependentDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_DirectorAgreementsMember" name="DirectorAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_UnderwritersMember" name="UnderwritersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ExercisePriceRangeOneMember" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_WarrantOneMember" name="WarrantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ExercisePriceRangeTwoMember" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_WarrantTwoMember" name="WarrantTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ExercisePriceRangeThreeMember" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_WarrantThreeMember" name="WarrantThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ExclusiveLicenseAgreementMember" name="ExclusiveLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_PhaseOneClinicalTrialMember" name="PhaseOneClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ItemOneAndTwoMember" name="ItemOneAndTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_PhaseTwoMember" name="PhaseTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ItemThreeMember" name="ItemThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_PhaseTwoClinicalTrialMember" name="PhaseTwoClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ItemFourMember" name="ItemFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_FoodAndDrugAdministrationMember" name="FoodAndDrugAdministrationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_PhaseThreeClinicalTrialMember" name="PhaseThreeClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_EnviroCedarsLicenseAgreementsMember" name="EnviroCedarsLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_PhaseThreeMember" name="PhaseThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_VendorAdvancesNet" name="VendorAdvancesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_CommonStockToBeIssuedValue" name="CommonStockToBeIssuedValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_CommonStockToBeIssuedSharesOutstanding" name="CommonStockToBeIssuedSharesOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts" name="AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" name="StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" name="StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" name="StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" name="StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_FairValueOfVestedRestrictedStockUnits" name="FairValueOfVestedRestrictedStockUnits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_IncreaseDecreaseInVendorAdvances" name="IncreaseDecreaseInVendorAdvances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_IssuanceOfCommonSharesForDeferredOfferingCosts" name="IssuanceOfCommonSharesForDeferredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_IssuanceOfCommonSharesForVendorAdvances" name="IssuanceOfCommonSharesForVendorAdvances" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_DisclosureVendorAgreementsAbstract" name="DisclosureVendorAgreementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_DisclosureOfVendorAgreementsTextBlock" name="DisclosureOfVendorAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_VendorAdvancesPolicyTextBlock" name="VendorAdvancesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ScheduleOfVendorAdvancesTableTextBlock" name="ScheduleOfVendorAdvancesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" name="ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_DeferredOfferingAdditionalCosts" name="DeferredOfferingAdditionalCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_VendorAdvancesGross" name="VendorAdvancesGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_VendorAdvancesAccumulatedAmortization" name="VendorAdvancesAccumulatedAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_VendorAdvancesInCash" name="VendorAdvancesInCash" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_IssuanceOfCommonSharesPaidForVendorsAdvances" name="IssuanceOfCommonSharesPaidForVendorsAdvances" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_AmortizationExpenseVendorAdvances" name="AmortizationExpenseVendorAdvances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_VendorAdvancesCurrent" name="VendorAdvancesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_MonthlyPayment" name="MonthlyPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_SettlementAgreementAmount" name="SettlementAgreementAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_VendorPaymentAdvances" name="VendorPaymentAdvances" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" name="ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted" name="ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled" name="ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised" name="ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited" name="ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable" name="ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit" name="ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit" name="ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_SharesAuthorized" name="SharesAuthorized" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription" name="ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_WarrantsUnexercised" name="WarrantsUnexercised" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_FairValueOfRestrictedStockUnits" name="FairValueOfRestrictedStockUnits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_FairValueOfUnamortizedCompensation" name="FairValueOfUnamortizedCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_LicenseFee" name="LicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_PatentProtectionCosts" name="PatentProtectionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_RoyaltyPercentage" name="RoyaltyPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_OtherNonroyaltySublicenseFeesPercentage" name="OtherNonroyaltySublicenseFeesPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_PaymentForMilestones" name="PaymentForMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_MinimumRequirermentOfCapital" name="MinimumRequirermentOfCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_PatentProductSalesPercentage" name="PatentProductSalesPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_LicenseAgreementDescription" name="LicenseAgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="KAPA_PurchaseOfCommonStock" name="PurchaseOfCommonStock" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>kapa-20250331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://kairospharma.com/role/Cover" xlink:href="kapa-20250331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/BalanceSheets" xlink:href="kapa-20250331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/BalanceSheetsParenthetical" xlink:href="kapa-20250331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/StatementsOfOperations" xlink:href="kapa-20250331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit" xlink:href="kapa-20250331.xsd#StatementsOfShareholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/StatementsOfCashFlows" xlink:href="kapa-20250331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/BasisOfPresentation" xlink:href="kapa-20250331.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="kapa-20250331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/VendorAgreements" xlink:href="kapa-20250331.xsd#VendorAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ShareholdersEquity" xlink:href="kapa-20250331.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/CommitmentsAndContingencies" xlink:href="kapa-20250331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SegmentInformation" xlink:href="kapa-20250331.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SubsequentEvents" xlink:href="kapa-20250331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="kapa-20250331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/VendorAgreementsPolicies" xlink:href="kapa-20250331.xsd#VendorAgreementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="kapa-20250331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/VendorAgreementsTables" xlink:href="kapa-20250331.xsd#VendorAgreementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ShareholdersEquityTables" xlink:href="kapa-20250331.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SegmentInformationTables" xlink:href="kapa-20250331.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/BasisOfPresentationDetailsNarrative" xlink:href="kapa-20250331.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:href="kapa-20250331.xsd#ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="kapa-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails" xlink:href="kapa-20250331.xsd#ScheduleOfVendorAdvancesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/VendorAgreementsDetailsNarrative" xlink:href="kapa-20250331.xsd#VendorAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails" xlink:href="kapa-20250331.xsd#ScheduleOfRestrictedCommonStockActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ScheduleOfWarrantActivityDetails" xlink:href="kapa-20250331.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails" xlink:href="kapa-20250331.xsd#ScheduleOfOutstandingAndExercisableWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ShareholdersEquityDetailsNarrative" xlink:href="kapa-20250331.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="kapa-20250331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails" xlink:href="kapa-20250331.xsd#ScheduleOfSegmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SegmentInformationDetailsNarrative" xlink:href="kapa-20250331.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="kapa-20250331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesNet" xlink:label="loc_KAPAVendorAdvancesNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_KAPAVendorAdvancesNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CommonStockToBeIssuedValue" xlink:label="loc_KAPACommonStockToBeIssuedValue" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_KAPACommonStockToBeIssuedValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaapInvestmentIncomeNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Shareholders&apos; Equity (Deficit) (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_FairValueOfVestedRestrictedStockUnits" xlink:label="loc_KAPAFairValueOfVestedRestrictedStockUnits" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_KAPAFairValueOfVestedRestrictedStockUnits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_IncreaseDecreaseInVendorAdvances" xlink:label="loc_KAPAIncreaseDecreaseInVendorAdvances" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_KAPAIncreaseDecreaseInVendorAdvances" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/BasisOfPresentation" xlink:title="999012 - Disclosure - BASIS OF PRESENTATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/VendorAgreements" xlink:title="999014 - Disclosure - VENDOR AGREEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ShareholdersEquity" xlink:title="999015 - Disclosure - SHAREHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/CommitmentsAndContingencies" xlink:title="999016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SegmentInformation" xlink:title="999017 - Disclosure - SEGMENT INFORMATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SubsequentEvents" xlink:title="999018 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/VendorAgreementsPolicies" xlink:title="999020 - Disclosure - VENDOR AGREEMENTS (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/VendorAgreementsTables" xlink:title="999022 - Disclosure - VENDOR AGREEMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ShareholdersEquityTables" xlink:title="999023 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SegmentInformationTables" xlink:title="999024 - Disclosure - SEGMENT INFORMATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/BasisOfPresentationDetailsNarrative" xlink:title="999025 - Disclosure - BASIS OF PRESENTATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:title="999026 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails" xlink:title="999028 - Disclosure - SCHEDULE OF VENDOR ADVANCES (Details)">
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesNet" xlink:label="loc_KAPAVendorAdvancesNet" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesGross" xlink:label="loc_KAPAVendorAdvancesGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_KAPAVendorAdvancesNet" xlink:to="loc_KAPAVendorAdvancesGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesAccumulatedAmortization" xlink:label="loc_KAPAVendorAdvancesAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_KAPAVendorAdvancesNet" xlink:to="loc_KAPAVendorAdvancesAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/VendorAgreementsDetailsNarrative" xlink:title="999029 - Disclosure - VENDOR AGREEMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails" xlink:title="999030 - Disclosure - SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999031 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails" xlink:title="999032 - Disclosure - SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ShareholdersEquityDetailsNarrative" xlink:title="999033 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails" xlink:title="999035 - Disclosure - SCHEDULE OF SEGMENT EXPENSES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SegmentInformationDetailsNarrative" xlink:title="999036 - Disclosure - SEGMENT INFORMATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>kapa-20250331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://kairospharma.com/role/Cover" xlink:href="kapa-20250331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/BalanceSheets" xlink:href="kapa-20250331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/BalanceSheetsParenthetical" xlink:href="kapa-20250331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/StatementsOfOperations" xlink:href="kapa-20250331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit" xlink:href="kapa-20250331.xsd#StatementsOfShareholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/StatementsOfCashFlows" xlink:href="kapa-20250331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/BasisOfPresentation" xlink:href="kapa-20250331.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="kapa-20250331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/VendorAgreements" xlink:href="kapa-20250331.xsd#VendorAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ShareholdersEquity" xlink:href="kapa-20250331.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/CommitmentsAndContingencies" xlink:href="kapa-20250331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SegmentInformation" xlink:href="kapa-20250331.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SubsequentEvents" xlink:href="kapa-20250331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="kapa-20250331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/VendorAgreementsPolicies" xlink:href="kapa-20250331.xsd#VendorAgreementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="kapa-20250331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/VendorAgreementsTables" xlink:href="kapa-20250331.xsd#VendorAgreementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ShareholdersEquityTables" xlink:href="kapa-20250331.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SegmentInformationTables" xlink:href="kapa-20250331.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/BasisOfPresentationDetailsNarrative" xlink:href="kapa-20250331.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:href="kapa-20250331.xsd#ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="kapa-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails" xlink:href="kapa-20250331.xsd#ScheduleOfVendorAdvancesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/VendorAgreementsDetailsNarrative" xlink:href="kapa-20250331.xsd#VendorAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails" xlink:href="kapa-20250331.xsd#ScheduleOfRestrictedCommonStockActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ScheduleOfWarrantActivityDetails" xlink:href="kapa-20250331.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails" xlink:href="kapa-20250331.xsd#ScheduleOfOutstandingAndExercisableWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ShareholdersEquityDetailsNarrative" xlink:href="kapa-20250331.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="kapa-20250331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails" xlink:href="kapa-20250331.xsd#ScheduleOfSegmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SegmentInformationDetailsNarrative" xlink:href="kapa-20250331.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="kapa-20250331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Shareholders&apos; Equity (Deficit) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CommonStockToBeIssuedMember" xlink:label="loc_KAPACommonStockToBeIssuedMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_KAPACommonStockToBeIssuedMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts" xlink:label="loc_KAPAAdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAAdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" xlink:label="loc_KAPAStockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAStockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" xlink:label="loc_KAPAStockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAStockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" xlink:label="loc_KAPAStockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAStockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" xlink:label="loc_KAPAStockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAStockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/BasisOfPresentation" xlink:title="999012 - Disclosure - BASIS OF PRESENTATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/VendorAgreements" xlink:title="999014 - Disclosure - VENDOR AGREEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ShareholdersEquity" xlink:title="999015 - Disclosure - SHAREHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/CommitmentsAndContingencies" xlink:title="999016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SegmentInformation" xlink:title="999017 - Disclosure - SEGMENT INFORMATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SubsequentEvents" xlink:title="999018 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/VendorAgreementsPolicies" xlink:title="999020 - Disclosure - VENDOR AGREEMENTS (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/VendorAgreementsTables" xlink:title="999022 - Disclosure - VENDOR AGREEMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ShareholdersEquityTables" xlink:title="999023 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SegmentInformationTables" xlink:title="999024 - Disclosure - SEGMENT INFORMATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/BasisOfPresentationDetailsNarrative" xlink:title="999025 - Disclosure - BASIS OF PRESENTATION (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:title="999026 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_WarrantsToPurchaseCommonStockMember" xlink:label="loc_KAPAWarrantsToPurchaseCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_KAPAWarrantsToPurchaseCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_EnviroThreapeuticsIncMember" xlink:label="loc_KAPAEnviroThreapeuticsIncMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_KAPAEnviroThreapeuticsIncMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_EquityLineOfCreditMember" xlink:label="loc_KAPAEquityLineOfCreditMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_KAPAEquityLineOfCreditMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaapBusinessAcquisitionCostOfAcquiredEntityTransactionCosts_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessAcquisitionCostOfAcquiredEntityTransactionCosts_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_DeferredOfferingAdditionalCosts" xlink:label="loc_KAPADeferredOfferingAdditionalCosts_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_KAPADeferredOfferingAdditionalCosts_80" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails" xlink:title="999028 - Disclosure - SCHEDULE OF VENDOR ADVANCES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PrevailInfoworksIncMember" xlink:label="loc_KAPAPrevailInfoworksIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPAPrevailInfoworksIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PreCheckHealthServicesIncMember" xlink:label="loc_KAPAPreCheckHealthServicesIncMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPAPreCheckHealthServicesIncMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CEOCATechnologiesLtdMember" xlink:label="loc_KAPACEOCATechnologiesLtdMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPACEOCATechnologiesLtdMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_BelairCapitalAdvisorsIncMember" xlink:label="loc_KAPABelairCapitalAdvisorsIncMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPABelairCapitalAdvisorsIncMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CrossCurrentCapitalLLCMember" xlink:label="loc_KAPACrossCurrentCapitalLLCMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPACrossCurrentCapitalLLCMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesGross" xlink:label="loc_KAPAVendorAdvancesGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAVendorAdvancesGross_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesAccumulatedAmortization" xlink:label="loc_KAPAVendorAdvancesAccumulatedAmortization_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAVendorAdvancesAccumulatedAmortization_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesNet" xlink:label="loc_KAPAVendorAdvancesNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAVendorAdvancesNet_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/VendorAgreementsDetailsNarrative" xlink:title="999029 - Disclosure - VENDOR AGREEMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_MasterServiceAndTechnologyAgreementMember" xlink:label="loc_KAPAMasterServiceAndTechnologyAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPAMasterServiceAndTechnologyAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_BioassayServicesAgreementMember" xlink:label="loc_KAPABioassayServicesAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPABioassayServicesAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_AdvisoryAndConsultingServicesAgreementMember" xlink:label="loc_KAPAAdvisoryAndConsultingServicesAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPAAdvisoryAndConsultingServicesAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_StrategicAdvisoryAgreementMember" xlink:label="loc_KAPAStrategicAdvisoryAgreementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPAStrategicAdvisoryAgreementMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ConsultingAgreementMember" xlink:label="loc_KAPAConsultingAgreementMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPAConsultingAgreementMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember" xlink:label="loc_KAPAHelenaGlobalInvestmentOpportunitiesILTDMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPAHelenaGlobalInvestmentOpportunitiesILTDMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PreCheckHealthServicesIncMember" xlink:label="loc_KAPAPreCheckHealthServicesIncMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPAPreCheckHealthServicesIncMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CEOCATechnologiesLtdMember" xlink:label="loc_KAPACEOCATechnologiesLtdMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPACEOCATechnologiesLtdMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_BelairCapitalAdvisorsIncMember" xlink:label="loc_KAPABelairCapitalAdvisorsIncMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPABelairCapitalAdvisorsIncMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CurrentCapitalLLCMember" xlink:label="loc_KAPACurrentCapitalLLCMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPACurrentCapitalLLCMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember" xlink:label="loc_KAPAHelenaGlobalInvestmentOpportunitiesILTDMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPAHelenaGlobalInvestmentOpportunitiesILTDMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerAdvancesAndDeposits" xlink:label="loc_us-gaapCustomerAdvancesAndDeposits_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCustomerAdvancesAndDeposits_240" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesInCash" xlink:label="loc_KAPAVendorAdvancesInCash_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAVendorAdvancesInCash_240" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_IssuanceOfCommonSharesPaidForVendorsAdvances" xlink:label="loc_KAPAIssuanceOfCommonSharesPaidForVendorsAdvances_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAIssuanceOfCommonSharesPaidForVendorsAdvances_240" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_AmortizationExpenseVendorAdvances" xlink:label="loc_KAPAAmortizationExpenseVendorAdvances_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAAmortizationExpenseVendorAdvances_240" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesCurrent" xlink:label="loc_KAPAVendorAdvancesCurrent_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAVendorAdvancesCurrent_240" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="loc_us-gaapPaymentsForAdvanceToAffiliate_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForAdvanceToAffiliate_240" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_MonthlyPayment" xlink:label="loc_KAPAMonthlyPayment_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAMonthlyPayment_240" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManagementFeeExpense" xlink:label="loc_us-gaapManagementFeeExpense_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapManagementFeeExpense_240" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_240" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_240" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_240" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_SettlementAgreementAmount" xlink:label="loc_KAPASettlementAgreementAmount_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPASettlementAgreementAmount_240" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorPaymentAdvances" xlink:label="loc_KAPAVendorPaymentAdvances_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAVendorPaymentAdvances_240" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalCollateralAggregateFairValue" xlink:label="loc_us-gaapAdditionalCollateralAggregateFairValue_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalCollateralAggregateFairValue_240" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_240" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_240" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails" xlink:title="999030 - Disclosure - SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1" xlink:label="loc_KAPASharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_KAPASharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1" xlink:label="loc_KAPASharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_KAPASharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999031 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" xlink:label="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted" xlink:label="loc_KAPAShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled" xlink:label="loc_KAPAShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xlink:label="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised" xlink:label="loc_KAPAShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:label="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited" xlink:label="loc_KAPAShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod" xlink:label="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod_100" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable" xlink:label="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_100" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_100" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails" xlink:title="999032 - Disclosure - SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ExercisePriceRangeOneMember" xlink:label="loc_KAPAExercisePriceRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_KAPAExercisePriceRangeOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ExercisePriceRangeTwoMember" xlink:label="loc_KAPAExercisePriceRangeTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_KAPAExercisePriceRangeTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ExercisePriceRangeThreeMember" xlink:label="loc_KAPAExercisePriceRangeThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_KAPAExercisePriceRangeThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_WarrantOneMember" xlink:label="loc_KAPAWarrantOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_KAPAWarrantOneMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_WarrantTwoMember" xlink:label="loc_KAPAWarrantTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_KAPAWarrantTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_WarrantThreeMember" xlink:label="loc_KAPAWarrantThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_KAPAWarrantThreeMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" xlink:label="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber" xlink:label="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" xlink:label="loc_KAPAShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit" xlink:label="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit" xlink:label="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_90" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ShareholdersEquityDetailsNarrative" xlink:title="999033 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_SecurityPurchaseAgreementMember" xlink:label="loc_KAPASecurityPurchaseAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_KAPASecurityPurchaseAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PreFundedWarrantMember" xlink:label="loc_KAPAPreFundedWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_KAPAPreFundedWarrantMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PrefundedWarrantsMember" xlink:label="loc_KAPAPrefundedWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_KAPAPrefundedWarrantsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CommonWarrantsMember" xlink:label="loc_KAPACommonWarrantsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_KAPACommonWarrantsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_TwentyTwentyThreeEquityIncentivePlanMember" xlink:label="loc_KAPATwentyTwentyThreeEquityIncentivePlanMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_KAPATwentyTwentyThreeEquityIncentivePlanMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_StrategicAdvisoryAgreementMember" xlink:label="loc_KAPAStrategicAdvisoryAgreementMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPAStrategicAdvisoryAgreementMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_FourOfficersAgreementMember" xlink:label="loc_KAPAFourOfficersAgreementMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPAFourOfficersAgreementMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_DirectorAgreementsMember" xlink:label="loc_KAPADirectorAgreementsMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPADirectorAgreementsMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ThreeIndependentDirectorsMember" xlink:label="loc_KAPAThreeIndependentDirectorsMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_KAPAThreeIndependentDirectorsMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_250" xlink:type="arc" order="252" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_UnderwritersMember" xlink:label="loc_KAPAUnderwritersMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_KAPAUnderwritersMember_330" xlink:type="arc" order="333" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_310" xlink:type="arc" order="313" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_SharesAuthorized" xlink:label="loc_KAPASharesAuthorized_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_KAPASharesAuthorized_390" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_390" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_390" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_390" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_390" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_390" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_390" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_390" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_390" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_390" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_390" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_390" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_390" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_390" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_390" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription" xlink:label="loc_KAPAClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_KAPAClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_390" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" xlink:label="loc_KAPAStockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_KAPAStockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_390" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_WarrantsUnexercised" xlink:label="loc_KAPAWarrantsUnexercised_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_KAPAWarrantsUnexercised_390" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_390" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_390" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_390" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_390" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_390" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_390" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_FairValueOfRestrictedStockUnits" xlink:label="loc_KAPAFairValueOfRestrictedStockUnits_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_KAPAFairValueOfRestrictedStockUnits_390" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_FairValueOfUnamortizedCompensation" xlink:label="loc_KAPAFairValueOfUnamortizedCompensation_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_KAPAFairValueOfUnamortizedCompensation_390" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_390" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_390" xlink:type="arc" order="27" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaapProductLiabilityContingencyLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaapProductLiabilityContingencyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapProductLiabilityContingencyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_LicenseAgreementMember" xlink:label="loc_KAPALicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPALicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ExclusiveLicenseAgreementMember" xlink:label="loc_KAPAExclusiveLicenseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPAExclusiveLicenseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_EnviroCedarsLicenseAgreementsMember" xlink:label="loc_KAPAEnviroCedarsLicenseAgreementsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPAEnviroCedarsLicenseAgreementsMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PhaseOneClinicalTrialMember" xlink:label="loc_KAPAPhaseOneClinicalTrialMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_KAPAPhaseOneClinicalTrialMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ItemOneAndTwoMember" xlink:label="loc_KAPAItemOneAndTwoMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_KAPAItemOneAndTwoMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ItemThreeMember" xlink:label="loc_KAPAItemThreeMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_KAPAItemThreeMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ItemFourMember" xlink:label="loc_KAPAItemFourMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_KAPAItemFourMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PhaseThreeClinicalTrialMember" xlink:label="loc_KAPAPhaseThreeClinicalTrialMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_KAPAPhaseThreeClinicalTrialMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PhaseTwoMember" xlink:label="loc_KAPAPhaseTwoMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_KAPAPhaseTwoMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PhaseTwoClinicalTrialMember" xlink:label="loc_KAPAPhaseTwoClinicalTrialMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_KAPAPhaseTwoClinicalTrialMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PhaseThreeMember" xlink:label="loc_KAPAPhaseThreeMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_KAPAPhaseThreeMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaapNonUsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_us-gaapNonUsMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_FoodAndDrugAdministrationMember" xlink:label="loc_KAPAFoodAndDrugAdministrationMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPAFoodAndDrugAdministrationMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_LicenseFee" xlink:label="loc_KAPALicenseFee_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_KAPALicenseFee_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PatentProtectionCosts" xlink:label="loc_KAPAPatentProtectionCosts_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_KAPAPatentProtectionCosts_200" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostMaintenance" xlink:label="loc_us-gaapCostMaintenance_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapCostMaintenance_200" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_RoyaltyPercentage" xlink:label="loc_KAPARoyaltyPercentage_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_KAPARoyaltyPercentage_200" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_OtherNonroyaltySublicenseFeesPercentage" xlink:label="loc_KAPAOtherNonroyaltySublicenseFeesPercentage_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_KAPAOtherNonroyaltySublicenseFeesPercentage_200" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PaymentForMilestones" xlink:label="loc_KAPAPaymentForMilestones_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_KAPAPaymentForMilestones_200" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapRevenues_200" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_MinimumRequirermentOfCapital" xlink:label="loc_KAPAMinimumRequirermentOfCapital_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_KAPAMinimumRequirermentOfCapital_200" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PatentProductSalesPercentage" xlink:label="loc_KAPAPatentProductSalesPercentage_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_KAPAPatentProductSalesPercentage_200" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_LicenseAgreementDescription" xlink:label="loc_KAPALicenseAgreementDescription_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_KAPALicenseAgreementDescription_200" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails" xlink:title="999035 - Disclosure - SCHEDULE OF SEGMENT EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srtConsolidationItemsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtConsolidationItemsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srtConsolidationItemsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidationItemsAxis" xlink:to="loc_srtConsolidationItemsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srtConsolidationItemsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidationItemsAxis" xlink:to="loc_srtConsolidationItemsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaapOperatingSegmentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidationItemsDomain" xlink:to="loc_us-gaapOperatingSegmentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenues_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOfficersCompensation_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceRecoveries" xlink:label="loc_us-gaapInsuranceRecoveries_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInsuranceRecoveries_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingExpenses_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaapOtherOperatingIncomeExpenseNet_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherOperatingIncomeExpenseNet_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss_30" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SegmentInformationDetailsNarrative" xlink:title="999036 - Disclosure - SEGMENT INFORMATION (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CrossCurrentCapitalLLCMember" xlink:label="loc_KAPACrossCurrentCapitalLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPACrossCurrentCapitalLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember" xlink:label="loc_KAPAHelenaGlobalInvestmentOpportunitiesILTDMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPAHelenaGlobalInvestmentOpportunitiesILTDMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PhaseTwoMember" xlink:label="loc_KAPAPhaseTwoMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_KAPAPhaseTwoMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PhaseTwoClinicalTrialMember" xlink:label="loc_KAPAPhaseTwoClinicalTrialMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_KAPAPhaseTwoClinicalTrialMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PhaseThreeMember" xlink:label="loc_KAPAPhaseThreeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_KAPAPhaseThreeMember" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>kapa-20250331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CommonStockToBeIssuedMember" xlink:label="KAPA_CommonStockToBeIssuedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_CommonStockToBeIssuedMember" xlink:to="KAPA_CommonStockToBeIssuedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_CommonStockToBeIssuedMember_lbl" xml:lang="en-US">Common Stock To Be Issued [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_EnviroThreapeuticsIncMember" xlink:label="KAPA_EnviroThreapeuticsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_EnviroThreapeuticsIncMember" xlink:to="KAPA_EnviroThreapeuticsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_EnviroThreapeuticsIncMember_lbl" xml:lang="en-US">Enviro Threapeutics Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_EquityLineOfCreditMember" xlink:label="KAPA_EquityLineOfCreditMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_EquityLineOfCreditMember" xlink:to="KAPA_EquityLineOfCreditMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_EquityLineOfCreditMember_lbl" xml:lang="en-US">Equity Line of Credit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_WarrantsToPurchaseCommonStockMember" xlink:label="KAPA_WarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_WarrantsToPurchaseCommonStockMember" xlink:to="KAPA_WarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Warrants To Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_MasterServiceAndTechnologyAgreementMember" xlink:label="KAPA_MasterServiceAndTechnologyAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_MasterServiceAndTechnologyAgreementMember" xlink:to="KAPA_MasterServiceAndTechnologyAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_MasterServiceAndTechnologyAgreementMember_lbl" xml:lang="en-US">Master Service And Technology Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_BioassayServicesAgreementMember" xlink:label="KAPA_BioassayServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_BioassayServicesAgreementMember" xlink:to="KAPA_BioassayServicesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_BioassayServicesAgreementMember_lbl" xml:lang="en-US">Bioassay Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PreCheckHealthServicesIncMember" xlink:label="KAPA_PreCheckHealthServicesIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PreCheckHealthServicesIncMember" xlink:to="KAPA_PreCheckHealthServicesIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_PreCheckHealthServicesIncMember_lbl" xml:lang="en-US">PreCheck Health Services, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_AdvisoryAndConsultingServicesAgreementMember" xlink:label="KAPA_AdvisoryAndConsultingServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_AdvisoryAndConsultingServicesAgreementMember" xlink:to="KAPA_AdvisoryAndConsultingServicesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_AdvisoryAndConsultingServicesAgreementMember_lbl" xml:lang="en-US">Advisory And Consulting Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CEOCATechnologiesLtdMember" xlink:label="KAPA_CEOCATechnologiesLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_CEOCATechnologiesLtdMember" xlink:to="KAPA_CEOCATechnologiesLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_CEOCATechnologiesLtdMember_lbl" xml:lang="en-US">CEO.CA Technologies Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_StrategicAdvisoryAgreementMember" xlink:label="KAPA_StrategicAdvisoryAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_StrategicAdvisoryAgreementMember" xlink:to="KAPA_StrategicAdvisoryAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_StrategicAdvisoryAgreementMember_lbl" xml:lang="en-US">Strategic Advisory Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_BelairCapitalAdvisorsIncMember" xlink:label="KAPA_BelairCapitalAdvisorsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_BelairCapitalAdvisorsIncMember" xlink:to="KAPA_BelairCapitalAdvisorsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_BelairCapitalAdvisorsIncMember_lbl" xml:lang="en-US">Belair Capital Advisors Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ConsultingAgreementMember" xlink:label="KAPA_ConsultingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ConsultingAgreementMember" xlink:to="KAPA_ConsultingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CurrentCapitalLLCMember" xlink:label="KAPA_CurrentCapitalLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_CurrentCapitalLLCMember" xlink:to="KAPA_CurrentCapitalLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_CurrentCapitalLLCMember_lbl" xml:lang="en-US">Current Capital LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember" xlink:label="KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember" xlink:to="KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember_lbl" xml:lang="en-US">Helena Global Investment Opportunities I LTD [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PrevailInfoworksIncMember" xlink:label="KAPA_PrevailInfoworksIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PrevailInfoworksIncMember" xlink:to="KAPA_PrevailInfoworksIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_PrevailInfoworksIncMember_lbl" xml:lang="en-US">Prevail Infoworks Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CrossCurrentCapitalLLCMember" xlink:label="KAPA_CrossCurrentCapitalLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_CrossCurrentCapitalLLCMember" xlink:to="KAPA_CrossCurrentCapitalLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_CrossCurrentCapitalLLCMember_lbl" xml:lang="en-US">Cross Current Capital LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_SecurityPurchaseAgreementMember" xlink:label="KAPA_SecurityPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_SecurityPurchaseAgreementMember" xlink:to="KAPA_SecurityPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_SecurityPurchaseAgreementMember_lbl" xml:lang="en-US">Security Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PreFundedWarrantMember" xlink:label="KAPA_PreFundedWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PreFundedWarrantMember" xlink:to="KAPA_PreFundedWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_PreFundedWarrantMember_lbl" xml:lang="en-US">Pre-Funded Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PrefundedWarrantsMember" xlink:label="KAPA_PrefundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PrefundedWarrantsMember" xlink:to="KAPA_PrefundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="KAPA_PrefundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CommonWarrantsMember" xlink:label="KAPA_CommonWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_CommonWarrantsMember" xlink:to="KAPA_CommonWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_CommonWarrantsMember_lbl" xml:lang="en-US">Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_TwentyTwentyThreeEquityIncentivePlanMember" xlink:label="KAPA_TwentyTwentyThreeEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_TwentyTwentyThreeEquityIncentivePlanMember" xlink:to="KAPA_TwentyTwentyThreeEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_TwentyTwentyThreeEquityIncentivePlanMember_lbl" xml:lang="en-US">2023 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_FourOfficersAgreementMember" xlink:label="KAPA_FourOfficersAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_FourOfficersAgreementMember" xlink:to="KAPA_FourOfficersAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_FourOfficersAgreementMember_lbl" xml:lang="en-US">Four Officers Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ThreeIndependentDirectorsMember" xlink:label="KAPA_ThreeIndependentDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ThreeIndependentDirectorsMember" xlink:to="KAPA_ThreeIndependentDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ThreeIndependentDirectorsMember_lbl" xml:lang="en-US">Three Independent Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_DirectorAgreementsMember" xlink:label="KAPA_DirectorAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_DirectorAgreementsMember" xlink:to="KAPA_DirectorAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_DirectorAgreementsMember_lbl" xml:lang="en-US">Director Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_UnderwritersMember" xlink:label="KAPA_UnderwritersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_UnderwritersMember" xlink:to="KAPA_UnderwritersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_UnderwritersMember_lbl" xml:lang="en-US">Underwriters [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ExercisePriceRangeOneMember" xlink:label="KAPA_ExercisePriceRangeOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ExercisePriceRangeOneMember" xlink:to="KAPA_ExercisePriceRangeOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ExercisePriceRangeOneMember_lbl" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_WarrantOneMember" xlink:label="KAPA_WarrantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_WarrantOneMember" xlink:to="KAPA_WarrantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_WarrantOneMember_lbl" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ExercisePriceRangeTwoMember" xlink:label="KAPA_ExercisePriceRangeTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ExercisePriceRangeTwoMember" xlink:to="KAPA_ExercisePriceRangeTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ExercisePriceRangeTwoMember_lbl" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_WarrantTwoMember" xlink:label="KAPA_WarrantTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_WarrantTwoMember" xlink:to="KAPA_WarrantTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_WarrantTwoMember_lbl" xml:lang="en-US">Warrant Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ExercisePriceRangeThreeMember" xlink:label="KAPA_ExercisePriceRangeThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ExercisePriceRangeThreeMember" xlink:to="KAPA_ExercisePriceRangeThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ExercisePriceRangeThreeMember_lbl" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_WarrantThreeMember" xlink:label="KAPA_WarrantThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_WarrantThreeMember" xlink:to="KAPA_WarrantThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_WarrantThreeMember_lbl" xml:lang="en-US">Warrant Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_LicenseAgreementMember" xlink:label="KAPA_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_LicenseAgreementMember" xlink:to="KAPA_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ExclusiveLicenseAgreementMember" xlink:label="KAPA_ExclusiveLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ExclusiveLicenseAgreementMember" xlink:to="KAPA_ExclusiveLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ExclusiveLicenseAgreementMember_lbl" xml:lang="en-US">Exclusive License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PhaseOneClinicalTrialMember" xlink:label="KAPA_PhaseOneClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PhaseOneClinicalTrialMember" xlink:to="KAPA_PhaseOneClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_PhaseOneClinicalTrialMember_lbl" xml:lang="en-US">Phase One Clinical Trial [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ItemOneAndTwoMember" xlink:label="KAPA_ItemOneAndTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ItemOneAndTwoMember" xlink:to="KAPA_ItemOneAndTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ItemOneAndTwoMember_lbl" xml:lang="en-US">Item One And Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PhaseTwoMember" xlink:label="KAPA_PhaseTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PhaseTwoMember" xlink:to="KAPA_PhaseTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_PhaseTwoMember_lbl" xml:lang="en-US">Phase Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ItemThreeMember" xlink:label="KAPA_ItemThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ItemThreeMember" xlink:to="KAPA_ItemThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ItemThreeMember_lbl" xml:lang="en-US">Item Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PhaseTwoClinicalTrialMember" xlink:label="KAPA_PhaseTwoClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PhaseTwoClinicalTrialMember" xlink:to="KAPA_PhaseTwoClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_PhaseTwoClinicalTrialMember_lbl" xml:lang="en-US">Phase Two Clinical Trial [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonUsMember_lbl" xml:lang="en-US">Non-US [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ItemFourMember" xlink:label="KAPA_ItemFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ItemFourMember" xlink:to="KAPA_ItemFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ItemFourMember_lbl" xml:lang="en-US">Item Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_FoodAndDrugAdministrationMember" xlink:label="KAPA_FoodAndDrugAdministrationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_FoodAndDrugAdministrationMember" xlink:to="KAPA_FoodAndDrugAdministrationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_FoodAndDrugAdministrationMember_lbl" xml:lang="en-US">Food and Drug Administration [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PhaseThreeClinicalTrialMember" xlink:label="KAPA_PhaseThreeClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PhaseThreeClinicalTrialMember" xlink:to="KAPA_PhaseThreeClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_PhaseThreeClinicalTrialMember_lbl" xml:lang="en-US">Phase Three Clinical Trial [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_EnviroCedarsLicenseAgreementsMember" xlink:label="KAPA_EnviroCedarsLicenseAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_EnviroCedarsLicenseAgreementsMember" xlink:to="KAPA_EnviroCedarsLicenseAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_EnviroCedarsLicenseAgreementsMember_lbl" xml:lang="en-US">Enviro Cedars License Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PhaseThreeMember" xlink:label="KAPA_PhaseThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PhaseThreeMember" xlink:to="KAPA_PhaseThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_PhaseThreeMember_lbl" xml:lang="en-US">Phase Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidationItemsAxis_lbl" xml:lang="en-US">Consolidation Items [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xml:lang="en-US">Operating Segments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesNet" xlink:label="KAPA_VendorAdvancesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_VendorAdvancesNet" xlink:to="KAPA_VendorAdvancesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_VendorAdvancesNet_lbl" xml:lang="en-US">Vendor advances, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, par value $0.001, 20,000,000 shares authorized; no shares issued and outstanding, respectively;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.001, 100,000,000 shares authorized; 15,825,118 and 13,736,597 shares issued and outstanding, respectively;</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CommonStockToBeIssuedValue" xlink:label="KAPA_CommonStockToBeIssuedValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_CommonStockToBeIssuedValue" xlink:to="KAPA_CommonStockToBeIssuedValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_CommonStockToBeIssuedValue_lbl" xml:lang="en-US">Common stock to be issued, 551,000 shares outstanding at March 31, 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Shareholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CommonStockToBeIssuedSharesOutstanding" xlink:label="KAPA_CommonStockToBeIssuedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_CommonStockToBeIssuedSharesOutstanding" xlink:to="KAPA_CommonStockToBeIssuedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_CommonStockToBeIssuedSharesOutstanding_lbl" xml:lang="en-US">Common stock to be issued, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Debt discount amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expenses)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">BASIC LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">DILUTED LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">BASIC</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts" xlink:label="KAPA_AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts" xlink:to="KAPA_AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts_lbl" xml:lang="en-US">Proceeds from the sale of pre-funded warrants, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" xlink:label="KAPA_StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" xlink:to="KAPA_StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_lbl" xml:lang="en-US">Issuance of common shares upon the exercise of pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" xlink:label="KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" xlink:to="KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_lbl" xml:lang="en-US">Issuance of common shares upon the exercise of pre-funded warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" xlink:label="KAPA_StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" xlink:to="KAPA_StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts_lbl" xml:lang="en-US">Fair value of common shares to be issued for vendor advance and deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" xlink:label="KAPA_StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" xlink:to="KAPA_StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts_lbl" xml:lang="en-US">Fair value of common shares to be issued for vendor advance and deferred offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Fair value of vested restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Fair value of vested restricted stock units, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense - intangible asset</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_FairValueOfVestedRestrictedStockUnits" xlink:label="KAPA_FairValueOfVestedRestrictedStockUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_FairValueOfVestedRestrictedStockUnits" xlink:to="KAPA_FairValueOfVestedRestrictedStockUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="KAPA_FairValueOfVestedRestrictedStockUnits_lbl" xml:lang="en-US">Fair value of vested restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_IncreaseDecreaseInVendorAdvances" xlink:label="KAPA_IncreaseDecreaseInVendorAdvances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_IncreaseDecreaseInVendorAdvances" xlink:to="KAPA_IncreaseDecreaseInVendorAdvances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_IncreaseDecreaseInVendorAdvances_lbl" xml:lang="en-US">Vendor advances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Sale and exercise of prefunded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Payment of deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US">Supplemental cash flows disclosures:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Taxes paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental non-cash financing disclosures:</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_IssuanceOfCommonSharesForDeferredOfferingCosts" xlink:label="KAPA_IssuanceOfCommonSharesForDeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_IssuanceOfCommonSharesForDeferredOfferingCosts" xlink:to="KAPA_IssuanceOfCommonSharesForDeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_IssuanceOfCommonSharesForDeferredOfferingCosts_lbl" xml:lang="en-US">Common shares issued for deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_IssuanceOfCommonSharesForVendorAdvances" xlink:label="KAPA_IssuanceOfCommonSharesForVendorAdvances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_IssuanceOfCommonSharesForVendorAdvances" xlink:to="KAPA_IssuanceOfCommonSharesForVendorAdvances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_IssuanceOfCommonSharesForVendorAdvances_lbl" xml:lang="en-US">Common shares issued for vendor advance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_DisclosureVendorAgreementsAbstract" xlink:label="KAPA_DisclosureVendorAgreementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_DisclosureVendorAgreementsAbstract" xlink:to="KAPA_DisclosureVendorAgreementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_DisclosureVendorAgreementsAbstract_lbl" xml:lang="en-US">Vendor Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_DisclosureOfVendorAgreementsTextBlock" xlink:label="KAPA_DisclosureOfVendorAgreementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_DisclosureOfVendorAgreementsTextBlock" xlink:to="KAPA_DisclosureOfVendorAgreementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_DisclosureOfVendorAgreementsTextBlock_lbl" xml:lang="en-US">VENDOR AGREEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Basis of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Income (Loss) Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesPolicyTextBlock" xlink:label="KAPA_VendorAdvancesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_VendorAdvancesPolicyTextBlock" xlink:to="KAPA_VendorAdvancesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_VendorAdvancesPolicyTextBlock_lbl" xml:lang="en-US">Vendor Advances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ScheduleOfVendorAdvancesTableTextBlock" xlink:label="KAPA_ScheduleOfVendorAdvancesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ScheduleOfVendorAdvancesTableTextBlock" xlink:to="KAPA_ScheduleOfVendorAdvancesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ScheduleOfVendorAdvancesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF VENDOR ADVANCES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANT ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:label="KAPA_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:to="KAPA_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF SEGMENT EXPENSES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash in operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Net proceeds from offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Shareholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US">Restructuring Cost [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Intangible assets useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xml:lang="en-US">Acquisition cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Intangible assets unamortized balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Impairment of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred Offering Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_DeferredOfferingAdditionalCosts" xlink:label="KAPA_DeferredOfferingAdditionalCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_DeferredOfferingAdditionalCosts" xlink:to="KAPA_DeferredOfferingAdditionalCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_DeferredOfferingAdditionalCosts_lbl" xml:lang="en-US">Deferred offering additional cost</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesGross" xlink:label="KAPA_VendorAdvancesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_VendorAdvancesGross" xlink:to="KAPA_VendorAdvancesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_VendorAdvancesGross_lbl" xml:lang="en-US">Vendor advances, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesAccumulatedAmortization" xlink:label="KAPA_VendorAdvancesAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_VendorAdvancesAccumulatedAmortization" xlink:to="KAPA_VendorAdvancesAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="KAPA_VendorAdvancesAccumulatedAmortization_lbl" xml:lang="en-US">Less: accumulated amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_VendorAdvancesNet" xlink:to="KAPA_VendorAdvancesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="KAPA_VendorAdvancesNet_2_lbl" xml:lang="en-US">Vendor advances, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerAdvancesAndDeposits" xlink:label="us-gaap_CustomerAdvancesAndDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerAdvancesAndDeposits" xlink:to="us-gaap_CustomerAdvancesAndDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerAdvancesAndDeposits_lbl" xml:lang="en-US">Advances to vendor amount</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesInCash" xlink:label="KAPA_VendorAdvancesInCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_VendorAdvancesInCash" xlink:to="KAPA_VendorAdvancesInCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="KAPA_VendorAdvancesInCash_lbl" xml:lang="en-US">Vendor advances in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_IssuanceOfCommonSharesPaidForVendorsAdvances" xlink:label="KAPA_IssuanceOfCommonSharesPaidForVendorsAdvances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_IssuanceOfCommonSharesPaidForVendorsAdvances" xlink:to="KAPA_IssuanceOfCommonSharesPaidForVendorsAdvances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_IssuanceOfCommonSharesPaidForVendorsAdvances_lbl" xml:lang="en-US">Issuance of common shares paid for vendors advances</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_AmortizationExpenseVendorAdvances" xlink:label="KAPA_AmortizationExpenseVendorAdvances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_AmortizationExpenseVendorAdvances" xlink:to="KAPA_AmortizationExpenseVendorAdvances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_AmortizationExpenseVendorAdvances_lbl" xml:lang="en-US">Amortization expense relating to vendor advances</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesCurrent" xlink:label="KAPA_VendorAdvancesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_VendorAdvancesCurrent" xlink:to="KAPA_VendorAdvancesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="KAPA_VendorAdvancesCurrent_lbl" xml:lang="en-US">Vendor advances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForAdvanceToAffiliate" xlink:to="us-gaap_PaymentsForAdvanceToAffiliate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate_lbl" xml:lang="en-US">Payments for vendor advance</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_MonthlyPayment" xlink:label="KAPA_MonthlyPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_MonthlyPayment" xlink:to="KAPA_MonthlyPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_MonthlyPayment_lbl" xml:lang="en-US">Monthly payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManagementFeeExpense" xlink:label="us-gaap_ManagementFeeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeeExpense" xlink:to="us-gaap_ManagementFeeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManagementFeeExpense_lbl" xml:lang="en-US">Service fee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Number of shares issued, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Number of shares issued, value</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_SettlementAgreementAmount" xlink:label="KAPA_SettlementAgreementAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_SettlementAgreementAmount" xlink:to="KAPA_SettlementAgreementAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_SettlementAgreementAmount_lbl" xml:lang="en-US">Settlement agreement amount</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorPaymentAdvances" xlink:label="KAPA_VendorPaymentAdvances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_VendorPaymentAdvances" xlink:to="KAPA_VendorPaymentAdvances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_VendorPaymentAdvances_lbl" xml:lang="en-US">Vendor payment advances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalCollateralAggregateFairValue" xlink:label="us-gaap_AdditionalCollateralAggregateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCollateralAggregateFairValue" xlink:to="us-gaap_AdditionalCollateralAggregateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalCollateralAggregateFairValue_lbl" xml:lang="en-US">Aggregate fair value of the common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Stock issued value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of Restricted Shares, Unvested Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Fair Value, Unvested, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Restricted shares Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1" xlink:label="KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1" xlink:to="KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1_lbl" xml:lang="en-US">Fair Value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of Restricted shares Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Fair Value, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Number of Restricted shares Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1" xlink:label="KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1" xlink:to="KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1_lbl" xml:lang="en-US">Fair Value, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xml:lang="en-US">Number of Restricted Shares, Unvested Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Fair Value, Unvested, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Warrants Shares, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" xlink:to="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_lbl" xml:lang="en-US">Exercise Price Range Per Share, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Warrant Warrant, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Warrants Shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted" xlink:to="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_lbl" xml:lang="en-US">Exercise Price Range Per Share, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Warrant, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:to="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xml:lang="en-US">Warrants Shares, Cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled" xlink:to="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled_lbl" xml:lang="en-US">Exercise Price Range Per Share, Cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xlink:to="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Warrant, Cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xml:lang="en-US">Warrants Shares, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised" xlink:to="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised_lbl" xml:lang="en-US">Exercise Price Range Per Share, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:to="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Warrant, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Warrants Shares, Forfeited/Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited" xlink:to="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited_lbl" xml:lang="en-US">Exercise Price Range Per Share, Forfeited/Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Warrant, Forfeited/Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Warrants Shares, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" xlink:to="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_2_lbl" xml:lang="en-US">Exercise Price Range Per Share, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Warrant, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod" xlink:to="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod_lbl" xml:lang="en-US">Number of Shares Warrants, Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable" xlink:to="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_lbl" xml:lang="en-US">Exercise Price Range Per Share, Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested and exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" xlink:to="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_3_lbl" xml:lang="en-US">Range of exercise prices</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Warrants Outstanding, Number Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Warrants Outstanding, Average Remaining Contractual Life (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants Outstanding, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber" xlink:to="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_lbl" xml:lang="en-US">Warrants Exercisable, Number Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" xlink:label="KAPA_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" xlink:to="KAPA_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Warrants Exercisable, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit" xlink:to="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of exercise prices lower range</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit" xlink:to="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of exercise prices upper range</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:to="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Warrants Exercisable, Average Remaining Contractual Life (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_SharesAuthorized" xlink:label="KAPA_SharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_SharesAuthorized" xlink:to="KAPA_SharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_SharesAuthorized_lbl" xml:lang="en-US">Shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Preferred stock par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock, number of shares issued in transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Exercisable price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrant to purchase of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Purchase price of pre-funded unit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Net proceeds received from financing</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercisable price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription" xlink:label="KAPA_ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription" xlink:to="KAPA_ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_lbl" xml:lang="en-US">Warrants exercisable description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" xlink:to="KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_2_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_WarrantsUnexercised" xlink:label="KAPA_WarrantsUnexercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_WarrantsUnexercised" xlink:to="KAPA_WarrantsUnexercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_WarrantsUnexercised_lbl" xml:lang="en-US">Warrants unexercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_3_lbl" xml:lang="en-US">Fair value of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2_lbl" xml:lang="en-US">Number of shares vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Granted shares</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_FairValueOfRestrictedStockUnits" xlink:label="KAPA_FairValueOfRestrictedStockUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_FairValueOfRestrictedStockUnits" xlink:to="KAPA_FairValueOfRestrictedStockUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_FairValueOfRestrictedStockUnits_lbl" xml:lang="en-US">Stock compensation-related expense for fair value vesting of restricted common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_FairValueOfUnamortizedCompensation" xlink:label="KAPA_FairValueOfUnamortizedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_FairValueOfUnamortizedCompensation" xlink:to="KAPA_FairValueOfUnamortizedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_FairValueOfUnamortizedCompensation_lbl" xml:lang="en-US">Fair value of unamortized compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Warrant shares outstanding, intrinsic value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Number of shares issued, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="us-gaap_ProductLiabilityContingencyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyTable" xlink:to="us-gaap_ProductLiabilityContingencyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityContingencyTable_lbl" xml:lang="en-US">Product Liability Contingency [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="us-gaap_ProductLiabilityContingencyLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyLineItems" xlink:to="us-gaap_ProductLiabilityContingencyLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityContingencyLineItems_lbl" xml:lang="en-US">Product Liability Contingency [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_LicenseFee" xlink:label="KAPA_LicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_LicenseFee" xlink:to="KAPA_LicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_LicenseFee_lbl" xml:lang="en-US">License fee</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PatentProtectionCosts" xlink:label="KAPA_PatentProtectionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PatentProtectionCosts" xlink:to="KAPA_PatentProtectionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_PatentProtectionCosts_lbl" xml:lang="en-US">Patent protection costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostMaintenance_lbl" xml:lang="en-US">Annual maintenance fee</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_RoyaltyPercentage" xlink:label="KAPA_RoyaltyPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_RoyaltyPercentage" xlink:to="KAPA_RoyaltyPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_RoyaltyPercentage_lbl" xml:lang="en-US">Royalty percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_OtherNonroyaltySublicenseFeesPercentage" xlink:label="KAPA_OtherNonroyaltySublicenseFeesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_OtherNonroyaltySublicenseFeesPercentage" xlink:to="KAPA_OtherNonroyaltySublicenseFeesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_OtherNonroyaltySublicenseFeesPercentage_lbl" xml:lang="en-US">Other non-royalty sublicense fees percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PaymentForMilestones" xlink:label="KAPA_PaymentForMilestones" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PaymentForMilestones" xlink:to="KAPA_PaymentForMilestones_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_PaymentForMilestones_lbl" xml:lang="en-US">Payment for milestone</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Net sales</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_MinimumRequirermentOfCapital" xlink:label="KAPA_MinimumRequirermentOfCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_MinimumRequirermentOfCapital" xlink:to="KAPA_MinimumRequirermentOfCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_MinimumRequirermentOfCapital_lbl" xml:lang="en-US">Minimum requirerment of capital</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PatentProductSalesPercentage" xlink:label="KAPA_PatentProductSalesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PatentProductSalesPercentage" xlink:to="KAPA_PatentProductSalesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_PatentProductSalesPercentage_lbl" xml:lang="en-US">Patent product sales</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_LicenseAgreementDescription" xlink:label="KAPA_LicenseAgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_LicenseAgreementDescription" xlink:to="KAPA_LicenseAgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_LicenseAgreementDescription_lbl" xml:lang="en-US">License agreement description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_3_lbl" xml:lang="en-US">Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development, less officer compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Officer compensation and wages</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceRecoveries" xlink:label="us-gaap_InsuranceRecoveries" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceRecoveries" xlink:to="us-gaap_InsuranceRecoveries_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InsuranceRecoveries_lbl" xml:lang="en-US">Insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xml:lang="en-US">Other income (expenses)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_5_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_VendorAdvancesNet" xlink:to="KAPA_VendorAdvancesNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_VendorAdvancesNet_doc" xml:lang="en-US">Vendor advances net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_CommonStockToBeIssuedValue" xlink:to="KAPA_CommonStockToBeIssuedValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_CommonStockToBeIssuedValue_doc" xml:lang="en-US">Common stock to be issued value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_CommonStockToBeIssuedSharesOutstanding" xlink:to="KAPA_CommonStockToBeIssuedSharesOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_CommonStockToBeIssuedSharesOutstanding_doc" xml:lang="en-US">Common stock to be issued shares outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_CommonStockToBeIssuedMember" xlink:to="KAPA_CommonStockToBeIssuedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_CommonStockToBeIssuedMember_doc" xml:lang="en-US">Common Stock To Be Issued [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts" xlink:to="KAPA_AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts_doc" xml:lang="en-US">Adjustments to additional paid in capital proceeds from sale of prefunded warrants net of offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" xlink:to="KAPA_StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_doc" xml:lang="en-US">Stock issued during period value issuance of common shares upon exercise of prefunded warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" xlink:to="KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_doc" xml:lang="en-US">Stock issued during period shares issuance of common shares upon exercise of prefunded warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_FairValueOfVestedRestrictedStockUnits" xlink:to="KAPA_FairValueOfVestedRestrictedStockUnits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_FairValueOfVestedRestrictedStockUnits_doc" xml:lang="en-US">Fair value of vested restricted stock units.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_IncreaseDecreaseInVendorAdvances" xlink:to="KAPA_IncreaseDecreaseInVendorAdvances_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_IncreaseDecreaseInVendorAdvances_doc" xml:lang="en-US">Increase decrease in vendor advances.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_IssuanceOfCommonSharesForDeferredOfferingCosts" xlink:to="KAPA_IssuanceOfCommonSharesForDeferredOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_IssuanceOfCommonSharesForDeferredOfferingCosts_doc" xml:lang="en-US">Issuance of common shares for deferred offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_IssuanceOfCommonSharesForVendorAdvances" xlink:to="KAPA_IssuanceOfCommonSharesForVendorAdvances_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_IssuanceOfCommonSharesForVendorAdvances_doc" xml:lang="en-US">Issuance of common shares for vendor advances.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_VendorAdvancesPolicyTextBlock" xlink:to="KAPA_VendorAdvancesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_VendorAdvancesPolicyTextBlock_doc" xml:lang="en-US">Vendor Advances [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_VendorAdvancesInCash" xlink:to="KAPA_VendorAdvancesInCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_VendorAdvancesInCash_doc" xml:lang="en-US">Vendor advances in cash.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_IssuanceOfCommonSharesPaidForVendorsAdvances" xlink:to="KAPA_IssuanceOfCommonSharesPaidForVendorsAdvances_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_IssuanceOfCommonSharesPaidForVendorsAdvances_doc" xml:lang="en-US">Issuance of common shares paid for vendors advances.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_AmortizationExpenseVendorAdvances" xlink:to="KAPA_AmortizationExpenseVendorAdvances_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_AmortizationExpenseVendorAdvances_doc" xml:lang="en-US">Amortization expense vendor advances.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_VendorAdvancesCurrent" xlink:to="KAPA_VendorAdvancesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_VendorAdvancesCurrent_doc" xml:lang="en-US">Vendor advances current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_EnviroThreapeuticsIncMember" xlink:to="KAPA_EnviroThreapeuticsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_EnviroThreapeuticsIncMember_doc" xml:lang="en-US">Enviro Threapeutics Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_EquityLineOfCreditMember" xlink:to="KAPA_EquityLineOfCreditMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_EquityLineOfCreditMember_doc" xml:lang="en-US">Equity Line of Credit [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_SharesAuthorized" xlink:to="KAPA_SharesAuthorized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_SharesAuthorized_doc" xml:lang="en-US">Shares authorized.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_SecurityPurchaseAgreementMember" xlink:to="KAPA_SecurityPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_SecurityPurchaseAgreementMember_doc" xml:lang="en-US">Security Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PreFundedWarrantMember" xlink:to="KAPA_PreFundedWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_PreFundedWarrantMember_doc" xml:lang="en-US">Pre-Funded Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PrefundedWarrantsMember" xlink:to="KAPA_PrefundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_PrefundedWarrantsMember_doc" xml:lang="en-US">Pre-Funded Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_CommonWarrantsMember" xlink:to="KAPA_CommonWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_CommonWarrantsMember_doc" xml:lang="en-US">Common Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription" xlink:to="KAPA_ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_doc" xml:lang="en-US">Class of warrant or rights date from which warrants or rights exercisable description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_WarrantsUnexercised" xlink:to="KAPA_WarrantsUnexercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_WarrantsUnexercised_doc" xml:lang="en-US">Warrants unexercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_TwentyTwentyThreeEquityIncentivePlanMember" xlink:to="KAPA_TwentyTwentyThreeEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_TwentyTwentyThreeEquityIncentivePlanMember_doc" xml:lang="en-US">2023 Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1" xlink:to="KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1_doc" xml:lang="en-US">Fair value of options granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1" xlink:to="KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1_doc" xml:lang="en-US">Fair value of options forfeited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_StrategicAdvisoryAgreementMember" xlink:to="KAPA_StrategicAdvisoryAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_StrategicAdvisoryAgreementMember_doc" xml:lang="en-US">Strategic Advisory Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_FourOfficersAgreementMember" xlink:to="KAPA_FourOfficersAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_FourOfficersAgreementMember_doc" xml:lang="en-US">Four Officers Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ThreeIndependentDirectorsMember" xlink:to="KAPA_ThreeIndependentDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ThreeIndependentDirectorsMember_doc" xml:lang="en-US">Three Independent Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_DirectorAgreementsMember" xlink:to="KAPA_DirectorAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_DirectorAgreementsMember_doc" xml:lang="en-US">Director Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_FairValueOfRestrictedStockUnits" xlink:to="KAPA_FairValueOfRestrictedStockUnits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_FairValueOfRestrictedStockUnits_doc" xml:lang="en-US">Fair value of restricted stock units.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:to="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_doc" xml:lang="en-US">The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_doc" xml:lang="en-US">The number of equity-based payment instruments, excluding stock (or unit) options, that were exercised during the reporting period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod" xlink:to="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options excercisable in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" xlink:to="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_doc" xml:lang="en-US">The number of shares reserved for issuance pertaining to the outstanding stock warrants as of the balance sheet date for all warrants in the customized range of exercise prices.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted" xlink:to="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_doc" xml:lang="en-US">Share based compensation shares exercisabler other than stock option plans exercise price range granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled" xlink:to="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled_doc" xml:lang="en-US">Share based compensation shares exercisabler other than stock option plans exercise price range cancelled.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised" xlink:to="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised_doc" xml:lang="en-US">Share based compensation shares exercisabler other than stock option plans exercise price range exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited" xlink:to="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited_doc" xml:lang="en-US">Share based compensation shares exercisabler other than stock option plans exercise price range forfeited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable" xlink:to="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_doc" xml:lang="en-US">The number of shares reserved for issuance pertaining to the warrants vested and exercisable as of the balance sheet date for all warrants in the customized range of exercise prices.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xlink:to="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">The weighted average fair value at grant date for nonvested equity-based awards cancelled during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:to="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">The weighted average fair value at grant date for nonvested equity-based awards exercised during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:to="KAPA_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_doc" xml:lang="en-US">Schedule of Warrants Outstanding and Exercisable [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit" xlink:to="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit_doc" xml:lang="en-US">Range of exercise prices lower range</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ExercisePriceRangeTwoMember" xlink:to="KAPA_ExercisePriceRangeTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ExercisePriceRangeTwoMember_doc" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_WarrantTwoMember" xlink:to="KAPA_WarrantTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_WarrantTwoMember_doc" xml:lang="en-US">Warrant Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit" xlink:to="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit_doc" xml:lang="en-US">Range of exercise prices upper range</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_WarrantOneMember" xlink:to="KAPA_WarrantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_WarrantOneMember_doc" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ExercisePriceRangeOneMember" xlink:to="KAPA_ExercisePriceRangeOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ExercisePriceRangeOneMember_doc" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber" xlink:to="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_doc" xml:lang="en-US">Number of shares warrants exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:to="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average remaining contractual terms.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" xlink:to="KAPA_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award equity instruments other than options nonvested weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_FairValueOfUnamortizedCompensation" xlink:to="KAPA_FairValueOfUnamortizedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_FairValueOfUnamortizedCompensation_doc" xml:lang="en-US">Fair value of unamortized compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" xlink:to="KAPA_StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts_doc" xml:lang="en-US">Stock issued during period value fair value of common shares to be issued for vendor advance and deferred offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" xlink:to="KAPA_StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts_doc" xml:lang="en-US">Stock issued during period shares fair value of common shares to be issued for vendor advance and deferred offering costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_MasterServiceAndTechnologyAgreementMember" xlink:to="KAPA_MasterServiceAndTechnologyAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_MasterServiceAndTechnologyAgreementMember_doc" xml:lang="en-US">Master Service And Technology Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_MonthlyPayment" xlink:to="KAPA_MonthlyPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_MonthlyPayment_doc" xml:lang="en-US">Monthly payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_BioassayServicesAgreementMember" xlink:to="KAPA_BioassayServicesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_BioassayServicesAgreementMember_doc" xml:lang="en-US">Bioassay Services Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PreCheckHealthServicesIncMember" xlink:to="KAPA_PreCheckHealthServicesIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_PreCheckHealthServicesIncMember_doc" xml:lang="en-US">PreCheck Health Services, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_AdvisoryAndConsultingServicesAgreementMember" xlink:to="KAPA_AdvisoryAndConsultingServicesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_AdvisoryAndConsultingServicesAgreementMember_doc" xml:lang="en-US">Advisory And Consulting Services Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_CEOCATechnologiesLtdMember" xlink:to="KAPA_CEOCATechnologiesLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_CEOCATechnologiesLtdMember_doc" xml:lang="en-US">CEO.CA Technologies Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_BelairCapitalAdvisorsIncMember" xlink:to="KAPA_BelairCapitalAdvisorsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_BelairCapitalAdvisorsIncMember_doc" xml:lang="en-US">Belair Capital Advisors Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ConsultingAgreementMember" xlink:to="KAPA_ConsultingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ConsultingAgreementMember_doc" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_CurrentCapitalLLCMember" xlink:to="KAPA_CurrentCapitalLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_CurrentCapitalLLCMember_doc" xml:lang="en-US">Current Capital LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_SettlementAgreementAmount" xlink:to="KAPA_SettlementAgreementAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_SettlementAgreementAmount_doc" xml:lang="en-US">Settlement agreement amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_VendorPaymentAdvances" xlink:to="KAPA_VendorPaymentAdvances_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_VendorPaymentAdvances_doc" xml:lang="en-US">Vendor payment advances.</link:label>
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PurchaseOfCommonStock" xlink:label="KAPA_PurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PurchaseOfCommonStock" xlink:to="KAPA_PurchaseOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_PurchaseOfCommonStock_doc" xml:lang="en-US">Purchase of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember" xlink:to="KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember_doc" xml:lang="en-US">Helena Global Investment Opportunities I LTD [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_LicenseFee" xlink:to="KAPA_LicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_LicenseFee_doc" xml:lang="en-US">License fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_LicenseAgreementMember" xlink:to="KAPA_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PatentProtectionCosts" xlink:to="KAPA_PatentProtectionCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_PatentProtectionCosts_doc" xml:lang="en-US">Patent protection costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ExclusiveLicenseAgreementMember" xlink:to="KAPA_ExclusiveLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ExclusiveLicenseAgreementMember_doc" xml:lang="en-US">Exclusive License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_RoyaltyPercentage" xlink:to="KAPA_RoyaltyPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_RoyaltyPercentage_doc" xml:lang="en-US">Royalty percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_OtherNonroyaltySublicenseFeesPercentage" xlink:to="KAPA_OtherNonroyaltySublicenseFeesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_OtherNonroyaltySublicenseFeesPercentage_doc" xml:lang="en-US">Other nonroyalty sublicense fees percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PaymentForMilestones" xlink:to="KAPA_PaymentForMilestones_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_PaymentForMilestones_doc" xml:lang="en-US">Payment for milestones.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PhaseOneClinicalTrialMember" xlink:to="KAPA_PhaseOneClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_PhaseOneClinicalTrialMember_doc" xml:lang="en-US">Phase One Clinical Trial [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ItemOneAndTwoMember" xlink:to="KAPA_ItemOneAndTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ItemOneAndTwoMember_doc" xml:lang="en-US">Item One And Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PhaseTwoMember" xlink:to="KAPA_PhaseTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_PhaseTwoMember_doc" xml:lang="en-US">Phase Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ItemThreeMember" xlink:to="KAPA_ItemThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ItemThreeMember_doc" xml:lang="en-US">Item Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PhaseTwoClinicalTrialMember" xlink:to="KAPA_PhaseTwoClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_PhaseTwoClinicalTrialMember_doc" xml:lang="en-US">Phase Two Clinical Trial [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ItemFourMember" xlink:to="KAPA_ItemFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ItemFourMember_doc" xml:lang="en-US">Item Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_MinimumRequirermentOfCapital" xlink:to="KAPA_MinimumRequirermentOfCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_MinimumRequirermentOfCapital_doc" xml:lang="en-US">Minimum requirerment of capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PatentProductSalesPercentage" xlink:to="KAPA_PatentProductSalesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_PatentProductSalesPercentage_doc" xml:lang="en-US">Patent product sales percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_FoodAndDrugAdministrationMember" xlink:to="KAPA_FoodAndDrugAdministrationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_FoodAndDrugAdministrationMember_doc" xml:lang="en-US">Food and Drug Administration [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PhaseThreeMember" xlink:to="KAPA_PhaseThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_PhaseThreeMember_doc" xml:lang="en-US">Phase Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_EnviroCedarsLicenseAgreementsMember" xlink:to="KAPA_EnviroCedarsLicenseAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_EnviroCedarsLicenseAgreementsMember_doc" xml:lang="en-US">Enviro Cedars License Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PhaseThreeClinicalTrialMember" xlink:to="KAPA_PhaseThreeClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_PhaseThreeClinicalTrialMember_doc" xml:lang="en-US">Phase Three Clinical Trial [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_LicenseAgreementDescription" xlink:to="KAPA_LicenseAgreementDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_LicenseAgreementDescription_doc" xml:lang="en-US">License agreement description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_CrossCurrentCapitalLLCMember" xlink:to="KAPA_CrossCurrentCapitalLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_CrossCurrentCapitalLLCMember_doc" xml:lang="en-US">Cross Current Capital LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_WarrantsToPurchaseCommonStockMember" xlink:to="KAPA_WarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_WarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Warrants To Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_WarrantThreeMember" xlink:to="KAPA_WarrantThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_WarrantThreeMember_doc" xml:lang="en-US">Warrant Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ExercisePriceRangeThreeMember" xlink:to="KAPA_ExercisePriceRangeThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ExercisePriceRangeThreeMember_doc" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_DisclosureOfVendorAgreementsTextBlock" xlink:to="KAPA_DisclosureOfVendorAgreementsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_DisclosureOfVendorAgreementsTextBlock_doc" xml:lang="en-US">Disclosure of Vendor Agreements [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ScheduleOfVendorAdvancesTableTextBlock" xlink:to="KAPA_ScheduleOfVendorAdvancesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_ScheduleOfVendorAdvancesTableTextBlock_doc" xml:lang="en-US">Schedule of Vendor Advances [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_VendorAdvancesGross" xlink:to="KAPA_VendorAdvancesGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_VendorAdvancesGross_doc" xml:lang="en-US">Vendor advances gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_VendorAdvancesAccumulatedAmortization" xlink:to="KAPA_VendorAdvancesAccumulatedAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_VendorAdvancesAccumulatedAmortization_doc" xml:lang="en-US">Vendor advances accumulated amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_UnderwritersMember" xlink:to="KAPA_UnderwritersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_UnderwritersMember_doc" xml:lang="en-US">Underwriters [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_DeferredOfferingAdditionalCosts" xlink:to="KAPA_DeferredOfferingAdditionalCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="KAPA_DeferredOfferingAdditionalCosts_doc" xml:lang="en-US">Deferred offering additional costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_PrefundedWarrantsMember" xlink:to="KAPA_PrefundedWarrantsMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_PrefundedWarrantsMember_3_lbl" xml:lang="en-US">Pre-Funded Warrant [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_2_lbl" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_FairValueOfVestedRestrictedStockUnits" xlink:to="KAPA_FairValueOfVestedRestrictedStockUnits_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_FairValueOfVestedRestrictedStockUnits_3_lbl" xml:lang="en-US">FairValueOfVestedRestrictedStockUnits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Payments of Financing Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_2_lbl" xml:lang="en-US">Deferred Offering Costs [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_VendorAdvancesAccumulatedAmortization" xlink:to="KAPA_VendorAdvancesAccumulatedAmortization_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_VendorAdvancesAccumulatedAmortization_3_lbl" xml:lang="en-US">Vendor advances accumulated amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_VendorAdvancesInCash" xlink:to="KAPA_VendorAdvancesInCash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_VendorAdvancesInCash_3_lbl" xml:lang="en-US">VendorAdvancesInCash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_VendorAdvancesCurrent" xlink:to="KAPA_VendorAdvancesCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_VendorAdvancesCurrent_3_lbl" xml:lang="en-US">VendorAdvancesCurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable" xlink:to="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_3_lbl" xml:lang="en-US">ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>kapa-20250331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://kairospharma.com/role/Cover" xlink:href="kapa-20250331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/BalanceSheets" xlink:href="kapa-20250331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/BalanceSheetsParenthetical" xlink:href="kapa-20250331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/StatementsOfOperations" xlink:href="kapa-20250331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit" xlink:href="kapa-20250331.xsd#StatementsOfShareholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/StatementsOfCashFlows" xlink:href="kapa-20250331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/BasisOfPresentation" xlink:href="kapa-20250331.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="kapa-20250331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/VendorAgreements" xlink:href="kapa-20250331.xsd#VendorAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ShareholdersEquity" xlink:href="kapa-20250331.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/CommitmentsAndContingencies" xlink:href="kapa-20250331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SegmentInformation" xlink:href="kapa-20250331.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SubsequentEvents" xlink:href="kapa-20250331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="kapa-20250331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/VendorAgreementsPolicies" xlink:href="kapa-20250331.xsd#VendorAgreementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="kapa-20250331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/VendorAgreementsTables" xlink:href="kapa-20250331.xsd#VendorAgreementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ShareholdersEquityTables" xlink:href="kapa-20250331.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SegmentInformationTables" xlink:href="kapa-20250331.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/BasisOfPresentationDetailsNarrative" xlink:href="kapa-20250331.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:href="kapa-20250331.xsd#ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="kapa-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails" xlink:href="kapa-20250331.xsd#ScheduleOfVendorAdvancesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/VendorAgreementsDetailsNarrative" xlink:href="kapa-20250331.xsd#VendorAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails" xlink:href="kapa-20250331.xsd#ScheduleOfRestrictedCommonStockActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ScheduleOfWarrantActivityDetails" xlink:href="kapa-20250331.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails" xlink:href="kapa-20250331.xsd#ScheduleOfOutstandingAndExercisableWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ShareholdersEquityDetailsNarrative" xlink:href="kapa-20250331.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="kapa-20250331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails" xlink:href="kapa-20250331.xsd#ScheduleOfSegmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SegmentInformationDetailsNarrative" xlink:href="kapa-20250331.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://kairospharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="kapa-20250331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesNet" xlink:label="loc_KAPAVendorAdvancesNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_KAPAVendorAdvancesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CommonStockToBeIssuedValue" xlink:label="loc_KAPACommonStockToBeIssuedValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_KAPACommonStockToBeIssuedValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CommonStockToBeIssuedSharesOutstanding" xlink:label="loc_KAPACommonStockToBeIssuedSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_KAPACommonStockToBeIssuedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaapInvestmentIncomeNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInvestmentIncomeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Shareholders&apos; Equity (Deficit) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CommonStockToBeIssuedMember" xlink:label="loc_KAPACommonStockToBeIssuedMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_KAPACommonStockToBeIssuedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts" xlink:label="loc_KAPAAdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAAdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" xlink:label="loc_KAPAStockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAStockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" xlink:label="loc_KAPAStockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAStockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" xlink:label="loc_KAPAStockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAStockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" xlink:label="loc_KAPAStockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAStockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_FairValueOfVestedRestrictedStockUnits" xlink:label="loc_KAPAFairValueOfVestedRestrictedStockUnits" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_KAPAFairValueOfVestedRestrictedStockUnits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_IncreaseDecreaseInVendorAdvances" xlink:label="loc_KAPAIncreaseDecreaseInVendorAdvances" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_KAPAIncreaseDecreaseInVendorAdvances" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaapSupplementalCashFlowElementsAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowElementsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowElementsAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowElementsAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_IssuanceOfCommonSharesForDeferredOfferingCosts" xlink:label="loc_KAPAIssuanceOfCommonSharesForDeferredOfferingCosts" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_KAPAIssuanceOfCommonSharesForDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_IssuanceOfCommonSharesForVendorAdvances" xlink:label="loc_KAPAIssuanceOfCommonSharesForVendorAdvances" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_KAPAIssuanceOfCommonSharesForVendorAdvances" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/BasisOfPresentation" xlink:title="999012 - Disclosure - BASIS OF PRESENTATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/VendorAgreements" xlink:title="999014 - Disclosure - VENDOR AGREEMENTS">
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_DisclosureVendorAgreementsAbstract" xlink:label="loc_KAPADisclosureVendorAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_DisclosureOfVendorAgreementsTextBlock" xlink:label="loc_KAPADisclosureOfVendorAgreementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_KAPADisclosureVendorAgreementsAbstract" xlink:to="loc_KAPADisclosureOfVendorAgreementsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ShareholdersEquity" xlink:title="999015 - Disclosure - SHAREHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/CommitmentsAndContingencies" xlink:title="999016 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SegmentInformation" xlink:title="999017 - Disclosure - SEGMENT INFORMATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SubsequentEvents" xlink:title="999018 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaapDeferredChargesPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDeferredChargesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/VendorAgreementsPolicies" xlink:title="999020 - Disclosure - VENDOR AGREEMENTS (Policies)">
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_DisclosureVendorAgreementsAbstract" xlink:label="loc_KAPADisclosureVendorAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesPolicyTextBlock" xlink:label="loc_KAPAVendorAdvancesPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_KAPADisclosureVendorAgreementsAbstract" xlink:to="loc_KAPAVendorAdvancesPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/VendorAgreementsTables" xlink:title="999022 - Disclosure - VENDOR AGREEMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_DisclosureVendorAgreementsAbstract" xlink:label="loc_KAPADisclosureVendorAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ScheduleOfVendorAdvancesTableTextBlock" xlink:label="loc_KAPAScheduleOfVendorAdvancesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_KAPADisclosureVendorAgreementsAbstract" xlink:to="loc_KAPAScheduleOfVendorAdvancesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ShareholdersEquityTables" xlink:title="999023 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:label="loc_KAPAScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_KAPAScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SegmentInformationTables" xlink:title="999024 - Disclosure - SEGMENT INFORMATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/BasisOfPresentationDetailsNarrative" xlink:title="999025 - Disclosure - BASIS OF PRESENTATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:title="999026 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_WarrantsToPurchaseCommonStockMember" xlink:label="loc_KAPAWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_KAPAWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapRestructuringCostAndReserveLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_EnviroThreapeuticsIncMember" xlink:label="loc_KAPAEnviroThreapeuticsIncMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_KAPAEnviroThreapeuticsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_EquityLineOfCreditMember" xlink:label="loc_KAPAEquityLineOfCreditMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_KAPAEquityLineOfCreditMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaapBusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_DeferredOfferingAdditionalCosts" xlink:label="loc_KAPADeferredOfferingAdditionalCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_KAPADeferredOfferingAdditionalCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails" xlink:title="999028 - Disclosure - SCHEDULE OF VENDOR ADVANCES (Details)">
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_DisclosureVendorAgreementsAbstract" xlink:label="loc_KAPADisclosureVendorAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_KAPADisclosureVendorAgreementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PrevailInfoworksIncMember" xlink:label="loc_KAPAPrevailInfoworksIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPAPrevailInfoworksIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PreCheckHealthServicesIncMember" xlink:label="loc_KAPAPreCheckHealthServicesIncMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPAPreCheckHealthServicesIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CEOCATechnologiesLtdMember" xlink:label="loc_KAPACEOCATechnologiesLtdMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPACEOCATechnologiesLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_BelairCapitalAdvisorsIncMember" xlink:label="loc_KAPABelairCapitalAdvisorsIncMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPABelairCapitalAdvisorsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CrossCurrentCapitalLLCMember" xlink:label="loc_KAPACrossCurrentCapitalLLCMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPACrossCurrentCapitalLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesGross" xlink:label="loc_KAPAVendorAdvancesGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAVendorAdvancesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesAccumulatedAmortization" xlink:label="loc_KAPAVendorAdvancesAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAVendorAdvancesAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesNet" xlink:label="loc_KAPAVendorAdvancesNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAVendorAdvancesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/VendorAgreementsDetailsNarrative" xlink:title="999029 - Disclosure - VENDOR AGREEMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_DisclosureVendorAgreementsAbstract" xlink:label="loc_KAPADisclosureVendorAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_KAPADisclosureVendorAgreementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_MasterServiceAndTechnologyAgreementMember" xlink:label="loc_KAPAMasterServiceAndTechnologyAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPAMasterServiceAndTechnologyAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_BioassayServicesAgreementMember" xlink:label="loc_KAPABioassayServicesAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPABioassayServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_AdvisoryAndConsultingServicesAgreementMember" xlink:label="loc_KAPAAdvisoryAndConsultingServicesAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPAAdvisoryAndConsultingServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_StrategicAdvisoryAgreementMember" xlink:label="loc_KAPAStrategicAdvisoryAgreementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPAStrategicAdvisoryAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ConsultingAgreementMember" xlink:label="loc_KAPAConsultingAgreementMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPAConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember" xlink:label="loc_KAPAHelenaGlobalInvestmentOpportunitiesILTDMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPAHelenaGlobalInvestmentOpportunitiesILTDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PreCheckHealthServicesIncMember" xlink:label="loc_KAPAPreCheckHealthServicesIncMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPAPreCheckHealthServicesIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CEOCATechnologiesLtdMember" xlink:label="loc_KAPACEOCATechnologiesLtdMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPACEOCATechnologiesLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_BelairCapitalAdvisorsIncMember" xlink:label="loc_KAPABelairCapitalAdvisorsIncMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPABelairCapitalAdvisorsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CurrentCapitalLLCMember" xlink:label="loc_KAPACurrentCapitalLLCMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPACurrentCapitalLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember" xlink:label="loc_KAPAHelenaGlobalInvestmentOpportunitiesILTDMember_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPAHelenaGlobalInvestmentOpportunitiesILTDMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerAdvancesAndDeposits" xlink:label="loc_us-gaapCustomerAdvancesAndDeposits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCustomerAdvancesAndDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesInCash" xlink:label="loc_KAPAVendorAdvancesInCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAVendorAdvancesInCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_IssuanceOfCommonSharesPaidForVendorsAdvances" xlink:label="loc_KAPAIssuanceOfCommonSharesPaidForVendorsAdvances" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAIssuanceOfCommonSharesPaidForVendorsAdvances" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_AmortizationExpenseVendorAdvances" xlink:label="loc_KAPAAmortizationExpenseVendorAdvances" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAAmortizationExpenseVendorAdvances" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorAdvancesCurrent" xlink:label="loc_KAPAVendorAdvancesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAVendorAdvancesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="loc_us-gaapPaymentsForAdvanceToAffiliate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForAdvanceToAffiliate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_MonthlyPayment" xlink:label="loc_KAPAMonthlyPayment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAMonthlyPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManagementFeeExpense" xlink:label="loc_us-gaapManagementFeeExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapManagementFeeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_SettlementAgreementAmount" xlink:label="loc_KAPASettlementAgreementAmount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPASettlementAgreementAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_VendorPaymentAdvances" xlink:label="loc_KAPAVendorPaymentAdvances" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_KAPAVendorPaymentAdvances" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalCollateralAggregateFairValue" xlink:label="loc_us-gaapAdditionalCollateralAggregateFairValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalCollateralAggregateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails" xlink:title="999030 - Disclosure - SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1" xlink:label="loc_KAPASharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_KAPASharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1" xlink:label="loc_KAPASharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_KAPASharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999031 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" xlink:label="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted" xlink:label="loc_KAPAShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled" xlink:label="loc_KAPAShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xlink:label="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised" xlink:label="loc_KAPAShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:label="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited" xlink:label="loc_KAPAShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" xlink:label="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod" xlink:label="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable" xlink:label="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails" xlink:title="999032 - Disclosure - SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ExercisePriceRangeOneMember" xlink:label="loc_KAPAExercisePriceRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_KAPAExercisePriceRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ExercisePriceRangeTwoMember" xlink:label="loc_KAPAExercisePriceRangeTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_KAPAExercisePriceRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ExercisePriceRangeThreeMember" xlink:label="loc_KAPAExercisePriceRangeThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_KAPAExercisePriceRangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_WarrantOneMember" xlink:label="loc_KAPAWarrantOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_KAPAWarrantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_WarrantTwoMember" xlink:label="loc_KAPAWarrantTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_KAPAWarrantTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_WarrantThreeMember" xlink:label="loc_KAPAWarrantThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_KAPAWarrantThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" xlink:label="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber" xlink:label="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" xlink:label="loc_KAPAShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit" xlink:label="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit" xlink:label="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_KAPAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ShareholdersEquityDetailsNarrative" xlink:title="999033 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_SecurityPurchaseAgreementMember" xlink:label="loc_KAPASecurityPurchaseAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_KAPASecurityPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PreFundedWarrantMember" xlink:label="loc_KAPAPreFundedWarrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_KAPAPreFundedWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PrefundedWarrantsMember" xlink:label="loc_KAPAPrefundedWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_KAPAPrefundedWarrantsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CommonWarrantsMember" xlink:label="loc_KAPACommonWarrantsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_KAPACommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_TwentyTwentyThreeEquityIncentivePlanMember" xlink:label="loc_KAPATwentyTwentyThreeEquityIncentivePlanMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_KAPATwentyTwentyThreeEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_StrategicAdvisoryAgreementMember" xlink:label="loc_KAPAStrategicAdvisoryAgreementMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPAStrategicAdvisoryAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_FourOfficersAgreementMember" xlink:label="loc_KAPAFourOfficersAgreementMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPAFourOfficersAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_DirectorAgreementsMember" xlink:label="loc_KAPADirectorAgreementsMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPADirectorAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ThreeIndependentDirectorsMember" xlink:label="loc_KAPAThreeIndependentDirectorsMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_KAPAThreeIndependentDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_UnderwritersMember" xlink:label="loc_KAPAUnderwritersMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_KAPAUnderwritersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_SharesAuthorized" xlink:label="loc_KAPASharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_KAPASharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription" xlink:label="loc_KAPAClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_KAPAClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" xlink:label="loc_KAPAStockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_KAPAStockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_WarrantsUnexercised" xlink:label="loc_KAPAWarrantsUnexercised" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_KAPAWarrantsUnexercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_FairValueOfRestrictedStockUnits" xlink:label="loc_KAPAFairValueOfRestrictedStockUnits" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_KAPAFairValueOfRestrictedStockUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_FairValueOfUnamortizedCompensation" xlink:label="loc_KAPAFairValueOfUnamortizedCompensation" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_KAPAFairValueOfUnamortizedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaapProductLiabilityContingencyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapProductLiabilityContingencyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaapProductLiabilityContingencyLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapProductLiabilityContingencyLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_LicenseAgreementMember" xlink:label="loc_KAPALicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPALicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ExclusiveLicenseAgreementMember" xlink:label="loc_KAPAExclusiveLicenseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPAExclusiveLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_EnviroCedarsLicenseAgreementsMember" xlink:label="loc_KAPAEnviroCedarsLicenseAgreementsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_KAPAEnviroCedarsLicenseAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtProductOrServiceAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PhaseOneClinicalTrialMember" xlink:label="loc_KAPAPhaseOneClinicalTrialMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_KAPAPhaseOneClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ItemOneAndTwoMember" xlink:label="loc_KAPAItemOneAndTwoMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_KAPAItemOneAndTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ItemThreeMember" xlink:label="loc_KAPAItemThreeMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_KAPAItemThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_ItemFourMember" xlink:label="loc_KAPAItemFourMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_KAPAItemFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PhaseThreeClinicalTrialMember" xlink:label="loc_KAPAPhaseThreeClinicalTrialMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_KAPAPhaseThreeClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PhaseTwoMember" xlink:label="loc_KAPAPhaseTwoMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_KAPAPhaseTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PhaseTwoClinicalTrialMember" xlink:label="loc_KAPAPhaseTwoClinicalTrialMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_KAPAPhaseTwoClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PhaseThreeMember" xlink:label="loc_KAPAPhaseThreeMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_KAPAPhaseThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtStatementGeographicalAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaapNonUsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_us-gaapNonUsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_deiLegalEntityAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_FoodAndDrugAdministrationMember" xlink:label="loc_KAPAFoodAndDrugAdministrationMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPAFoodAndDrugAdministrationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_LicenseFee" xlink:label="loc_KAPALicenseFee" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_KAPALicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PatentProtectionCosts" xlink:label="loc_KAPAPatentProtectionCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_KAPAPatentProtectionCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostMaintenance" xlink:label="loc_us-gaapCostMaintenance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapCostMaintenance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_RoyaltyPercentage" xlink:label="loc_KAPARoyaltyPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_KAPARoyaltyPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_OtherNonroyaltySublicenseFeesPercentage" xlink:label="loc_KAPAOtherNonroyaltySublicenseFeesPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_KAPAOtherNonroyaltySublicenseFeesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PaymentForMilestones" xlink:label="loc_KAPAPaymentForMilestones" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_KAPAPaymentForMilestones" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_MinimumRequirermentOfCapital" xlink:label="loc_KAPAMinimumRequirermentOfCapital" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_KAPAMinimumRequirermentOfCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_PatentProductSalesPercentage" xlink:label="loc_KAPAPatentProductSalesPercentage" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_KAPAPatentProductSalesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_LicenseAgreementDescription" xlink:label="loc_KAPALicenseAgreementDescription" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_KAPALicenseAgreementDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails" xlink:title="999035 - Disclosure - SCHEDULE OF SEGMENT EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srtConsolidationItemsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtConsolidationItemsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srtConsolidationItemsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidationItemsAxis" xlink:to="loc_srtConsolidationItemsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaapOperatingSegmentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidationItemsDomain" xlink:to="loc_us-gaapOperatingSegmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceRecoveries" xlink:label="loc_us-gaapInsuranceRecoveries" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInsuranceRecoveries" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaapOtherOperatingIncomeExpenseNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherOperatingIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SegmentInformationDetailsNarrative" xlink:title="999036 - Disclosure - SEGMENT INFORMATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_CrossCurrentCapitalLLCMember" xlink:label="loc_KAPACrossCurrentCapitalLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPACrossCurrentCapitalLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="kapa-20250331.xsd#KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember" xlink:label="loc_KAPAHelenaGlobalInvestmentOpportunitiesILTDMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_KAPAHelenaGlobalInvestmentOpportunitiesILTDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 13, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KAIROS
PHARMA, LTD.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001962011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-2993314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2355 Westwood Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">#139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Los Angeles<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">948-2356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KAPA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,849,306<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,616<span></span>
</td>
<td class="nump">$ 1,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_VendorAdvancesNet', window );">Vendor advances, net</a></td>
<td class="nump">2,379<span></span>
</td>
<td class="nump">2,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">6,050<span></span>
</td>
<td class="nump">4,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="nump">1,705<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Other Assets</a></td>
<td class="nump">1,887<span></span>
</td>
<td class="nump">1,599<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">7,937<span></span>
</td>
<td class="nump">5,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001, 20,000,000 shares authorized; no shares issued and outstanding, respectively;</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001, 100,000,000 shares authorized; 15,825,118 and 13,736,597 shares issued and outstanding, respectively;</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_CommonStockToBeIssuedValue', window );">Common stock to be issued, 551,000 shares outstanding at March 31, 2025</a></td>
<td class="nump">484<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">16,709<span></span>
</td>
<td class="nump">13,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(10,077)<span></span>
</td>
<td class="num">(8,815)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders&#8217; Equity</a></td>
<td class="nump">7,132<span></span>
</td>
<td class="nump">4,776<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 7,937<span></span>
</td>
<td class="nump">$ 5,768<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_CommonStockToBeIssuedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock to be issued value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_CommonStockToBeIssuedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_VendorAdvancesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vendor advances net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_VendorAdvancesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">15,825,118<span></span>
</td>
<td class="nump">13,736,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">15,825,118<span></span>
</td>
<td class="nump">13,736,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_CommonStockToBeIssuedSharesOutstanding', window );">Common stock to be issued, shares outstanding</a></td>
<td class="nump">551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_CommonStockToBeIssuedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock to be issued shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_CommonStockToBeIssuedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">493<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">773<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,266<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,266)<span></span>
</td>
<td class="num">(287)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Debt discount amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="nump">4<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expenses)</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (1,262)<span></span>
</td>
<td class="num">$ (323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">BASIC LOSS PER COMMON SHARE</a></td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">DILUTED LOSS PER COMMON SHARE</a></td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">BASIC</a></td>
<td class="nump">15,875,485<span></span>
</td>
<td class="nump">10,562,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">DILUTED</a></td>
<td class="nump">15,875,485<span></span>
</td>
<td class="nump">10,562,640<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity (Deficit) (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Common Stock To Be Issued [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,123<span></span>
</td>
<td class="num">$ (6,212)<span></span>
</td>
<td class="num">$ (2,078)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">10,562,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(323)<span></span>
</td>
<td class="num">(323)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,123<span></span>
</td>
<td class="num">(6,535)<span></span>
</td>
<td class="num">(2,401)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="nump">10,562,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,123<span></span>
</td>
<td class="num">(6,212)<span></span>
</td>
<td class="num">(2,078)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">10,562,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13,577<span></span>
</td>
<td class="num">(8,815)<span></span>
</td>
<td class="nump">4,776<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">13,736,597<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts', window );">Proceeds from the sale of pre-funded warrants, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,056<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants', window );">Issuance of common shares upon the exercise of pre-funded warrants</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants', window );">Issuance of common shares upon the exercise of pre-funded warrants, shares</a></td>
<td class="nump">2,010,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts', window );">Fair value of common shares to be issued for vendor advance and deferred offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 484<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts', window );">Fair value of common shares to be issued for vendor advance and deferred offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Fair value of vested restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Fair value of vested restricted stock units, shares</a></td>
<td class="nump">78,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,262)<span></span>
</td>
<td class="num">(1,262)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 484<span></span>
</td>
<td class="nump">$ 16,709<span></span>
</td>
<td class="num">$ (10,077)<span></span>
</td>
<td class="nump">$ 7,132<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2025</a></td>
<td class="nump">15,825,118<span></span>
</td>
<td class="nump">551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital proceeds from sale of prefunded warrants net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares fair value of common shares to be issued for vendor advance and deferred offering costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issuance of common shares upon exercise of prefunded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value fair value of common shares to be issued for vendor advance and deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of common shares upon exercise of prefunded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,262)<span></span>
</td>
<td class="num">$ (323)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense - intangible asset</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_FairValueOfVestedRestrictedStockUnits', window );">Fair value of vested restricted stock units</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_IncreaseDecreaseInVendorAdvances', window );">Vendor advances</a></td>
<td class="nump">636<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(187)<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(714)<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Sale and exercise of prefunded warrants</a></td>
<td class="nump">3,058<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of deferred offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">3,058<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash</a></td>
<td class="nump">2,344<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents beginning of period</a></td>
<td class="nump">1,272<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents end of period</a></td>
<td class="nump">3,616<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental cash flows disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Taxes paid</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental non-cash financing disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_IssuanceOfCommonSharesForDeferredOfferingCosts', window );">Common shares issued for deferred offering costs</a></td>
<td class="nump">328<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_IssuanceOfCommonSharesForVendorAdvances', window );">Common shares issued for vendor advance</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_FairValueOfVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of vested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_FairValueOfVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_IncreaseDecreaseInVendorAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in vendor advances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_IncreaseDecreaseInVendorAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_IssuanceOfCommonSharesForDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares for deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_IssuanceOfCommonSharesForDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_IssuanceOfCommonSharesForVendorAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares for vendor advances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_IssuanceOfCommonSharesForVendorAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (1,262)<span></span>
</td>
<td class="num">$ (323)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zeNelbWjJVki" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>NOTE 1 &#8211; <span id="xdx_82B_zFS9CXK2zAq7">BASIS OF PRESENTATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>Organization and Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Kairos Pharma, Ltd. (the &#8220;Company&#8221; or
&#8220;Kairos&#8221;) was incorporated on June 17, 2013 under the laws of the state of California as NanoGB13, Inc. The Company changed
its name to Kairos Pharma, Ltd. on July 15, 2016 and subsequently converted into a Delaware corporation under the same name, Kairos Pharma,
Ltd., on May 10, 2023. The Company is an early-stage biotechnology company focused on the development of immunotherapy and cell therapy
treatments for oncology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b>Basis of Presentation
of Unaudited Financial Information </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">The
accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles
generally accepted in the United States for interim financial information and the instructions to Form 10-Q and Rule 10-01 of
Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting
principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary
for a fair presentation have been included. Operating results for the three months ended March 31, 2025, are not necessarily
indicative of the results that may be expected for the year ending December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization
of assets and the settlement of liabilities and commitments in the normal course of business.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2025, the Company incurred a net loss of $<span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20250101__20250331_ztt2sJYsJd6l" title="Net loss">1,262</span>&#160;and used cash in operations of $<span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20250101__20250331_zs7bN1jDJTP7" title="Cash in operations">714</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, the Company closed a private financing in which the Company received net proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20250101__20250131_zpBuO4rEE97h" title="Net proceeds from offering">3,145</span>, and at March 31, 2025,
the Company had cash and cash equivalents totaling $<span id="xdx_90F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20250331_zb8TldjEhKXe" title="Cash and cash equivalents">3,616</span>&#160;and shareholders&#8217; equity of $<span id="xdx_905_eus-gaap--StockholdersEquity_iI_pn3n3_c20250331_zcd23idEH5P1" title="Shareholders' equity">7,132</span>. The Company expects its
current cash reserves to fund the Company&#8217;s operations for at least 12 months from the date of this filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in
the future, which will primarily be accomplished by raising additional capital to meet its operating needs and repay its liabilities
arising from normal business operations when they come due. Since inception, the Company has funded its operations primarily through
equity and debt financings and it expects to continue to rely on these sources of capital in the future until it is able to generate
revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to
the Company. Even if the Company is able to obtain additional financing, such financing may contain undue restrictions on our operations,
in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zIAdKQ2HwWO1" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="background-color: white"><b>NOTE 2 -
<span id="xdx_826_zf0OtYmGdAJi">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zOkRiq0UKjP9" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="background-color: white"><b><span id="xdx_864_zYxatAsNGs2h">Basis of
Consolidation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The
accompanying condensed consolidated financial statements and accompanying notes have been prepared in accordance with accounting
principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying condensed consolidated
financial statements include the accounts of the Company and its wholly owned subsidiary, Enviro Therapeutics, Inc.
(&#8220;Enviro&#8221;). All intercompany balances and transactions have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p id="xdx_84E_eus-gaap--UseOfEstimates_zDiSjzzSHV3h" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_860_zJyaYE3qESYe">Use of Estimates</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The preparation of the financial statements in conformity
with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts
of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accruals for potential liabilities,
valuations of stock-based compensation, the realization of deferred tax assets, and impairment analysis and useful life for intangible
assets among others. Actual results could differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zhq94cFuVsZ8" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_86C_z4sbsgETDg8a">Concentration of Credit Risk</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Financial instruments, which potentially subject the
Company to concentration of credit risk, consist primarily of cash deposits. The Company maintains deposits in federally insured financial
institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due
to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses
on deposits since its inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQVxrqcLBLh7" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_86B_zC44RJl7CIr4">Cash Equivalents</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Company considers all highly liquid investments
with original maturities of three months or less on the date of purchase to be cash equivalents. Cash equivalents consisted of money market
funds as of March 31, 2025. There were <span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20241231_zdo5haAu0w6g" title="Cash equivalents">no</span> cash equivalents as of December 31, 2024. As of March 31, 2025, the amount of cash equivalents
included in cash and cash equivalents totaled $<span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20250331_zBdf2sxHleOj" title="Cash equivalents">3,504</span>. The underlying securities in the money market funds held by the Company are all
government backed securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p id="xdx_844_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zQYCNnpXR7eb" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_86D_zSDuiKUe9A82">Intangible Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Company&#8217;s intangible assets are stated at
fair value as of the date acquired, less accumulated amortization. Amortization is calculated based on the estimated useful lives of the
assets, which were determined to be <span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dc_c20250331_zTbXG9AR5Lll" title="Intangible assets useful life">five years</span>, using the straight-line method. The intangible asset consists of a licensing agreement
that the Company acquired through its acquisition of Enviro during the year ended December 31, 2021, with an acquisition
cost of $<span id="xdx_90D_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_pn3n3_c20211231__us-gaap--BusinessAcquisitionAxis__custom--EnviroThreapeuticsIncMember_zHpRYAmvGkFi" title="Acquisition cost">800</span>. Amortization expense relating to the intangible asset during the three months ended March 31, 2025 and 2024 was $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20250101__20250331_zunLGsSr22Q9" title="Amortization expenses"><span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240101__20240331_zfqPWqgpJ6i9" title="Amortization expenses">40</span></span>, respectively,
with an unamortized balance of $<span id="xdx_90B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20250331_z4ulo3hNsNr7" title="Intangible assets unamortized balance">182</span> and $<span id="xdx_90E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20241231_zwUj3ulbgYVf" title="Intangible assets unamortized balance">222</span> at March 31, 2025 and December 31, 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zdkZtWrXr199" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><b><span><span id="xdx_862_zzgt8VHN0Ug7">Impairment of Long-Lived
Assets</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Company applies the provisions of ASC Topic 360,
<i>Property, Plant, and Equipment</i>, which addresses financial accounting and reporting for the impairment of long-lived assets. A long-lived
asset that is held and used should be tested for recoverability whenever events or changes in circumstances indicate that the carrying
amount of the asset group may not be recoverable. If the estimated undiscounted
future cash flows are less than the carrying value, an impairment determination is required. In that event, a loss is recognized based
on the amount by which the carrying amount exceeds the fair value of the long-lived assets. <span id="xdx_90A_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pn3n3_do_c20250101__20250331_zmYqEVsxlK6b" title="Impairment of intangible assets"><span id="xdx_90A_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pn3n3_do_c20240101__20240331_zuftzu83Acma" title="Impairment of intangible assets">No</span></span> impairment was recorded relating to the
Company&#8217;s intangible asset during the three months ended March 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zSNqSpNPsyxl" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_86C_ztQC0cp5KIS8">Income (Loss) Per Share</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Basic loss per share is computed by dividing net loss
applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share
is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus
the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zEr8aWBQ0z0l" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">For the three months ended March 31, 2025 and 2024,
the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. The potentially
dilutive securities consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="xdx_8B0_zX66bhEgul26" style="display: none">SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20250101__20250331_zTIhOkr4S1xl" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20240331_zWHWDvfZ4Qpl" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2024</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zJlzlViCK8J9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Warrants to purchase common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4,543,188</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">150,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zNxS3XyLOHVh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">113,599</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zhQVSBZIkIth" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,656,787</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">150,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zoYQPGs7Sij" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b>&#160;</b></p>

<p id="xdx_845_eus-gaap--DeferredChargesPolicyTextBlock_z1yrQvKC7rKh" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><span id="xdx_863_zzoCf4kSJiNe">Deferred Offering Costs</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The
Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity
issuances as deferred offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs
are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be delayed or abandoned,
the deferred offering costs will be expensed immediately as a charge to operating expenses in the Statement of Operations. As of December
31, 2024, the Company incurred $<span id="xdx_902_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--EquityLineOfCreditMember_zWXIMHUyHEk7">1,377
</span>of deferred offering costs related to the Company&#8217;s pending Equity Line of Credit (ELOC) offering. During the three months
ended March 31, 2025, the Company incurred $<span id="xdx_90D_ecustom--DeferredOfferingAdditionalCosts_iI_pn3n3_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--EquityLineofCreditMember_zaTIoYRuDcW5" title="Deferred offering additional cost">328
</span>of additional costs related to the ELOC, and as of March 31, 2025, total deferred offering costs were $<span id="xdx_907_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--EquityLineofCreditMember_zK0Ol2liMitg">1,705</span> related to the ELOC. The ELOC was declared effective on April 24, 2025, and the Company will amortize these costs as cost of capital as
the funds are raised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p id="xdx_84B_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z36aILlhLgRj" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_866_zjflgjo1cuYd">Fair Value Measurements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; text-indent: 0.2pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Company determines the fair value of its assets
and liabilities based on the exchange price in U.S. dollars that would be received to sell an asset or paid to transfer a liability (an
exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of
unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable
and the last unobservable, to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><i>Level 1 &#8212;</i> Quoted prices in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><i>Level 2 &#8212;</i> Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><i>Level 3 &#8212;</i> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The
carrying amounts of financial instruments such as cash, and accounts payable and accrued liabilities, approximate the related fair values
due to the short-term maturities of these instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Cash equivalents consisted of money market funds at
March 31, 2025. Money market funds were valued by the Company using quoted prices in active markets for identical securities, which represent
a Level 1 measurement within the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zs1TfzBwDLZ" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_868_z8xjIVgzQhaj">Recent Accounting Pronouncements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">In November 2024, FASB issued ASU 2024-03 Income Statement&#8212;Reporting
Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses. The guidance
in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information
about certain costs and expenses including purchases of inventory; employee compensation; and depreciation and amortization expense for
each caption on the income statement where such expenses are included. The update is effective for annual reporting periods beginning
after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments
may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial
statements. We are currently evaluating the provisions of this guidance and assessing the potential impact on our financial statement
disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Other recent accounting pronouncements issued by the
FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange
Commission did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated financial
statements.</p>

<p id="xdx_859_zVmeNxeIMm97" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>VENDOR AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_DisclosureVendorAgreementsAbstract', window );"><strong>Vendor Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_DisclosureOfVendorAgreementsTextBlock', window );">VENDOR AGREEMENTS</a></td>
<td class="text"><p id="xdx_807_ecustom--DisclosureOfVendorAgreementsTextBlock_zQJpXCyjjeek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8211; <span id="xdx_821_zT9jWaEcGprl">VENDOR AGREEMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84A_ecustom--VendorAdvancesPolicyTextBlock_zOtuPccDdpK8" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_86F_z3UKkIMW4u24">Vendor Advances</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The
Company has entered into various contracts with service providers pursuant to which the Company pays the vendor an advance at the
beginning of the contractual period. These vendor advances could be paid by the Company either in cash or in shares of common stock,
depending on the terms of the contract. The advances are reduced by the accumulated value of the services performed by the vendor or
are amortized on a straight-line basis over the service period, whichever is shorter. As of December 31, 2024, advances to vendors
totaled $<span id="xdx_90C_eus-gaap--CustomerAdvancesAndDeposits_iI_pn3n3_c20241231_zugSftaZDSWc" title="Advances to vendor amount">3,115</span>, with $<span id="xdx_90C_ecustom--VendorAdvancesInCash_iNI_pn3n3_di_c20241231_zNSTeIrdLhXb" title="Vendor advances in cash">2,615</span> being paid in cash and $<span id="xdx_902_ecustom--IssuanceOfCommonSharesPaidForVendorsAdvances_pn3n3_c20240101__20241231_zswPgID777F7" title="Issuance of common shares paid for vendors advances">500</span> being paid with shares of the Company&#8217;s common stock (see Note 4).
Amortization expense relating to the vendor advances during the year ended December 31, 2024 was $<span id="xdx_901_ecustom--AmortizationExpenseVendorAdvances_pn3n3_c20240101__20241231_zG0xS9taYI12" title="Amortization expense relating to vendor advances">256</span>, with an unamortized balance
of $<span id="xdx_900_ecustom--VendorAdvancesCurrent_iI_pn3n3_c20241231_zNdSyV9ug8A7" title="Vendor advances">2,859</span> as of December 31, 2024. During the three months ended March 31, 2025, additional advances to vendors totaled $<span id="xdx_905_ecustom--IssuanceOfCommonSharesPaidForVendorsAdvances_pn3n3_c20250101__20250331_zGHRqulU2S7e" title="Issuance of common shares paid for vendors advances">156</span>, with
the advance being paid with shares of the Company&#8217;s common stock (see Notes 3 and 4). Amortization expense relating to the
vendor advances was $<span id="xdx_90A_ecustom--AmortizationExpenseVendorAdvances_pn3n3_c20250101__20250331_zUHuliREq3Tl" title="Amortization expense relating to vendor advances">636</span>, with an unamortized balance of $<span id="xdx_903_ecustom--VendorAdvancesCurrent_iI_pn3n3_c20250331_znuraBHHDmT4" title="Vendor advances">2,379</span> as of March 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p id="xdx_897_ecustom--ScheduleOfVendorAdvancesTableTextBlock_zBHJpnMELoPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vendor
advances consisted of the following at March 31, 2025, and December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zPEy2vznLef8" style="display: none">SCHEDULE
OF VENDOR ADVANCES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250331_zMBMKTy3m0M7" style="border-bottom: Black 1pt solid; text-align: center">March 31,<br/> 2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_zWgJyV0SPHV3" style="border-bottom: Black 1pt solid; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_409_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--PrevailInfoworksIncMember_zYsH4hFTQDu" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F4F_zIlElyXVuLjf" style="width: 64%; text-align: justify; text-indent: -12pt; padding-left: 12pt">Prevail Infoworks (a)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">900</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">900</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zu0l7EtIN1j4" style="vertical-align: bottom; background-color: White">
    <td id="xdx_F42_z2mPBU0QOL15" style="text-align: justify; text-indent: -12pt; padding-left: 12pt">PreCheck Health Services (b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">900</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zEW5CuxIuXF3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F45_z27GEf7cW9mh" style="text-align: justify; text-indent: -12pt; padding-left: 12pt">CEO.CA Technologies (c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zaYjFvFN5kvk" style="vertical-align: bottom; background-color: White">
    <td id="xdx_F48_zhHNaFSHYl53" style="text-align: justify; text-indent: -12pt; padding-left: 12pt">Belair Capital Advisors (d)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">365</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--CrossCurrentCapitalLLCMember_z9WNeQNhcHRf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F46_zp8WQRJ4lTFf" style="text-align: justify; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Cross Current Capital (e)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">856</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">700</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--VendorAdvancesGross_iI_maVANzSvy_zniJYtW0OSve" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Vendor advances, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,271</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,115</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--VendorAdvancesAccumulatedAmortization_iNI_di_msVANzSvy_zjnKmRDVplX8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(892</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(256</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--VendorAdvancesNet_iTI_mtVANzSvy_zmvZB94q6Je4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: justify; text-indent: -12pt; padding-left: 12pt">Vendor advances, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,379</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,859</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(a)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with Prevail Infoworks, Inc.</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2024, the Company entered into a master service and technology agreement with Prevail Infoworks, Inc. (&#8220;Prevail&#8221;),
pursuant to which Prevail agreed to provide certain clinical research services to the Company. As part of the agreement, the Company
was required to make an advance payment of $<span id="xdx_905_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_zprPoAiaebDh" title="Advance payment">900</span> to Prevail before commencement of services and, at such time as we notify Prevail to
engage their services related to the relevant clinical trial, or six months from the date of the agreement, pay approximately $<span id="xdx_90A_ecustom--MonthlyPayment_pn3n3_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_z5ccsCCqpfnh" title="Monthly payment">80</span> per
month during the time Prevail performs clinical research services for the Company&#8217;s Phase 2 ENV 105 prostate and Phase 1 ENV 105
lung clinical trials. The agreement with Prevail is subject to cancellation at any time upon 30 days&#8217; written notice to the other
party. The Company made the advance payment to Prevail in October 2024 and it is included in vendor advances on the accompanying balance
sheet as of March 31, 2025 and December 31, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(b)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with PreCheck Health Services, Inc.</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2024, the Company entered into a bioassay services agreement (the &#8220;Bioassay Services Agreement&#8221;) with PreCheck
Health Services, Inc., a Florida-based corporation (&#8220;PreCheck&#8221;). Pursuant to the Bioassay Services Agreement, PreCheck will
provide certain biomarker screening services for the Company&#8217;s ongoing carotuximab (ENV105) clinical trials in order to assist
the Company in identifying lung and prostate cancer patients suitable to the Company&#8217;s ongoing Phase 1 clinical trials for lung
cancer patients and Phase 2 clinical trials for patients with castrate resistant prostate cancer. In exchange for PreCheck&#8217;s services,
and according to the terms of the Bioassay Services Agreement, the Company paid $<span id="xdx_904_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240920__20240920__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zduXccqjwVB3" title="Payments for services">900</span> to PreCheck as an advance for the future laboratory
services to be performed. The payment of $<span id="xdx_90D_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zwLbkpGeqLZc" title="Payments for vendor advance"><span id="xdx_90F_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zjW07xt7c818" title="Payments for vendor advance">900</span></span> is included in vendor advances on the accompanying balance sheet as of March 31, 2025 and
December 31, 2024 (see Note 2). The term of the agreement is one year from the effective date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(c)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with CEO.CA Technologies Ltd.</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2024, the Company entered into an advisory and consulting services agreement (the &#8220;CEO.CA Agreement&#8221;) with
CEO.CA Technologies Ltd., a Canadian company (&#8220;CEO.CA&#8221;), pursuant to which CEO.CA will provide certain internet-based financial
information and communications services for a period of one year for a services fee of $<span id="xdx_90B_eus-gaap--ManagementFeeExpense_pn3n3_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zdwOjkCdY2mk" title="Service fee">250</span>. The service fee is an advance on future
services to be performed. The CEO.CA Agreement includes such services as strategic news placement, news releases, interviews, monthly
analytics and a video launch. The CEO.CA Agreement contains other customary clauses, including representations and warranties, indemnification
clauses and governing law clauses. The payment of $<span id="xdx_907_eus-gaap--ManagementFeeExpense_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zCcYQ0z44iD2" title="Service fee"><span id="xdx_90E_eus-gaap--ManagementFeeExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zQ4vCZ1jJsAd" title="Service fee">250</span></span> is included in vendor advances on the accompanying balance sheet as of March 31,
2025, and December 31, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(d)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with Belair Capital Advisors Inc.</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2024, the Company entered into a strategic advisory agreement (the &#8220;Strategic Advisory Agreement&#8221;) with Belair
Capital Advisors Inc. (&#8220;BCA&#8221;). BCA, a venture capital and corporate finance advisory firm, has been a long-term investor
and advisor to the Company and frequently works with early-stage pharmaceutical companies. The strategic advisory services provided by
BCA consist of corporate strategy, market positioning and long-term growth plans within the pharmaceutical sector, digital marketing
and engagement, market research analysis and business development assistance, among other things. During the one-year term of the Strategic
Advisory Agreement, in exchange for its services, the Company will pay BCA a $<span id="xdx_90B_eus-gaap--ManagementFeeExpense_pn3n3_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zWK09mzIVjcf" title="Service fee">365</span> fee and will issue BCA <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zH4wUeKY4gce" title="Number of shares issued">50,000</span> RSUs, which will vest
at the end of six months following the date of issuance. The payment of $<span id="xdx_904_eus-gaap--ManagementFeeExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_z5u2qaE8GJ13" title="Service fee"><span id="xdx_90E_eus-gaap--ManagementFeeExpense_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zqWNwT1AmMp2" title="Service fee">365</span></span> is included in vendor advances on the accompanying balance
sheet as of March 31, 2025, and December 31, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(e)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with Cross Current Capital LLC</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2024, the Company entered into a consulting agreement (the &#8220;Consulting Agreement&#8221;) with Cross Current Capital
LLC, a limited liability company organized under the laws of Puerto Rico (&#8220;Cross Current&#8221;), and Alan Masley (the &#8220;Advisor&#8221;),
pursuant to which Cross Current agreed to provide certain financial and business consulting services to the Company including, but not
limited, to (a) help drafting a public company competitive overview, (b) help preparing and/or reviewing a valuation analysis, (c) help
in drafting marketing materials and presentations, (d) reviewing the Company&#8217;s business requirements and discuss financing and
businesses opportunities, (e) investor marketing, (f) investor relations introductions, (g) legal counsel introductions, (h) auditor
introductions, (i) investment banking and research introductions, (j) M&amp;A canvassing and ways to grow the business organically, and
(k) stand by capital markets advisory services. For the services rendered thereunder, the Company agreed to pay Cross Current $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zs967aIjw35a" title="Number of shares issued, value">200,000</span>
in cash and agreed to issue to the Advisor $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zg32SQq41PFa" title="Number of shares issued, value">500</span> of restricted shares of the Company&#8217;s common stock under the Company&#8217;s 2023
Plan , calculated at <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zwdhN9xZw456" title="Number of shares issued">367,647</span> shares (the &#8220;Shares&#8221;) as of the date of the agreement. The term of the Consulting Agreement
is 24 months and can be extended for another 12 months with the written consent of both parties. The Company made the $<span id="xdx_900_ecustom--SettlementAgreementAmount_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z06niaGMIAY" title="Settlement agreement amount">200</span> payment in
October 2024. The payment of $<span id="xdx_903_ecustom--VendorPaymentAdvances_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zuE1Up2Yf3Oc" title="Vendor payment advances">200</span> and the value of the shares issued of $<span id="xdx_90B_eus-gaap--AdditionalCollateralAggregateFairValue_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z6yCdjjdyhR4" title="Aggregate fair value of the common stock"><span id="xdx_904_eus-gaap--AdditionalCollateralAggregateFairValue_iI_pn3n3_c20250331__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zdHaZRYlUKB9" title="Aggregate fair value of the common stock">500</span></span> are included in vendor advances on the accompanying balance
sheet as of March 31, 2025, and December 31, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTfiiSp4Yj82" title="Stock issued shares">367,647</span> shares issued in 2024 were subject to a &#8220;true up&#8221; on April 1, 2025, at which time additional shares will be issued
to the Advisor (or returned by the Advisor to the Company) in order to ensure the shares are valued at $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIZpvH8zT7f" title="Number of shares issued, value">500</span> as of April 1, 2025. On April
1, 2025, the Company issued an additional<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z30ZJg7BXA84" title="Number of shares issued">166,541</span> shares of its common stock to the Advisor. The fair value of the additional shares on
the date of grant was $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgBbAS3MRlag" title="Number of shares issued, value">156</span>. The Company recorded the shares as common stock to be issued as of March 31, 2025, and recorded the fair
value of the shares as a vendor advance as of the same date (see Notes 2 and 4).</span></p>

<p id="xdx_8A1_zKXzBpgYIBPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Agreement
with Helena Global Investment Opportunities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2024, the Company entered into an agreement with Helena Global Investment Opportunities I LTD (&#8220;Helena&#8221;) pursuant
to which the Company will have the right to issue and sell to Helena, from time to time, and Helena shall purchase from the Company,
up to $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20241112__20241112__us-gaap--TypeOfArrangementAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember_zX8ZODczRail" title="Number of shares issued, value">30,000</span> of the Company&#8217;s shares of common stock (the &#8220;Equity Line of Credit&#8221;). The Equity Line of Credit will
become available to the Company at such time as it files a registration statement on Form S-1 registering the shares issuable under the
Equity Line of Credit. In exchange for the Equity Line of Credit, the Company is obligated to issue Helena a certain number of shares
of common stock, calculated using $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20241112__20241112_zOkFyaO9FIBl" title="Number of shares issued, value">900</span> divided by the lowest one-day VWAP during the five trading days prior to entry into the agreement.
As a result, the Company issued Helena <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241112__20241112__us-gaap--TypeOfArrangementAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember_zoIsXhxdEUKl" title="Number of shares issued">670,641</span> shares of its common stock valued at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueOther_pn3n3_c20241112__20241112__us-gaap--TypeOfArrangementAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember_zENKFjeTkvdl" title="Stock issued  value">1,377</span> on the date of issuance. The Company accounted
for the value of the shares issued as deferred offering costs (see Note 2). The shares vested on the date of the agreement, were issued
to Helena, and are subject to a &#8220;true up&#8221; based upon the value of the stock at the time the company files and obtains effectiveness
of a registration statement registering the shares for resale. In addition, the Company agreed to register such shares for resale pursuant
to a registration statement on Form S-1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 24, 2025, the Company issued another <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250424__20250424__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkWtQCztnWb7" title="Number of shares issued">384,459</span> shares of its common stock to Helena. The fair value of the shares on the date of
grant was $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250424__20250424__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9lasvQbcC87" title="Number of shares issued, value">328</span>. The Company recorded the shares as common stock to be issued as of March 31, 2025, and recorded the fair value of the
shares as deferred offering costs as of the same date (see Notes 2 and 4).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_DisclosureOfVendorAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Vendor Agreements [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_DisclosureOfVendorAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_DisclosureVendorAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_DisclosureVendorAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zqWGd9INJv04" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>NOTE 4 &#8211; <span id="xdx_828_zDtkd8Qtsvn8">SHAREHOLDERS&#8217; EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><span style="text-decoration: underline">Common Stock</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><i><span style="text-decoration: underline">Authorized Shares</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">The Company&#8217;s Certificate
of Incorporation, as filed with the State of Delaware on May 10, 2023, following the Company&#8217;s conversion from a California corporation
into a Delaware corporation, authorizes the Company to issue up to <span id="xdx_90F_ecustom--SharesAuthorized_iI_pid_c20230510_zVuRxtV3P1T5" title="Shares authorized">120,000,000</span> shares, consisting of <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230510_zerZJjFwF7aj" title="Common stock, shares issued">100,000,000</span> shares of common stock,
par value of $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230510_zeJcxOJO54t4" title="Common stock, par value">0.001</span> per share, and <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230510_zhx6sbUePF2g" title="Preferred stock, shares authorized">20,000,000</span> shares of preferred stock, par value $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230510_zabv1cM2QXPe" title="Preferred stock par value">0.001</span> per share. Holders of shares of common stock
have full voting rights, one vote for each share held of record. Shareholders are entitled to receive dividends as may be declared by
the board of directors out of funds legally available and share pro rata in any distributions with shareholders upon liquidation. Shareholders
have no conversion, pre-emptive or subscription rights. All outstanding shares of common stock are fully paid and non-assessable. As of
March 31, 2025 and December 31, 2024 there were <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pid_c20250331_zgju3NGCas83" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20250331_z5xf7gWD7cL7" title="Common stock, shares outstanding">15,825,118</span></span> and <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zmY8yK5eKIjl" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zK0shRWPUan2" title="Common stock, shares outstanding">13,736,597</span></span> shares of common stock issued and outstanding, respectively,
and <span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20250331_zwac76Gpjpra" title="Preferred stock, shares outstanding"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20241231_z21CK91DRuaj" title="Preferred stock, shares outstanding">no</span></span> shares of preferred stock outstanding, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><i><span style="text-decoration: underline">Common Stock Issued
for Cash Upon Closing of the Company&#8217;s Private Financing</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">On
January 14, 2025, the Company entered into a securities purchase agreement (&#8220;SPA&#8221;) and registration rights agreement
with an investor for the sale and issuance of <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250114__20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_z9qSKWCISLid" title="Sale of stock, number of shares issued in transaction">2,500,000</span> units (the &#8220;Pre-Funded Units&#8221;), with each Pre-Funded Unit
consisting of a pre-funded warrant to purchase one share of common stock, exercisable for $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_z36o49zonGr8" title="Exercisable price per share">0.001</span> per share, and a common warrant to
purchase one and one half shares of common stock (an aggregate of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pp0p0_c20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zE8QburIr3qg" title="Warrants to purchase of common stock">3,750,000</span>), exercisable at $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQ7rERlMaaEb" title="Exercisable price per share">1.399</span> per share. On January 16, 2025, the
Company closed on the sale of the Pre-Funded Units for a total purchase price of $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn3n3_c20250116__20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember_zcFWsRsjX6Xk" title="Purchase price of pre-funded unit">3,500</span> (or $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember_zzoT0Wrr1w2b" title="Shares issued, price per share">1.40</span> per Pre-Funded Unit). Net proceeds
received by the Company relating to the financing, and subsequent exercise of prefunded warrants was $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3n3_c20250116__20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember_zWh4D7F7V9kk" title="Net proceeds received from financing">3,058</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">The pre-funded warrants have
an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250114__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zsS1eMWJ75nl" title="Exercise price">0.001</span> per share and are immediately exercisable and will expire when exercised in full. The common warrants have
an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250114__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember_z8w3gUancoX2" title="Exercise price">1.40</span> per share, <span id="xdx_904_ecustom--ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_c20250114__20250114_z9WWjrlP8b9e" title="Warrants exercisable description">will be exercisable six months from issuance and will expire five and a half years from the issuance
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">During
the three months ended March 31, 2025, the investor exercised <span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z92sb2DPyc3l" title="Warrants exercised">2,010,000</span>
shares of the pre-funded warrants and as of March 31, 2025, there were <span id="xdx_90C_ecustom--WarrantsUnexercised_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zAca6jILQrF9" title="Warrants unexercised">490,000</span>
pre-funded shares remaining unexercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><i><span style="text-decoration: underline">Adoption of the
2023 Equity Incentive Plan</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">In
July 2023, the Company&#8217;s board of directors and stockholders adopted the 2023 Equity Incentive Plan (the &#8220;2023
Plan&#8221;). Under the 2023 Plan, the Company may grant incentive stock options to employees, including employees of any parent or
subsidiary, and nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards and
other forms of stock compensation to employees, directors and consultants, including employees and consultants of the
Company&#8217;s affiliates. As approved, a total of <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230731__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeEquityIncentivePlanMember_zJKlaYqX7lQi" title="Common stock reserved for future issuance">1,650,000</span>
shares of common stock were initially reserved for issuance under the 2023 Plan. As of March 31, 2025 and December 31, 2024, a total
of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20250331__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeEquityIncentivePlanMember_zd0lN1yAEhm9" title="Shares available for grant"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeEquityIncentivePlanMember_zDw46Pp9xELa" title="Shares available for grant">1,457,880</span></span>
shares remained available for issuance under the 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><i><span style="text-decoration: underline">Grant of Restricted
Stock Units (RSUs)</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_znOl1UY3MWR5" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="background-color: white">The following
table summarizes restricted common stock activity during the three months ended March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="xdx_8B2_zro0G2YkumV7" style="display: none">SCHEDULE
OF RESTRICTED COMMON STOCK ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>Number of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>Restricted Shares</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted Average Grant Date Fair</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Value</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: justify">Unvested, December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zo4J5tjWOVG6" style="width: 14%; text-align: right" title="Number of Restricted Shares, Unvested Beginning balance">172,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zACBeqUT19tj" style="width: 14%; text-align: right" title="Fair Value, Unvested, Beginning balance">314</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5euLO2mchWa" style="width: 14%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">1.83</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyYJ5CNyaCOb" style="text-align: right" title="Number of Restricted shares Granted">20,120</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztjSGHgO3D82" style="text-align: right" title="Fair Value, Granted">50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGJWSKYxQbW9" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">2.49</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkN7GfUl4ntc" style="text-align: right" title="Number of Restricted shares Vested">(78,521</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_iN_pn3n3_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrxA1bTiYca6" style="text-align: right" title="Fair Value, Vested">(76</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD6xx18OPh1j" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">0.97</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNz4dFXhXYUa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted shares Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0615">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z333fYfpkiI5" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0617">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEKJ7p9cuqpg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0619">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Unvested, March 31, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFYmZdchnf48" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted Shares, Unvested Ending balance">113,599</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzKw5fFxyMs2" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value, Unvested, Ending balance">288</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpM4dMoxwrqh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance">2.54</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zJVGc2waC3yg" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On September 23, 2024, the Company entered into a
strategic advisory agreement with Belair Capital Advisors Inc. (&#8220;Belair&#8221;). During the one-year term of the agreement, in exchange
for its services, the Company issued Belair <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240923__20240923__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember_zcz9Ohyp3V0h" title="Number of shares issued">50,000</span> RSUs, which vest six months from the date of issuance. The fair value of the shares
on the date of grant was $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20240923__20240923_zXr8MdCRYdU4" title="Fair value of shares">100</span>, which value will be amortized over the one-year service period of the agreement. <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_dn_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember_z2zxdkYdRpZi" title="Number of shares vested">None</span> of these shares vested
or were issued during the year ended December 31, 2024. During the three months ended March 31, 2025, the <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember_zbJbW6AP3Ype" title="Number of shares vested">50,000</span> RSUs vested and the shares
were issued to Belair.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Upon
the closing of the Company&#8217;s IPO, the Company entered into agreements with each of its four officers. Such agreements provided
for annual grants of RSUs in accordance with the terms of the Company&#8217;s 2023 Equity Incentive Plan. The RSUs vest over one- or
two-year periods and are subject to full acceleration of vesting upon the sale of the Company. Upon the closing of the
Company&#8217;s IPO in September 2024, the Company granted the officers <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240901__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--FourOfficersAgreementMember_zBNejeGo5Wh8" title="Number of shares issued">92,000</span>
RSUs. The fair value of the shares on the date of grant was $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20240901__20240930__us-gaap--TypeOfArrangementAxis__custom--FourOfficersAgreementMember_zv3V5m3mMtl6" title="Fair value of shares">226</span>. <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_dn_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--FourOfficersAgreementMember_z6uOZwCLZtPc" title="Number of shares vested">None</span>
of these RSUs vested during the year ended December 31, 2024. During the three months ended March 31, 2025, a total of <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--FourOfficersAgreementMember_zYiqIMoyUJVi" title="Number of shares vested">28,521</span>
RSUs vested and the shares were issued to the officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Upon the closing of the Company&#8217;s IPO, the Company
entered into agreements with each of its three independent directors. The Company&#8217;s policy provides that, upon initial election
or appointment to its board of directors, each new non-employee director will be granted a one-time grant, or Director Initial Grant,
with a value of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20250101__20250331__srt--TitleOfIndividualAxis__custom--ThreeIndependentDirectorsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQPNDjBYzN0a" title="Number of shares issued, value">50</span> of RSUs that will vest in substantially equal annual installments over a period of three years. The Director Initial
Grant is subject to full acceleration vesting upon the sale of the Company, in accordance with the terms of the Company&#8217;s 2023 Plan.
In 2024, a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zvwlcTay1F6e" title="Number of shares granted">30,000</span> RSUs were granted to the directors. The fair value of the shares on the date of grant was $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zPVmkLXW2sr" title="Fair value of shares">74</span>. During the three
months ended March 31, 2025, an additional <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zlvZXs4Pkf87" title="Granted shares">20,120</span> RSUs was granted to the Company&#8217;s new director with a fair value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z7peKzrpAsek" title="Fair value of shares">31</span>. <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_dn_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--DirectorAgreementsMember_z2iIr5bevzgi" title="Number of shares vested"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_dn_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--DirectorAgreementsMember_ztKsNAPZoN4d" title="Number of shares vested">None</span></span>
of these RSUs had vested as of the three months ended March 31, 2025 or the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">During the three months ended March 31, 2025, the
Company recorded $<span id="xdx_90B_ecustom--FairValueOfRestrictedStockUnits_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zr3JfvgEROWk" title="Stock compensation-related expense for fair value vesting of restricted common stock">76</span> of stock compensation-related expense for the fair value vesting of restricted common stock. As of March 31, 2025,
$<span id="xdx_900_ecustom--FairValueOfUnamortizedCompensation_iI_pn3n3_c20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm8PfokPuF3f" title="Fair value of unamortized compensation">280</span> of unamortized compensation remained.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i><span style="text-decoration: underline">Stock Warrants</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zRPh3JBqEOK9" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The table below summarizes the Company&#8217;s warrant
activities for three months ended March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="xdx_8BD_zx5peycnu1Ri" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Warrant</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Shares</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Price</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Range</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Per Share</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Balance, December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG7ExkPdZU5h" style="width: 14%; text-align: right" title="Warrants Shares, Beginning Balance">278,188</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_905_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zw3RnSMwO1zf" title="Exercise Price Range Per Share, Beginning Balance">2.40</span> - <span id="xdx_903_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zHYp8JiW4h56" title="Exercise Price Range Per Share, Beginning Balance">4.80</span> &#160;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhTHISzzX9v9" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Warrant Warrant, Beginning Balance">4.29</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zx9rkEE2e1Pl" style="text-align: right" title="Warrants Shares, Granted">6,425,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zLg00osw0D24" title="Exercise Price Range Per Share, Granted">0.001</span>
&#8211; <span id="xdx_905_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zYa4xrmSX0S6" title="Exercise Price Range Per Share, Granted">1.40</span> &#160;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zalttfYULl4a" style="text-align: right" title="Weighted Average Exercise Price Warrant, Granted">0.86</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoMomLkOoL31" style="text-align: right" title="Warrants Shares, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0679">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zz0Cgyu0ZGUj" style="text-align: right" title="Exercise Price Range Per Share, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0681">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYK9e5nbujj5" style="text-align: right" title="Weighted Average Exercise Price Warrant, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0683">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_iN_pid_di_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXSSmCr7kJPb" style="text-align: right" title="Warrants Shares, Exercised">(2,010,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRxuISik6huc" style="text-align: right" title="Exercise Price Range Per Share, Exercised">0.001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zicNkvsQa6yf" style="text-align: right" title="Weighted Average Exercise Price Warrant, Exercised">0.001</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Forfeited/Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmI19NGAzaF9" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Shares, Forfeited/Expired">(150,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIiD5R6BaEva" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price Range Per Share, Forfeited/Expired">4.17</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zD9fUkg6oNae" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Warrant, Forfeited/Expired">4.17</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Balance, March 31, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zm2nfrTaknP" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Shares, Ending Balance">4,543,188</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_908_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zXAJuNDqIm6a" title="Exercise Price Range Per Share, Ending Balance">0.001</span> &#8211; <span id="xdx_90B_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zOFcJpaWLmM" title="Exercise Price Range Per Share, Ending Balance">4.80</span> &#160;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcbNWOHZ8cHf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Warrant, Ending Balance">1.33</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Vested and exercisable, March 31, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwbE3cf7Nrv8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Warrants, Vested and exercisable">793,188</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zZmT94eyvOe6" title="Exercise Price Range Per Share, Vested and exercisable">0.001</span>
&#8211; <span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z3edkZ4ytpfg" title="Exercise Price Range Per Share, Vested and exercisable">4.80</span> &#160;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyWdYxVLXWb1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested and exercisable">1.03</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A8_zVylqT4mjkTg" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p id="xdx_891_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zljZNQpyXmFi" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The following table summarizes information concerning
outstanding and exercisable warrants as of March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="xdx_8B7_zSVp0cQWvB86" style="display: none">SCHEDULE
OF OUTSTANDING AND EXERCISABLE WARRANTS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Warrants Outstanding</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Warrants Exercisable</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Range of</b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>Exercise Prices</b></p></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><b>Number Outstanding</b></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>Average</b></p>
                                                                                                                                                                                             <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>Remaining Contractual Life</b> <b>(in years)</b></p></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Weighted Average</b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>Exercise Price</b></p></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Number</b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>Exercisable</b></p></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Average Remaining</b></p>
                                                                                                                                                                                             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Contractual Life</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>(in years)</b></p></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Weighted Average</b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>Exercise Price</b></p></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zBsvWacU2RMg" title="Range of exercise prices">0.001</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_z3Rgrws4GxJl" title="Warrants Outstanding, Number Outstanding">490,000</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zeNTwOUURfie" style="display: none" title="Warrants Outstanding, Average Remaining Contractual Life (in years)">0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zj5vfy4uPEng" title="Warrants Outstanding, Weighted Average Exercise Price">0.001</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zYPx8I5dHgi3" title="Warrants Exercisable, Number Exercisable">490,000</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zyHT23wh2jX4" title="Warrants Exercisable, Weighted Average Exercise Price">0.001</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_904_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zqHqZmhEYfN4" title="Range of exercise prices lower range">1.40</span> - <span id="xdx_909_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zBEkkdCMQREd" title="Range of exercise prices upper range">2.40</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zmPfOod4vwN1" title="Warrants Outstanding, Number Outstanding">3,944,688</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_ziS65o1YNYql" title="Warrants Outstanding, Average Remaining Contractual Life (in years)">4.74</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zGB04cnxTQ91" title="Warrants Outstanding, Weighted Average Exercise Price">1.40</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zLeh8lehsKc9" title="Warrants Exercisable, Number Exercisable">194,688</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zFy7qWTmkTXj" title="Warrants Exercisable, Average Remaining Contractual Life (in years)">4.51</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zWkh6uWUCFDi" title="Warrants Exercisable, Weighted Average Exercise Price">1.50</span></p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember_zCopYuf7owIc" title="Range of exercise prices">4.80</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zITZqVCczLT6" title="Warrants Outstanding, Number Outstanding">108,500</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zztv0kFlmqX3" title="Warrants Outstanding, Average Remaining Contractual Life (in years)">4.50</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zz6dJWbG6832" title="Warrants Outstanding, Weighted Average Exercise Price">4.80</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z8AtC8v8Smag" title="Warrants Exercisable, Number Exercisable">108,500</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z9iVFZbxptK8" title="Warrants Exercisable, Average Remaining Contractual Life (in years)">4.50</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zA4BYzGpUTV3" title="Warrants Exercisable, Weighted Average Exercise Price">4.17</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcPQleayNeF9" title="Range of exercise prices lower range">0.001</span>&#8211; <span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhYijr2DKKNa" title="Range of exercise prices upper range">4.80</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z18mFrjx5gP8" title="Warrants Outstanding, Number Outstanding">4,543,188</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmwVo1Ycqmaa" title="Warrants Outstanding, Average Remaining Contractual Life (in years)">4.22</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgKuGxXlQv4k" title="Warrants Outstanding, Weighted Average Exercise Price">1.33</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8ZAoGVLPSL5" title="Warrants Exercisable, Number Exercisable">793,188</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsxWURbruItf" title="Warrants Exercisable, Average Remaining Contractual Life (in years)">1.72</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zycoAar2cEA2" title="Warrants Exercisable, Weighted Average Exercise Price">1.03</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A9_zrc89PTGlkuh" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>Warrant Grants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">On
January 14, 2025, as amended on January 16, 2025, the Company entered into a securities purchase agreement (&#8220;SPA&#8221;) and
registration rights agreement with a select investor. In connection with the agreement, on January 16, 2025, the Company issued the
investor a pre-funded warrant to purchase up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_ztgVNiX7CVa8" title="Warants to purchase of common stock">2,500,000</span>
shares of the Company&#8217;s common stock at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zbLWTlofQhri" title="Exercisable price per share">0.001</span>
per share. The warrant is immediately exercisable and will expire when exercised in full. The investor also received a warrant to
purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zVTnO8Dz05yl" title="Warrants to purchase of common stock">3,750,000</span>
shares of the Company&#8217;s common stock at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zaF9XPqLZssj" title="Exercisable price per share">1.40</span>
per share. <span id="xdx_90B_ecustom--ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_c20250114__20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zNBsOczw7Ic8" title="Warrants exercisable description">The
warrant will be exercisable six months from the date of issuance and will expire five years from the issuance
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">On
January 16, 2025, the Company issued a warrant to purchase common stock to the underwriters of the SPA for the purchase of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zA8uUcE7iKkb" title="Warrant to purchase of common stock">175,000</span>
shares of the Company&#8217;s common stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zx1C0yWejQql" title="Exercisable price per share">1.40</span>
per share. The warrant vested upon grant. The warrant was issued to the underwriters as they were the placement agents for the SPA
noted above. <span id="xdx_90D_ecustom--ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_c20250114__20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_z8Aln3v8AWn7" title="Warrants exercisable description">The
warrant expires five years from the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><i>Warrant Exercises</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">During the three months ended
March 31, 2025, the SPA investor exercised <span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zKRCDrGnU1t7" title="Warrants exercised">2,010,000</span> shares of the pre-funded warrant, and as of March 31, 2025, there <span id="xdx_90C_ecustom--WarrantsUnexercised_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zp3x1ohmSLoe" title="Warrants unexercised">490,000</span> shares
remained unexercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">The intrinsic value for warrant
shares outstanding as of March 31, 2025 was $<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pn3n3_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQaYqcEIcBM4" title="Warrant shares outstanding, intrinsic value">458</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><span style="text-decoration: underline">Common
Stock to be Issued</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company has entered into
agreements with certain vendors as describes in Note 3 that require the issuance of additional shares of common stock based upon a
defined true calculation.&#160;&#160; As of March 31, 2025, the vendors became due an aggregate of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250331_zz5iCA03Uz5f" title="Number of shares issued">551,100</span>
shares of common stock with an aggregate fair value of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250101__20250331_zolkGKn0U2Pd" title="Number of shares issued, fair value">484</span>.
The shares were issued in April 2025 and have been reflected as common stock issuable as of March 31, 2025.&#160; See further
discussion at Note 5.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z5LoqcZiAgz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_827_z2spAiTwEO9h">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i><span style="text-decoration: underline">Kairos Exclusive License Agreements with
Cedars-Sinai Medical Center (Cedars)</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Company has entered into four Exclusive License
Agreements with Cedars, each of which grants the Company licensing rights with respect to certain patent rights owned by Cedars as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Methods of use of compounds that bind to RelA of NFkB;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Composition and methods for treating fibrosis;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Compositions and methods for treating cancer and autoimmune diseases; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Method of generating activated T cells for cancer therapy.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">For each of the exclusive license agreement in items
1, 2 and 3, the Company was required to pay an initial license fee of $<span id="xdx_90C_ecustom--LicenseFee_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zq9YVMHPZyNj" title="License fee">5</span>, reimburse Cedars for patent protection costs ranging from approximately
$<span id="xdx_90B_ecustom--PatentProtectionCosts_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zO00ZMtnBIj7" title="Patent protection costs">9</span> to $<span id="xdx_90C_ecustom--PatentProtectionCosts_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zZ6XSFEu0tn4" title="Patent protection costs">61</span>, pay an annual maintenance fee of $<span id="xdx_90A_eus-gaap--CostMaintenance_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zHsBuWgyXUN6" title="Annual maintenance fee">10</span>, and pay royalties based on <span id="xdx_90A_ecustom--RoyaltyPercentage_pid_dp_uPure_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zTm78Hf66O35" title="Royalty percentage">3.75</span>% of net sales and pay other non-royalty sublicense fees
ranging from <span id="xdx_901_ecustom--OtherNonroyaltySublicenseFeesPercentage_pid_dp_uPure_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_ze8A7Ebqt32c" title="Other non-royalty sublicense fees percentage">5</span>% to <span id="xdx_905_ecustom--OtherNonroyaltySublicenseFeesPercentage_pid_dp_uPure_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zCJ3urpOvibi" title="Other non-royalty sublicense fees percentage">35</span>% of sales of products. In addition, for items 1, 2 and 3, the Company is required to pay Cedars based on the following
milestones:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">$<span id="xdx_906_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--PhaseOneClinicalTrialMember_z7QHM5phOP6e" title="Payment for milestone">150</span> upon the successful completing of Phase I clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">$<span id="xdx_907_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemOneAndTwoMember__us-gaap--AwardTypeAxis__custom--PhaseTwoMember_zjVI82Unn4m7" title="Payment for milestone">250</span> (for items 1 and 2) and $<span id="xdx_907_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemThreeMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_zm7vZWoeqq6a" title="Payment for milestone">500</span> (for item 3) upon the successful completing of Phase II clinical trial for a product and receipt of Food and Drug Administration (&#8220;FDA&#8221;) approval for a Phase III clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">$<span id="xdx_90F_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemOneAndTwoMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zvySZwFkR5ei" title="Payment for milestone">1,500</span> upon receipt of FDA approval of a new drug application or equivalent foreign regulatory approval in a non-United States major commercial market; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">$<span id="xdx_904_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemOneAndTwoMember_zxmGz7iKTrQf" title="Payment for milestone">250</span> upon cumulative net sales exceeding $<span id="xdx_906_eus-gaap--Revenues_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemOneAndTwoMember_zuBk6S1wUUk9" title="Net sales">5,000</span>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">For the exclusive license agreement in item 4, the
Company is required to pay an initial license fee of $<span id="xdx_907_ecustom--LicenseFee_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zStwRHN7l564" title="License fee">50</span> upon raising $<span id="xdx_90E_ecustom--MinimumRequirermentOfCapital_iI_pn3n3_c20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zEktpNNKeepl" title="Minimum requirerment of capital">500</span> in capital, pay an annual maintenance fee of $<span id="xdx_90E_eus-gaap--CostMaintenance_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zt1mUwE1r7mc" title="Annual maintenance fee">10</span>, pay
royalties based on <span id="xdx_902_ecustom--RoyaltyPercentage_pid_dp_uPure_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zuxeb3PHTeej" title="Royalty percentage">4.25</span>% of patent product sales and <span id="xdx_903_ecustom--PatentProductSalesPercentage_pid_dp_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemFourMember_z4rbAzw48kCi" title="Patent product sales">0.5</span>% of other sales and pay other non-royalty sublicense fees ranging from <span id="xdx_902_ecustom--OtherNonroyaltySublicenseFeesPercentage_pid_dp_uPure_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zCXg6uA3KWkl" title="Other non-royalty sublicense fees percentage">5</span>% to
<span id="xdx_908_ecustom--OtherNonroyaltySublicenseFeesPercentage_pid_dp_uPure_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zKORXKiUKBQ6" title="Other non-royalty sublicense fees percentage">35</span>%. In addition, the Company is required to pay Cedars based on the following milestones:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">$<span id="xdx_901_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--PhaseOneClinicalTrialMember_z9XuO3ozOqoi" title="Payment for milestone">150</span> upon the successful completing of Phase I clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">$<span id="xdx_909_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemFourMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_zMvzfWAhHkea" title="Payment for milestone">250</span> upon the successful completing of Phase II clinical trial and receipt of Food and Drug Administration (&#8220;FDA&#8221;) or equivalent regulatory agency in another jurisdiction approval for a Phase III clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">$<span id="xdx_90C_ecustom--PaymentForMilestones_pn3n3_c20240101__20241231__srt--ProductOrServiceAxis__custom--ItemFourMember__dei--LegalEntityAxis__custom--FoodAndDrugAdministrationMember_znidBqZg6Akc" title="Payment for milestone">1,500</span> upon receipt of FDA approval of a new drug application; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">$<span id="xdx_905_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemFourMember_zjtqcDBsC8y4" title="Payment for milestone">2,500</span> upon cumulative net sales exceeding $<span id="xdx_904_eus-gaap--Revenues_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemFourMember_zqZUiMfZ5r5i" title="Net sales">50,000</span>.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><i><span style="text-decoration: underline">Enviro Therapeutics</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On June 2, 2021, the Company&#8217;s wholly owned
subsidiary, Enviro,  entered into two Exclusive License Agreements with Cedars, which granted Enviro exclusive
licensing rights (which include the right to sublicense) with respect to certain patent rights owned by Cedars, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">an Exclusive License Agreement (the &#8220;Enviro-Cedars License Agreement (Mitochondrial DNA)&#8221;) for Enviro to develop, manufacture, use and sell products utilized or derived from patent rights worldwide related to the &#8220;Compositions and Methods for Treating Diseases and Conditions by Depletion of Mitochondrial DNA from Circulation and for Detection of Mitochondrial DNA&#8221; invented by Dr. Neil Bhowmick and others; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">an Exclusive License Agreement (the &#8220;Enviro-Cedars License Agreement (Endoglin Antagonism)&#8221; and, collectively with the Enviro-Cedars License Agreement (Mitochondrial DNA), the &#8220;Enviro-Cedars License Agreements&#8221;) for Enviro to develop, manufacture, use and sell products utilized or derived from the patent rights and technical information worldwide related to the &#8220;Sensitization of Tumors to Therapies Through Endoglin Antagonism&#8221; invented by Dr. Neil Bhowmick and others.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">In exchange for each of the licenses, Enviro is required
to pay an upfront license fee in the mid four-figures and low-five figures, respectively. Enviro is also required to reimburse Cedars
for the costs in the mid-to-high six figures incurred in the prosecution of the patent rights subject to the Enviro-Cedars License Agreements
prior to the date of execution of such agreements, and certain costs and fees then outstanding aggregating in the low-six figures owed
by Kairos pursuant to the Kairos-Cedars License Agreements. Pursuant to the Enviro-Cedars License Agreements, Cedars shall also receive
royalty payments of a mid-single-digit percentage of net sales of products associated with the licensed patent right and less than one
percent of net sales of other products derived from Cedars&#8217; technical information, with a minimum annual royalty fee in the low
five-digits due beginning on the third anniversary of the effective date of the Enviro-Cedars License Agreements. To the extent Enviro
derives non-royalty sublicensing revenues, a high single-digit to low double-digit percentage of such revenues would be due and payable
to Cedars, with the actual percentage of such revenues dependent on the stage of FDA authorization at the time the sublicense revenue
is generated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Enviro is also required to pay Cedars in connection
with achieving the following Payment Milestones relating to products derived from the patent rights: successful completion of a Phase
I clinical trial; successful completion of a Phase II clinical trial, receipt of FDA approval, and approval for a Phase III clinical trial;
FDA approval of an NDA or BLA; cumulative net sales exceeding $<span id="xdx_90E_eus-gaap--Revenues_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--PhaseThreeClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--EnviroCedarsLicenseAgreementsMember_zpFIc1ZuVdAa" title="Net sales">50,000</span>; and cumulative net sales exceeding $<span id="xdx_907_eus-gaap--Revenues_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemOneAndTwoMember__us-gaap--AwardTypeAxis__custom--PhaseThreeMember__us-gaap--TypeOfArrangementAxis__custom--EnviroCedarsLicenseAgreementsMember_zauTHZg3VKHk" title="Net sales">100,000</span>. If all of these payment
milestones are met among both of the Enviro-Cedars License Agreements, the required milestone payments would total in the mid-to-high
seven-figures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Pursuant to the Enviro-Cedars License Agreements,
Enviro is obligated to meet the following Commercialization Milestones. Pursuant to the Enviro-Cedars License Agreement (Endoglin Antagonism),
Enviro is obligated to <span id="xdx_902_ecustom--LicenseAgreementDescription_c20250101__20250331_zOLJGelSyXYa" title="License agreement description">(1) obtain an IND for a patent product within 1 year of the effective date of the agreement, (2) commence a Phase
II trial within 2 years of the effective date of the agreement, and (3) submit an NDA or BLA to the FDA or equivalent regulatory agency
in another jurisdiction within 7 years of the effective date of the agreement. Pursuant to the Enviro-Cedars License Agreement (Mitochondrial
DNA), Enviro is obligated to (1) complete preclinical studies of a patent product within 2 years of the effective date of the agreement,
(2) complete toxicology studies within 2.5 years of the effective date of the agreement, (3) obtain IND within 3 years of the effective
date of the agreement, (4) begin a Phase I trial within 4 years of the effective date of the agreement, and (5) submit an NDA or BLA to
the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. If the Commercialization
Milestones are not met or extended, Cedars may convert the exclusive licenses into non-exclusive licenses or to a co-exclusive licenses
or terminate the licenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Enviro-Cedars License Agreements will, unless
sooner terminated, continue in effect on a country-by-country basis until the last of the patents covering the patent rights or future
patent rights expires. Under the terms of the Enviro-Cedars License Agreements, unless waived by Cedars, the agreements would automatically
terminate: (a) if Enviro ceases, dissolves or winds up its business operations; (b) if performance by either party jeopardizes the licensure,
accreditation or tax exempt status of Cedars or the agreement is deemed illegal by a governmental body; (c) within 30 days for non-payment
of royalties or if Enviro fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (d)
within 60 days of Cedars&#8217; failure to cure any breach or default of a material obligation under the agreements; (e) within 90 days
of Enviro&#8217;s failure to cure any breach or default of a material obligation under the agreements; or (f) upon mutual written agreement
of the parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Matters</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Company&#8217;s knowledge, it is not currently the subject of any material legal proceeding. In the future, the Company may be involved
in actual and/or threatened legal proceedings, claims, investigations and government inquiries arising in the ordinary course of our
business, including legal proceedings, claims, investigations and government inquiries involving intellectual property, data privacy
and security, other torts, illegal or objectionable content, consumer protection, securities, employment, contractual rights, civil rights
infringement, false or misleading advertising, or other legal claims relating to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p id="xdx_809_eus-gaap--SegmentReportingDisclosureTextBlock_z8XkEY1EvlC1" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>NOTE
6 &#8211; <span id="xdx_82A_zlsq603MtRA1">SEGMENT INFORMATION</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Company operates and manages its business as <span id="xdx_906_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20250101__20250331_zFNtCtNOXoy5" title="Number of reportable segments">one</span>
reportable segment and operates as a clinical-stage biopharmaceutical company. The Company&#8217;s current focus is on developing immunotherapy
and cell therapies for the treatment of cancer. The Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) is the Chief Executive
Officer, who reviews financial information presented and decides how to allocate resources based on net income (loss). Net income (loss)
is used for evaluating financial performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Significant segment expenses include research and
development, officer compensation, insurance, and stock-based compensation. Operating expenses include all the remaining costs necessary
to operate our business, which primarily include external professional services and other administrative expenses. The following table
presents the significant segment expenses and other segment items regularly reviewed by our CODM:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zwOoPqF4lB2d" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="xdx_8BF_zfYjnLQ59nya" style="display: none">SCHEDULE
OF SEGMENT EXPENSES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20250101__20250331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zE3wkZgjfXWe" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20240331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zFLJtujBKoZ7" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Three Months Ended</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">March 31,</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Revenues_pn3n3_zjIfQN6O33e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0863">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Less:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_zJIVhMBFVLx1" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Research and development, less officer compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">448</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">165</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OfficersCompensation_pn3n3_zBkkTeuBOPTh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Officer compensation and wages</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0870">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InsuranceRecoveries_pn3n3_zmOpMxR28Ti6" style="vertical-align: bottom; background-color: White">
    <td>Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_z8UGnZMYgXXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingExpenses_pn3n3_zgPWkL9ZBq17" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherOperatingIncomeExpenseNet_pn3n3_zgeUMAx9qARf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other income (expenses)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(36</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_pn3n3_ziiUdJ3hBZDe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,262</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(323</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p id="xdx_8A6_z6TV6oU9LaXd" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zzUq306wPoH1" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>NOTE 7 &#8211; <span id="xdx_825_zUsElv5Zo8xd">SUBSEQUENT EVENTS</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On
April 1, 2025, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__dei--LegalEntityAxis__custom--CrossCurrentCapitalLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zF0NRtAgXVFj" title="Number of shares issued">166,541</span>
shares of its common stock to Cross Current in connection with its agreement with Cross Current (see Notes 3 and 4).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On April 24, 2025, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250424__20250424__dei--LegalEntityAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znBlc2wdF5hg" title="Number of shares issued">384,459</span>
shares of its common stock to Helena in connection with its agreement with Helena (see Notes 3 and 4).</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zOkRiq0UKjP9" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="background-color: white"><b><span id="xdx_864_zYxatAsNGs2h">Basis of
Consolidation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The
accompanying condensed consolidated financial statements and accompanying notes have been prepared in accordance with accounting
principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying condensed consolidated
financial statements include the accounts of the Company and its wholly owned subsidiary, Enviro Therapeutics, Inc.
(&#8220;Enviro&#8221;). All intercompany balances and transactions have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--UseOfEstimates_zDiSjzzSHV3h" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_860_zJyaYE3qESYe">Use of Estimates</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The preparation of the financial statements in conformity
with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts
of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accruals for potential liabilities,
valuations of stock-based compensation, the realization of deferred tax assets, and impairment analysis and useful life for intangible
assets among others. Actual results could differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zhq94cFuVsZ8" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_86C_z4sbsgETDg8a">Concentration of Credit Risk</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Financial instruments, which potentially subject the
Company to concentration of credit risk, consist primarily of cash deposits. The Company maintains deposits in federally insured financial
institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due
to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses
on deposits since its inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQVxrqcLBLh7" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_86B_zC44RJl7CIr4">Cash Equivalents</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Company considers all highly liquid investments
with original maturities of three months or less on the date of purchase to be cash equivalents. Cash equivalents consisted of money market
funds as of March 31, 2025. There were <span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20241231_zdo5haAu0w6g" title="Cash equivalents">no</span> cash equivalents as of December 31, 2024. As of March 31, 2025, the amount of cash equivalents
included in cash and cash equivalents totaled $<span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20250331_zBdf2sxHleOj" title="Cash equivalents">3,504</span>. The underlying securities in the money market funds held by the Company are all
government backed securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_844_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zQYCNnpXR7eb" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_86D_zSDuiKUe9A82">Intangible Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Company&#8217;s intangible assets are stated at
fair value as of the date acquired, less accumulated amortization. Amortization is calculated based on the estimated useful lives of the
assets, which were determined to be <span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dc_c20250331_zTbXG9AR5Lll" title="Intangible assets useful life">five years</span>, using the straight-line method. The intangible asset consists of a licensing agreement
that the Company acquired through its acquisition of Enviro during the year ended December 31, 2021, with an acquisition
cost of $<span id="xdx_90D_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_pn3n3_c20211231__us-gaap--BusinessAcquisitionAxis__custom--EnviroThreapeuticsIncMember_zHpRYAmvGkFi" title="Acquisition cost">800</span>. Amortization expense relating to the intangible asset during the three months ended March 31, 2025 and 2024 was $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20250101__20250331_zunLGsSr22Q9" title="Amortization expenses"><span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240101__20240331_zfqPWqgpJ6i9" title="Amortization expenses">40</span></span>, respectively,
with an unamortized balance of $<span id="xdx_90B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20250331_z4ulo3hNsNr7" title="Intangible assets unamortized balance">182</span> and $<span id="xdx_90E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20241231_zwUj3ulbgYVf" title="Intangible assets unamortized balance">222</span> at March 31, 2025 and December 31, 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zdkZtWrXr199" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><b><span><span id="xdx_862_zzgt8VHN0Ug7">Impairment of Long-Lived
Assets</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Company applies the provisions of ASC Topic 360,
<i>Property, Plant, and Equipment</i>, which addresses financial accounting and reporting for the impairment of long-lived assets. A long-lived
asset that is held and used should be tested for recoverability whenever events or changes in circumstances indicate that the carrying
amount of the asset group may not be recoverable. If the estimated undiscounted
future cash flows are less than the carrying value, an impairment determination is required. In that event, a loss is recognized based
on the amount by which the carrying amount exceeds the fair value of the long-lived assets. <span id="xdx_90A_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pn3n3_do_c20250101__20250331_zmYqEVsxlK6b" title="Impairment of intangible assets"><span id="xdx_90A_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pn3n3_do_c20240101__20240331_zuftzu83Acma" title="Impairment of intangible assets">No</span></span> impairment was recorded relating to the
Company&#8217;s intangible asset during the three months ended March 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Income (Loss) Per Share</a></td>
<td class="text"><p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zSNqSpNPsyxl" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_86C_ztQC0cp5KIS8">Income (Loss) Per Share</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Basic loss per share is computed by dividing net loss
applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share
is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus
the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zEr8aWBQ0z0l" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">For the three months ended March 31, 2025 and 2024,
the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. The potentially
dilutive securities consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="xdx_8B0_zX66bhEgul26" style="display: none">SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20250101__20250331_zTIhOkr4S1xl" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20240331_zWHWDvfZ4Qpl" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2024</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zJlzlViCK8J9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Warrants to purchase common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4,543,188</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">150,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zNxS3XyLOHVh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">113,599</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zhQVSBZIkIth" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,656,787</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">150,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zoYQPGs7Sij" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b>&#160;</b></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p id="xdx_845_eus-gaap--DeferredChargesPolicyTextBlock_z1yrQvKC7rKh" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"><b><span id="xdx_863_zzoCf4kSJiNe">Deferred Offering Costs</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The
Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity
issuances as deferred offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs
are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be delayed or abandoned,
the deferred offering costs will be expensed immediately as a charge to operating expenses in the Statement of Operations. As of December
31, 2024, the Company incurred $<span id="xdx_902_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--EquityLineOfCreditMember_zWXIMHUyHEk7">1,377
</span>of deferred offering costs related to the Company&#8217;s pending Equity Line of Credit (ELOC) offering. During the three months
ended March 31, 2025, the Company incurred $<span id="xdx_90D_ecustom--DeferredOfferingAdditionalCosts_iI_pn3n3_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--EquityLineofCreditMember_zaTIoYRuDcW5" title="Deferred offering additional cost">328
</span>of additional costs related to the ELOC, and as of March 31, 2025, total deferred offering costs were $<span id="xdx_907_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--EquityLineofCreditMember_zK0Ol2liMitg">1,705</span> related to the ELOC. The ELOC was declared effective on April 24, 2025, and the Company will amortize these costs as cost of capital as
the funds are raised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z36aILlhLgRj" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_866_zjflgjo1cuYd">Fair Value Measurements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; text-indent: 0.2pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Company determines the fair value of its assets
and liabilities based on the exchange price in U.S. dollars that would be received to sell an asset or paid to transfer a liability (an
exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of
unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable
and the last unobservable, to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><i>Level 1 &#8212;</i> Quoted prices in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><i>Level 2 &#8212;</i> Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><i>Level 3 &#8212;</i> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The
carrying amounts of financial instruments such as cash, and accounts payable and accrued liabilities, approximate the related fair values
due to the short-term maturities of these instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Cash equivalents consisted of money market funds at
March 31, 2025. Money market funds were valued by the Company using quoted prices in active markets for identical securities, which represent
a Level 1 measurement within the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zs1TfzBwDLZ" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_868_z8xjIVgzQhaj">Recent Accounting Pronouncements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">In November 2024, FASB issued ASU 2024-03 Income Statement&#8212;Reporting
Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses. The guidance
in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information
about certain costs and expenses including purchases of inventory; employee compensation; and depreciation and amortization expense for
each caption on the income statement where such expenses are included. The update is effective for annual reporting periods beginning
after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments
may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial
statements. We are currently evaluating the provisions of this guidance and assessing the potential impact on our financial statement
disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Other recent accounting pronouncements issued by the
FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange
Commission did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated financial
statements.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>VENDOR AGREEMENTS (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_DisclosureVendorAgreementsAbstract', window );"><strong>Vendor Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_VendorAdvancesPolicyTextBlock', window );">Vendor Advances</a></td>
<td class="text"><p id="xdx_84A_ecustom--VendorAdvancesPolicyTextBlock_zOtuPccDdpK8" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><b><span id="xdx_86F_z3UKkIMW4u24">Vendor Advances</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The
Company has entered into various contracts with service providers pursuant to which the Company pays the vendor an advance at the
beginning of the contractual period. These vendor advances could be paid by the Company either in cash or in shares of common stock,
depending on the terms of the contract. The advances are reduced by the accumulated value of the services performed by the vendor or
are amortized on a straight-line basis over the service period, whichever is shorter. As of December 31, 2024, advances to vendors
totaled $<span id="xdx_90C_eus-gaap--CustomerAdvancesAndDeposits_iI_pn3n3_c20241231_zugSftaZDSWc" title="Advances to vendor amount">3,115</span>, with $<span id="xdx_90C_ecustom--VendorAdvancesInCash_iNI_pn3n3_di_c20241231_zNSTeIrdLhXb" title="Vendor advances in cash">2,615</span> being paid in cash and $<span id="xdx_902_ecustom--IssuanceOfCommonSharesPaidForVendorsAdvances_pn3n3_c20240101__20241231_zswPgID777F7" title="Issuance of common shares paid for vendors advances">500</span> being paid with shares of the Company&#8217;s common stock (see Note 4).
Amortization expense relating to the vendor advances during the year ended December 31, 2024 was $<span id="xdx_901_ecustom--AmortizationExpenseVendorAdvances_pn3n3_c20240101__20241231_zG0xS9taYI12" title="Amortization expense relating to vendor advances">256</span>, with an unamortized balance
of $<span id="xdx_900_ecustom--VendorAdvancesCurrent_iI_pn3n3_c20241231_zNdSyV9ug8A7" title="Vendor advances">2,859</span> as of December 31, 2024. During the three months ended March 31, 2025, additional advances to vendors totaled $<span id="xdx_905_ecustom--IssuanceOfCommonSharesPaidForVendorsAdvances_pn3n3_c20250101__20250331_zGHRqulU2S7e" title="Issuance of common shares paid for vendors advances">156</span>, with
the advance being paid with shares of the Company&#8217;s common stock (see Notes 3 and 4). Amortization expense relating to the
vendor advances was $<span id="xdx_90A_ecustom--AmortizationExpenseVendorAdvances_pn3n3_c20250101__20250331_zUHuliREq3Tl" title="Amortization expense relating to vendor advances">636</span>, with an unamortized balance of $<span id="xdx_903_ecustom--VendorAdvancesCurrent_iI_pn3n3_c20250331_znuraBHHDmT4" title="Vendor advances">2,379</span> as of March 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p id="xdx_897_ecustom--ScheduleOfVendorAdvancesTableTextBlock_zBHJpnMELoPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vendor
advances consisted of the following at March 31, 2025, and December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zPEy2vznLef8" style="display: none">SCHEDULE
OF VENDOR ADVANCES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250331_zMBMKTy3m0M7" style="border-bottom: Black 1pt solid; text-align: center">March 31,<br/> 2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_zWgJyV0SPHV3" style="border-bottom: Black 1pt solid; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_409_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--PrevailInfoworksIncMember_zYsH4hFTQDu" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F4F_zIlElyXVuLjf" style="width: 64%; text-align: justify; text-indent: -12pt; padding-left: 12pt">Prevail Infoworks (a)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">900</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">900</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zu0l7EtIN1j4" style="vertical-align: bottom; background-color: White">
    <td id="xdx_F42_z2mPBU0QOL15" style="text-align: justify; text-indent: -12pt; padding-left: 12pt">PreCheck Health Services (b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">900</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zEW5CuxIuXF3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F45_z27GEf7cW9mh" style="text-align: justify; text-indent: -12pt; padding-left: 12pt">CEO.CA Technologies (c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zaYjFvFN5kvk" style="vertical-align: bottom; background-color: White">
    <td id="xdx_F48_zhHNaFSHYl53" style="text-align: justify; text-indent: -12pt; padding-left: 12pt">Belair Capital Advisors (d)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">365</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--CrossCurrentCapitalLLCMember_z9WNeQNhcHRf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F46_zp8WQRJ4lTFf" style="text-align: justify; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Cross Current Capital (e)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">856</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">700</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--VendorAdvancesGross_iI_maVANzSvy_zniJYtW0OSve" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Vendor advances, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,271</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,115</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--VendorAdvancesAccumulatedAmortization_iNI_di_msVANzSvy_zjnKmRDVplX8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(892</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(256</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--VendorAdvancesNet_iTI_mtVANzSvy_zmvZB94q6Je4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: justify; text-indent: -12pt; padding-left: 12pt">Vendor advances, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,379</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,859</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(a)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with Prevail Infoworks, Inc.</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2024, the Company entered into a master service and technology agreement with Prevail Infoworks, Inc. (&#8220;Prevail&#8221;),
pursuant to which Prevail agreed to provide certain clinical research services to the Company. As part of the agreement, the Company
was required to make an advance payment of $<span id="xdx_905_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_zprPoAiaebDh" title="Advance payment">900</span> to Prevail before commencement of services and, at such time as we notify Prevail to
engage their services related to the relevant clinical trial, or six months from the date of the agreement, pay approximately $<span id="xdx_90A_ecustom--MonthlyPayment_pn3n3_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_z5ccsCCqpfnh" title="Monthly payment">80</span> per
month during the time Prevail performs clinical research services for the Company&#8217;s Phase 2 ENV 105 prostate and Phase 1 ENV 105
lung clinical trials. The agreement with Prevail is subject to cancellation at any time upon 30 days&#8217; written notice to the other
party. The Company made the advance payment to Prevail in October 2024 and it is included in vendor advances on the accompanying balance
sheet as of March 31, 2025 and December 31, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(b)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with PreCheck Health Services, Inc.</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2024, the Company entered into a bioassay services agreement (the &#8220;Bioassay Services Agreement&#8221;) with PreCheck
Health Services, Inc., a Florida-based corporation (&#8220;PreCheck&#8221;). Pursuant to the Bioassay Services Agreement, PreCheck will
provide certain biomarker screening services for the Company&#8217;s ongoing carotuximab (ENV105) clinical trials in order to assist
the Company in identifying lung and prostate cancer patients suitable to the Company&#8217;s ongoing Phase 1 clinical trials for lung
cancer patients and Phase 2 clinical trials for patients with castrate resistant prostate cancer. In exchange for PreCheck&#8217;s services,
and according to the terms of the Bioassay Services Agreement, the Company paid $<span id="xdx_904_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240920__20240920__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zduXccqjwVB3" title="Payments for services">900</span> to PreCheck as an advance for the future laboratory
services to be performed. The payment of $<span id="xdx_90D_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zwLbkpGeqLZc" title="Payments for vendor advance"><span id="xdx_90F_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zjW07xt7c818" title="Payments for vendor advance">900</span></span> is included in vendor advances on the accompanying balance sheet as of March 31, 2025 and
December 31, 2024 (see Note 2). The term of the agreement is one year from the effective date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(c)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with CEO.CA Technologies Ltd.</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2024, the Company entered into an advisory and consulting services agreement (the &#8220;CEO.CA Agreement&#8221;) with
CEO.CA Technologies Ltd., a Canadian company (&#8220;CEO.CA&#8221;), pursuant to which CEO.CA will provide certain internet-based financial
information and communications services for a period of one year for a services fee of $<span id="xdx_90B_eus-gaap--ManagementFeeExpense_pn3n3_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zdwOjkCdY2mk" title="Service fee">250</span>. The service fee is an advance on future
services to be performed. The CEO.CA Agreement includes such services as strategic news placement, news releases, interviews, monthly
analytics and a video launch. The CEO.CA Agreement contains other customary clauses, including representations and warranties, indemnification
clauses and governing law clauses. The payment of $<span id="xdx_907_eus-gaap--ManagementFeeExpense_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zCcYQ0z44iD2" title="Service fee"><span id="xdx_90E_eus-gaap--ManagementFeeExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zQ4vCZ1jJsAd" title="Service fee">250</span></span> is included in vendor advances on the accompanying balance sheet as of March 31,
2025, and December 31, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(d)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with Belair Capital Advisors Inc.</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2024, the Company entered into a strategic advisory agreement (the &#8220;Strategic Advisory Agreement&#8221;) with Belair
Capital Advisors Inc. (&#8220;BCA&#8221;). BCA, a venture capital and corporate finance advisory firm, has been a long-term investor
and advisor to the Company and frequently works with early-stage pharmaceutical companies. The strategic advisory services provided by
BCA consist of corporate strategy, market positioning and long-term growth plans within the pharmaceutical sector, digital marketing
and engagement, market research analysis and business development assistance, among other things. During the one-year term of the Strategic
Advisory Agreement, in exchange for its services, the Company will pay BCA a $<span id="xdx_90B_eus-gaap--ManagementFeeExpense_pn3n3_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zWK09mzIVjcf" title="Service fee">365</span> fee and will issue BCA <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zH4wUeKY4gce" title="Number of shares issued">50,000</span> RSUs, which will vest
at the end of six months following the date of issuance. The payment of $<span id="xdx_904_eus-gaap--ManagementFeeExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_z5u2qaE8GJ13" title="Service fee"><span id="xdx_90E_eus-gaap--ManagementFeeExpense_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zqWNwT1AmMp2" title="Service fee">365</span></span> is included in vendor advances on the accompanying balance
sheet as of March 31, 2025, and December 31, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(e)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with Cross Current Capital LLC</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2024, the Company entered into a consulting agreement (the &#8220;Consulting Agreement&#8221;) with Cross Current Capital
LLC, a limited liability company organized under the laws of Puerto Rico (&#8220;Cross Current&#8221;), and Alan Masley (the &#8220;Advisor&#8221;),
pursuant to which Cross Current agreed to provide certain financial and business consulting services to the Company including, but not
limited, to (a) help drafting a public company competitive overview, (b) help preparing and/or reviewing a valuation analysis, (c) help
in drafting marketing materials and presentations, (d) reviewing the Company&#8217;s business requirements and discuss financing and
businesses opportunities, (e) investor marketing, (f) investor relations introductions, (g) legal counsel introductions, (h) auditor
introductions, (i) investment banking and research introductions, (j) M&amp;A canvassing and ways to grow the business organically, and
(k) stand by capital markets advisory services. For the services rendered thereunder, the Company agreed to pay Cross Current $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zs967aIjw35a" title="Number of shares issued, value">200,000</span>
in cash and agreed to issue to the Advisor $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zg32SQq41PFa" title="Number of shares issued, value">500</span> of restricted shares of the Company&#8217;s common stock under the Company&#8217;s 2023
Plan , calculated at <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zwdhN9xZw456" title="Number of shares issued">367,647</span> shares (the &#8220;Shares&#8221;) as of the date of the agreement. The term of the Consulting Agreement
is 24 months and can be extended for another 12 months with the written consent of both parties. The Company made the $<span id="xdx_900_ecustom--SettlementAgreementAmount_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z06niaGMIAY" title="Settlement agreement amount">200</span> payment in
October 2024. The payment of $<span id="xdx_903_ecustom--VendorPaymentAdvances_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zuE1Up2Yf3Oc" title="Vendor payment advances">200</span> and the value of the shares issued of $<span id="xdx_90B_eus-gaap--AdditionalCollateralAggregateFairValue_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z6yCdjjdyhR4" title="Aggregate fair value of the common stock"><span id="xdx_904_eus-gaap--AdditionalCollateralAggregateFairValue_iI_pn3n3_c20250331__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zdHaZRYlUKB9" title="Aggregate fair value of the common stock">500</span></span> are included in vendor advances on the accompanying balance
sheet as of March 31, 2025, and December 31, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTfiiSp4Yj82" title="Stock issued shares">367,647</span> shares issued in 2024 were subject to a &#8220;true up&#8221; on April 1, 2025, at which time additional shares will be issued
to the Advisor (or returned by the Advisor to the Company) in order to ensure the shares are valued at $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIZpvH8zT7f" title="Number of shares issued, value">500</span> as of April 1, 2025. On April
1, 2025, the Company issued an additional<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z30ZJg7BXA84" title="Number of shares issued">166,541</span> shares of its common stock to the Advisor. The fair value of the additional shares on
the date of grant was $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgBbAS3MRlag" title="Number of shares issued, value">156</span>. The Company recorded the shares as common stock to be issued as of March 31, 2025, and recorded the fair
value of the shares as a vendor advance as of the same date (see Notes 2 and 4).</span></p>

<p id="xdx_8A1_zKXzBpgYIBPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Agreement
with Helena Global Investment Opportunities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2024, the Company entered into an agreement with Helena Global Investment Opportunities I LTD (&#8220;Helena&#8221;) pursuant
to which the Company will have the right to issue and sell to Helena, from time to time, and Helena shall purchase from the Company,
up to $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20241112__20241112__us-gaap--TypeOfArrangementAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember_zX8ZODczRail" title="Number of shares issued, value">30,000</span> of the Company&#8217;s shares of common stock (the &#8220;Equity Line of Credit&#8221;). The Equity Line of Credit will
become available to the Company at such time as it files a registration statement on Form S-1 registering the shares issuable under the
Equity Line of Credit. In exchange for the Equity Line of Credit, the Company is obligated to issue Helena a certain number of shares
of common stock, calculated using $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20241112__20241112_zOkFyaO9FIBl" title="Number of shares issued, value">900</span> divided by the lowest one-day VWAP during the five trading days prior to entry into the agreement.
As a result, the Company issued Helena <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241112__20241112__us-gaap--TypeOfArrangementAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember_zoIsXhxdEUKl" title="Number of shares issued">670,641</span> shares of its common stock valued at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueOther_pn3n3_c20241112__20241112__us-gaap--TypeOfArrangementAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember_zENKFjeTkvdl" title="Stock issued  value">1,377</span> on the date of issuance. The Company accounted
for the value of the shares issued as deferred offering costs (see Note 2). The shares vested on the date of the agreement, were issued
to Helena, and are subject to a &#8220;true up&#8221; based upon the value of the stock at the time the company files and obtains effectiveness
of a registration statement registering the shares for resale. In addition, the Company agreed to register such shares for resale pursuant
to a registration statement on Form S-1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 24, 2025, the Company issued another <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250424__20250424__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkWtQCztnWb7" title="Number of shares issued">384,459</span> shares of its common stock to Helena. The fair value of the shares on the date of
grant was $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250424__20250424__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9lasvQbcC87" title="Number of shares issued, value">328</span>. The Company recorded the shares as common stock to be issued as of March 31, 2025, and recorded the fair value of the
shares as deferred offering costs as of the same date (see Notes 2 and 4).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_DisclosureVendorAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_DisclosureVendorAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_VendorAdvancesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vendor Advances [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_VendorAdvancesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zEr8aWBQ0z0l" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">For the three months ended March 31, 2025 and 2024,
the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. The potentially
dilutive securities consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="xdx_8B0_zX66bhEgul26" style="display: none">SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20250101__20250331_zTIhOkr4S1xl" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20240331_zWHWDvfZ4Qpl" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2024</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zJlzlViCK8J9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Warrants to purchase common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4,543,188</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">150,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zNxS3XyLOHVh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">113,599</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zhQVSBZIkIth" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,656,787</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">150,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>VENDOR AGREEMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_DisclosureVendorAgreementsAbstract', window );"><strong>Vendor Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ScheduleOfVendorAdvancesTableTextBlock', window );">SCHEDULE OF VENDOR ADVANCES</a></td>
<td class="text"><p id="xdx_897_ecustom--ScheduleOfVendorAdvancesTableTextBlock_zBHJpnMELoPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vendor
advances consisted of the following at March 31, 2025, and December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zPEy2vznLef8" style="display: none">SCHEDULE
OF VENDOR ADVANCES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250331_zMBMKTy3m0M7" style="border-bottom: Black 1pt solid; text-align: center">March 31,<br/> 2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_zWgJyV0SPHV3" style="border-bottom: Black 1pt solid; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_409_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--PrevailInfoworksIncMember_zYsH4hFTQDu" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F4F_zIlElyXVuLjf" style="width: 64%; text-align: justify; text-indent: -12pt; padding-left: 12pt">Prevail Infoworks (a)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">900</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">900</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zu0l7EtIN1j4" style="vertical-align: bottom; background-color: White">
    <td id="xdx_F42_z2mPBU0QOL15" style="text-align: justify; text-indent: -12pt; padding-left: 12pt">PreCheck Health Services (b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">900</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zEW5CuxIuXF3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F45_z27GEf7cW9mh" style="text-align: justify; text-indent: -12pt; padding-left: 12pt">CEO.CA Technologies (c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zaYjFvFN5kvk" style="vertical-align: bottom; background-color: White">
    <td id="xdx_F48_zhHNaFSHYl53" style="text-align: justify; text-indent: -12pt; padding-left: 12pt">Belair Capital Advisors (d)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">365</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--CrossCurrentCapitalLLCMember_z9WNeQNhcHRf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F46_zp8WQRJ4lTFf" style="text-align: justify; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Cross Current Capital (e)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">856</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">700</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--VendorAdvancesGross_iI_maVANzSvy_zniJYtW0OSve" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Vendor advances, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,271</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,115</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--VendorAdvancesAccumulatedAmortization_iNI_di_msVANzSvy_zjnKmRDVplX8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(892</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(256</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--VendorAdvancesNet_iTI_mtVANzSvy_zmvZB94q6Je4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: justify; text-indent: -12pt; padding-left: 12pt">Vendor advances, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,379</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,859</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(a)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with Prevail Infoworks, Inc.</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2024, the Company entered into a master service and technology agreement with Prevail Infoworks, Inc. (&#8220;Prevail&#8221;),
pursuant to which Prevail agreed to provide certain clinical research services to the Company. As part of the agreement, the Company
was required to make an advance payment of $<span id="xdx_905_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_zprPoAiaebDh" title="Advance payment">900</span> to Prevail before commencement of services and, at such time as we notify Prevail to
engage their services related to the relevant clinical trial, or six months from the date of the agreement, pay approximately $<span id="xdx_90A_ecustom--MonthlyPayment_pn3n3_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_z5ccsCCqpfnh" title="Monthly payment">80</span> per
month during the time Prevail performs clinical research services for the Company&#8217;s Phase 2 ENV 105 prostate and Phase 1 ENV 105
lung clinical trials. The agreement with Prevail is subject to cancellation at any time upon 30 days&#8217; written notice to the other
party. The Company made the advance payment to Prevail in October 2024 and it is included in vendor advances on the accompanying balance
sheet as of March 31, 2025 and December 31, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(b)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with PreCheck Health Services, Inc.</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2024, the Company entered into a bioassay services agreement (the &#8220;Bioassay Services Agreement&#8221;) with PreCheck
Health Services, Inc., a Florida-based corporation (&#8220;PreCheck&#8221;). Pursuant to the Bioassay Services Agreement, PreCheck will
provide certain biomarker screening services for the Company&#8217;s ongoing carotuximab (ENV105) clinical trials in order to assist
the Company in identifying lung and prostate cancer patients suitable to the Company&#8217;s ongoing Phase 1 clinical trials for lung
cancer patients and Phase 2 clinical trials for patients with castrate resistant prostate cancer. In exchange for PreCheck&#8217;s services,
and according to the terms of the Bioassay Services Agreement, the Company paid $<span id="xdx_904_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240920__20240920__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zduXccqjwVB3" title="Payments for services">900</span> to PreCheck as an advance for the future laboratory
services to be performed. The payment of $<span id="xdx_90D_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zwLbkpGeqLZc" title="Payments for vendor advance"><span id="xdx_90F_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zjW07xt7c818" title="Payments for vendor advance">900</span></span> is included in vendor advances on the accompanying balance sheet as of March 31, 2025 and
December 31, 2024 (see Note 2). The term of the agreement is one year from the effective date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(c)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with CEO.CA Technologies Ltd.</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2024, the Company entered into an advisory and consulting services agreement (the &#8220;CEO.CA Agreement&#8221;) with
CEO.CA Technologies Ltd., a Canadian company (&#8220;CEO.CA&#8221;), pursuant to which CEO.CA will provide certain internet-based financial
information and communications services for a period of one year for a services fee of $<span id="xdx_90B_eus-gaap--ManagementFeeExpense_pn3n3_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zdwOjkCdY2mk" title="Service fee">250</span>. The service fee is an advance on future
services to be performed. The CEO.CA Agreement includes such services as strategic news placement, news releases, interviews, monthly
analytics and a video launch. The CEO.CA Agreement contains other customary clauses, including representations and warranties, indemnification
clauses and governing law clauses. The payment of $<span id="xdx_907_eus-gaap--ManagementFeeExpense_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zCcYQ0z44iD2" title="Service fee"><span id="xdx_90E_eus-gaap--ManagementFeeExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zQ4vCZ1jJsAd" title="Service fee">250</span></span> is included in vendor advances on the accompanying balance sheet as of March 31,
2025, and December 31, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(d)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with Belair Capital Advisors Inc.</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2024, the Company entered into a strategic advisory agreement (the &#8220;Strategic Advisory Agreement&#8221;) with Belair
Capital Advisors Inc. (&#8220;BCA&#8221;). BCA, a venture capital and corporate finance advisory firm, has been a long-term investor
and advisor to the Company and frequently works with early-stage pharmaceutical companies. The strategic advisory services provided by
BCA consist of corporate strategy, market positioning and long-term growth plans within the pharmaceutical sector, digital marketing
and engagement, market research analysis and business development assistance, among other things. During the one-year term of the Strategic
Advisory Agreement, in exchange for its services, the Company will pay BCA a $<span id="xdx_90B_eus-gaap--ManagementFeeExpense_pn3n3_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zWK09mzIVjcf" title="Service fee">365</span> fee and will issue BCA <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zH4wUeKY4gce" title="Number of shares issued">50,000</span> RSUs, which will vest
at the end of six months following the date of issuance. The payment of $<span id="xdx_904_eus-gaap--ManagementFeeExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_z5u2qaE8GJ13" title="Service fee"><span id="xdx_90E_eus-gaap--ManagementFeeExpense_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zqWNwT1AmMp2" title="Service fee">365</span></span> is included in vendor advances on the accompanying balance
sheet as of March 31, 2025, and December 31, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">(e)</span></i></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Kairos
                                            Agreement with Cross Current Capital LLC</span></i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2024, the Company entered into a consulting agreement (the &#8220;Consulting Agreement&#8221;) with Cross Current Capital
LLC, a limited liability company organized under the laws of Puerto Rico (&#8220;Cross Current&#8221;), and Alan Masley (the &#8220;Advisor&#8221;),
pursuant to which Cross Current agreed to provide certain financial and business consulting services to the Company including, but not
limited, to (a) help drafting a public company competitive overview, (b) help preparing and/or reviewing a valuation analysis, (c) help
in drafting marketing materials and presentations, (d) reviewing the Company&#8217;s business requirements and discuss financing and
businesses opportunities, (e) investor marketing, (f) investor relations introductions, (g) legal counsel introductions, (h) auditor
introductions, (i) investment banking and research introductions, (j) M&amp;A canvassing and ways to grow the business organically, and
(k) stand by capital markets advisory services. For the services rendered thereunder, the Company agreed to pay Cross Current $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zs967aIjw35a" title="Number of shares issued, value">200,000</span>
in cash and agreed to issue to the Advisor $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zg32SQq41PFa" title="Number of shares issued, value">500</span> of restricted shares of the Company&#8217;s common stock under the Company&#8217;s 2023
Plan , calculated at <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zwdhN9xZw456" title="Number of shares issued">367,647</span> shares (the &#8220;Shares&#8221;) as of the date of the agreement. The term of the Consulting Agreement
is 24 months and can be extended for another 12 months with the written consent of both parties. The Company made the $<span id="xdx_900_ecustom--SettlementAgreementAmount_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z06niaGMIAY" title="Settlement agreement amount">200</span> payment in
October 2024. The payment of $<span id="xdx_903_ecustom--VendorPaymentAdvances_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zuE1Up2Yf3Oc" title="Vendor payment advances">200</span> and the value of the shares issued of $<span id="xdx_90B_eus-gaap--AdditionalCollateralAggregateFairValue_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z6yCdjjdyhR4" title="Aggregate fair value of the common stock"><span id="xdx_904_eus-gaap--AdditionalCollateralAggregateFairValue_iI_pn3n3_c20250331__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zdHaZRYlUKB9" title="Aggregate fair value of the common stock">500</span></span> are included in vendor advances on the accompanying balance
sheet as of March 31, 2025, and December 31, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTfiiSp4Yj82" title="Stock issued shares">367,647</span> shares issued in 2024 were subject to a &#8220;true up&#8221; on April 1, 2025, at which time additional shares will be issued
to the Advisor (or returned by the Advisor to the Company) in order to ensure the shares are valued at $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIZpvH8zT7f" title="Number of shares issued, value">500</span> as of April 1, 2025. On April
1, 2025, the Company issued an additional<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z30ZJg7BXA84" title="Number of shares issued">166,541</span> shares of its common stock to the Advisor. The fair value of the additional shares on
the date of grant was $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgBbAS3MRlag" title="Number of shares issued, value">156</span>. The Company recorded the shares as common stock to be issued as of March 31, 2025, and recorded the fair
value of the shares as a vendor advance as of the same date (see Notes 2 and 4).</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_DisclosureVendorAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_DisclosureVendorAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ScheduleOfVendorAdvancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Vendor Advances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ScheduleOfVendorAdvancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_znOl1UY3MWR5" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="background-color: white">The following
table summarizes restricted common stock activity during the three months ended March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="xdx_8B2_zro0G2YkumV7" style="display: none">SCHEDULE
OF RESTRICTED COMMON STOCK ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>Number of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>Restricted Shares</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted Average Grant Date Fair</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Value</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: justify">Unvested, December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zo4J5tjWOVG6" style="width: 14%; text-align: right" title="Number of Restricted Shares, Unvested Beginning balance">172,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zACBeqUT19tj" style="width: 14%; text-align: right" title="Fair Value, Unvested, Beginning balance">314</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5euLO2mchWa" style="width: 14%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">1.83</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyYJ5CNyaCOb" style="text-align: right" title="Number of Restricted shares Granted">20,120</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztjSGHgO3D82" style="text-align: right" title="Fair Value, Granted">50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGJWSKYxQbW9" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">2.49</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkN7GfUl4ntc" style="text-align: right" title="Number of Restricted shares Vested">(78,521</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_iN_pn3n3_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrxA1bTiYca6" style="text-align: right" title="Fair Value, Vested">(76</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD6xx18OPh1j" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">0.97</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNz4dFXhXYUa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted shares Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0615">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z333fYfpkiI5" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0617">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEKJ7p9cuqpg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0619">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Unvested, March 31, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFYmZdchnf48" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted Shares, Unvested Ending balance">113,599</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzKw5fFxyMs2" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value, Unvested, Ending balance">288</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpM4dMoxwrqh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance">2.54</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">SCHEDULE OF WARRANT ACTIVITY</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zRPh3JBqEOK9" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The table below summarizes the Company&#8217;s warrant
activities for three months ended March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="xdx_8BD_zx5peycnu1Ri" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Warrant</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Shares</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Price</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Range</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Per Share</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Balance, December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG7ExkPdZU5h" style="width: 14%; text-align: right" title="Warrants Shares, Beginning Balance">278,188</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_905_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zw3RnSMwO1zf" title="Exercise Price Range Per Share, Beginning Balance">2.40</span> - <span id="xdx_903_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zHYp8JiW4h56" title="Exercise Price Range Per Share, Beginning Balance">4.80</span> &#160;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhTHISzzX9v9" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Warrant Warrant, Beginning Balance">4.29</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zx9rkEE2e1Pl" style="text-align: right" title="Warrants Shares, Granted">6,425,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zLg00osw0D24" title="Exercise Price Range Per Share, Granted">0.001</span>
&#8211; <span id="xdx_905_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zYa4xrmSX0S6" title="Exercise Price Range Per Share, Granted">1.40</span> &#160;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zalttfYULl4a" style="text-align: right" title="Weighted Average Exercise Price Warrant, Granted">0.86</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoMomLkOoL31" style="text-align: right" title="Warrants Shares, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0679">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zz0Cgyu0ZGUj" style="text-align: right" title="Exercise Price Range Per Share, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0681">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYK9e5nbujj5" style="text-align: right" title="Weighted Average Exercise Price Warrant, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0683">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_iN_pid_di_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXSSmCr7kJPb" style="text-align: right" title="Warrants Shares, Exercised">(2,010,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRxuISik6huc" style="text-align: right" title="Exercise Price Range Per Share, Exercised">0.001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zicNkvsQa6yf" style="text-align: right" title="Weighted Average Exercise Price Warrant, Exercised">0.001</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Forfeited/Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmI19NGAzaF9" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Shares, Forfeited/Expired">(150,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIiD5R6BaEva" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price Range Per Share, Forfeited/Expired">4.17</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zD9fUkg6oNae" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Warrant, Forfeited/Expired">4.17</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Balance, March 31, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zm2nfrTaknP" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Shares, Ending Balance">4,543,188</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_908_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zXAJuNDqIm6a" title="Exercise Price Range Per Share, Ending Balance">0.001</span> &#8211; <span id="xdx_90B_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zOFcJpaWLmM" title="Exercise Price Range Per Share, Ending Balance">4.80</span> &#160;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcbNWOHZ8cHf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Warrant, Ending Balance">1.33</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Vested and exercisable, March 31, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwbE3cf7Nrv8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Warrants, Vested and exercisable">793,188</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zZmT94eyvOe6" title="Exercise Price Range Per Share, Vested and exercisable">0.001</span>
&#8211; <span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z3edkZ4ytpfg" title="Exercise Price Range Per Share, Vested and exercisable">4.80</span> &#160;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyWdYxVLXWb1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested and exercisable">1.03</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock', window );">SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS</a></td>
<td class="text"><p id="xdx_891_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zljZNQpyXmFi" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The following table summarizes information concerning
outstanding and exercisable warrants as of March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="xdx_8B7_zSVp0cQWvB86" style="display: none">SCHEDULE
OF OUTSTANDING AND EXERCISABLE WARRANTS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Warrants Outstanding</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Warrants Exercisable</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Range of</b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>Exercise Prices</b></p></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><b>Number Outstanding</b></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>Average</b></p>
                                                                                                                                                                                             <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>Remaining Contractual Life</b> <b>(in years)</b></p></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Weighted Average</b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>Exercise Price</b></p></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Number</b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>Exercisable</b></p></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Average Remaining</b></p>
                                                                                                                                                                                             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Contractual Life</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>(in years)</b></p></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Weighted Average</b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>Exercise Price</b></p></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zBsvWacU2RMg" title="Range of exercise prices">0.001</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_z3Rgrws4GxJl" title="Warrants Outstanding, Number Outstanding">490,000</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zeNTwOUURfie" style="display: none" title="Warrants Outstanding, Average Remaining Contractual Life (in years)">0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zj5vfy4uPEng" title="Warrants Outstanding, Weighted Average Exercise Price">0.001</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zYPx8I5dHgi3" title="Warrants Exercisable, Number Exercisable">490,000</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zyHT23wh2jX4" title="Warrants Exercisable, Weighted Average Exercise Price">0.001</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_904_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zqHqZmhEYfN4" title="Range of exercise prices lower range">1.40</span> - <span id="xdx_909_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zBEkkdCMQREd" title="Range of exercise prices upper range">2.40</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zmPfOod4vwN1" title="Warrants Outstanding, Number Outstanding">3,944,688</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_ziS65o1YNYql" title="Warrants Outstanding, Average Remaining Contractual Life (in years)">4.74</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zGB04cnxTQ91" title="Warrants Outstanding, Weighted Average Exercise Price">1.40</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zLeh8lehsKc9" title="Warrants Exercisable, Number Exercisable">194,688</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zFy7qWTmkTXj" title="Warrants Exercisable, Average Remaining Contractual Life (in years)">4.51</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zWkh6uWUCFDi" title="Warrants Exercisable, Weighted Average Exercise Price">1.50</span></p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember_zCopYuf7owIc" title="Range of exercise prices">4.80</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zITZqVCczLT6" title="Warrants Outstanding, Number Outstanding">108,500</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zztv0kFlmqX3" title="Warrants Outstanding, Average Remaining Contractual Life (in years)">4.50</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zz6dJWbG6832" title="Warrants Outstanding, Weighted Average Exercise Price">4.80</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z8AtC8v8Smag" title="Warrants Exercisable, Number Exercisable">108,500</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z9iVFZbxptK8" title="Warrants Exercisable, Average Remaining Contractual Life (in years)">4.50</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zA4BYzGpUTV3" title="Warrants Exercisable, Weighted Average Exercise Price">4.17</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcPQleayNeF9" title="Range of exercise prices lower range">0.001</span>&#8211; <span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhYijr2DKKNa" title="Range of exercise prices upper range">4.80</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z18mFrjx5gP8" title="Warrants Outstanding, Number Outstanding">4,543,188</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmwVo1Ycqmaa" title="Warrants Outstanding, Average Remaining Contractual Life (in years)">4.22</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgKuGxXlQv4k" title="Warrants Outstanding, Weighted Average Exercise Price">1.33</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8ZAoGVLPSL5" title="Warrants Exercisable, Number Exercisable">793,188</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsxWURbruItf" title="Warrants Exercisable, Average Remaining Contractual Life (in years)">1.72</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zycoAar2cEA2" title="Warrants Exercisable, Weighted Average Exercise Price">1.03</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Warrants Outstanding and Exercisable [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">SCHEDULE OF SEGMENT EXPENSES</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zwOoPqF4lB2d" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span id="xdx_8BF_zfYjnLQ59nya" style="display: none">SCHEDULE
OF SEGMENT EXPENSES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20250101__20250331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zE3wkZgjfXWe" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20240331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zFLJtujBKoZ7" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Three Months Ended</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">March 31,</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Revenues_pn3n3_zjIfQN6O33e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0863">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Less:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_zJIVhMBFVLx1" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Research and development, less officer compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">448</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">165</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OfficersCompensation_pn3n3_zBkkTeuBOPTh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Officer compensation and wages</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0870">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InsuranceRecoveries_pn3n3_zmOpMxR28Ti6" style="vertical-align: bottom; background-color: White">
    <td>Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_z8UGnZMYgXXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingExpenses_pn3n3_zgPWkL9ZBq17" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherOperatingIncomeExpenseNet_pn3n3_zgeUMAx9qARf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other income (expenses)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(36</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_pn3n3_ziiUdJ3hBZDe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,262</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(323</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,262<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from offering</a></td>
<td class="nump">$ 3,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,132<span></span>
</td>
<td class="num">$ (2,401)<span></span>
</td>
<td class="nump">$ 4,776<span></span>
</td>
<td class="num">$ (2,078)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">4,656,787<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=KAPA_WarrantsToPurchaseCommonStockMember', window );">Warrants To Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">4,543,188<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">113,599<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=KAPA_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=KAPA_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 3,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expenses</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets unamortized balance</a></td>
<td class="nump">182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=KAPA_EquityLineOfCreditMember', window );">Equity Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred Offering Costs</a></td>
<td class="nump">1,705,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,377,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_DeferredOfferingAdditionalCosts', window );">Deferred offering additional cost</a></td>
<td class="nump">$ 328,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=KAPA_EnviroThreapeuticsIncMember', window );">Enviro Threapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Acquisition cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_DeferredOfferingAdditionalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering additional costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_DeferredOfferingAdditionalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=KAPA_EquityLineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=KAPA_EquityLineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=KAPA_EnviroThreapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=KAPA_EnviroThreapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF VENDOR ADVANCES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_VendorAdvancesGross', window );">Vendor advances, gross</a></td>
<td class="nump">$ 3,271<span></span>
</td>
<td class="nump">$ 3,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_VendorAdvancesAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="num">(892)<span></span>
</td>
<td class="num">(256)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_VendorAdvancesNet', window );">Vendor advances, net</a></td>
<td class="nump">2,379<span></span>
</td>
<td class="nump">2,859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=KAPA_PrevailInfoworksIncMember', window );">Prevail Infoworks Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_VendorAdvancesGross', window );">Vendor advances, gross</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=KAPA_PreCheckHealthServicesIncMember', window );">PreCheck Health Services, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_VendorAdvancesGross', window );">Vendor advances, gross</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=KAPA_CEOCATechnologiesLtdMember', window );">CEO.CA Technologies Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_VendorAdvancesGross', window );">Vendor advances, gross</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=KAPA_BelairCapitalAdvisorsIncMember', window );">Belair Capital Advisors Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_VendorAdvancesGross', window );">Vendor advances, gross</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=KAPA_CrossCurrentCapitalLLCMember', window );">Cross Current Capital LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_VendorAdvancesGross', window );">Vendor advances, gross</a></td>
<td class="nump">$ 856<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_VendorAdvancesAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vendor advances accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_VendorAdvancesAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_VendorAdvancesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vendor advances gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_VendorAdvancesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_VendorAdvancesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vendor advances net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_VendorAdvancesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=KAPA_PrevailInfoworksIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=KAPA_PrevailInfoworksIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=KAPA_PreCheckHealthServicesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=KAPA_PreCheckHealthServicesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=KAPA_CEOCATechnologiesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=KAPA_CEOCATechnologiesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=KAPA_BelairCapitalAdvisorsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=KAPA_BelairCapitalAdvisorsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=KAPA_CrossCurrentCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=KAPA_CrossCurrentCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>VENDOR AGREEMENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 24, 2025</div></th>
<th class="th"><div>Apr. 01, 2025</div></th>
<th class="th"><div>Nov. 12, 2024</div></th>
<th class="th"><div>Oct. 01, 2024</div></th>
<th class="th"><div>Sep. 23, 2024</div></th>
<th class="th"><div>Sep. 20, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerAdvancesAndDeposits', window );">Advances to vendor amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,115,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_VendorAdvancesInCash', window );">Vendor advances in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,615,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_IssuanceOfCommonSharesPaidForVendorsAdvances', window );">Issuance of common shares paid for vendors advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_AmortizationExpenseVendorAdvances', window );">Amortization expense relating to vendor advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">636,000<span></span>
</td>
<td class="nump">256,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_VendorAdvancesCurrent', window );">Vendor advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,379,000<span></span>
</td>
<td class="nump">2,859,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">551,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember', window );">Helena Global Investment Opportunities I LTD [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">384,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember', window );">Helena Global Investment Opportunities I LTD [Member] | Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, value</a></td>
<td class="nump">$ 328,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">384,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_MasterServiceAndTechnologyAgreementMember', window );">Master Service And Technology Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForAdvanceToAffiliate', window );">Payments for vendor advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_MonthlyPayment', window );">Monthly payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_BioassayServicesAgreementMember', window );">Bioassay Services Agreement [Member] | PreCheck Health Services, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForAdvanceToAffiliate', window );">Payments for vendor advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_AdvisoryAndConsultingServicesAgreementMember', window );">Advisory And Consulting Services Agreement [Member] | CEO.CA Technologies Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_StrategicAdvisoryAgreementMember', window );">Strategic Advisory Agreement [Member] | Belair Capital Advisors Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,000<span></span>
</td>
<td class="nump">365,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_ConsultingAgreementMember', window );">Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_SettlementAgreementAmount', window );">Settlement agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_VendorPaymentAdvances', window );">Vendor payment advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalCollateralAggregateFairValue', window );">Aggregate fair value of the common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Current Capital LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember', window );">Helena Global Investment Opportunities I LTD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Stock issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,377,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_AmortizationExpenseVendorAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization expense vendor advances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_AmortizationExpenseVendorAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_IssuanceOfCommonSharesPaidForVendorsAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares paid for vendors advances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_IssuanceOfCommonSharesPaidForVendorsAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_MonthlyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monthly payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_MonthlyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_SettlementAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement agreement amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_SettlementAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_VendorAdvancesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vendor advances current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_VendorAdvancesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_VendorAdvancesInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vendor advances in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_VendorAdvancesInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_VendorPaymentAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vendor payment advances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_VendorPaymentAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCollateralAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of additional assets that would be required to be posted as collateral for derivative instruments with credit-risk-related contingent features if the credit-risk-related contingent features were triggered at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCollateralAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerAdvancesAndDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refundable consideration, usually cash, held by the entity pending satisfactory completion of the entity's obligations or pending the closing of a contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerAdvancesAndDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForAdvanceToAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForAdvanceToAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=KAPA_MasterServiceAndTechnologyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=KAPA_MasterServiceAndTechnologyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=KAPA_BioassayServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=KAPA_BioassayServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=KAPA_PreCheckHealthServicesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=KAPA_PreCheckHealthServicesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=KAPA_AdvisoryAndConsultingServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=KAPA_AdvisoryAndConsultingServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=KAPA_CEOCATechnologiesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=KAPA_CEOCATechnologiesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=KAPA_StrategicAdvisoryAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=KAPA_StrategicAdvisoryAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=KAPA_BelairCapitalAdvisorsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=KAPA_BelairCapitalAdvisorsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=KAPA_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=KAPA_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=KAPA_CurrentCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=KAPA_CurrentCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY (Details) - Restricted Stock Units (RSUs) [Member]<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Restricted Shares, Unvested Beginning balance | shares</a></td>
<td class="nump">172,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Fair Value, Unvested, Beginning balance | $</a></td>
<td class="nump">$ 314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning balance | $ / shares</a></td>
<td class="nump">$ 1.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Restricted shares Granted | shares</a></td>
<td class="nump">20,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1', window );">Fair Value, Granted | $</a></td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">$ 2.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Restricted shares Vested | shares</a></td>
<td class="num">(78,521)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair Value, Vested | $</a></td>
<td class="num">$ (76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">$ 0.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of Restricted shares Forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1', window );">Fair Value, Forfeited | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Restricted Shares, Unvested Ending balance | shares</a></td>
<td class="nump">113,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Fair Value, Unvested, Ending balance | $</a></td>
<td class="nump">$ 288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending balance | $ / shares</a></td>
<td class="nump">$ 2.54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANT ACTIVITY (Details) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants Shares, Beginning Balance | shares</a></td>
<td class="nump">278,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Warrant Warrant, Beginning Balance</a></td>
<td class="nump">$ 4.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Warrants Shares, Granted | shares</a></td>
<td class="nump">6,425,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Warrant, Granted</a></td>
<td class="nump">$ 0.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Warrants Shares, Cancelled | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled', window );">Exercise Price Range Per Share, Cancelled</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Warrant, Cancelled</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Warrants Shares, Exercised | shares</a></td>
<td class="num">(2,010,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised', window );">Exercise Price Range Per Share, Exercised</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Warrant, Exercised</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Warrants Shares, Forfeited/Expired | shares</a></td>
<td class="num">(150,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited', window );">Exercise Price Range Per Share, Forfeited/Expired</a></td>
<td class="nump">$ 4.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Warrant, Forfeited/Expired</a></td>
<td class="nump">$ 4.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants Shares, Ending Balance | shares</a></td>
<td class="nump">4,543,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Warrant, Ending Balance</a></td>
<td class="nump">$ 1.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod', window );">Number of Shares Warrants, Vested and exercisable | shares</a></td>
<td class="nump">793,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Vested and exercisable</a></td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants', window );">Exercise Price Range Per Share, Beginning Balance</a></td>
<td class="nump">2.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted', window );">Exercise Price Range Per Share, Granted</a></td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants', window );">Exercise Price Range Per Share, Ending Balance</a></td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable', window );">Exercise Price Range Per Share, Vested and exercisable</a></td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants', window );">Exercise Price Range Per Share, Beginning Balance</a></td>
<td class="nump">4.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted', window );">Exercise Price Range Per Share, Granted</a></td>
<td class="nump">1.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants', window );">Exercise Price Range Per Share, Ending Balance</a></td>
<td class="nump">4.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable', window );">Exercise Price Range Per Share, Vested and exercisable</a></td>
<td class="nump">$ 4.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards cancelled during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were exercised during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards exercised during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options excercisable in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation shares exercisabler other than stock option plans exercise price range cancelled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation shares exercisabler other than stock option plans exercise price range exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation shares exercisabler other than stock option plans exercise price range forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation shares exercisabler other than stock option plans exercise price range granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock warrants as of the balance sheet date for all warrants in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the warrants vested and exercisable as of the balance sheet date for all warrants in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants Outstanding, Number Outstanding</a></td>
<td class="nump">4,543,188<span></span>
</td>
<td class="nump">278,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants Outstanding, Average Remaining Contractual Life (in years)</a></td>
<td class="text">4 years 2 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber', window );">Warrants Exercisable, Number Exercisable</a></td>
<td class="nump">793,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice', window );">Warrants Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices lower range</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices upper range</a></td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms', window );">Warrants Exercisable, Average Remaining Contractual Life (in years)</a></td>
<td class="text">1 year 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=KAPA_ExercisePriceRangeOneMember', window );">Exercise Price Range One [Member] | Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants', window );">Range of exercise prices</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants Outstanding, Number Outstanding</a></td>
<td class="nump">490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants Outstanding, Average Remaining Contractual Life (in years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber', window );">Warrants Exercisable, Number Exercisable</a></td>
<td class="nump">490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice', window );">Warrants Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=KAPA_ExercisePriceRangeTwoMember', window );">Exercise Price Range Two [Member] | Warrant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants Outstanding, Number Outstanding</a></td>
<td class="nump">3,944,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants Outstanding, Average Remaining Contractual Life (in years)</a></td>
<td class="text">4 years 8 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber', window );">Warrants Exercisable, Number Exercisable</a></td>
<td class="nump">194,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice', window );">Warrants Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices lower range</a></td>
<td class="nump">1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices upper range</a></td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms', window );">Warrants Exercisable, Average Remaining Contractual Life (in years)</a></td>
<td class="text">4 years 6 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=KAPA_ExercisePriceRangeThreeMember', window );">Exercise Price Range Three [Member] | Warrant Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants', window );">Range of exercise prices</a></td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants Outstanding, Number Outstanding</a></td>
<td class="nump">108,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants Outstanding, Average Remaining Contractual Life (in years)</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber', window );">Warrants Exercisable, Number Exercisable</a></td>
<td class="nump">108,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice', window );">Warrants Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 4.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms', window );">Warrants Exercisable, Average Remaining Contractual Life (in years)</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average remaining contractual terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares warrants exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award equity instruments other than options nonvested weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise prices lower range</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock warrants as of the balance sheet date for all warrants in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise prices upper range</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=KAPA_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=KAPA_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=KAPA_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=KAPA_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=KAPA_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=KAPA_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=KAPA_WarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=KAPA_WarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=KAPA_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=KAPA_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=KAPA_WarrantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=KAPA_WarrantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 16, 2025</div></th>
<th class="th"><div>Jan. 14, 2025</div></th>
<th class="th"><div>Nov. 12, 2024</div></th>
<th class="th"><div>Sep. 23, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>May 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_SharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,825,118<span></span>
</td>
<td class="nump">13,736,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,825,118<span></span>
</td>
<td class="nump">13,736,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription', window );">Warrants exercisable description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">will be exercisable six months from issuance and will expire five and a half years from the issuance
date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">551,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_StrategicAdvisoryAgreementMember', window );">Strategic Advisory Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_FourOfficersAgreementMember', window );">Four Officers Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,521<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_DirectorAgreementsMember', window );">Director Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_FairValueOfRestrictedStockUnits', window );">Stock compensation-related expense for fair value vesting of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_FairValueOfUnamortizedCompensation', window );">Fair value of unamortized compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Three Independent Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,120<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Strategic Advisory Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Four Officers Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=KAPA_TwentyTwentyThreeEquityIncentivePlanMember', window );">2023 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,457,880<span></span>
</td>
<td class="nump">1,457,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Warrant shares outstanding, intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=KAPA_PrefundedWarrantsMember', window );">Pre-Funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_WarrantsUnexercised', window );">Warrants unexercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=KAPA_CommonWarrantsMember', window );">Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=KAPA_SecurityPurchaseAgreementMember', window );">Security Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Purchase price of pre-funded unit</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds received from financing</a></td>
<td class="nump">$ 3,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=KAPA_SecurityPurchaseAgreementMember', window );">Security Purchase Agreement [Member] | Pre-Funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription', window );">Warrants exercisable description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
warrant will be exercisable six months from the date of issuance and will expire five years from the issuance
date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=KAPA_SecurityPurchaseAgreementMember', window );">Security Purchase Agreement [Member] | Pre-Funded Warrant [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase of common stock</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercisable price per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=KAPA_SecurityPurchaseAgreementMember', window );">Security Purchase Agreement [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=KAPA_SecurityPurchaseAgreementMember', window );">Security Purchase Agreement [Member] | Warrant [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase of common stock</a></td>
<td class="nump">3,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercisable price per share</a></td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=KAPA_SecurityPurchaseAgreementMember', window );">Security Purchase Agreement [Member] | Warrant [Member] | Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase of common stock</a></td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription', window );">Warrants exercisable description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
warrant expires five years from the date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights date from which warrants or rights exercisable description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_FairValueOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_FairValueOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_FairValueOfUnamortizedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of unamortized compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_FairValueOfUnamortizedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_SharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_SharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issuance of common shares upon exercise of prefunded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_WarrantsUnexercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants unexercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_WarrantsUnexercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=KAPA_StrategicAdvisoryAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=KAPA_StrategicAdvisoryAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=KAPA_FourOfficersAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=KAPA_FourOfficersAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=KAPA_DirectorAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=KAPA_DirectorAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=KAPA_ThreeIndependentDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=KAPA_ThreeIndependentDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=KAPA_TwentyTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=KAPA_TwentyTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=KAPA_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=KAPA_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=KAPA_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=KAPA_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=KAPA_SecurityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=KAPA_SecurityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=KAPA_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=KAPA_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=KAPA_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=KAPA_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_LicenseAgreementDescription', window );">License agreement description</a></td>
<td class="text">(1) obtain an IND for a patent product within 1 year of the effective date of the agreement, (2) commence a Phase
II trial within 2 years of the effective date of the agreement, and (3) submit an NDA or BLA to the FDA or equivalent regulatory agency
in another jurisdiction within 7 years of the effective date of the agreement. Pursuant to the Enviro-Cedars License Agreement (Mitochondrial
DNA), Enviro is obligated to (1) complete preclinical studies of a patent product within 2 years of the effective date of the agreement,
(2) complete toxicology studies within 2.5 years of the effective date of the agreement, (3) obtain IND within 3 years of the effective
date of the agreement, (4) begin a Phase I trial within 4 years of the effective date of the agreement, and (5) submit an NDA or BLA to
the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. If the Commercialization
Milestones are not met or extended, Cedars may convert the exclusive licenses into non-exclusive licenses or to a co-exclusive licenses
or terminate the licenses.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=KAPA_PhaseOneClinicalTrialMember', window );">Phase One Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_PaymentForMilestones', window );">Payment for milestone</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=KAPA_ItemOneAndTwoMember', window );">Item One And Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_PaymentForMilestones', window );">Payment for milestone</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=KAPA_ItemOneAndTwoMember', window );">Item One And Two [Member] | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_PaymentForMilestones', window );">Payment for milestone</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=KAPA_ItemOneAndTwoMember', window );">Item One And Two [Member] | Phase Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_PaymentForMilestones', window );">Payment for milestone</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=KAPA_ItemThreeMember', window );">Item Three [Member] | Phase Two Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_PaymentForMilestones', window );">Payment for milestone</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=KAPA_ItemFourMember', window );">Item Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_PaymentForMilestones', window );">Payment for milestone</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_PatentProductSalesPercentage', window );">Patent product sales</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=KAPA_ItemFourMember', window );">Item Four [Member] | Food and Drug Administration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_PaymentForMilestones', window );">Payment for milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=KAPA_ItemFourMember', window );">Item Four [Member] | Phase Two Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_PaymentForMilestones', window );">Payment for milestone</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_LicenseFee', window );">License fee</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Annual maintenance fee</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member] | Item Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_LicenseFee', window );">License fee</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Annual maintenance fee</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_MinimumRequirermentOfCapital', window );">Minimum requirerment of capital</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_PatentProtectionCosts', window );">Patent protection costs</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_OtherNonroyaltySublicenseFeesPercentage', window );">Other non-royalty sublicense fees percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member] | Minimum [Member] | Item Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_OtherNonroyaltySublicenseFeesPercentage', window );">Other non-royalty sublicense fees percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_PatentProtectionCosts', window );">Patent protection costs</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_OtherNonroyaltySublicenseFeesPercentage', window );">Other non-royalty sublicense fees percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member] | Maximum [Member] | Item Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_KAPA_OtherNonroyaltySublicenseFeesPercentage', window );">Other non-royalty sublicense fees percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_EnviroCedarsLicenseAgreementsMember', window );">Enviro Cedars License Agreements [Member] | Item One And Two [Member] | Phase Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=KAPA_EnviroCedarsLicenseAgreementsMember', window );">Enviro Cedars License Agreements [Member] | Phase Three Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_LicenseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_LicenseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_MinimumRequirermentOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum requirerment of capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_MinimumRequirermentOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_OtherNonroyaltySublicenseFeesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other nonroyalty sublicense fees percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_OtherNonroyaltySublicenseFeesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_PatentProductSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent product sales percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_PatentProductSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_PatentProtectionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent protection costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_PatentProtectionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_PaymentForMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_PaymentForMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_KAPA_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">KAPA_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>KAPA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=KAPA_PhaseOneClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=KAPA_PhaseOneClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=KAPA_ItemOneAndTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=KAPA_ItemOneAndTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=KAPA_PhaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=KAPA_PhaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=KAPA_ItemThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=KAPA_ItemThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=KAPA_PhaseTwoClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=KAPA_PhaseTwoClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=KAPA_ItemFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=KAPA_ItemFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=KAPA_FoodAndDrugAdministrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=KAPA_FoodAndDrugAdministrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=KAPA_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=KAPA_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=KAPA_ExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=KAPA_ExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=KAPA_EnviroCedarsLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=KAPA_EnviroCedarsLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=KAPA_PhaseThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=KAPA_PhaseThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=KAPA_PhaseThreeClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=KAPA_PhaseThreeClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF SEGMENT EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, less officer compensation</a></td>
<td class="nump">493<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">1,266<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">(1,262)<span></span>
</td>
<td class="num">(323)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, less officer compensation</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Officer compensation and wages</a></td>
<td class="nump">101<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceRecoveries', window );">Insurance</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">76<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (expenses)</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (1,262)<span></span>
</td>
<td class="num">$ (323)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>Integer</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 24, 2025</div></th>
<th class="th"><div>Apr. 01, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">551,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=KAPA_CrossCurrentCapitalLLCMember', window );">Cross Current Capital LLC [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember', window );">Helena Global Investment Opportunities I LTD [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">384,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=KAPA_CrossCurrentCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=KAPA_CrossCurrentCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>46
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $@TKEI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( $@TKEJ:NU<+\@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%.PS ,AE\%Y=ZZ:;L=HJX7IIU 0F(2B%N4
M>%M$TT:)4;NW)PU;!X('X!C[S^?/DAOEA!H\/OG!H2>#X6ZR71^$<AMV(G("
M(*@36AGRF.AC\S!X*RD^_1&<5._RB% 6Q1HLDM22),S S"U$UC9:">51TN O
M>*T6O/OP78)I!=BAQ9X"\)P#:^>)[CQU#=P ,XS0V_!50+T04_5/;.H NR2G
M8);4.([Y6*5<W('#Z^/#<UHW,WT@V2N,OX(1=':X8=?)+]7]=K]C;5F4JZQ8
M9;S>\T)4M>#UV^SZP^\F; =M#N:?&:^_&5\%VP9^W47["5!+ P04    " !(
M-*Y:F5R<(Q &  "<)P  $P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4
M?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-
MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( $@TKEJF%<30$08  *\@   8
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M#SIMW_':;L__>&XUDN)4#>MLN@W[R%YU0+/L.,P($!0L<$FB#5P7'B;B@!!
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M[WS?=]\=OHMJ(1]5#J#14\&XBKU<ZW**L4IS*(@:B!*XN=D(61!M3+G%JI1
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M&W!%BX\E[L3D> .^\]3N%FQ@>\L^^Q=02P,$%     @ 2#2N6KZQ*9Z,#
M@QX  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&ULK5EM;]LX$OZN7T%D
M#XL64!+'>6W3!G"==-= T@1QLHO%X3[0$FWS*HE:DHJ3_?7WS)"2Y;P4>[C[
ML-U()H<SPYEGGAE]6AG[W2V5\N*Q+"KW>6OI??UQ=]=E2U5*MV-J5>&7N;&E
M]'BTBUU76R5SWE06N\/!X&BWE+K:.OO$[V[LV2?3^$)7ZL8*UY2EM$]?5&%6
MG[?VMMH7MWJQ]/1B]^Q3+1=JJOQ]?6/QM-M)R76I*J=-):R:?]X:[7W\<D#K
M><%O6JU<[V]!ELR,^4X/D_SSUH 44H7*/$F0^-^#&JNB($%0X\\H<ZL[DC;V
M_VZE?V7;8<M,.C4VQ>\Z]\O/6R=;(E=SV13^UJQ^5=&>0Y*7F<+QOV(5UA[L
M;XFL<=Z4<3,T*'45_B\?HQ]Z&TX&;VP8Q@U#UCL<Q%J>2R_//EFS$I960QK]
MP:;R;BBG*[J4J;?X56.?/YO>7UV-;O\0UU_%=/++M\G7R7CT[4Z,QN/K^V]W
MDV^_B)OKR\EX<C']M.MQ'NW:S:+L+T'V\ W9^^+*5'[IQ$65JWQS_R[T[)0=
MMLI^&?Y0X)6T.V)_+Q7#P?#P!_+V.^/W6=[^&_)&66::RNMJ(6Y,H3.MG/CG
M:.:\1;#\ZS6#@[R#U^51 GUTM<S4YRUDB%/V06V=_?S3WM'@] ?:'G3:'OQ(
M^O]X53^4_;KFWZ[O+L10;"=__V3Q13KMA)DG8U,Y^#27G'QW2Y5(>+NL9?5$
M_LX,8J)R*J>_XD(\S'4EJTS+0CB/%\A^[X2L<K&QN3(>-[64#TK,E*H$5*ZE
MQ79=\4*;0XA")ODE/X<[3FJK(;LNL'>A*F5E43S1[ZKV8:]?*G%?:7J:TO%D
MB!B5RNI,BG<__W0R' Y.[W>F.^*7T>B&G_=.W^^0=>)O6)>\:AUT*II<\>%1
M63Z7GL=!)'M X_5J:4AGLZH@VC4SIW,-*$V180_:&E+$REHU7F<N%9,JVTE:
MM<.*M<ZCHL#17MFH-K"M(*\%=R,#*B<9./N.5H4&!LGHKJQ_Q3OBWBG2^\)Y
M7;+SR"WA:D(01*/>\ *)HR*C_5/R[.;$W[LYNABK_FPT(A@86:&HD'#A#9Z^
M*Z$ZS3BB' I1'2ST2^F%G,]1*E@4E#:6;DR6W7U@O8K!6&@YTX7VP(M4Y-IE
MA7&-9>MA!&E,Q[Z^04C_EA<$10FO;\\7\?P$DJUZ4%43?E>/-867$WECR3]K
MG=E;"%B3[XBI7E1ZCMB%Z)[M4+1Q:[<]R*+I[@<^M8TLG,!-B!II!FN@8M_@
MI-O ;D&%RKYO4V&D8"])+_XQC4K)0O_5B4>Y5)82U<O'Z)\T!#=B4%MV NZM
M>"(0H?=0=-[0^7/%*B%B9;70LP)P$MU;&IAL<)AUB.K,0WT<ZU"5'11JBAPW
MA)NU8FY-24JY7B3L(,40])5?A^@8^FDO;K7[+KYVEZ0K5(6&8S5%&NILN78/
M8A&Y^.\8/$F;M B[[+GP+ BW$)YR_FCG*;I!B#0E-E9(MX2?:N.0\ %:6H'$
ML3S^<]WO=(=SE<>$P"^-[8-H0EIKWX3+PEKUB 3G:WNYBU*;3KQ:)\X,^8ZH
MB_G1!R1<#T"8XM#0Q<-4UPNVGI6(4)7@Y\V09^U[D!#M,9;5V5 Y^-HO<<[:
M;(KAI2KR3?\L9:<5,D#!]4@@O$=V(E<2'-<)<)H*1/ @H0@#V)A<?P'\0(0S
M*/6%\V7!9S@<R+D$V8/O"HW5E$EPDN?@"-!EK%[ V )7YI&AG/=LJE5*E($4
M(9H+OHR0AIS[6%,W-H,ABGPZ4R$<U%JGJ&7O31M&,!;;(5Q1I-CORB?SILJA
M+Y\-[@0_MN2)'0<GKNB?RHC]]'!P@(+19I<8A>SJ>8!*Q][QJ>OE8 =Q$,(H
M!G_C5&0RHXJ*1W?FR8S!.4^#Y0";IFP*&8$.X/57+"6CWA/%6B:++"X,2!.=
MUN9Q#R@>6E>W"-&F*YN:*U0\E+ 0LS.*2=2V)R5QKR>#@3@8B+V3H1@.AV*R
MAB3(NP3*;%]B<9Z\=(V0=5UHSA.J>.9!NQ8>1].QN#.USL3^T2!-;BS:*>M1
ML6]0;7T /PJYF@_Z9JAHFU*)=Y<(VO?B!K@U79)_B5AE',J$[\+Q2W(-5&C8
M,4\ N@<0 B)(Z.9H:<**99+NBN&H1'P$R :3X&C&-M)ZQ>T+7<0#<&&!H&C*
M&<Z!"6CE<+E5'HA-D$"G;U2?MN:<ZX*UV50T>4M1VMHJ*_X?RFXJV%>]+AJ7
M\'G=8IGG#$-(U,U]C'<K+AYK\M,7IN<, SE92Q&T+I6;@I8R#YLUV(:"?]!*
ML@D;4*"H/WJ6H1P9^.,@9:5G?/WT+H\>?L5$#G%:[62I4LJ^?HWJE(T[>74+
M:PR57F^WBP*R]K8GZ^TJ:S%M WH8XL%/S0JZ?!33\:\7Y_>7%PFZAAMT$F@4
M1I>7?XCSR>7]W>2W"S&]&-_?3N[0-23/3-]X/$A^EQ9T%"F'J.C@L1\>XB ]
M/-A/]TY.Q-[A(!T,!LDMH &TG1W%2YJ*T'YO#TCWX8-@,!N>)G?&X\X.TJ/#
MH_3XY+C=+LY;HG)-U(%\.S8N)'U7WS-9:T_TAAR!I$9E!JXM9)$2!LR!<!Q:
M:9_(T@4R5X&WM,VWP8W]$XIQ&W.4U#D@,O-$<)TS*)=D U<576U#,%=PPG_P
M9(JJ2-K=FER95N>,=::CP3*;;!FWB=ZV& (TDO$4GZ,Y '+]JE>CG^U-(Y7B
M,Q*2 ZW1>5$@02Z>\B8,7B+/7+NKI;4O#'SE&+#8)>?A*[\1?N>JD$]DLQ5R
M!N^B_.4A8]YRQTHC<;$S<FCBGB7H"K1@ET-U!)A=, 816$N^N(YQ1VNF'6F'
M>Z[#,C@-#F38/U>9(I1)VB!.-^E3A10BW?XA]M+]X^-D?WB2[*7'@T/QE:KG
M;UP]KY0D:E:^X")=%0L5IU=P<33S(RY1R?/68[-V/L).="I$/XD+5:&!RI'!
M5 U[$#CCNU54_)CI*3A05N$0<CSJ)/_ 32,Q;=F=^B3>R2I1C]J'8]ZW_HL=
M'9(/ DI<#,#X 4D.-#>-BP2&*3_WQ>U1:[G4ZB,V$7 6]];K5Z&N7Q'D1AF4
M8IJ.XCXJG%ZN/<O,9(<]'L+=JVQ9@=?!7TWDMG%YW]&E? 1?_BO ;1,Z7S.C
MP0G7+UVAUH46!O?T?&725"_6;E+9AD)-]@]<:L08L.^I316J'P78><$!%X2D
M]&?+F(G<6#C6KTR7YQ'JUZ=SC-#:0F)I7Z_T=<L_)C__].'H^,.IN*3#Q5Z'
MI9OOAV^\WV_?,Y9F@':>F/0:[?EK35? +^F8$*?=2(CWU/*)'1E?VD8]:]%!
M+*QY9*88N]+ )==6N01]BHA]BEN"?6Y3BKW@[X1X/:W^&S8N(AOWR7,J?O5R
M%==FUBQO2<\Z-,A??S:&SN"D<F'NQ<4Y2 G].RX;T)_1B*$KV2T;MHKG?)5/
M9'>1_:R@((NI^EH0[HA;19VMZ(]0K:GP=Q8!:U*!SCXP"D8$_#J:?HE$"+SX
MGM]N#_9;RMM!:@R0VW:@P177JB5]"H")87E<=!%P&;S3R<7"HOQR$I]W0QDG
MWDV;F6<*/AP.M@\&[Y\OQD4]5T%$N3$M%^CRJ.*@H=[0O)LVU<T,U%7,Z'*X
M/L,E'#4(J3@@4BWTA>GEBYYX/0Q+^T,-(@K5 N]<K3)JL"$F?(N!ZHF<@?]U
M[",4N(T!49@N,O^-S"G"Q0-.0K]]*E19%^9)J8WIS6F@FA0D5*#Y^TFUV:6U
M9U"H)4HBIE#A@S^#G3KX=#W>6G'+&8A(JQ]W,6$"&KOYIN9>$1V#XH$<73E%
MLZRJ,-K9''.AJBGTVA7%B63RTM9>D#G.L*,X8J)AIRY_)$"\+N!X1UQ(JC(R
M-W7;DM94@;VG9K:%4)#N*@]3@%(^4=D,?2&EJ:'K(UL*'@R]5"(<S86Y,SO,
M!"Q6^^<"J/MHM\9,7H_TU@.@=5#MB-]5* /$/"KBERI.\MH6;J-Q1=BY+N[;
M@2EQVG9UU_'0["[S=.NFL:\%=+(>D4*-:XYJ&^!C8\:[ 1\1)P+X)00=:2^8
MB>1<E,HNZ&%"2\&0)$WLC(W<M!W<5TCN,%+B(CU&KB"-(/HFY&Q$,%FULTBF
M=^L>ASOTR)4(B4K-Q!YIG?.TB4*3ARC=O(RUWIP_<Q<IJ9Q IPV?]:"]F[#$
M"R71\\8WL7:__$BR<;VO?6':[7T8)&_QYT\>BU8^?"/LWG9?6$?AP^)Z>?@\
MBZ*UH-%CH>;8.M@Y/MP2-GSR# ^ 6/[,.#/>FY+_7"H)OD$+\/O<(&+B QW0
M?7<^^P]02P,$%     @ 2#2N6J79#'N5"0  I!@  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&ULC5EK4]NZ%OWN7Z')Z9PA,RYY$:#E,0,A/>U<"DSI
MZ?VLV$JLBVWY2'+2W%]_UY;\2,!P^5!BR]+6VJ^UM]3SC=)/)A'"LM]9FIN+
M7F)M\7DP,%$B,FX.52%R?%DJG7&+5[T:F$(+'KM%63H8#X?'@XS+O'=Y[L8>
M].6Y*FTJ<_&@F2FSC.OMM4C5YJ(WZM4#/^0JL30PN#PO^$H\"OMW\:#Q-FBD
MQ#(3N9$J9UHL+WI7H\_71S3?3?@EQ<;L/#/29*'4$[U\BR]Z0P(D4A%9DL#Q
MLQ8SD:8D"##^J63VFBUIX>YS+?V+TQVZ++@1,Y7^6\8VN>B=]E@LEKQ,[0^U
M^2HJ?:8D+U*I<7_9QL\=87)4&JNR:C$09#+WO_QW98>=!:?#5Q:,JP5CA]MO
MY%#><,LOS[7:,$VS(8T>G*IN-<#)G)SR:#6^2JRSE[_F=S?W/]C57S_F\^_S
MNY^/YP,+L?1Q$%4BKKV(\2LB)NR[RFUBV#R/1;R_?@ X#:9QC>EZ_*; [UP?
MLLDH9./A>/J&O$FCX\3)F[RFH\ACI=G52@N!>+*F2T<OXJA;!*7&9U/P2%ST
M$/M&Z+7H7?[YQ^AX>/8&P*,&X-%;TM_GA#=%= .\N_\Y#R;LSS].QZ/1&7NQ
M#:LM$Z]Y'@G#?B8BF*FLX/F6)=PP&$MH$3.96\767$M5&A;!VQK99!"J-F&T
MEXP$*[1:RUAHPXI2FY+GEF'1)I%1PFPB6"VWX%OC!M9^<X[4]/LS;NE#L! K
MF><R7S&U=#/K'4N>LD( 17Q(4$TKHU8@4F4:LP70<(G?[=[. G"%AC(LXB9A
MRCV:A,->M%.DL@P\@92+GL(@%N"]V('(G118(C//$3D<[?80!::*RT@TF_,H
M*K,RY19#:YZ6HA91V<V01D2N[9)**:4#DL<SI:W\+SX3B0&>YL0T'RD"B) D
M0*VAUH[,RDBAM[Z@KYAE$@@22*TKI\:-B$2VP*<JTX["5@_RM@-A JLL3['Y
M!S8)1Z,I&X?'^#L=#MEX>HRWT^DG-L+3\83>)B>?JJ *=GP""C>D?Z7Y4J6H
M!61:.!S)C@"ILQT8\O@EM,_L<?9U?O/W[3RX_]+$\<VOJ[O9_#%H1>PN#!ZT
M6'.9LF_Y4KDBQPYX'WI\ G;WEV;,$A$]L:^"IPCEQ]HE!XN^FT:39O/[P]D5
M^RFB)%>I6DGZ'O6A/IE@&*"P<:G9C!<2EJ)<D@:&8P=QGTV.I_0OF&EE#)N5
M6B.CFJD'HL].8;H3[/)K/Y!#MG)+)N'X9.0M']P*8S[OQ5,5&MS5MX/33V/6
M9P?DEOY+>3D*_(?*0Q^\WP*RQ[\ 7IF@(4>?U"]L%^(Q.F3W>7!5KE"66!,T
M>QFVRQ<<=0INUTU4DFMM;<8MX^_;\H#H:SP\J[Z[M]%9/PQ>TDPMPDF.:;PB
M)18);3DE/K)&1K ]<:0+FR8-,7M'%9<E!=>V#MH&[9[&P08LJ<4_I=1^PXP_
MB5U* ]LY%2'%1][I,*#H>M7LG0'96O]1%-:'^'CX#@\LI.+&\&VK9FOU UI7
M&?>ZGM>D0(.L-O@^PJ 3(=*7?4F5EC'_2+U2C.37A=)5A+:>=#)JR8?L8<>5
MA.H-.&%KI(U,T^"YAZ$QNLLG"KL(2UP9:90'S^Y:RQ7&DS/08;Y2-#'B6MGR
MM\SX@AW,[WZ-AM-^&S-62YX:*AI*Q\2XL+ A:@MV/8#/P)-;N=R2R+0DGD/D
M ZBQ2%ML@L#0B PKJ1E!/PPV6*3B602^ /> BBS8Z 4>4HIV"9X+IEW]HG'G
MHF:B\RQJ(DJ+I0)&.I$WGD$^A(^9^!TE/%\))V'7DPYK;>DPH,W!5; 48:]4
MVZNA;SIYOV.0<94]1,A$OMWITT75MS9^GCB3_Y\X+H&)Q[?.BE3"T.;OQ5)W
M(E40NK.GLY800,J;&<]Y++%S5"$ZV!/9\%Y'>U6)I7QXP7B2] +Y5_FXE#E\
MB1 (9.Z/=.YLY'3,LI)BA$;,?L[PJJ,@URFT'5MP9_6AG2>$9[FZ,%(![/;3
M:R6S@^3>X2OFXW8EHQVG=3KGL9EX54]\A>8\PJ ;8>V8Z]8KAPPOY$6T3;;4
ME#%^I;>LYT!165^T.)=29Z%KM1?@*JQ/D>T?*4V@W%J@%]4^D_R"9Q3AI"^I
M_&#7=,M\E^,4@(/2[4=D+S*U0(N;X6A06L< /KX0>KYY[;!>VYKZ8*+.-(""
M=2OGN^5:J4K -F2.>$$;RD@*(EDQ7ZL3FIH-P!4ISSU.Z7OK9P@-CNQ*ARR6
M*V=$+Q?BG"U$OH)6GB:J'9MJCAQ*M]02T\1%:= CHXN*T0*GJG#QX!F;O!!2
M_T3]O3L5$)853')3:D=80(5(_^@BW6&O6*N)H>!E#(5$_GL$*>T.)^ZYSB<K
MV(_LRJF]/J:V.AR"Y:AEI.;P%9;K;"9O;V>4.O>P'"7.>]JS'59[A<S:":_D
M22>6 %@H%U*926I34\D7,I5VVU";TBM$()UIRCRNSBXIW[C2\%""N13[(2/5
M4N#N-BT3DI.O$$LX1)A4;/>P5]YYJUW<!_]ZT]APYGY4=16%9_DI\R@MJ0"&
M6&99KFQ0&26DJ=1_)R(M6*SYTOL![+Y(D8NUI>@7H4]75^Z8MY9B$[KSB5N(
MLSZ:U"K1!@@X=,"8X471<;/F=Y\6H3NYT$K0?[MKDU]X0H2X!L&W+,BKW/J*
M$+H332N_JU5I;%.UQ%G3A\321"4^5+;T@(-Z/AW "]")10%"3T)[(?QK!FSQ
M87RY,Z[!TKY:(:*UPKF[1KKJLU2L'-F5N1'IBPE)GW%XAOCU^2=9[^#R8<'S
MIYK(&IIYON0_??;]3YX59U?4*JV)8ZHE&W?;H1SS.9,U)O(Y +I+MRZ2@X.G
M/B-F<O< =?WPJIN7W'S(OBB]?Y& ,(Y=?A.A"9=9^_F_$^(@GOWP1]T>>O:9
M.@8Z"8^/3FC,_:,QNARJQ^E]='P<3H]&[O3?T$/@:.&K2$7.V5^I6G ZT376
MO-_U,O'5'8+:5?K1^%U=V3X5OG.?;^SVYTU#)GY1PV,U+P2=MU6.IA..[*-1
M33<O9#]I3.D/M BNE$:\U!#E6&7,RLRW\_CU-%4A-0DGVB\11-27^\GM=F%0
M%K0.U<#[@GK>XY,A; X[X^Q^XD[@A<8AETSEKTSV&(> H5_(?56;G!Z%1]-/
M;#(^95T7E8.=F^-,Z)6['W?7:+GUE\C-:',%?^5OGMOI_O[^.]<KB51,Q1)+
MAX<GTYZW5_UB5>'NH1?*6I6YQT1P!"E-P/>E4K9^H0V:_YBX_!]02P,$%
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MM$A!:+.LW1J&GDT'EV 0L'U7R-VMR_VU*);Z+PRZ^ZS2TMSSMZ/MOR1#\^?
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MM-/^UG=!UF].?=&BM'M^+32]&O:8TC.-TBB0?".$/ER,@^;AG_X+4$L#!!0
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M\(R2GEH<Y7AIQ,J+)3D^)\0,..!+&_0"C%K81II=\0R!O/H9F6F.X"^S*?A
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M<JD=M2ID+( CZE<DLKE,>X2E,Z0T=O]>NRDE)^.^ Q;5)ME'G^M>4;)6<4'
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M[Y>'1=<^IZ&OL'(^-RA=&%R^UL-I*]Y-RJGC-G X[.\?]]]O+H8#;8H@ MT
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MK8Q:@4B5:<P60,,E?K=[.PO %1K*L(B;A"GW:!(.<]!.D<HR\ %2*WH*@UB
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MQT1P!"E-P/>E4K9^H0V:_X"X^A]02P,$%     @ 2#2N6N)8OFDA P  A@8
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M1"N^\B[[ 577R; W%F0=_5>>65_BP_XO9& N%#.&;6LWZZBW2:\([GTI5[5
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M;XER!]</<Y:^E416T<RARO\Z\/4#2[+K"8U*:^*80F7#MJXJB/E<R*H0^1Y
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M:5=7)XH06 P4W^8YZH8KG<KRVU@'9Q1F@7Z^YEP]#,P&510/_@!02P,$%
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MXW*]S\?UO%?6^X9Y#_GN1^0Y7M"2'IG3YQ!7Z?UFNJV45_*]2KY7X/5?P7L
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M#DP](/]?4"KV%RI!OE,]_ ]02P,$%     @ 2#2N6HUJ^5O2!0  S2<  !D
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M&AXG[?UQRRMKFIK6;H,F'1^ZT_'K^HWL'^)DL7G/P:H#;JNK/EKK'DVZ42U
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M1NQNM7/Y']\P>S!IN9-(@$XK4$VBFD*U$-4B5-.49C= DUU/W-GUX57=FR>
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MA2I(KPRB:NTB\,[<H;G85-BVL?U>8[/%WF_8^YWL[PI@N%R6\*KX@78+^^W
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M:XEGGCB^0CP@2RFPU&0N<LC_QX=&9*<T/BF=Q3<)EU3UR*#_@<11/"(+@5"
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M=AN6??L(-LYW+$&59KXBLQKG=L6YK3:3VRHQJC3S%9G5,'8JC!U5F=QH="S
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MN7NC P  2!<   \   !X;"]W;W)K8F]O:RYX;6S%F-]OFSH4@/\5BZ?>EYM
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MV+:BFTO:'!>"CXO8G_X%4$L#!!0    ( $@TKEJ,WU^M;@$  -T4   :
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M#T'[\$$4HXRQ@*0%U@*T)N2:!'A-"#8)$)N0;!)@-B':)$!M0K9)@-N$<),
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M4$L! A0#%     @ 2#2N6NO%P><% P  TPH  !@              ("!O1,
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( $@TKEI(U,$U
M7@0  *L1   8              " @?@6  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " !(-*Y:E5;C!KT%   2(P  &
M@(&,&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 2#2N
M6KBRB-UN!0  >A<  !@              ("!?R$  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( $@TKEHJ19.34@(  *@%   8
M      " @2,G  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" !(-*Y:-"F@B4("  "0!@  &               @(&K*0  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 2#2N6IQ[S<KE!@  <0\  !@
M             ("!(RP  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( $@TKEJ^L2F>C P  (,>   9              " @3XS  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 2#2N6J79#'N5"0
MI!@  !D              ("! 4   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " !(-*Y:38L6.@D*  !'&@  &0              @('-
M20  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( $@TKEJ2
M]HHR6 L  /4?   9              " @0U4  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ 2#2N6HN'\#2E P  ! @  !D
M     ("!G%\  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M" !(-*Y:F. .34 "   '!0  &0              @(%X8P  >&PO=V]R:W-H
M965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( $@TKEJ(]?*K3@T  .@C   9
M              " @>]E  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L!
M A0#%     @ 2#2N6I7%#0V1"0  C!@  !D              ("!=',  'AL
M+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !(-*Y:XEB^:2$#
M  "&!@  &0              @($\?0  >&PO=V]R:W-H965T<R]S:&5E=#$X
M+GAM;%!+ 0(4 Q0    ( $@TKEI B3/+$0@  (<4   9              "
M@92   !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ 2#2N
M6A8<42^X!   0 P  !D              ("!W(@  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " !(-*Y:SU*QG=8"   $!@  &0
M        @('+C0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( $@TKEI;[12AA@,   $/   9              " @=B0  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 2#2N6DBLB#(Z P  E@L
M !D              ("!E90  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " !(-*Y:[?U)=6<$  #)%P  &0              @($&F
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( $@TKEHIB)./
M= ,  ) -   9              " @:2<  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ 2#2N6B=N$>[X"@  F8L  !D
M ("!3Z   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !(
M-*Y:Y][*L $$   \#@  &0              @(%^JP  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( $@TKEJS/OXBJP0  +46   9
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M970S,BYX;6Q02P$"% ,4    " !(-*Y:Y:X@EC("  "F!   &0
M    @($WVP  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M $@TKEJU\<F(-@,  &8.   9              " @:#=  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ 2#2N6K,]=_TT P  T!,   T
M             ( !#>$  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !(-*Y:
MEXJ[',     3 @  "P              @ %LY   7W)E;',O+G)E;'-02P$"
M% ,4    " !(-*Y:PIZY>Z,#  !(%P  #P              @ %5Y0  >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ 2#2N6HS?7ZUN 0  W10  !H
M         ( !)>D  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ 2#2N6@970G>/ 0  <!4  !,              ( !R^H  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     "H *@!="P  B^P

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>141</ContextCount>
  <ElementCount>212</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>57</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>999012 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/BasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999014 - Disclosure - VENDOR AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/VendorAgreements</Role>
      <ShortName>VENDOR AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999015 - Disclosure - SHAREHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/ShareholdersEquity</Role>
      <ShortName>SHAREHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999016 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999017 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/SegmentInformation</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999018 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999020 - Disclosure - VENDOR AGREEMENTS (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/VendorAgreementsPolicies</Role>
      <ShortName>VENDOR AGREEMENTS (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://kairospharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999022 - Disclosure - VENDOR AGREEMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/VendorAgreementsTables</Role>
      <ShortName>VENDOR AGREEMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://kairospharma.com/role/VendorAgreements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999023 - Disclosure - SHAREHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/ShareholdersEquityTables</Role>
      <ShortName>SHAREHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://kairospharma.com/role/ShareholdersEquity</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999024 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/SegmentInformationTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://kairospharma.com/role/SegmentInformation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999025 - Disclosure - BASIS OF PRESENTATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/BasisOfPresentationDetailsNarrative</Role>
      <ShortName>BASIS OF PRESENTATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://kairospharma.com/role/BasisOfPresentation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999026 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails</Role>
      <ShortName>SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999028 - Disclosure - SCHEDULE OF VENDOR ADVANCES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails</Role>
      <ShortName>SCHEDULE OF VENDOR ADVANCES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999029 - Disclosure - VENDOR AGREEMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/VendorAgreementsDetailsNarrative</Role>
      <ShortName>VENDOR AGREEMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://kairospharma.com/role/VendorAgreementsTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999030 - Disclosure - SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails</Role>
      <ShortName>SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999031 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/ScheduleOfWarrantActivityDetails</Role>
      <ShortName>SCHEDULE OF WARRANT ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999032 - Disclosure - SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails</Role>
      <ShortName>SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999033 - Disclosure - SHAREHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/ShareholdersEquityDetailsNarrative</Role>
      <ShortName>SHAREHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://kairospharma.com/role/ShareholdersEquityTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://kairospharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999035 - Disclosure - SCHEDULE OF SEGMENT EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails</Role>
      <ShortName>SCHEDULE OF SEGMENT EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999036 - Disclosure - SEGMENT INFORMATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/SegmentInformationDetailsNarrative</Role>
      <ShortName>SEGMENT INFORMATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://kairospharma.com/role/SegmentInformationTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kairospharma.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://kairospharma.com/role/SubsequentEvents</ParentRole>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="form10-q.htm">form10-q.htm</File>
    <File>kapa-20250331.xsd</File>
    <File>kapa-20250331_cal.xml</File>
    <File>kapa-20250331_def.xml</File>
    <File>kapa-20250331_lab.xml</File>
    <File>kapa-20250331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="336">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>52
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-q.htm": {
   "nsprefix": "KAPA",
   "nsuri": "http://kairospharma.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "schema": {
     "local": [
      "kapa-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "kapa-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "kapa-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "kapa-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kapa-20250331_pre.xml"
     ]
    }
   },
   "keyStandard": 155,
   "keyCustom": 57,
   "axisStandard": 16,
   "axisCustom": 0,
   "memberStandard": 12,
   "memberCustom": 43,
   "hidden": {
    "total": 61,
    "http://fasb.org/us-gaap/2024": 40,
    "http://kairospharma.com/20250331": 17,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 141,
   "entityCount": 1,
   "segmentCount": 57,
   "elementCount": 448,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 336,
    "http://xbrl.sec.gov/dei/2024": 31,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://kairospharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://kairospharma.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://kairospharma.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://kairospharma.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Deficit) (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Deficit) (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_us-gaap_RetainedEarningsMember",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://kairospharma.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "KAPA:FairValueOfVestedRestrictedStockUnits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://kairospharma.com/role/BasisOfPresentation",
     "longName": "999012 - Disclosure - BASIS OF PRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://kairospharma.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://kairospharma.com/role/VendorAgreements",
     "longName": "999014 - Disclosure - VENDOR AGREEMENTS",
     "shortName": "VENDOR AGREEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "KAPA:DisclosureOfVendorAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "KAPA:DisclosureOfVendorAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://kairospharma.com/role/ShareholdersEquity",
     "longName": "999015 - Disclosure - SHAREHOLDERS\u2019 EQUITY",
     "shortName": "SHAREHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://kairospharma.com/role/CommitmentsAndContingencies",
     "longName": "999016 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://kairospharma.com/role/SegmentInformation",
     "longName": "999017 - Disclosure - SEGMENT INFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://kairospharma.com/role/SubsequentEvents",
     "longName": "999018 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://kairospharma.com/role/VendorAgreementsPolicies",
     "longName": "999020 - Disclosure - VENDOR AGREEMENTS (Policies)",
     "shortName": "VENDOR AGREEMENTS (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "KAPA:VendorAdvancesPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "KAPA:DisclosureOfVendorAgreementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "KAPA:VendorAdvancesPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "KAPA:DisclosureOfVendorAgreementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://kairospharma.com/role/VendorAgreementsTables",
     "longName": "999022 - Disclosure - VENDOR AGREEMENTS (Tables)",
     "shortName": "VENDOR AGREEMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "KAPA:ScheduleOfVendorAdvancesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "KAPA:VendorAdvancesPolicyTextBlock",
       "KAPA:DisclosureOfVendorAgreementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "KAPA:ScheduleOfVendorAdvancesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "KAPA:VendorAdvancesPolicyTextBlock",
       "KAPA:DisclosureOfVendorAgreementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://kairospharma.com/role/ShareholdersEquityTables",
     "longName": "999023 - Disclosure - SHAREHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "SHAREHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://kairospharma.com/role/SegmentInformationTables",
     "longName": "999024 - Disclosure - SEGMENT INFORMATION (Tables)",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://kairospharma.com/role/BasisOfPresentationDetailsNarrative",
     "longName": "999025 - Disclosure - BASIS OF PRESENTATION (Details Narrative)",
     "shortName": "BASIS OF PRESENTATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-01-31",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R23": {
     "role": "http://kairospharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails",
     "longName": "999026 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)",
     "shortName": "SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails",
     "longName": "999028 - Disclosure - SCHEDULE OF VENDOR ADVANCES (Details)",
     "shortName": "SCHEDULE OF VENDOR ADVANCES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "KAPA:VendorAdvancesGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "KAPA:ScheduleOfVendorAdvancesTableTextBlock",
       "KAPA:VendorAdvancesPolicyTextBlock",
       "KAPA:DisclosureOfVendorAgreementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "KAPA:VendorAdvancesGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "KAPA:ScheduleOfVendorAdvancesTableTextBlock",
       "KAPA:VendorAdvancesPolicyTextBlock",
       "KAPA:DisclosureOfVendorAgreementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://kairospharma.com/role/VendorAgreementsDetailsNarrative",
     "longName": "999029 - Disclosure - VENDOR AGREEMENTS (Details Narrative)",
     "shortName": "VENDOR AGREEMENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CustomerAdvancesAndDeposits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "KAPA:VendorAdvancesPolicyTextBlock",
       "KAPA:DisclosureOfVendorAgreementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CustomerAdvancesAndDeposits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "KAPA:VendorAdvancesPolicyTextBlock",
       "KAPA:DisclosureOfVendorAgreementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails",
     "longName": "999030 - Disclosure - SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY (Details)",
     "shortName": "SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails",
     "longName": "999031 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)",
     "shortName": "SCHEDULE OF WARRANT ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails",
     "longName": "999032 - Disclosure - SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS (Details)",
     "shortName": "SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-03-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "KAPA:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative",
     "longName": "999033 - Disclosure - SHAREHOLDERS\u2019 EQUITY (Details Narrative)",
     "shortName": "SHAREHOLDERS\u2019 EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2023-05-10",
      "name": "KAPA:SharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-05-10",
      "name": "KAPA:SharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "KAPA:LicenseAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "KAPA:LicenseAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails",
     "longName": "999035 - Disclosure - SCHEDULE OF SEGMENT EXPENSES (Details)",
     "shortName": "SCHEDULE OF SEGMENT EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-03-31_us-gaap_OperatingSegmentsMember",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://kairospharma.com/role/SegmentInformationDetailsNarrative",
     "longName": "999036 - Disclosure - SEGMENT INFORMATION (Details Narrative)",
     "shortName": "SEGMENT INFORMATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Integer",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Integer",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://kairospharma.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012025-04-01_custom_CrossCurrentCapitalLLCMember_us-gaap_SubsequentEventMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://kairospharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails",
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails",
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_AdditionalCollateralAggregateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalCollateralAggregateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate fair value of the common stock",
        "documentation": "The aggregate fair value of additional assets that would be required to be posted as collateral for derivative instruments with credit-risk-related contingent features if the credit-risk-related contingent features were triggered at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://kairospharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r459",
      "r683"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r581",
      "r582",
      "r583",
      "r584",
      "r634",
      "r685"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of pre-funded warrants, net of offering costs",
        "documentation": "Adjustments to additional paid in capital proceeds from sale of prefunded warrants net of offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_AdvisoryAndConsultingServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "AdvisoryAndConsultingServicesAgreementMember",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advisory And Consulting Services Agreement [Member]",
        "documentation": "Advisory And Consulting Services Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r503",
      "r514",
      "r524",
      "r549"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r506",
      "r517",
      "r527",
      "r552"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r538"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r545"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r507",
      "r518",
      "r528",
      "r545",
      "r553",
      "r557",
      "r565"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_AmortizationExpenseVendorAdvances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "AmortizationExpenseVendorAdvances",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense relating to vendor advances",
        "documentation": "Amortization expense vendor advances."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount amortization",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r47",
      "r191",
      "r637"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows",
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense - intangible asset",
        "verboseLabel": "Amortization expenses",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r157",
      "r163",
      "r448"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r68",
      "r81",
      "r98",
      "r124",
      "r130",
      "r139",
      "r143",
      "r152",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r255",
      "r257",
      "r270",
      "r322",
      "r377",
      "r442",
      "r443",
      "r459",
      "r484",
      "r604",
      "r605",
      "r642"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r82",
      "r98",
      "r152",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r255",
      "r257",
      "r270",
      "r459",
      "r604",
      "r605",
      "r642"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r152",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r255",
      "r257",
      "r270",
      "r604",
      "r605",
      "r642"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r556"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails",
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "KAPA_BelairCapitalAdvisorsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "BelairCapitalAdvisorsIncMember",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Belair Capital Advisors Inc [Member]",
        "documentation": "Belair Capital Advisors Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_BioassayServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "BioassayServicesAgreementMember",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bioassay Services Agreement [Member]",
        "documentation": "Bioassay Services Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r251",
      "r452",
      "r453"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r251",
      "r452",
      "r453"
     ]
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition cost",
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://kairospharma.com/role/BasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r51",
      "r52"
     ]
    },
    "KAPA_CEOCATechnologiesLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "CEOCATechnologiesLtdMember",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CEO.CA Technologies Ltd [Member]",
        "documentation": "CEO.CA Technologies Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets",
      "http://kairospharma.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r79",
      "r435"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents beginning of period",
        "periodEndLabel": "Cash and cash equivalents end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r48",
      "r95"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r48"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r573",
      "r651"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails",
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant to purchase of common stock",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "KAPA_ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable description",
        "documentation": "Class of warrant or rights date from which warrants or rights exercisable description."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://kairospharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r62",
      "r324",
      "r364"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r174",
      "r175",
      "r420",
      "r597",
      "r599"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r581",
      "r582",
      "r584",
      "r634",
      "r681",
      "r685"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://kairospharma.com/role/BalanceSheetsParenthetical",
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://kairospharma.com/role/BalanceSheetsParenthetical",
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "verboseLabel": "Common stock, shares issued",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r365"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://kairospharma.com/role/BalanceSheetsParenthetical",
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://kairospharma.com/role/BalanceSheetsParenthetical",
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r35",
      "r365",
      "r383",
      "r685",
      "r686"
     ]
    },
    "KAPA_CommonStockToBeIssuedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "CommonStockToBeIssuedMember",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock To Be Issued [Member]",
        "documentation": "Common Stock To Be Issued [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_CommonStockToBeIssuedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "CommonStockToBeIssuedSharesOutstanding",
     "presentation": [
      "http://kairospharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock to be issued, shares outstanding",
        "documentation": "Common stock to be issued shares outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_CommonStockToBeIssuedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "CommonStockToBeIssuedValue",
     "crdr": "credit",
     "calculation": {
      "http://kairospharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock to be issued, 551,000 shares outstanding at March 31, 2025",
        "documentation": "Common stock to be issued value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://kairospharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value $0.001, 100,000,000 shares authorized; 15,825,118 and 13,736,597 shares issued and outstanding, respectively;",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r326",
      "r459"
     ]
    },
    "KAPA_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Warrants [Member]",
        "documentation": "Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r72"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r66",
      "r99",
      "r124",
      "r132",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r143",
      "r144",
      "r145",
      "r180",
      "r181",
      "r182",
      "r183",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r442",
      "r443",
      "r604",
      "r605"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails"
     ],
     "auth_ref": [
      "r66",
      "r99",
      "r124",
      "r132",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r143",
      "r144",
      "r145",
      "r180",
      "r181",
      "r182",
      "r183",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r442",
      "r443",
      "r604",
      "r605"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r436"
     ]
    },
    "KAPA_ConsultingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ConsultingAgreementMember",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreement [Member]",
        "documentation": "Consulting Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostMaintenance",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual maintenance fee",
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_CrossCurrentCapitalLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "CrossCurrentCapitalLLCMember",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails",
      "http://kairospharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cross Current Capital LLC [Member]",
        "documentation": "Cross Current Capital LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_CurrentCapitalLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "CurrentCapitalLLCMember",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Capital LLC [Member]",
        "documentation": "Current Capital LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerAdvancesAndDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerAdvancesAndDeposits",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advances to vendor amount",
        "documentation": "Refundable consideration, usually cash, held by the entity pending satisfactory completion of the entity's obligations or pending the closing of a contract."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r574"
     ]
    },
    "KAPA_DeferredOfferingAdditionalCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "DeferredOfferingAdditionalCosts",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering additional cost",
        "documentation": "Deferred offering additional costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred Offering Costs",
        "label": "Deferred Offering Costs [Default Label]",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "KAPA_DirectorAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "DirectorAgreementsMember",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director Agreements [Member]",
        "documentation": "Director Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r591",
      "r682"
     ]
    },
    "KAPA_DisclosureOfVendorAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "DisclosureOfVendorAgreementsTextBlock",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "VENDOR AGREEMENTS",
        "documentation": "Disclosure of Vendor Agreements [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_DisclosureVendorAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "DisclosureVendorAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r498",
      "r510"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIC LOSS PER COMMON SHARE",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r114",
      "r116",
      "r118",
      "r119",
      "r120",
      "r123",
      "r249",
      "r253",
      "r267",
      "r268",
      "r320",
      "r332",
      "r437"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DILUTED LOSS PER COMMON SHARE",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r116",
      "r118",
      "r119",
      "r120",
      "r123",
      "r249",
      "r253",
      "r267",
      "r268",
      "r320",
      "r332",
      "r437"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r122"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails",
      "http://kairospharma.com/role/SubsequentEventsDetailsNarrative",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "KAPA_EnviroCedarsLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "EnviroCedarsLicenseAgreementsMember",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Enviro Cedars License Agreements [Member]",
        "documentation": "Enviro Cedars License Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_EnviroThreapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "EnviroThreapeuticsIncMember",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Enviro Threapeutics Inc [Member]",
        "documentation": "Enviro Threapeutics Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails",
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r75",
      "r85",
      "r86",
      "r87",
      "r100",
      "r101",
      "r102",
      "r104",
      "r109",
      "r111",
      "r113",
      "r125",
      "r153",
      "r154",
      "r166",
      "r206",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r252",
      "r253",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r331",
      "r342",
      "r343",
      "r344",
      "r351",
      "r402"
     ]
    },
    "KAPA_EquityLineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "EquityLineOfCreditMember",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Line of Credit [Member]",
        "documentation": "Equity Line of Credit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r503",
      "r514",
      "r524",
      "r549"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r500",
      "r511",
      "r521",
      "r546"
     ]
    },
    "KAPA_ExclusiveLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ExclusiveLicenseAgreementMember",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exclusive License Agreement [Member]",
        "documentation": "Exclusive License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "KAPA_ExercisePriceRangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ExercisePriceRangeOneMember",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range One [Member]",
        "documentation": "Exercise Price Range One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_ExercisePriceRangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ExercisePriceRangeThreeMember",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Three [Member]",
        "documentation": "Exercise Price Range Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_ExercisePriceRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ExercisePriceRangeTwoMember",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Two [Member]",
        "documentation": "Exercise Price Range Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_FairValueOfRestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "FairValueOfRestrictedStockUnits",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock compensation-related expense for fair value vesting of restricted common stock",
        "documentation": "Fair value of restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_FairValueOfUnamortizedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "FairValueOfUnamortizedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of unamortized compensation",
        "documentation": "Fair value of unamortized compensation."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_FairValueOfVestedRestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "FairValueOfVestedRestrictedStockUnits",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value of vested restricted stock units",
        "documentation": "Fair value of vested restricted stock units.",
        "label": "FairValueOfVestedRestrictedStockUnits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets useful life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_FoodAndDrugAdministrationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "FoodAndDrugAdministrationMember",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Food and Drug Administration [Member]",
        "documentation": "Food and Drug Administration [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r507",
      "r518",
      "r528",
      "r553"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r507",
      "r518",
      "r528",
      "r553"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r507",
      "r518",
      "r528",
      "r553"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r507",
      "r518",
      "r528",
      "r553"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r507",
      "r518",
      "r528",
      "r553"
     ]
    },
    "KAPA_FourOfficersAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "FourOfficersAgreementMember",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Officers Agreement [Member]",
        "documentation": "Four Officers Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r387"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r164",
      "r165"
     ]
    },
    "KAPA_HelenaGlobalInvestmentOpportunitiesILTDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "HelenaGlobalInvestmentOpportunitiesILTDMember",
     "presentation": [
      "http://kairospharma.com/role/SubsequentEventsDetailsNarrative",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Helena Global Investment Opportunities I LTD [Member]",
        "documentation": "Helena Global Investment Opportunities I LTD [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of intangible assets",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r579",
      "r596"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r54"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes paid",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r94",
      "r242",
      "r243"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "KAPA_IncreaseDecreaseInVendorAdvances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "IncreaseDecreaseInVendorAdvances",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor advances",
        "documentation": "Increase decrease in vendor advances."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r507",
      "r518",
      "r528",
      "r545",
      "r553",
      "r557",
      "r565"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r499",
      "r568"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r499",
      "r568"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r499",
      "r568"
     ]
    },
    "us-gaap_InsuranceRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InsuranceRecoveries",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance",
        "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets",
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "verboseLabel": "Intangible assets unamortized balance",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r594",
      "r595"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r578"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r92",
      "r93"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r47"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestorMember",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r639"
     ]
    },
    "KAPA_IssuanceOfCommonSharesForDeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "IssuanceOfCommonSharesForDeferredOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares issued for deferred offering costs",
        "documentation": "Issuance of common shares for deferred offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_IssuanceOfCommonSharesForVendorAdvances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "IssuanceOfCommonSharesForVendorAdvances",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares issued for vendor advance",
        "documentation": "Issuance of common shares for vendor advances."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_IssuanceOfCommonSharesPaidForVendorsAdvances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "IssuanceOfCommonSharesPaidForVendorsAdvances",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares paid for vendors advances",
        "documentation": "Issuance of common shares paid for vendors advances."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_ItemFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ItemFourMember",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Item Four [Member]",
        "documentation": "Item Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_ItemOneAndTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ItemOneAndTwoMember",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Item One And Two [Member]",
        "documentation": "Item One And Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_ItemThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ItemThreeMember",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Item Three [Member]",
        "documentation": "Item Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails",
      "http://kairospharma.com/role/SubsequentEventsDetailsNarrative",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://kairospharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r63",
      "r328",
      "r459",
      "r580",
      "r592",
      "r636"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://kairospharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r78",
      "r98",
      "r152",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r256",
      "r257",
      "r258",
      "r270",
      "r459",
      "r604",
      "r642",
      "r643"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_LicenseAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "LicenseAgreementDescription",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License agreement description",
        "documentation": "License agreement description."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]",
        "documentation": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_LicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "LicenseFee",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License fee",
        "documentation": "License fee."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ManagementFeeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ManagementFeeExpense",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service fee",
        "documentation": "Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r387",
      "r482",
      "r684"
     ]
    },
    "KAPA_MasterServiceAndTechnologyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "MasterServiceAndTechnologyAgreementMember",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Master Service And Technology Agreement [Member]",
        "documentation": "Master Service And Technology Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r179",
      "r209",
      "r240",
      "r269",
      "r288",
      "r340",
      "r341",
      "r347",
      "r356",
      "r357",
      "r408",
      "r410",
      "r412",
      "r413",
      "r415",
      "r430",
      "r431",
      "r447",
      "r449",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r469",
      "r606",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r179",
      "r209",
      "r240",
      "r269",
      "r288",
      "r340",
      "r341",
      "r347",
      "r356",
      "r357",
      "r408",
      "r410",
      "r412",
      "r413",
      "r415",
      "r430",
      "r431",
      "r447",
      "r449",
      "r454",
      "r455",
      "r456",
      "r457",
      "r469",
      "r606",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649"
     ]
    },
    "KAPA_MinimumRequirermentOfCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "MinimumRequirermentOfCapital",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum requirerment of capital",
        "documentation": "Minimum requirerment of capital."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "KAPA_MonthlyPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "MonthlyPayment",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly payment",
        "documentation": "Monthly payment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BasisOfPresentationDetailsNarrative",
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "negatedLabel": "Cash in operations",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r50"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Operating Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://kairospharma.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BasisOfPresentationDetailsNarrative",
      "http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails",
      "http://kairospharma.com/role/StatementsOfCashFlows",
      "http://kairospharma.com/role/StatementsOfOperations",
      "http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "terseLabel": "NET LOSS",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r50",
      "r64",
      "r76",
      "r83",
      "r84",
      "r87",
      "r98",
      "r103",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r112",
      "r113",
      "r117",
      "r152",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r249",
      "r253",
      "r268",
      "r270",
      "r330",
      "r385",
      "r400",
      "r401",
      "r482",
      "r604"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonUsMember",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r688",
      "r689",
      "r690"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental non-cash financing disclosures:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expenses)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expenses):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://kairospharma.com/role/SegmentInformationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r446",
      "r586"
     ]
    },
    "us-gaap_OfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer compensation and wages",
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails",
      "http://kairospharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r438",
      "r585",
      "r587",
      "r588",
      "r589",
      "r590"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r144",
      "r442",
      "r443"
     ]
    },
    "KAPA_OtherNonroyaltySublicenseFeesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "OtherNonroyaltySublicenseFeesPercentage",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-royalty sublicense fees percentage",
        "documentation": "Other nonroyalty sublicense fees percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expenses)",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r505",
      "r516",
      "r526",
      "r551"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r508",
      "r519",
      "r529",
      "r554"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r508",
      "r519",
      "r529",
      "r554"
     ]
    },
    "KAPA_PatentProductSalesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "PatentProductSalesPercentage",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent product sales",
        "documentation": "Patent product sales percentage."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_PatentProtectionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "PatentProtectionCosts",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent protection costs",
        "documentation": "Patent protection costs."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r533"
     ]
    },
    "KAPA_PaymentForMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "PaymentForMilestones",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for milestone",
        "documentation": "Payment for milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForAdvanceToAffiliate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForAdvanceToAffiliate",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for vendor advance",
        "documentation": "The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity)."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of deferred offering costs",
        "label": "Payments of Financing Costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "KAPA_PhaseOneClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "PhaseOneClinicalTrialMember",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase One Clinical Trial [Member]",
        "documentation": "Phase One Clinical Trial [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_PhaseThreeClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "PhaseThreeClinicalTrialMember",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase Three Clinical Trial [Member]",
        "documentation": "Phase Three Clinical Trial [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_PhaseThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "PhaseThreeMember",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase Three [Member]",
        "documentation": "Phase Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_PhaseTwoClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "PhaseTwoClinicalTrialMember",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase Two Clinical Trial [Member]",
        "documentation": "Phase Two Clinical Trial [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_PhaseTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "PhaseTwoMember",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase Two [Member]",
        "documentation": "Phase Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "KAPA_PreCheckHealthServicesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "PreCheckHealthServicesIncMember",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PreCheck Health Services, Inc. [Member]",
        "documentation": "PreCheck Health Services, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "KAPA_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrant [Member]",
        "documentation": "Pre-Funded Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://kairospharma.com/role/BalanceSheetsParenthetical",
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "verboseLabel": "Preferred stock par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r193"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://kairospharma.com/role/BalanceSheetsParenthetical",
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r365"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://kairospharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r193"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://kairospharma.com/role/BalanceSheetsParenthetical",
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r365",
      "r383",
      "r685",
      "r686"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://kairospharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value $0.001, 20,000,000 shares authorized; no shares issued and outstanding, respectively;",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r325",
      "r459"
     ]
    },
    "KAPA_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Pre-Funded Warrant [Member]",
        "documentation": "Pre-Funded Warrant [Member]",
        "label": "Pre-Funded Warrant [Member] [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "KAPA_PrevailInfoworksIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "PrevailInfoworksIncMember",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prevail Infoworks Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from offering",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale and exercise of prefunded warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds received from financing",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r349"
     ]
    },
    "us-gaap_ProductLiabilityContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductLiabilityContingencyLineItems",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Liability Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r600",
      "r601",
      "r602"
     ]
    },
    "us-gaap_ProductLiabilityContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductLiabilityContingencyTable",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Liability Contingency [Table]",
        "documentation": "Disclosure of information about product liability contingency arising from reasonably possible loss from liability related to individual product."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r600",
      "r601",
      "r602"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r146",
      "r289",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r433",
      "r450",
      "r468",
      "r469",
      "r470",
      "r472",
      "r473",
      "r602",
      "r603",
      "r607",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "auth_ref": [
      "r146",
      "r289",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r433",
      "r450",
      "r468",
      "r469",
      "r470",
      "r472",
      "r473",
      "r602",
      "r603",
      "r607",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r179",
      "r207",
      "r209",
      "r234",
      "r235",
      "r236",
      "r240",
      "r269",
      "r286",
      "r287",
      "r288",
      "r340",
      "r341",
      "r347",
      "r356",
      "r357",
      "r408",
      "r410",
      "r412",
      "r413",
      "r415",
      "r430",
      "r431",
      "r447",
      "r449",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r469",
      "r476",
      "r598",
      "r606",
      "r635",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r179",
      "r207",
      "r209",
      "r234",
      "r235",
      "r236",
      "r240",
      "r269",
      "r286",
      "r287",
      "r288",
      "r340",
      "r341",
      "r347",
      "r356",
      "r357",
      "r408",
      "r410",
      "r412",
      "r413",
      "r415",
      "r430",
      "r431",
      "r447",
      "r449",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r469",
      "r476",
      "r598",
      "r606",
      "r635",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r500",
      "r511",
      "r521",
      "r546"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r208",
      "r281",
      "r282",
      "r323",
      "r329",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r382",
      "r384",
      "r407"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r208",
      "r281",
      "r282",
      "r323",
      "r329",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r382",
      "r384",
      "r407",
      "r641"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails",
      "http://kairospharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and development, less officer compensation",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r432",
      "r442",
      "r650"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r501",
      "r512",
      "r522",
      "r547"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r502",
      "r513",
      "r523",
      "r548"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r509",
      "r520",
      "r530",
      "r555"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails",
      "http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails",
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://kairospharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r57",
      "r327",
      "r345",
      "r346",
      "r350",
      "r366",
      "r459"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r100",
      "r101",
      "r102",
      "r104",
      "r109",
      "r111",
      "r113",
      "r153",
      "r154",
      "r166",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r252",
      "r253",
      "r259",
      "r261",
      "r262",
      "r264",
      "r266",
      "r278",
      "r279",
      "r342",
      "r344",
      "r351",
      "r685"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://kairospharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails",
      "http://kairospharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "verboseLabel": "Net sales",
        "terseLabel": "Revenue",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r88",
      "r98",
      "r124",
      "r131",
      "r132",
      "r137",
      "r143",
      "r146",
      "r148",
      "r150",
      "r152",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r270",
      "r321",
      "r442",
      "r604"
     ]
    },
    "KAPA_RoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "RoyaltyPercentage",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty percentage",
        "documentation": "Royalty percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price of pre-funded unit",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, number of shares issued in transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r18"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://kairospharma.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF SEGMENT EXPENSES",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r18"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WARRANT ACTIVITY",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "KAPA_ScheduleOfVendorAdvancesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ScheduleOfVendorAdvancesTableTextBlock",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF VENDOR ADVANCES",
        "documentation": "Schedule of Vendor Advances [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS",
        "documentation": "Schedule of Warrants Outstanding and Exercisable [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "KAPA_SecurityPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "SecurityPurchaseAgreementMember",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Purchase Agreement [Member]",
        "documentation": "Security Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "auth_ref": [
      "r148",
      "r149",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r353",
      "r354",
      "r355",
      "r409",
      "r411",
      "r414",
      "r416",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r434",
      "r451",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r471",
      "r476",
      "r607",
      "r652",
      "r653",
      "r654",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://kairospharma.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT INFORMATION",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r124",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r134",
      "r135",
      "r136",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r150",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r445",
      "r446"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_SettlementAgreementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "SettlementAgreementAmount",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement agreement amount",
        "documentation": "Settlement agreement amount."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Shares, Cancelled",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Warrant, Cancelled",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards cancelled during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Exercisable, Average Remaining Contractual Life (in years)",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average remaining contractual terms."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrants Shares, Exercised",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were exercised during the reporting period.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Warrant, Exercised",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards exercised during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Shares, Forfeited/Expired",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Warrant, Forfeited/Expired",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Shares, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Warrant, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Exercisable, Number Exercisable",
        "documentation": "Number of shares warrants exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails",
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants Shares, Beginning Balance",
        "periodEndLabel": "Warrants Shares, Ending Balance",
        "label": "Warrants Outstanding, Number Outstanding",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price Warrant Warrant, Beginning Balance",
        "periodEndLabel": "Weighted Average Exercise Price Warrant, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Outstanding, Average Remaining Contractual Life (in years)",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Vested and exercisable",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "KAPA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares Warrants, Vested and exercisable",
        "documentation": "Share based compensation arrangement by share based payment award options excercisable in period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails",
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Restricted shares Granted",
        "verboseLabel": "Granted shares",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, Granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair Value, Unvested, Beginning balance",
        "periodEndLabel": "Fair Value, Unvested, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails",
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237"
     ]
    },
    "KAPA_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Exercisable, Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangements by share based payment award equity instruments other than options nonvested weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Per Share, Cancelled",
        "documentation": "Share based compensation shares exercisabler other than stock option plans exercise price range cancelled."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Per Share, Exercised",
        "documentation": "Share based compensation shares exercisabler other than stock option plans exercise price range exercised."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Per Share, Forfeited/Expired",
        "documentation": "Share based compensation shares exercisabler other than stock option plans exercise price range forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Per Share, Granted",
        "documentation": "Share based compensation shares exercisabler other than stock option plans exercise price range granted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise prices lower range",
        "documentation": "Range of exercise prices lower range"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails",
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Exercise Price Range Per Share, Beginning Balance",
        "periodEndLabel": "Exercise Price Range Per Share, Ending Balance",
        "label": "Range of exercise prices",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock warrants as of the balance sheet date for all warrants in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercise Price Range Per Share, Vested and exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the warrants vested and exercisable as of the balance sheet date for all warrants in the customized range of exercise prices.",
        "label": "ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise prices upper range",
        "documentation": "Range of exercise prices upper range"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant shares outstanding, intrinsic value",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Forfeited",
        "documentation": "Fair value of options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Granted",
        "documentation": "Fair value of options granted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Restricted Shares, Unvested Beginning balance",
        "periodEndLabel": "Number of Restricted Shares, Unvested Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Restricted shares Forfeited",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, Forfeited",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning balance",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fair Value, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails",
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Restricted shares Vested",
        "label": "Number of shares vested",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, Vested",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_SharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "SharesAuthorized",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares authorized",
        "documentation": "Shares authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued, price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r96"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails",
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r35",
      "r38",
      "r39",
      "r75",
      "r85",
      "r86",
      "r87",
      "r100",
      "r101",
      "r102",
      "r104",
      "r109",
      "r111",
      "r113",
      "r125",
      "r153",
      "r154",
      "r166",
      "r206",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r252",
      "r253",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r331",
      "r342",
      "r343",
      "r344",
      "r351",
      "r402"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r353",
      "r354",
      "r355",
      "r409",
      "r411",
      "r414",
      "r416",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r434",
      "r451",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r471",
      "r476",
      "r607",
      "r652",
      "r653",
      "r654",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails",
      "http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r125",
      "r279",
      "r289",
      "r348",
      "r352",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r402",
      "r477"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails",
      "http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r125",
      "r151",
      "r279",
      "r289",
      "r348",
      "r352",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r402",
      "r477"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r504",
      "r515",
      "r525",
      "r550"
     ]
    },
    "KAPA_StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of common shares to be issued for vendor advance and deferred offering costs, shares",
        "documentation": "Stock issued during period shares fair value of common shares to be issued for vendor advance and deferred offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares upon the exercise of pre-funded warrants, shares",
        "verboseLabel": "Warrants exercised",
        "documentation": "Stock issued during period shares issuance of common shares upon exercise of prefunded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://kairospharma.com/role/SubsequentEventsDetailsNarrative",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r34",
      "r35",
      "r57",
      "r349",
      "r402",
      "r417"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of vested restricted stock units, shares",
        "verboseLabel": "Number of shares issued",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r57"
     ]
    },
    "KAPA_StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of common shares to be issued for vendor advance and deferred offering costs",
        "documentation": "Stock issued during period value fair value of common shares to be issued for vendor advance and deferred offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares upon the exercise of pre-funded warrants",
        "documentation": "Stock issued during period value issuance of common shares upon exercise of prefunded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued, value",
        "verboseLabel": "Number of shares issued, fair value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r34",
      "r35",
      "r57",
      "r351",
      "r402",
      "r417",
      "r483"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued value",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of vested restricted stock units",
        "verboseLabel": "Number of shares issued, value",
        "terseLabel": "Fair value of shares",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r34",
      "r35",
      "r57"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://kairospharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets",
      "http://kairospharma.com/role/BasisOfPresentationDetailsNarrative",
      "http://kairospharma.com/role/StatementsOfShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Shareholders\u2019 Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Shareholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r38",
      "r39",
      "r53",
      "r367",
      "r383",
      "r403",
      "r404",
      "r459",
      "r484",
      "r580",
      "r592",
      "r636",
      "r685"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS\u2019 EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r97",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r206",
      "r265",
      "r405",
      "r406",
      "r418"
     ]
    },
    "KAPA_StrategicAdvisoryAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "StrategicAdvisoryAgreementMember",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Strategic Advisory Agreement [Member]",
        "documentation": "Strategic Advisory Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://kairospharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r284"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://kairospharma.com/role/SubsequentEventsDetailsNarrative",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r284"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://kairospharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r284"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://kairospharma.com/role/SubsequentEventsDetailsNarrative",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r284"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://kairospharma.com/role/SubsequentEventsDetailsNarrative",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r284"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://kairospharma.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r285"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flows disclosures:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "KAPA_ThreeIndependentDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "ThreeIndependentDirectorsMember",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three Independent Directors [Member]",
        "documentation": "Three Independent Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r591",
      "r640"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "KAPA_TwentyTwentyThreeEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "TwentyTwentyThreeEquityIncentivePlanMember",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Equity Incentive Plan [Member]",
        "documentation": "2023 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "KAPA_UnderwritersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "UnderwritersMember",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriters [Member]",
        "documentation": "Underwriters [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r70",
      "r71",
      "r73",
      "r74"
     ]
    },
    "KAPA_VendorAdvancesAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "VendorAdvancesAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails": {
       "parentTag": "KAPA_VendorAdvancesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated amortization",
        "documentation": "Vendor advances accumulated amortization.",
        "label": "Vendor advances accumulated amortization"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_VendorAdvancesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "VendorAdvancesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vendor advances",
        "documentation": "Vendor advances current.",
        "label": "VendorAdvancesCurrent"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_VendorAdvancesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "VendorAdvancesGross",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails": {
       "parentTag": "KAPA_VendorAdvancesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor advances, gross",
        "documentation": "Vendor advances gross."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_VendorAdvancesInCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "VendorAdvancesInCash",
     "crdr": "credit",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vendor advances in cash",
        "documentation": "Vendor advances in cash.",
        "label": "VendorAdvancesInCash"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_VendorAdvancesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "VendorAdvancesNet",
     "crdr": "debit",
     "calculation": {
      "http://kairospharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://kairospharma.com/role/BalanceSheets",
      "http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor advances, net",
        "totalLabel": "Vendor advances, net",
        "documentation": "Vendor advances net."
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_VendorAdvancesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "VendorAdvancesPolicyTextBlock",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor Advances",
        "documentation": "Vendor Advances [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_VendorPaymentAdvances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "VendorPaymentAdvances",
     "crdr": "debit",
     "presentation": [
      "http://kairospharma.com/role/VendorAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor payment advances",
        "documentation": "Vendor payment advances."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails",
      "http://kairospharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r475",
      "r478",
      "r479",
      "r480",
      "r481"
     ]
    },
    "KAPA_WarrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "WarrantOneMember",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant One [Member]",
        "documentation": "Warrant One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_WarrantThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "WarrantThreeMember",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Three [Member]",
        "documentation": "Warrant Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_WarrantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "WarrantTwoMember",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Two [Member]",
        "documentation": "Warrant Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_WarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "WarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://kairospharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants To Purchase Common Stock [Member]",
        "documentation": "Warrants To Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "KAPA_WarrantsUnexercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://kairospharma.com/20250331",
     "localname": "WarrantsUnexercised",
     "presentation": [
      "http://kairospharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants unexercised",
        "documentation": "Warrants unexercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DILUTED",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r120"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://kairospharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIC",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r120"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://kairospharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4H",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4H"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>53
<FILENAME>0001641172-25-010089-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-010089-xbrl.zip
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MG&V(E1N$CP?H:<12][[)UL+DH@LH!ROJ.<M@,'N3)UA43-O.IJ@X&R_MGNW
MDQZRCE#U0PU=\< #8;403+)WY@7E/%<S93I3\4Q0X4SYI+C[UX5\BF0:JX7
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ME<!6 YFH2-FALJ&X+/GZGS& O^?I&W_ZOW]T#?7^JWPAIMZ;_0502P,$%
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MZ2[WU*V=76;3!=*MJYS[LEV1Y,Z8)X3]W#E)K6*_% 'VR315I*+#OJNXY_J
M464HC.?G/X' BE*%?4/NGMP$BE.RQP^]_&OM>OBK/(I.KZ_"K,%!T#H@:4(
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MX"? ), DP(0-X*^KA63+I6)M7%S,_XYC7 RY,JW^B HXDCHW'\.XF-1N!5_
M2:[^X+Y9D?+US3XD+=:A;$T3Y(^"JZUK\W)FQ64N1-I8,5PK6 ]/)1O AT[J
M+4/0U$&T<!&/O1'-U8"L>AN0Q:?9_:^"//KQPN[C;&"M/7G$;)=8B7[[S9K9
M0Q\%5XF5>%@KL918B9M*;=+HYM!68BD3;X,CH:F+E5@*-[5]OU9B<BZ1 ),
MDP 3]EPB2X5(1ZOW%U?=T7-[UKW-_/T3RWX<N3CWX\@%+:7?2<X;D[V9YZJ/
M?XLWA1A7T#O-+)\TKM+>TN(^5#UN)"D>FY)R3QEYQT'(#<QE7VINL)"3QL/!
MHQBEW,91C'A2)<YJ9H,4R-+^4B _%%VC21$,%7&)./LRG\TGW1QV054'V2).
M_(0&=.1D6]/6<&,WZD:NW?.+T1/3^W.0JAX_KRH>FWW@:J$=>TZSPE#Z/>9>
M[COCT_&<RMM-!TL\I_AX3N5P$>O$<TH\IV/QG,J;9PG&DRIQ5C,;>$[E*((U
MB><4(\^I'&E&8^(Y[<ES*D>:T[A#SPG^FX;XN4REOD^M?HFV$_AM'!-:&G'"
MN:2Y,!GT.OTK19SJ7UC?_T>5%6XX-Z\R0-4VG8')* ,(W71/,#'0VP"2.TB]
M,2!HAH%."2W,(6[AWJK =T-;FX#[(P=O'$DT#[TV24'3BY4QD$$*\@C<)V7
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M.T?=5=J5BT!H#2>F9!3)=47_,<&Q$M,MD>HCJF0XQ\61JK 342U:ME-HD4F
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M1EQV&-VV$X6;.32-DJ-Q,T/Y,"XD"[G!19&5L_L-+KX:9$L"^>F4<%D^'D&
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MI)3V+=S.Z!B1P1!$#(MF$S;5"7P/$]@^!=#.G"*5):G 8:U"!]]^RGNERIP
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MK;/;HITO8DXCFQ'Y;G@]UA[Y!WMU WOKU6$R) DK$H,*WU0O$K:S;!(NL:#
MS:0E#) )@,H38C<1:"UL8D/%-;G>W"H&_MRQ-*7U+B_T;* $A1X/&X4LN(8H
MB_OS-X+AR]'!.B36Q9_!SI<-^,4F)REF"81A6,*.#SLC^3H'NLC%^X(JQHR
MC7Y6N,NN8HBWF<$545O=>3VM:Y?MGAL#\D[V\24S&-V("0V>C/L5MBGL3Y#9
M7PXB/7@?HG_0#$ QX46],)O9.0M")!8X(KBP^%,D;(B,8,VY!_/=V0><-EF$
M*22;_D9T!W*T1EV3C]G8T% T?GMPU;>D/\=7MSUW>L;<RUG0=>$DN.B7)P?>
M+Z91!%K(Y'*11:!LXDX8'<-5;TN#2.6#<LX)*"M>&IY?=5#+D$^'=RXL[$U
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M^HL/6PQA0AO(:X& JB.W'/&38VM+$H8*/3?U/LI!Z\_XY4=UUJGT=QXTW+!
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MX\)-=AAB<IM>3."%BBP144)#PL6#;.T@7W!_2J:.'&C7!=L,J*WUBK3CP1H
M;P2SU01 \D30RW-P=\!Q,AN*P'N:*>AD']C.&4Y,$,?).P6&/\Z_13%80C&"
M$S IN0H"9"5LR"KD'+LUR+6S.Z-Z)C<N[^7KHM_N=-9L)FN*7V5AR?@F<-)I
MU"OGH@_;.6>R?XYU*(UTPX(1PJ+^PAK5'1W%% \@T> =SVFKPUB$EXW4$L@:
M.VQN>@4Q)M96,?G9J_QT+U^._RC1*H::,-M)6R4H%"@Z.:H J,)RJJ:PYG0^
M;-NA2$U#F<=$?A(*^(JCR##T-O-T,Q,.I%W,<]U1OBLU(<9C[$2M3?#JIOR$
M%)F]^[-[6ZY?%.['Z,TP^XH)V15%8KT2X 2W+R,O 33R7*)>H<"F*;7R_GK@
MD+#% ,0HP7KMQ<]=;%VTXVQ_S@6F9] 9V#QD6(H-\M#'5Z%A'HI7-OZ3Y_.
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MOM'AC3'GE9IG$%)QN(*9YIPKR5?2PX5VGA"C@W'C;EV"TT$VJYN3['&^F-A
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M_3S5;1WAYL\K7ELL;46&FXR<;!%CAQQT] VIFZW^W[:)=TDF7($3U<#O@[B
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MCG^0E1F-DC+>AS2'(/5ZV.)4+ ?*T))>(00[@KH__%N;4(61@@6//1!3$'C
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MN]W7Q>V@+:0ZWQ9B=TW2>V0U 8_6C&H&R7FK$J.^\S";73\7LN7)A?YC7UI
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M#9*NQ8/Y_'<,+9Z.1L@() ",#1'7=R*7);Y"62[1,[B3T0"_6%)5A4:3:5H
M)F(2]\XP)#;CB\;263S9IJ/%( PCD5BW_VS(A%F/2)-%,=Q\=QXH./^>YXN3
M(=+(L5-O%=O/V#N@[X&!I&2&&$3H5)4Z )X)D'05S#\5^<L%]^6>UTITD]ZW
M]4C:A3@@GFF19'Z9B3QS6?WY\?#R)&*ISN=;#@5L $@FP_XAO(;I.% @>4,#
MCY#@I1:N<\)4$O#GI!>\5T(*W2 ZU_E%AGY;L9S/0@B)#'!UXIF "V/2!# 9
MB>#I+W#31_ZF Y&?+Y\O[CE@OCHR!9#-*28?PB=ODTD06/.Q3#<CFC<91=,%
M0D^BL_7\/$T.N2?9)O+)OHQ/FK OOTU(X?I05[%=2!_)'\?DQGG@A\(-#^U?
M(K#;1 _HH;E'<?Y]H]9_%3\X$/FNC'I,J_Y+ U'8Q$*?OC4I!Y[B?Y!YN62B
ML'=X?/.TW?CB  =]E%K%M#F>ZR\T")/+\R ,W+.@W$GZ&,Q%302">GI4?.4]
M\">']DYMHK>-A;;RB&XOC^AKYA%:XFGGV!E]1+_DEB,1RP*,!+P4FH9ECR7K
MD6F*V.B1:?=.(0+7L_88_OZ?0C:3S6;);"9O6P[L0_#N@[;ZN%5*G>%<GUBY
MDLV4BSG1[?;AZI@BF/F?SJE$:FKHWD\0"KQ'<-N#2( C]#N\IH<'G_QTITOU
M_R[D;N-?#DRE$N VP%<9N<@MS&_>^3INF04)_? D QT,WJ=V)<1NL6O"IO40
M"K#4-/NU.S/=0V>R'/KM0Z%NL9JF$;UE@N^A8XCBWN3C2B<7<HS_[#(3V_S\
M61!B"5UWOB[QD]C3H.W\P![S(YCC2'[ETFH".H.(/A6, YB(!4%LBZ(M8Z-!
M$_]3 W:D7_*O-2-X+ '371N9UTM9T&47_%,WE++,!@$WE;Z++.+CJ@Y93)3@
M@(D'#@2B]4'^>GM:-O*O^%GYPB3$,"T8I.[D)R$6CJW?5RL@2X7R ?T;Y'[
M_(5!R"&E38$EP=QTA;V,?HP5I0B,%8;@DC ]*'L.WU5]'O[X8(3_W]Z7=J>M
M+&M_YU=HY>:^*[G&-F)FYYR]%F:PL0%CP ;[RUX"-2 C)*R!Z=>_7=7=&A@<
M.W%BO,,=SDF"I)ZJ:ZZG7D8(W!CS2$$5H=6"2'X8H G&ZSW!T<@<](JSC<]B
MHI1%F%\'O#>:2GA*$)8:2"P;T L?&*:#3=%,UP%%'1./@6<R,1@4-A$X_B5!
MEN0Q"C_G3,@P)!)%4[&QFRC+,><AGN+GEX8W(YC]O(6-V@?">B/U]E(Q7& *
M&#=K5!HEZ9K[* XJ[4N*_<7^R5O+_<.J;: [>\33(K<KN@WQ\Z:RRZJ: DH)
MZ^"^XT/-X)--]N3&-R->GB?K<T]O/53>,SZAA3.S*_P);SY"S?-BZL /F+ML
M(,6CJ1B3":!_AZN]&A8Y+KL8G;V%'SW%B4V'*)3MK#TC\=Q4GH>K0 3S>,!^
MGZ/WR=DU1(?]'"@M\S5YT^ L95UICT;( GS)MJ?0?HZ=Q&*R7UG(V)XBWMHV
MB0+[Z7L30.^? ?%F?1!0^-F'(VPZ4G ZE)%_ED^2,7\RH6%WW^Q 9OU>7*.7
M1S-SAVCFKXQFY@[1S$,T\SN2+B*GMTDZ:&?/38'=C <Y*!B2X-;WF-_4TIBP
M^)R()G-9Z0NP6?DDD<LA9UL3 =2N!O$044)>[,]Q2FM+I"#/@ I**E2(.?/T
MK)Y-Z8"YP&#*["-K?/?)8*1X)D0[G#AS\0>TH&VT$1&&@3B0#8\?5O)Y>3G@
MXA)N%NY:V%2'0J(NCV7CS2V/^<X89K^*FD'T_F!81=#"Y@@L=XNUIA95).R'
M4=CB$E$5E,$LBN$'S"EU@X)DHEK$BCDC4*G"'$UR[B27^U\QB8V&\4$/'^H9
MNFU*P36$=0MTQ4R4,6IN$T@+)JI&MU)?AA4'W&35[6,:MG\M6)4-\VNF3E*8
M/F>S^.>,)=-!KA[&_;ZW=S#$^MQ87V\^<9NNXG#)MDSFS*2_$LPY5*7BB71&
MK39=XLAS4K5:\'S7XD=/BU?0+:P W1Q/J>K#CV*(<5*AIN_FSI@*0A7L1]=@
M];BH_@.S_?X=#UWIB"(UO.'S0_:?(<@I;Y$A97W7.[Z+_-8O1PT1X*XWHQ%Z
M4SU&%9PO.B:VO&NCETV! "1S>O#*!GK](=O&E++>;1TB0!Z]YGU"5'C/\U@H
MDOR_T,+Z6.GWP>V!7>-YZHHT((09<>ABFP=NKF\3<A$)#"*30O-IW2"07F00
M1/T*/O9%6%:$M==BADJH[Y8]U:F-A4O5P1?ES"']?RM%'N[N\_Z >&S;+6&"
M@K- (2*@%C:5.DEZA!60(VOX*,JC:4$TLA5X8L,0]^QOJ#A\E:2)<$GCH&4-
M6EF/Z.:<YT8QMSX+ST,N&J:8, )KNI3\,G)"?+Y^WRI)>42+H^(=F);8@7-7
M4PF5(H94)CV+,91M6Q5AJ"6LAG6@0?".RJ!6?T3E%AU+3A8\?^-6L=LC??!@
M^&4JE+Q9<C?/[3X0\';G(>R_:1!>6;05F>K@#GS.]5JG-Z4%V60'S^FSE9\[
M2F]8-BRD=6(Y?-T4^7J1N0(Z9!_\+5Q)Q>=9JIRDNEYL\F4%(I!_<& ".\G8
M;QI5\II&'>CYN2)8OW3'RU+F[FI@GZ!6!LM1@C4VH1(@IA>R2\'*<A1U0@4@
M\^+/B/?P@7AW$F^H!W4@*>Y RR^83-$ZD9K*1(&:9Y4:"5+-I92H01HIY&K>
M@5[8@()DE:.*B-V.K.WVB02?\M]6)-6$K%4&CM*',GVX'%3=+!!5L>SCEF8H
MFE0#;!"P>=&FC/*8DA>>H@:FQ>T:S$&&3.(!Y_E,_8Q,%<B6!O51%*]J))A
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MAQ81L$#&=T$9 B6H(9''%&MJB#[W(3::,D'P".A#HA(>?;!=>H,$/(Q!X 1
M$UDO!_R&$C<X9V<-:I"*"--RN/"T$,85MVX^,B<P*B@Y@8+"M9K&0!7A-X9
MZ5?O"F@(5NK+X22"0_/%<97,AZQ!["73()N?##_B5TM"Z=HS$T/7LT>F$711
M*QX6(Z_6YN2YKO?B9C#1";"#.K'$?'C9 Q.P7*KNJ/T3!.PC+T6>PURBWW:=
M$<8/OO$"!ZH(347,G9=3B[#:EMIOFSO=IE.Z1SC&EF\#12)Y\#H0MBI0,AA0
M2"^ 8A4"$P%]%"I#Z-'R?^)[MU6?^!;&(F)80(PR\.^>\292&_T2] "<B<61
MXSQH(<0Q\=%*MA39^Y<\K&E%!6;GML)XB]HJ''YH@_I$169@!1*S7RE[=2Q
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M_3,)][%A5PG(V4,M8WD>I._"-P4Z. &4:6MJ,B2S(-I9"-L-$>2@/,M>G]N
M9X'9)Y&7K  S$T6ZI [=)R'1B>/TH*0RN5H3F%A4JC2NC\72)HKCH(1AZP7-
M E[D__P-!0)#-Q4?QUO-4JP84@]TVF&I7LIBVW1AG[FLL@&AN0_F0%"50,?I
MVDOTOP&H52SU6V0BH(+"<3LF%?TH('[MP%>V1_\!"81[<+U& [MCGA%OH[%:
MEH,G>J*- ZTP.$3O1_@DU3I4I(\@\E,0]R6@5Z%L81FV:Y/C($81AD<E!E W
M:2_*2#\:D$'10+*4P)*BEI<(@YE@ZZ$='"+"T,WTBK(8]A$"$K)[!?JA3X-K
M0K5'6"XB5\#V#,)P'_'($4CED/#TVG0Q*J5L9NG!96QC)+;&LF]*X>R;2"C[
M9H^VE6DZP58">S.U]BB$D,%,)'<">L**V+O[A$1>AY<+!_+7GBPY1.2O\M6_
M?,(OBZ5\ A?],]$3-NU/W)'OJ"%_OQ\FX#/W5BD'5TD?%:_#)*#J^K^?XNM!
MGYUQILT0Q*>__1,,'<+F;G_ZVR,%W&[I;?_G%?, 0H0IO';K#KO\REU._M N
M0^SJ)5>!7BRZ<T.+ZD4J7"[3^DNRAKTO\5@R&D]DH_%4ZFO@NC19;J<MYK/U
MN+;$VEB0\O/Z,H*/("N"163C<GR#5C8_%J:I/9G(SVQ[9Z0Y9"=K>MT"MU^X
MK:O\WH,_O]N_=#*_AM!WCWV]D37ZUQ[NREY-Y@TOQ3K_@\&8_N"I >GD_VY+
MD&CN@)9?7PK_2OQ_MXNBM1R#K4-MWR/QROKT^,8F<XE=;[Q^D-\^>SF=^N'9
M_]H;O(U2UN?S3=HJ3W?[T7Y8D_D![>6Y4WG-=_A)93(;=+9E]B^?P@=:NAR/
MO\'2?P$W>R$]MEF1Z88 ^LA'$HVGTW\J/<:SF7>FQV<T_;W5)O9J,N_'#*I0
MS(X!?#/@]_RP=^'+SW""KQ]YX3_.!;Z^DP6$<;.#];-?UL_F)"H(\6%[U8J_
M?&]^@^/FQ;/Y(F\PDW>Z0"\[K"+T8<"*%@A^*A,(IK.,O#_KV.*QWW)L/W&Q
M=LAC[[9I!J1M?6")E/Q3]?'CO=7&?\Q0#,GI*'3L_,"'\\=2Y9?$3ZK%[V>C
MU'F/V-^_^QL!GA\U27[48_0.)LF;K#D1_U'WX!JU\;JY/<M.>+Z$5#Z4D&[>
M[[<K(94/):3[4T*ZQQE4!TR8-TE"8Q3/$ $W$]"V!D/]O-U#,MKO3T9[J9A!
M7C\G;+=ZIJY^^OYE^>N']9$_.OGJD.+V.W9YGU+<?C3#9(<)5 A6](O*F5V!
M6R][8\?'?L)<>#8;X]66PT_ELOR4X?YOV:+G$V8^8%K"+I7B';,4WL(@WD+*
M>^YX>HM5;Z'.GR#)_70%O/MD=F4D^A5B<\!J^TQ)$!_Y3$_E!XI$HJ)$7*,C
M+%DOV&!!7A.;<13]4>F_X0>\XE8?;<3TD0(C<8Y>QP! L 4(U&=#<5R/T,4:
MK'G& ;?WY=7:^7 AZ\'0_6E#]R4EJ@=3]T.9NB^X, =C]X?,L(.Q^SMV^=]@
M['[ZNP6=1XY?;-#^>#G"ACK['<,JLQ$M?9\RBM?.>T<>SF^IHOBI-+-KCH@0
MZDS$6A8-?[10\,7Y0JD79'G]ILS WUPM^%:)9PT$>=GIFOI%V[59B?%.YY;[
M(,F<583H^4VGLU\Y@:\DE7VX5'D/:.9W'5EZ(XG\O4[K!0F<>W&CK@7 HP]2
MQ3&FPC!1@%SUB_<LD=V3PWNE--V'JU9>1RW;; CR1W'+Q&]DES]9GB 0M'X3
MBY1C&T[M=SJC5U[W?;AF=P@>*_I)VZ$*A=]48!)/OE*T_+*9;"2*[^T5<Q2#
M-6IYA_/:F^-Z[43>_[[MB+2&*^]^?VCQS7+:Y?B&W;7G4=4W6_I;!E;?*];_
M@F:''S/N_?' ,=XDVO^FN!B':/\/PTJS>#\E0FS]\)F>RP\$)]?C_2W-0WGG
M&.^VURI^2A=JJAZ>-72L&TB*]%E.Q+T<@8C&F]=[WOX@#F[(Z[N>0A -&6:\
M6?E<L53>FT.Q1VL?4"R#=6'#%@IL#.]SWR*BI=EGJ@N&DAAF(?5TJ[:S?5(P
MSFQ-M^4/'I(6=B8M,$6D@I6NTA<1=OUZ2%1XIN,P;IG&MTS<E*\BQX=E^'Q)
MI+^**Q_Y\2M?$92.?22" \\5WJ[$KU06EXYAB4 K$=,@T'8'0-,%9/9)A'TS
M&?QFF&]I:W #P$H^RVF>W;2KNAV?BL?V\:X]7RL6/]2*;6J.;U<K%C_4BNU/
MK=A>,5(J@:K:DZNIHIU309EJ8)4TB4W95Y_L$_S[?R#/)3B'XX$RT?3E7]^;
MQ<8=%6< '_SIU>'L_/_?L:!-XW'.C,>W6Q7TC@01@ZT.6!,.*N@,&SNG&,@J
M4>5D35(@W1033=&M+XV4&:3]@1YKD:EBL8;+BC0T^9>H\FA )V:-SH!.O3_"
M!E9D,M6Q"Q)KJJ>(UF?0PT6Q;2):'T&_0.(X.A'-E'2--5X3/5Z@JYCF3$3+
M+NSK:%H3[#<&K<S@'=&WXN3?=G+_3GHL8G/ R(LL+J8*%1CM2MAK!$A0 : -
MA#U@&A" "+#-PE:E2-I@^$ /+ ^Y#1_-R,D#F7R(556,R*5BN-!L=9,2^O3L
MD0ZFEC:#K'C.O%@Z/.-#P>=Y@W,5Z69JF= AC1%$(BHG4ZP)C>*L4U\D^(V1
MPJG*LZNA:?M,T5D3=O#:P?CTBVDY[5.C/:)<<V3J5&VT,8R9^88OLA:@GS-1
M.1%G%0-B(%#N^\#O'-MKYXKC0?V/-2/8_Q"ZS@:7R#\=;-[#>D'1>T(M>$>2
MX^*BH16"[>5@Y[!%B4;_58/I'R['AU@5R/3U@P]T+!4])+&'V9JLAD[/9 K,
M%B2N$;HFBK.KSRAVGF0Z>Z"=2JC7E)#_V([*+VSI89=1[/=DCUA?0I3BU"26
MH+4N>*)$?^5 5^4^USBAOS&AEW8+J4=\F%X#[S-ODJ8LPVJ$Q3Z.9,^5ARVM
MKEC/53K,4D*3774)./; (H+_F++NU8%I1$9T=^$:PJ*<T*?\U5,)9[K#D;CQ
MGJ'N\2LV:\WQ;GWP^.B?+4*_PHZ):CM<^Z:7-B(V*-SO"S*B=/B<!@2AXR=8
M* $;P++.$H=+_B%653>AS[IH@48_2J_2D$HQ@_>^IA>6G[HO_?#R];Q6TW!=
M+=;!5_Q#E+U-240\"]2%/:YWM=0.BL$3J00ST 9AS<RG-M&\.= @7<P.>N92
M!N'/%KJ6 K'#"W0G72!1V[&T/E?8C/4VOX+C]!6F^H?O$C;B[2O0,IMWU7;
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M.])0G:'7"@C0AJW00Z6=>*/[L)VXY1YS!:N*&6<<H(A,'2Q#XZ?"+A51M_
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M90 1PBY5X(QZ]!EQ'7;#,T0EWR#!$G0),64)U=@D*LLUC-]$([[JQE3' ,'
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MBT*(%C WPW2 L ?*S+0$4H7K[:!B447$$/^^<=?"6^O?KG4D%X_.PSL&N#+
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MNHK![[57-LN/F1/JEN.)K+'Y )DCOQM"L1#GEB^0$I(!V'\.I.Z/Z/W$YC%
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M^GQ0J1>!OK&6AJ(&7M ,E5(!@(T!')EBJ7N)ZOKNDPESEL0F9\F?8/ZN5%8
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M\UQB>MCBJ1AU#(^:/U03N@W64CD5GH=;&=+\R57&G;8@_G3Z,A /?2\HZ,$
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M]<L4P.O.=AB&;R>EUFKS\/@G7N8*+3EMLQ]W8F-3@^:QW;1H__R?;(88I6O
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MK_VE2YV9W=08&DWFNA"Z9(=4HM5G+V2N[[!.E(\;1AOCRF/D',VMV-L^\JA
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ME+%+A!>!M;RG&@1'L!G-6^,:L]D ESBEJ*0F.4\=*X[*:*X^ELV7+18AW(R
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M%G?9"-4H^O8GJ%2U+8_F+U7+K/;VIP"((:GR:*\!==[^!, 49<+>]J@VZ=/
MHL]]Y]E_-7D9,?0_](UQ\IO_!U!+ P04    " !(-*Y:K%>:K71>  #S:04
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MWDM.=LA%7'%#!:[FQ/ [""XH0(DG ID88G*H%/32\O4N05JP=Q25Q1F*N66
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M<Q0P^XP9" %BBAR9@B&-,"JE_5S0+J-'-$X6,WC2$#!Z<<?7M;6@![>VI;*
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M_6T"=3O(Y, UA 8D\)8HIUF&9I )P6H##4+%L8[FW5*OM?\*7K^&U<Y'+I9
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M_NGIZ=LPVCE/$?T:?^M&:]B \\1)MO%AM.^>O\O_+^O^M\ /O_[$_^?!B<F
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M0;1,U+[O6=OM[.UO%D/I5O7K&^^%\Q!TA?;I6.:PAM$L[V72>@(Q5?0S::&
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M]_XO) C^$49/X9PX<102+]OJRSS\PBY0*2#>(2K811'!ERC8,I1H&@A*!7-
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MKQ@J<R<@TR5/4MUR9](O#J5.F)8WGRZG2\86?WY.4&V??]#@]ZQ9&H4Z8A@
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M9]C3@P*CB%.A-"W"QF#@NX]LT !>P6O?VYXH9+3<,F78K=2V1=P:C'WWH0O
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MCU5UC6WB8^@QJ[8:;HEH3!5O:CG_4HKYPZT9R8?9]D%T:V[N>^@!NIUKE6'
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MI6#Z-;H8C 7B:*R<ICP,^$5>>:ES1O@COWQC7 71IK"KETE1V@W[ J>5; &
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M)/\+_Q_^(AC[S?\'4$L! A0#%     @ 2#2N6H=>2J1C!P  !BT   H
M         ( !     &5X,S$M,2YH=&U02P$"% ,4    " !(-*Y:Q(V3B8 '
M   <,   "@              @ &+!P  97@S,2TR+FAT;5!+ 0(4 Q0    (
M $@TKEHLOE174@0  (4:   *              "  3,/  !E>#,R+3$N:'1M
M4$L! A0#%     @ 2#2N6F.'$P@Y!   /AL   H              ( !K1,
M &5X,S(M,BYH=&U02P$"% ,4    " !(-*Y:0S8*QY$9 0 J,0H #
M        @ $.&   9F]R;3$P+7$N:'1M4$L! A0#%     @ 2#2N6G4&+VM:
M#P  6J,  !$              ( !R3$! &MA<&$M,C R-3 S,S$N>'-D4$L!
M A0#%     @ 2#2N6C3@>141"P  ('0  !4              ( !4D$! &MA
M<&$M,C R-3 S,S%?8V%L+GAM;%!+ 0(4 Q0    ( $@TKEIT.(/YUB4  ")N
M @ 5              "  99, 0!K87!A+3(P,C4P,S,Q7V1E9BYX;6Q02P$"
M% ,4    " !(-*Y:K%>:K71>  #S:04 %0              @ &?<@$ :V%P
M82TR,#(U,#,S,5]L86(N>&UL4$L! A0#%     @ 2#2N6A4C,SMD/0  P/0#
M !4              ( !1M$! &MA<&$M,C R-3 S,S%?<')E+GAM;%!+!08
1    "@ * &4"  #=#@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:KAPA="http://kairospharma.com/20250331"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="kapa-20250331.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
        </entity>
        <period>
            <instant>2025-05-13</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_EnviroThreapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">KAPA:EnviroThreapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_EquityLineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:EquityLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_EquityLineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:EquityLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">KAPA:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">KAPA:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-08-31_custom_MasterServiceAndTechnologyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:MasterServiceAndTechnologyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="From2024-09-202024-09-20_custom_BioassayServicesAgreementMember_custom_PreCheckHealthServicesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:BioassayServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:PreCheckHealthServicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-20</startDate>
            <endDate>2024-09-20</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BioassayServicesAgreementMember_custom_PreCheckHealthServicesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:BioassayServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:PreCheckHealthServicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_BioassayServicesAgreementMember_custom_PreCheckHealthServicesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:BioassayServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:PreCheckHealthServicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-09-232024-09-23_custom_AdvisoryAndConsultingServicesAgreementMember_custom_CEOCATechnologiesLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:AdvisoryAndConsultingServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:CEOCATechnologiesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-23</startDate>
            <endDate>2024-09-23</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_AdvisoryAndConsultingServicesAgreementMember_custom_CEOCATechnologiesLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:AdvisoryAndConsultingServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:CEOCATechnologiesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AdvisoryAndConsultingServicesAgreementMember_custom_CEOCATechnologiesLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:AdvisoryAndConsultingServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:CEOCATechnologiesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-09-232024-09-23_custom_StrategicAdvisoryAgreementMember_custom_BelairCapitalAdvisorsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:StrategicAdvisoryAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:BelairCapitalAdvisorsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-23</startDate>
            <endDate>2024-09-23</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_StrategicAdvisoryAgreementMember_custom_BelairCapitalAdvisorsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:StrategicAdvisoryAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:BelairCapitalAdvisorsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_StrategicAdvisoryAgreementMember_custom_BelairCapitalAdvisorsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:StrategicAdvisoryAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:BelairCapitalAdvisorsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012024-10-01_custom_ConsultingAgreementMember_custom_CurrentCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:CurrentCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-01</endDate>
        </period>
    </context>
    <context id="From2024-10-012024-10-01_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-01</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012025-04-01_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-04-01_custom_ConsultingAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="From2024-11-122024-11-12_custom_HelenaGlobalInvestmentOpportunitiesILTDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:HelenaGlobalInvestmentOpportunitiesILTDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <context id="From2024-11-122024-11-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <context id="From2025-04-242025-04-24_us-gaap_CommonStockMember_custom_HelenaGlobalInvestmentOpportunitiesILTDMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:HelenaGlobalInvestmentOpportunitiesILTDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-24</startDate>
            <endDate>2025-04-24</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PrevailInfoworksIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:PrevailInfoworksIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PrevailInfoworksIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:PrevailInfoworksIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PreCheckHealthServicesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:PreCheckHealthServicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PreCheckHealthServicesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:PreCheckHealthServicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_CEOCATechnologiesLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:CEOCATechnologiesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CEOCATechnologiesLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:CEOCATechnologiesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_BelairCapitalAdvisorsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:BelairCapitalAdvisorsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_BelairCapitalAdvisorsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:BelairCapitalAdvisorsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_CrossCurrentCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:CrossCurrentCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CrossCurrentCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:CrossCurrentCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="From2025-01-142025-01-14_custom_SecurityPurchaseAgreementMember_custom_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-14</startDate>
            <endDate>2025-01-14</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-14_custom_SecurityPurchaseAgreementMember_custom_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-14</instant>
        </period>
    </context>
    <context id="AsOf2025-01-14_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-14</instant>
        </period>
    </context>
    <context id="From2025-01-162025-01-16_custom_SecurityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-16</startDate>
            <endDate>2025-01-16</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-16</instant>
        </period>
    </context>
    <context id="AsOf2025-01-14_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-14</instant>
        </period>
    </context>
    <context id="AsOf2025-01-14_custom_CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-14</instant>
        </period>
    </context>
    <context id="From2025-01-142025-01-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
        </entity>
        <period>
            <startDate>2025-01-14</startDate>
            <endDate>2025-01-14</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-07-31_custom_TwentyTwentyThreeEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">KAPA:TwentyTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_TwentyTwentyThreeEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">KAPA:TwentyTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwentyTwentyThreeEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">KAPA:TwentyTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-09-232024-09-23_us-gaap_RestrictedStockUnitsRSUMember_custom_StrategicAdvisoryAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:StrategicAdvisoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-23</startDate>
            <endDate>2024-09-23</endDate>
        </period>
    </context>
    <context id="From2024-09-232024-09-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
        </entity>
        <period>
            <startDate>2024-09-23</startDate>
            <endDate>2024-09-23</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_StrategicAdvisoryAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:StrategicAdvisoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember_custom_StrategicAdvisoryAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:StrategicAdvisoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-09-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember_custom_FourOfficersAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:FourOfficersAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-09-012024-09-30_custom_FourOfficersAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:FourOfficersAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_FourOfficersAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:FourOfficersAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_FourOfficersAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:FourOfficersAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ThreeIndependentDirectorsMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">KAPA:ThreeIndependentDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_DirectorAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:DirectorAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DirectorAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:DirectorAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember_custom_PreFundedWarrantMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-16</instant>
        </period>
    </context>
    <context id="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-16</instant>
        </period>
    </context>
    <context id="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember_custom_UnderwritersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">KAPA:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-16</instant>
        </period>
    </context>
    <context id="AsOf2025-01-14_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember_custom_UnderwritersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">KAPA:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-14</instant>
        </period>
    </context>
    <context id="From2025-01-142025-01-14_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember_custom_UnderwritersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">KAPA:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">KAPA:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-14</startDate>
            <endDate>2025-01-14</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_ExercisePriceRangeOneMember_custom_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">KAPA:ExercisePriceRangeOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_WarrantOneMember_custom_ExercisePriceRangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">KAPA:ExercisePriceRangeOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ExercisePriceRangeTwoMember_custom_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">KAPA:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_WarrantTwoMember_custom_ExercisePriceRangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">KAPA:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_ExercisePriceRangeThreeMember_custom_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">KAPA:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_WarrantThreeMember_custom_ExercisePriceRangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">KAPA:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">KAPA:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_PhaseOneClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:PhaseOneClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ItemOneAndTwoMember_custom_PhaseTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemOneAndTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">KAPA:PhaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ItemThreeMember_custom_PhaseTwoClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">KAPA:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ItemOneAndTwoMember_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemOneAndTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ItemOneAndTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemOneAndTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_custom_ItemFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_ExclusiveLicenseAgreementMember_custom_ItemFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ItemFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MinimumMember_custom_ItemFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MaximumMember_custom_ItemFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ItemFourMember_custom_PhaseTwoClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">KAPA:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ItemFourMember_custom_FoodAndDrugAdministrationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:FoodAndDrugAdministrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_PhaseThreeClinicalTrialMember_custom_EnviroCedarsLicenseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:EnviroCedarsLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ItemOneAndTwoMember_custom_PhaseThreeMember_custom_EnviroCedarsLicenseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">KAPA:ItemOneAndTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">KAPA:PhaseThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">KAPA:EnviroCedarsLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-04-01_custom_CrossCurrentCapitalLLCMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:CrossCurrentCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="From2025-04-242025-04-24_custom_HelenaGlobalInvestmentOpportunitiesILTDMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001962011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">KAPA:HelenaGlobalInvestmentOpportunitiesILTDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-24</startDate>
            <endDate>2025-04-24</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Integer">
        <measure>KAPA:Integer</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-03-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-01-01to2025-03-31" id="Fact000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-01-01to2025-03-31" id="Fact000005">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-03-31" id="Fact000006">0001962011</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0083"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0084"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0089"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0090"
      unitRef="USD"
      xsi:nil="true"/>
    <KAPA:CommonStockToBeIssuedValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0128"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0144"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0145"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0165"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0168"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0172"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0200"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0207"
      unitRef="Shares"
      xsi:nil="true"/>
    <KAPA:AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0209"
      unitRef="USD"
      xsi:nil="true"/>
    <KAPA:AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2025-01-012025-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0210"
      unitRef="USD"
      xsi:nil="true"/>
    <KAPA:AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0212"
      unitRef="USD"
      xsi:nil="true"/>
    <KAPA:StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants
      contextRef="From2025-01-012025-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0216"
      unitRef="USD"
      xsi:nil="true"/>
    <KAPA:StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0217"
      unitRef="USD"
      xsi:nil="true"/>
    <KAPA:StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <KAPA:StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0223"
      unitRef="USD"
      xsi:nil="true"/>
    <KAPA:StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <KAPA:StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0226"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0231"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-01-012025-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0234"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0239"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0240"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0241"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <KAPA:IncreaseDecreaseInVendorAdvances
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <KAPA:IssuanceOfCommonSharesForDeferredOfferingCosts
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <KAPA:IssuanceOfCommonSharesForVendorAdvances
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl0422"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046"
      id="xdx2ixbrl0615"
      unitRef="Shares"
      xsi:nil="true"/>
    <KAPA:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046"
      id="xdx2ixbrl0617"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046"
      id="xdx2ixbrl0619"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0679"
      unitRef="Shares"
      xsi:nil="true"/>
    <KAPA:ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0681"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0683"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl0863"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-03-31_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl0864"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OfficersCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl0870"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-03-31_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl0876"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-01-01to2025-03-31" id="Fact000013">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2025-01-01to2025-03-31" id="Fact000014">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-01-01to2025-03-31" id="Fact000015">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2025-01-01to2025-03-31" id="Fact000016">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2025-01-01to2025-03-31" id="Fact000017">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-01-01to2025-03-31" id="Fact000018">001-42275</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-03-31" id="Fact000019">KAIROS PHARMA, LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-03-31" id="Fact000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-01-01to2025-03-31" id="Fact000021">46-2993314</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-03-31" id="Fact000022">2355 Westwood Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-01-01to2025-03-31" id="Fact000023">#139</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-03-31" id="Fact000024">Los Angeles</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-01-01to2025-03-31" id="Fact000025">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-03-31" id="Fact000026">90064</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-03-31" id="Fact000027">(310)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-03-31" id="Fact000028">948-2356</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2025-01-01to2025-03-31" id="Fact000029">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2025-01-01to2025-03-31" id="Fact000030">KAPA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2025-01-01to2025-03-31" id="Fact000031">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2025-01-01to2025-03-31" id="Fact000032">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-01-01to2025-03-31" id="Fact000033">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-03-31" id="Fact000034">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-01-01to2025-03-31" id="Fact000035">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-03-31" id="Fact000036">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2025-01-01to2025-03-31" id="Fact000037">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="From2025-01-01to2025-03-31" id="Fact000038">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-05-13"
      decimals="INF"
      id="Fact000039"
      unitRef="Shares">16849306</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000047"
      unitRef="USD">3616000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000048"
      unitRef="USD">1272000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <KAPA:VendorAdvancesNet
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000050"
      unitRef="USD">2379000</KAPA:VendorAdvancesNet>
    <KAPA:VendorAdvancesNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000051"
      unitRef="USD">2859000</KAPA:VendorAdvancesNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000053"
      unitRef="USD">55000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000054"
      unitRef="USD">38000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000056"
      unitRef="USD">6050000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000057"
      unitRef="USD">4169000</us-gaap:AssetsCurrent>
    <us-gaap:DeferredCosts
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000059"
      unitRef="USD">1705000</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000060"
      unitRef="USD">1377000</us-gaap:DeferredCosts>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000062"
      unitRef="USD">182000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000063"
      unitRef="USD">222000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000065"
      unitRef="USD">1887000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000066"
      unitRef="USD">1599000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000068"
      unitRef="USD">7937000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000069"
      unitRef="USD">5768000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000077"
      unitRef="USD">805000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000078"
      unitRef="USD">992000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000080"
      unitRef="USD">805000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000081"
      unitRef="USD">992000</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000092"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000094"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000096"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000098"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000100"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000102"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000104"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000106"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000111"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000113"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000115"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000117"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000119"
      unitRef="Shares">15825118</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000121"
      unitRef="Shares">15825118</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000123"
      unitRef="Shares">13736597</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000125"
      unitRef="Shares">13736597</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000108"
      unitRef="USD">16000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000109"
      unitRef="USD">14000</us-gaap:CommonStockValue>
    <KAPA:CommonStockToBeIssuedSharesOutstanding
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000130"
      unitRef="Shares">551000</KAPA:CommonStockToBeIssuedSharesOutstanding>
    <KAPA:CommonStockToBeIssuedValue
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000127"
      unitRef="USD">484000</KAPA:CommonStockToBeIssuedValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000132"
      unitRef="USD">16709000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000133"
      unitRef="USD">13577000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000135"
      unitRef="USD">-10077000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000136"
      unitRef="USD">-8815000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000138"
      unitRef="USD">7132000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000139"
      unitRef="USD">4776000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000141"
      unitRef="USD">7937000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000142"
      unitRef="USD">5768000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000150"
      unitRef="USD">493000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000151"
      unitRef="USD">165000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000153"
      unitRef="USD">773000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000154"
      unitRef="USD">122000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000156"
      unitRef="USD">1266000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000157"
      unitRef="USD">287000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000159"
      unitRef="USD">-1266000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000160"
      unitRef="USD">-287000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000166"
      unitRef="USD">16000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000169"
      unitRef="USD">20000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000171"
      unitRef="USD">4000</us-gaap:InvestmentIncomeNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000174"
      unitRef="USD">4000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000175"
      unitRef="USD">-36000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000177"
      unitRef="USD">-1262000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000178"
      unitRef="USD">-323000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact000180"
      unitRef="USDPShares">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact000182"
      unitRef="USDPShares">-0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact000184"
      unitRef="USDPShares">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact000186"
      unitRef="USDPShares">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact000191"
      unitRef="Shares">15875485</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact000193"
      unitRef="Shares">15875485</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact000195"
      unitRef="Shares">10562640</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact000197"
      unitRef="Shares">10562640</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000205"
      unitRef="Shares">13736597</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000199"
      unitRef="USD">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000201"
      unitRef="USD">13577000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000202"
      unitRef="USD">-8815000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000203"
      unitRef="USD">4776000</us-gaap:StockholdersEquity>
    <KAPA:AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000211"
      unitRef="USD">3056000</KAPA:AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts>
    <KAPA:AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000213"
      unitRef="USD">3056000</KAPA:AdjustmentsToAdditionalPaidInCapitalProceedsFromSaleOfPrefundedWarrantsNetOfOfferingCosts>
    <KAPA:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000221"
      unitRef="Shares">2010000</KAPA:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants>
    <KAPA:StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000215"
      unitRef="USD">2000</KAPA:StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants>
    <KAPA:StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000219"
      unitRef="USD">2000</KAPA:StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants>
    <KAPA:StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts
      contextRef="From2025-01-012025-03-31_custom_CommonStockToBeIssuedMember"
      decimals="INF"
      id="Fact000229"
      unitRef="Shares">551000</KAPA:StockIssuedDuringPeriodSharesFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts>
    <KAPA:StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts
      contextRef="From2025-01-012025-03-31_custom_CommonStockToBeIssuedMember"
      decimals="-3"
      id="Fact000224"
      unitRef="USD">484000</KAPA:StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts>
    <KAPA:StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000227"
      unitRef="USD">484000</KAPA:StockIssuedDuringPeriodValueFairValueOfCommonSharesToBeIssuedForVendorAdvanceAndDeferredOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000237"
      unitRef="Shares">78521</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000233"
      unitRef="USD">76000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000235"
      unitRef="USD">76000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000242"
      unitRef="USD">-1262000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000243"
      unitRef="USD">-1262000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000251"
      unitRef="Shares">15825118</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000245"
      unitRef="USD">16000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_custom_CommonStockToBeIssuedMember"
      decimals="INF"
      id="Fact000253"
      unitRef="Shares">551000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_custom_CommonStockToBeIssuedMember"
      decimals="-3"
      id="Fact000246"
      unitRef="USD">484000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000247"
      unitRef="USD">16709000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000248"
      unitRef="USD">-10077000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000249"
      unitRef="USD">7132000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000261"
      unitRef="Shares">10562640</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000255"
      unitRef="USD">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000257"
      unitRef="USD">4123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000258"
      unitRef="USD">-6212000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000259"
      unitRef="USD">-2078000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000269"
      unitRef="Shares">10562640</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000263"
      unitRef="USD">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000265"
      unitRef="USD">4123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000266"
      unitRef="USD">-6212000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000267"
      unitRef="USD">-2078000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000274"
      unitRef="USD">-323000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000275"
      unitRef="USD">-323000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000280"
      unitRef="USD">-323000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000281"
      unitRef="USD">-323000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000289"
      unitRef="Shares">10562640</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000283"
      unitRef="USD">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000285"
      unitRef="USD">4123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000286"
      unitRef="USD">-6535000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000287"
      unitRef="USD">-2401000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000297"
      unitRef="Shares">10562640</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000291"
      unitRef="USD">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000293"
      unitRef="USD">4123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000294"
      unitRef="USD">-6535000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000295"
      unitRef="USD">-2401000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000302"
      unitRef="USD">-1262000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000303"
      unitRef="USD">-323000</us-gaap:NetIncomeLoss>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000308"
      unitRef="USD">40000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000309"
      unitRef="USD">40000</us-gaap:AmortizationOfIntangibleAssets>
    <KAPA:FairValueOfVestedRestrictedStockUnits
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000311"
      unitRef="USD">76000</KAPA:FairValueOfVestedRestrictedStockUnits>
    <KAPA:FairValueOfVestedRestrictedStockUnits
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000312"
      unitRef="USD">20000</KAPA:FairValueOfVestedRestrictedStockUnits>
    <KAPA:IncreaseDecreaseInVendorAdvances
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000317"
      unitRef="USD">636000</KAPA:IncreaseDecreaseInVendorAdvances>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000320"
      unitRef="USD">17000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000321"
      unitRef="USD">11000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000323"
      unitRef="USD">-187000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000324"
      unitRef="USD">310000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000326"
      unitRef="USD">-714000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000327"
      unitRef="USD">36000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000332"
      unitRef="USD">3058000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000336"
      unitRef="USD">89000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000338"
      unitRef="USD">3058000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000339"
      unitRef="USD">-89000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000341"
      unitRef="USD">2344000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000342"
      unitRef="USD">-53000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000344"
      unitRef="USD">1272000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000345"
      unitRef="USD">93000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000347"
      unitRef="USD">3616000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000348"
      unitRef="USD">40000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <KAPA:IssuanceOfCommonSharesForDeferredOfferingCosts
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000362"
      unitRef="USD">328000</KAPA:IssuanceOfCommonSharesForDeferredOfferingCosts>
    <KAPA:IssuanceOfCommonSharesForVendorAdvances
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000365"
      unitRef="USD">156000</KAPA:IssuanceOfCommonSharesForVendorAdvances>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000368">&lt;p id="xdx_80A_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zeNelbWjJVki" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;NOTE 1 &#x2013; &lt;span id="xdx_82B_zFS9CXK2zAq7"&gt;BASIS OF PRESENTATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;Organization and Operations&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;Kairos Pharma, Ltd. (the &#x201c;Company&#x201d; or
&#x201c;Kairos&#x201d;) was incorporated on June 17, 2013 under the laws of the state of California as NanoGB13, Inc. The Company changed
its name to Kairos Pharma, Ltd. on July 15, 2016 and subsequently converted into a Delaware corporation under the same name, Kairos Pharma,
Ltd., on May 10, 2023. The Company is an early-stage biotechnology company focused on the development of immunotherapy and cell therapy
treatments for oncology.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&lt;b&gt;Basis of Presentation
of Unaudited Financial Information &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;The
accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles
generally accepted in the United States for interim financial information and the instructions to Form 10-Q and Rule 10-01 of
Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting
principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary
for a fair presentation have been included. Operating results for the three months ended March 31, 2025, are not necessarily
indicative of the results that may be expected for the year ending December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;Liquidity and Capital Resources&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization
of assets and the settlement of liabilities and commitments in the normal course of business.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2025, the Company incurred a net loss of $&lt;span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20250101__20250331_ztt2sJYsJd6l" title="Net loss"&gt;1,262&lt;/span&gt;&#160;and used cash in operations of $&lt;span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20250101__20250331_zs7bN1jDJTP7" title="Cash in operations"&gt;714&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2025, the Company closed a private financing in which the Company received net proceeds of $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20250101__20250131_zpBuO4rEE97h" title="Net proceeds from offering"&gt;3,145&lt;/span&gt;, and at March 31, 2025,
the Company had cash and cash equivalents totaling $&lt;span id="xdx_90F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20250331_zb8TldjEhKXe" title="Cash and cash equivalents"&gt;3,616&lt;/span&gt;&#160;and shareholders&#x2019; equity of $&lt;span id="xdx_905_eus-gaap--StockholdersEquity_iI_pn3n3_c20250331_zcd23idEH5P1" title="Shareholders' equity"&gt;7,132&lt;/span&gt;. The Company expects its
current cash reserves to fund the Company&#x2019;s operations for at least 12 months from the date of this filing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in
the future, which will primarily be accomplished by raising additional capital to meet its operating needs and repay its liabilities
arising from normal business operations when they come due. Since inception, the Company has funded its operations primarily through
equity and debt financings and it expects to continue to rely on these sources of capital in the future until it is able to generate
revenues.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No
assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to
the Company. Even if the Company is able to obtain additional financing, such financing may contain undue restrictions on our operations,
in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000370"
      unitRef="USD">-1262000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000372"
      unitRef="USD">-714000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2025-01-012025-01-31"
      decimals="-3"
      id="Fact000374"
      unitRef="USD">3145000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000376"
      unitRef="USD">3616000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000378"
      unitRef="USD">7132000</us-gaap:StockholdersEquity>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000380">&lt;p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zIAdKQ2HwWO1" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;NOTE 2 -
&lt;span id="xdx_826_zf0OtYmGdAJi"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zOkRiq0UKjP9" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_864_zYxatAsNGs2h"&gt;Basis of
Consolidation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The
accompanying condensed consolidated financial statements and accompanying notes have been prepared in accordance with accounting
principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). The accompanying condensed consolidated
financial statements include the accounts of the Company and its wholly owned subsidiary, Enviro Therapeutics, Inc.
(&#x201c;Enviro&#x201d;). All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--UseOfEstimates_zDiSjzzSHV3h" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zJyaYE3qESYe"&gt;Use of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The preparation of the financial statements in conformity
with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts
of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accruals for potential liabilities,
valuations of stock-based compensation, the realization of deferred tax assets, and impairment analysis and useful life for intangible
assets among others. Actual results could differ from these estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zhq94cFuVsZ8" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_z4sbsgETDg8a"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;Financial instruments, which potentially subject the
Company to concentration of credit risk, consist primarily of cash deposits. The Company maintains deposits in federally insured financial
institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due
to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses
on deposits since its inception.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQVxrqcLBLh7" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zC44RJl7CIr4"&gt;Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The Company considers all highly liquid investments
with original maturities of three months or less on the date of purchase to be cash equivalents. Cash equivalents consisted of money market
funds as of March 31, 2025. There were &lt;span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20241231_zdo5haAu0w6g" title="Cash equivalents"&gt;no&lt;/span&gt; cash equivalents as of December 31, 2024. As of March 31, 2025, the amount of cash equivalents
included in cash and cash equivalents totaled $&lt;span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20250331_zBdf2sxHleOj" title="Cash equivalents"&gt;3,504&lt;/span&gt;. The underlying securities in the money market funds held by the Company are all
government backed securities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zQYCNnpXR7eb" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zSDuiKUe9A82"&gt;Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The Company&#x2019;s intangible assets are stated at
fair value as of the date acquired, less accumulated amortization. Amortization is calculated based on the estimated useful lives of the
assets, which were determined to be &lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dc_c20250331_zTbXG9AR5Lll" title="Intangible assets useful life"&gt;five years&lt;/span&gt;, using the straight-line method. The intangible asset consists of a licensing agreement
that the Company acquired through its acquisition of Enviro during the year ended December 31, 2021, with an acquisition
cost of $&lt;span id="xdx_90D_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_pn3n3_c20211231__us-gaap--BusinessAcquisitionAxis__custom--EnviroThreapeuticsIncMember_zHpRYAmvGkFi" title="Acquisition cost"&gt;800&lt;/span&gt;. Amortization expense relating to the intangible asset during the three months ended March 31, 2025 and 2024 was $&lt;span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20250101__20250331_zunLGsSr22Q9" title="Amortization expenses"&gt;&lt;span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240101__20240331_zfqPWqgpJ6i9" title="Amortization expenses"&gt;40&lt;/span&gt;&lt;/span&gt;, respectively,
with an unamortized balance of $&lt;span id="xdx_90B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20250331_z4ulo3hNsNr7" title="Intangible assets unamortized balance"&gt;182&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20241231_zwUj3ulbgYVf" title="Intangible assets unamortized balance"&gt;222&lt;/span&gt; at March 31, 2025 and December 31, 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zdkZtWrXr199" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span id="xdx_862_zzgt8VHN0Ug7"&gt;Impairment of Long-Lived
Assets&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The Company applies the provisions of ASC Topic 360,
&lt;i&gt;Property, Plant, and Equipment&lt;/i&gt;, which addresses financial accounting and reporting for the impairment of long-lived assets. A long-lived
asset that is held and used should be tested for recoverability whenever events or changes in circumstances indicate that the carrying
amount of the asset group may not be recoverable. If the estimated undiscounted
future cash flows are less than the carrying value, an impairment determination is required. In that event, a loss is recognized based
on the amount by which the carrying amount exceeds the fair value of the long-lived assets. &lt;span id="xdx_90A_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pn3n3_do_c20250101__20250331_zmYqEVsxlK6b" title="Impairment of intangible assets"&gt;&lt;span id="xdx_90A_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pn3n3_do_c20240101__20240331_zuftzu83Acma" title="Impairment of intangible assets"&gt;No&lt;/span&gt;&lt;/span&gt; impairment was recorded relating to the
Company&#x2019;s intangible asset during the three months ended March 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zSNqSpNPsyxl" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_ztQC0cp5KIS8"&gt;Income (Loss) Per Share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;Basic loss per share is computed by dividing net loss
applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share
is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus
the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zEr8aWBQ0z0l" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;For the three months ended March 31, 2025 and 2024,
the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. The potentially
dilutive securities consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span id="xdx_8B0_zX66bhEgul26" style="display: none"&gt;SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250101__20250331_zTIhOkr4S1xl" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20240331_zWHWDvfZ4Qpl" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zJlzlViCK8J9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4,543,188&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zNxS3XyLOHVh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;113,599&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0422"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zhQVSBZIkIth" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,656,787&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zoYQPGs7Sij" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--DeferredChargesPolicyTextBlock_z1yrQvKC7rKh" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zzoCf4kSJiNe"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The
Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity
issuances as deferred offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs
are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be delayed or abandoned,
the deferred offering costs will be expensed immediately as a charge to operating expenses in the Statement of Operations. As of December
31, 2024, the Company incurred $&lt;span id="xdx_902_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--EquityLineOfCreditMember_zWXIMHUyHEk7"&gt;1,377
&lt;/span&gt;of deferred offering costs related to the Company&#x2019;s pending Equity Line of Credit (ELOC) offering. During the three months
ended March 31, 2025, the Company incurred $&lt;span id="xdx_90D_ecustom--DeferredOfferingAdditionalCosts_iI_pn3n3_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--EquityLineofCreditMember_zaTIoYRuDcW5" title="Deferred offering additional cost"&gt;328
&lt;/span&gt;of additional costs related to the ELOC, and as of March 31, 2025, total deferred offering costs were $&lt;span id="xdx_907_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--EquityLineofCreditMember_zK0Ol2liMitg"&gt;1,705&lt;/span&gt; related to the ELOC. The ELOC was declared effective on April 24, 2025, and the Company will amortize these costs as cost of capital as
the funds are raised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z36aILlhLgRj" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zjflgjo1cuYd"&gt;Fair Value Measurements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; text-indent: 0.2pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The Company determines the fair value of its assets
and liabilities based on the exchange price in U.S. dollars that would be received to sell an asset or paid to transfer a liability (an
exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of
unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable
and the last unobservable, to measure fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Level 1 &#x2014;&lt;/i&gt; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Level 2 &#x2014;&lt;/i&gt; Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Level 3 &#x2014;&lt;/i&gt; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The
carrying amounts of financial instruments such as cash, and accounts payable and accrued liabilities, approximate the related fair values
due to the short-term maturities of these instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;Cash equivalents consisted of money market funds at
March 31, 2025. Money market funds were valued by the Company using quoted prices in active markets for identical securities, which represent
a Level 1 measurement within the fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zs1TfzBwDLZ" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span id="xdx_868_z8xjIVgzQhaj"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;In November 2024, FASB issued ASU 2024-03 Income Statement&#x2014;Reporting
Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses. The guidance
in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information
about certain costs and expenses including purchases of inventory; employee compensation; and depreciation and amortization expense for
each caption on the income statement where such expenses are included. The update is effective for annual reporting periods beginning
after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments
may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial
statements. We are currently evaluating the provisions of this guidance and assessing the potential impact on our financial statement
disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;Other recent accounting pronouncements issued by the
FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange
Commission did not or are not believed by management to have a material impact on the Company&#x2019;s present or future consolidated financial
statements.&lt;/p&gt;

&lt;p id="xdx_859_zVmeNxeIMm97" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000382">&lt;p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zOkRiq0UKjP9" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_864_zYxatAsNGs2h"&gt;Basis of
Consolidation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The
accompanying condensed consolidated financial statements and accompanying notes have been prepared in accordance with accounting
principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). The accompanying condensed consolidated
financial statements include the accounts of the Company and its wholly owned subsidiary, Enviro Therapeutics, Inc.
(&#x201c;Enviro&#x201d;). All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2025-01-01to2025-03-31" id="Fact000384">&lt;p id="xdx_84E_eus-gaap--UseOfEstimates_zDiSjzzSHV3h" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zJyaYE3qESYe"&gt;Use of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The preparation of the financial statements in conformity
with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts
of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accruals for potential liabilities,
valuations of stock-based compensation, the realization of deferred tax assets, and impairment analysis and useful life for intangible
assets among others. Actual results could differ from these estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2025-01-01to2025-03-31" id="Fact000386">&lt;p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zhq94cFuVsZ8" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_z4sbsgETDg8a"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;Financial instruments, which potentially subject the
Company to concentration of credit risk, consist primarily of cash deposits. The Company maintains deposits in federally insured financial
institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due
to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses
on deposits since its inception.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000388">&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQVxrqcLBLh7" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zC44RJl7CIr4"&gt;Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The Company considers all highly liquid investments
with original maturities of three months or less on the date of purchase to be cash equivalents. Cash equivalents consisted of money market
funds as of March 31, 2025. There were &lt;span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20241231_zdo5haAu0w6g" title="Cash equivalents"&gt;no&lt;/span&gt; cash equivalents as of December 31, 2024. As of March 31, 2025, the amount of cash equivalents
included in cash and cash equivalents totaled $&lt;span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20250331_zBdf2sxHleOj" title="Cash equivalents"&gt;3,504&lt;/span&gt;. The underlying securities in the money market funds held by the Company are all
government backed securities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000390"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000392"
      unitRef="USD">3504</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="From2025-01-01to2025-03-31" id="Fact000394">&lt;p id="xdx_844_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zQYCNnpXR7eb" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zSDuiKUe9A82"&gt;Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The Company&#x2019;s intangible assets are stated at
fair value as of the date acquired, less accumulated amortization. Amortization is calculated based on the estimated useful lives of the
assets, which were determined to be &lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dc_c20250331_zTbXG9AR5Lll" title="Intangible assets useful life"&gt;five years&lt;/span&gt;, using the straight-line method. The intangible asset consists of a licensing agreement
that the Company acquired through its acquisition of Enviro during the year ended December 31, 2021, with an acquisition
cost of $&lt;span id="xdx_90D_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_pn3n3_c20211231__us-gaap--BusinessAcquisitionAxis__custom--EnviroThreapeuticsIncMember_zHpRYAmvGkFi" title="Acquisition cost"&gt;800&lt;/span&gt;. Amortization expense relating to the intangible asset during the three months ended March 31, 2025 and 2024 was $&lt;span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20250101__20250331_zunLGsSr22Q9" title="Amortization expenses"&gt;&lt;span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240101__20240331_zfqPWqgpJ6i9" title="Amortization expenses"&gt;40&lt;/span&gt;&lt;/span&gt;, respectively,
with an unamortized balance of $&lt;span id="xdx_90B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20250331_z4ulo3hNsNr7" title="Intangible assets unamortized balance"&gt;182&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20241231_zwUj3ulbgYVf" title="Intangible assets unamortized balance"&gt;222&lt;/span&gt; at March 31, 2025 and December 31, 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="AsOf2025-03-31" id="Fact000396">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="AsOf2021-12-31_custom_EnviroThreapeuticsIncMember"
      decimals="-3"
      id="Fact000398"
      unitRef="USD">800000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000400"
      unitRef="USD">40000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000402"
      unitRef="USD">40000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000404"
      unitRef="USD">182000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000406"
      unitRef="USD">222000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000408">&lt;p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zdkZtWrXr199" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span id="xdx_862_zzgt8VHN0Ug7"&gt;Impairment of Long-Lived
Assets&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The Company applies the provisions of ASC Topic 360,
&lt;i&gt;Property, Plant, and Equipment&lt;/i&gt;, which addresses financial accounting and reporting for the impairment of long-lived assets. A long-lived
asset that is held and used should be tested for recoverability whenever events or changes in circumstances indicate that the carrying
amount of the asset group may not be recoverable. If the estimated undiscounted
future cash flows are less than the carrying value, an impairment determination is required. In that event, a loss is recognized based
on the amount by which the carrying amount exceeds the fair value of the long-lived assets. &lt;span id="xdx_90A_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pn3n3_do_c20250101__20250331_zmYqEVsxlK6b" title="Impairment of intangible assets"&gt;&lt;span id="xdx_90A_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pn3n3_do_c20240101__20240331_zuftzu83Acma" title="Impairment of intangible assets"&gt;No&lt;/span&gt;&lt;/span&gt; impairment was recorded relating to the
Company&#x2019;s intangible asset during the three months ended March 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000410"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000412"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000414">&lt;p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zSNqSpNPsyxl" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_ztQC0cp5KIS8"&gt;Income (Loss) Per Share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;Basic loss per share is computed by dividing net loss
applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share
is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus
the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zEr8aWBQ0z0l" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;For the three months ended March 31, 2025 and 2024,
the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. The potentially
dilutive securities consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span id="xdx_8B0_zX66bhEgul26" style="display: none"&gt;SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250101__20250331_zTIhOkr4S1xl" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20240331_zWHWDvfZ4Qpl" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zJlzlViCK8J9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4,543,188&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zNxS3XyLOHVh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;113,599&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0422"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zhQVSBZIkIth" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,656,787&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zoYQPGs7Sij" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000416">&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zEr8aWBQ0z0l" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;For the three months ended March 31, 2025 and 2024,
the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. The potentially
dilutive securities consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span id="xdx_8B0_zX66bhEgul26" style="display: none"&gt;SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250101__20250331_zTIhOkr4S1xl" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20240331_zWHWDvfZ4Qpl" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zJlzlViCK8J9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4,543,188&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zNxS3XyLOHVh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;113,599&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0422"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zhQVSBZIkIth" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,656,787&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-03-31_custom_WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact000418"
      unitRef="Shares">4543188</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31_custom_WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact000419"
      unitRef="Shares">150000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000421"
      unitRef="Shares">113599</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact000424"
      unitRef="Shares">4656787</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact000425"
      unitRef="Shares">150000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000427">&lt;p id="xdx_845_eus-gaap--DeferredChargesPolicyTextBlock_z1yrQvKC7rKh" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zzoCf4kSJiNe"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The
Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity
issuances as deferred offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs
are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be delayed or abandoned,
the deferred offering costs will be expensed immediately as a charge to operating expenses in the Statement of Operations. As of December
31, 2024, the Company incurred $&lt;span id="xdx_902_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--EquityLineOfCreditMember_zWXIMHUyHEk7"&gt;1,377
&lt;/span&gt;of deferred offering costs related to the Company&#x2019;s pending Equity Line of Credit (ELOC) offering. During the three months
ended March 31, 2025, the Company incurred $&lt;span id="xdx_90D_ecustom--DeferredOfferingAdditionalCosts_iI_pn3n3_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--EquityLineofCreditMember_zaTIoYRuDcW5" title="Deferred offering additional cost"&gt;328
&lt;/span&gt;of additional costs related to the ELOC, and as of March 31, 2025, total deferred offering costs were $&lt;span id="xdx_907_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--EquityLineofCreditMember_zK0Ol2liMitg"&gt;1,705&lt;/span&gt; related to the ELOC. The ELOC was declared effective on April 24, 2025, and the Company will amortize these costs as cost of capital as
the funds are raised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2024-12-31_custom_EquityLineOfCreditMember"
      decimals="-3"
      id="Fact000428"
      unitRef="USD">1377000</us-gaap:DeferredOfferingCosts>
    <KAPA:DeferredOfferingAdditionalCosts
      contextRef="AsOf2025-03-31_custom_EquityLineOfCreditMember"
      decimals="-3"
      id="Fact000430"
      unitRef="USD">328000</KAPA:DeferredOfferingAdditionalCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2025-03-31_custom_EquityLineOfCreditMember"
      decimals="-3"
      id="Fact000431"
      unitRef="USD">1705000</us-gaap:DeferredOfferingCosts>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000433">&lt;p id="xdx_84B_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z36aILlhLgRj" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zjflgjo1cuYd"&gt;Fair Value Measurements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; text-indent: 0.2pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The Company determines the fair value of its assets
and liabilities based on the exchange price in U.S. dollars that would be received to sell an asset or paid to transfer a liability (an
exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of
unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable
and the last unobservable, to measure fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Level 1 &#x2014;&lt;/i&gt; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Level 2 &#x2014;&lt;/i&gt; Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Level 3 &#x2014;&lt;/i&gt; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The
carrying amounts of financial instruments such as cash, and accounts payable and accrued liabilities, approximate the related fair values
due to the short-term maturities of these instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;Cash equivalents consisted of money market funds at
March 31, 2025. Money market funds were valued by the Company using quoted prices in active markets for identical securities, which represent
a Level 1 measurement within the fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000435">&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zs1TfzBwDLZ" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span id="xdx_868_z8xjIVgzQhaj"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;In November 2024, FASB issued ASU 2024-03 Income Statement&#x2014;Reporting
Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses. The guidance
in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information
about certain costs and expenses including purchases of inventory; employee compensation; and depreciation and amortization expense for
each caption on the income statement where such expenses are included. The update is effective for annual reporting periods beginning
after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments
may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial
statements. We are currently evaluating the provisions of this guidance and assessing the potential impact on our financial statement
disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;Other recent accounting pronouncements issued by the
FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange
Commission did not or are not believed by management to have a material impact on the Company&#x2019;s present or future consolidated financial
statements.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <KAPA:DisclosureOfVendorAgreementsTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000437">&lt;p id="xdx_807_ecustom--DisclosureOfVendorAgreementsTextBlock_zQJpXCyjjeek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 &#x2013; &lt;span id="xdx_821_zT9jWaEcGprl"&gt;VENDOR AGREEMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--VendorAdvancesPolicyTextBlock_zOtuPccDdpK8" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_z3UKkIMW4u24"&gt;Vendor Advances&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The
Company has entered into various contracts with service providers pursuant to which the Company pays the vendor an advance at the
beginning of the contractual period. These vendor advances could be paid by the Company either in cash or in shares of common stock,
depending on the terms of the contract. The advances are reduced by the accumulated value of the services performed by the vendor or
are amortized on a straight-line basis over the service period, whichever is shorter. As of December 31, 2024, advances to vendors
totaled $&lt;span id="xdx_90C_eus-gaap--CustomerAdvancesAndDeposits_iI_pn3n3_c20241231_zugSftaZDSWc" title="Advances to vendor amount"&gt;3,115&lt;/span&gt;, with $&lt;span id="xdx_90C_ecustom--VendorAdvancesInCash_iNI_pn3n3_di_c20241231_zNSTeIrdLhXb" title="Vendor advances in cash"&gt;2,615&lt;/span&gt; being paid in cash and $&lt;span id="xdx_902_ecustom--IssuanceOfCommonSharesPaidForVendorsAdvances_pn3n3_c20240101__20241231_zswPgID777F7" title="Issuance of common shares paid for vendors advances"&gt;500&lt;/span&gt; being paid with shares of the Company&#x2019;s common stock (see Note 4).
Amortization expense relating to the vendor advances during the year ended December 31, 2024 was $&lt;span id="xdx_901_ecustom--AmortizationExpenseVendorAdvances_pn3n3_c20240101__20241231_zG0xS9taYI12" title="Amortization expense relating to vendor advances"&gt;256&lt;/span&gt;, with an unamortized balance
of $&lt;span id="xdx_900_ecustom--VendorAdvancesCurrent_iI_pn3n3_c20241231_zNdSyV9ug8A7" title="Vendor advances"&gt;2,859&lt;/span&gt; as of December 31, 2024. During the three months ended March 31, 2025, additional advances to vendors totaled $&lt;span id="xdx_905_ecustom--IssuanceOfCommonSharesPaidForVendorsAdvances_pn3n3_c20250101__20250331_zGHRqulU2S7e" title="Issuance of common shares paid for vendors advances"&gt;156&lt;/span&gt;, with
the advance being paid with shares of the Company&#x2019;s common stock (see Notes 3 and 4). Amortization expense relating to the
vendor advances was $&lt;span id="xdx_90A_ecustom--AmortizationExpenseVendorAdvances_pn3n3_c20250101__20250331_zUHuliREq3Tl" title="Amortization expense relating to vendor advances"&gt;636&lt;/span&gt;, with an unamortized balance of $&lt;span id="xdx_903_ecustom--VendorAdvancesCurrent_iI_pn3n3_c20250331_znuraBHHDmT4" title="Vendor advances"&gt;2,379&lt;/span&gt; as of March 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_ecustom--ScheduleOfVendorAdvancesTableTextBlock_zBHJpnMELoPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vendor
advances consisted of the following at March 31, 2025, and December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zPEy2vznLef8" style="display: none"&gt;SCHEDULE
OF VENDOR ADVANCES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250331_zMBMKTy3m0M7" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_zWgJyV0SPHV3" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--PrevailInfoworksIncMember_zYsH4hFTQDu" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F4F_zIlElyXVuLjf" style="width: 64%; text-align: justify; text-indent: -12pt; padding-left: 12pt"&gt;Prevail Infoworks (a)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;900&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;900&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zu0l7EtIN1j4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F42_z2mPBU0QOL15" style="text-align: justify; text-indent: -12pt; padding-left: 12pt"&gt;PreCheck Health Services (b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zEW5CuxIuXF3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F45_z27GEf7cW9mh" style="text-align: justify; text-indent: -12pt; padding-left: 12pt"&gt;CEO.CA Technologies (c)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zaYjFvFN5kvk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F48_zhHNaFSHYl53" style="text-align: justify; text-indent: -12pt; padding-left: 12pt"&gt;Belair Capital Advisors (d)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--CrossCurrentCapitalLLCMember_z9WNeQNhcHRf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F46_zp8WQRJ4lTFf" style="text-align: justify; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt"&gt;Cross Current Capital (e)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;856&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;700&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--VendorAdvancesGross_iI_maVANzSvy_zniJYtW0OSve" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vendor advances, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,271&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,115&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--VendorAdvancesAccumulatedAmortization_iNI_di_msVANzSvy_zjnKmRDVplX8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(892&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(256&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--VendorAdvancesNet_iTI_mtVANzSvy_zmvZB94q6Je4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify; text-indent: -12pt; padding-left: 12pt"&gt;Vendor advances, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,379&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,859&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;(a)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Kairos
                                            Agreement with Prevail Infoworks, Inc.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 1, 2024, the Company entered into a master service and technology agreement with Prevail Infoworks, Inc. (&#x201c;Prevail&#x201d;),
pursuant to which Prevail agreed to provide certain clinical research services to the Company. As part of the agreement, the Company
was required to make an advance payment of $&lt;span id="xdx_905_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_zprPoAiaebDh" title="Advance payment"&gt;900&lt;/span&gt; to Prevail before commencement of services and, at such time as we notify Prevail to
engage their services related to the relevant clinical trial, or six months from the date of the agreement, pay approximately $&lt;span id="xdx_90A_ecustom--MonthlyPayment_pn3n3_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_z5ccsCCqpfnh" title="Monthly payment"&gt;80&lt;/span&gt; per
month during the time Prevail performs clinical research services for the Company&#x2019;s Phase 2 ENV 105 prostate and Phase 1 ENV 105
lung clinical trials. The agreement with Prevail is subject to cancellation at any time upon 30 days&#x2019; written notice to the other
party. The Company made the advance payment to Prevail in October 2024 and it is included in vendor advances on the accompanying balance
sheet as of March 31, 2025 and December 31, 2024 (see Note 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;(b)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Kairos
                                            Agreement with PreCheck Health Services, Inc.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 20, 2024, the Company entered into a bioassay services agreement (the &#x201c;Bioassay Services Agreement&#x201d;) with PreCheck
Health Services, Inc., a Florida-based corporation (&#x201c;PreCheck&#x201d;). Pursuant to the Bioassay Services Agreement, PreCheck will
provide certain biomarker screening services for the Company&#x2019;s ongoing carotuximab (ENV105) clinical trials in order to assist
the Company in identifying lung and prostate cancer patients suitable to the Company&#x2019;s ongoing Phase 1 clinical trials for lung
cancer patients and Phase 2 clinical trials for patients with castrate resistant prostate cancer. In exchange for PreCheck&#x2019;s services,
and according to the terms of the Bioassay Services Agreement, the Company paid $&lt;span id="xdx_904_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240920__20240920__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zduXccqjwVB3" title="Payments for services"&gt;900&lt;/span&gt; to PreCheck as an advance for the future laboratory
services to be performed. The payment of $&lt;span id="xdx_90D_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zwLbkpGeqLZc" title="Payments for vendor advance"&gt;&lt;span id="xdx_90F_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zjW07xt7c818" title="Payments for vendor advance"&gt;900&lt;/span&gt;&lt;/span&gt; is included in vendor advances on the accompanying balance sheet as of March 31, 2025 and
December 31, 2024 (see Note 2). The term of the agreement is one year from the effective date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;(c)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Kairos
                                            Agreement with CEO.CA Technologies Ltd.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 23, 2024, the Company entered into an advisory and consulting services agreement (the &#x201c;CEO.CA Agreement&#x201d;) with
CEO.CA Technologies Ltd., a Canadian company (&#x201c;CEO.CA&#x201d;), pursuant to which CEO.CA will provide certain internet-based financial
information and communications services for a period of one year for a services fee of $&lt;span id="xdx_90B_eus-gaap--ManagementFeeExpense_pn3n3_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zdwOjkCdY2mk" title="Service fee"&gt;250&lt;/span&gt;. The service fee is an advance on future
services to be performed. The CEO.CA Agreement includes such services as strategic news placement, news releases, interviews, monthly
analytics and a video launch. The CEO.CA Agreement contains other customary clauses, including representations and warranties, indemnification
clauses and governing law clauses. The payment of $&lt;span id="xdx_907_eus-gaap--ManagementFeeExpense_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zCcYQ0z44iD2" title="Service fee"&gt;&lt;span id="xdx_90E_eus-gaap--ManagementFeeExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zQ4vCZ1jJsAd" title="Service fee"&gt;250&lt;/span&gt;&lt;/span&gt; is included in vendor advances on the accompanying balance sheet as of March 31,
2025, and December 31, 2024 (see Note 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;(d)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Kairos
                                            Agreement with Belair Capital Advisors Inc.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 23, 2024, the Company entered into a strategic advisory agreement (the &#x201c;Strategic Advisory Agreement&#x201d;) with Belair
Capital Advisors Inc. (&#x201c;BCA&#x201d;). BCA, a venture capital and corporate finance advisory firm, has been a long-term investor
and advisor to the Company and frequently works with early-stage pharmaceutical companies. The strategic advisory services provided by
BCA consist of corporate strategy, market positioning and long-term growth plans within the pharmaceutical sector, digital marketing
and engagement, market research analysis and business development assistance, among other things. During the one-year term of the Strategic
Advisory Agreement, in exchange for its services, the Company will pay BCA a $&lt;span id="xdx_90B_eus-gaap--ManagementFeeExpense_pn3n3_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zWK09mzIVjcf" title="Service fee"&gt;365&lt;/span&gt; fee and will issue BCA &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zH4wUeKY4gce" title="Number of shares issued"&gt;50,000&lt;/span&gt; RSUs, which will vest
at the end of six months following the date of issuance. The payment of $&lt;span id="xdx_904_eus-gaap--ManagementFeeExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_z5u2qaE8GJ13" title="Service fee"&gt;&lt;span id="xdx_90E_eus-gaap--ManagementFeeExpense_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zqWNwT1AmMp2" title="Service fee"&gt;365&lt;/span&gt;&lt;/span&gt; is included in vendor advances on the accompanying balance
sheet as of March 31, 2025, and December 31, 2024 (see Note 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;(e)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Kairos
                                            Agreement with Cross Current Capital LLC&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 1, 2024, the Company entered into a consulting agreement (the &#x201c;Consulting Agreement&#x201d;) with Cross Current Capital
LLC, a limited liability company organized under the laws of Puerto Rico (&#x201c;Cross Current&#x201d;), and Alan Masley (the &#x201c;Advisor&#x201d;),
pursuant to which Cross Current agreed to provide certain financial and business consulting services to the Company including, but not
limited, to (a) help drafting a public company competitive overview, (b) help preparing and/or reviewing a valuation analysis, (c) help
in drafting marketing materials and presentations, (d) reviewing the Company&#x2019;s business requirements and discuss financing and
businesses opportunities, (e) investor marketing, (f) investor relations introductions, (g) legal counsel introductions, (h) auditor
introductions, (i) investment banking and research introductions, (j) M&amp;amp;A canvassing and ways to grow the business organically, and
(k) stand by capital markets advisory services. For the services rendered thereunder, the Company agreed to pay Cross Current $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zs967aIjw35a" title="Number of shares issued, value"&gt;200,000&lt;/span&gt;
in cash and agreed to issue to the Advisor $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zg32SQq41PFa" title="Number of shares issued, value"&gt;500&lt;/span&gt; of restricted shares of the Company&#x2019;s common stock under the Company&#x2019;s 2023
Plan , calculated at &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zwdhN9xZw456" title="Number of shares issued"&gt;367,647&lt;/span&gt; shares (the &#x201c;Shares&#x201d;) as of the date of the agreement. The term of the Consulting Agreement
is 24 months and can be extended for another 12 months with the written consent of both parties. The Company made the $&lt;span id="xdx_900_ecustom--SettlementAgreementAmount_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z06niaGMIAY" title="Settlement agreement amount"&gt;200&lt;/span&gt; payment in
October 2024. The payment of $&lt;span id="xdx_903_ecustom--VendorPaymentAdvances_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zuE1Up2Yf3Oc" title="Vendor payment advances"&gt;200&lt;/span&gt; and the value of the shares issued of $&lt;span id="xdx_90B_eus-gaap--AdditionalCollateralAggregateFairValue_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z6yCdjjdyhR4" title="Aggregate fair value of the common stock"&gt;&lt;span id="xdx_904_eus-gaap--AdditionalCollateralAggregateFairValue_iI_pn3n3_c20250331__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zdHaZRYlUKB9" title="Aggregate fair value of the common stock"&gt;500&lt;/span&gt;&lt;/span&gt; are included in vendor advances on the accompanying balance
sheet as of March 31, 2025, and December 31, 2024 (see Note 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTfiiSp4Yj82" title="Stock issued shares"&gt;367,647&lt;/span&gt; shares issued in 2024 were subject to a &#x201c;true up&#x201d; on April 1, 2025, at which time additional shares will be issued
to the Advisor (or returned by the Advisor to the Company) in order to ensure the shares are valued at $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIZpvH8zT7f" title="Number of shares issued, value"&gt;500&lt;/span&gt; as of April 1, 2025. On April
1, 2025, the Company issued an additional&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z30ZJg7BXA84" title="Number of shares issued"&gt;166,541&lt;/span&gt; shares of its common stock to the Advisor. The fair value of the additional shares on
the date of grant was $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgBbAS3MRlag" title="Number of shares issued, value"&gt;156&lt;/span&gt;. The Company recorded the shares as common stock to be issued as of March 31, 2025, and recorded the fair
value of the shares as a vendor advance as of the same date (see Notes 2 and 4).&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A1_zKXzBpgYIBPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Agreement
with Helena Global Investment Opportunities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 12, 2024, the Company entered into an agreement with Helena Global Investment Opportunities I LTD (&#x201c;Helena&#x201d;) pursuant
to which the Company will have the right to issue and sell to Helena, from time to time, and Helena shall purchase from the Company,
up to $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20241112__20241112__us-gaap--TypeOfArrangementAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember_zX8ZODczRail" title="Number of shares issued, value"&gt;30,000&lt;/span&gt; of the Company&#x2019;s shares of common stock (the &#x201c;Equity Line of Credit&#x201d;). The Equity Line of Credit will
become available to the Company at such time as it files a registration statement on Form S-1 registering the shares issuable under the
Equity Line of Credit. In exchange for the Equity Line of Credit, the Company is obligated to issue Helena a certain number of shares
of common stock, calculated using $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20241112__20241112_zOkFyaO9FIBl" title="Number of shares issued, value"&gt;900&lt;/span&gt; divided by the lowest one-day VWAP during the five trading days prior to entry into the agreement.
As a result, the Company issued Helena &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241112__20241112__us-gaap--TypeOfArrangementAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember_zoIsXhxdEUKl" title="Number of shares issued"&gt;670,641&lt;/span&gt; shares of its common stock valued at $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueOther_pn3n3_c20241112__20241112__us-gaap--TypeOfArrangementAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember_zENKFjeTkvdl" title="Stock issued  value"&gt;1,377&lt;/span&gt; on the date of issuance. The Company accounted
for the value of the shares issued as deferred offering costs (see Note 2). The shares vested on the date of the agreement, were issued
to Helena, and are subject to a &#x201c;true up&#x201d; based upon the value of the stock at the time the company files and obtains effectiveness
of a registration statement registering the shares for resale. In addition, the Company agreed to register such shares for resale pursuant
to a registration statement on Form S-1.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 24, 2025, the Company issued another &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250424__20250424__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkWtQCztnWb7" title="Number of shares issued"&gt;384,459&lt;/span&gt; shares of its common stock to Helena. The fair value of the shares on the date of
grant was $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250424__20250424__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9lasvQbcC87" title="Number of shares issued, value"&gt;328&lt;/span&gt;. The Company recorded the shares as common stock to be issued as of March 31, 2025, and recorded the fair value of the
shares as deferred offering costs as of the same date (see Notes 2 and 4).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</KAPA:DisclosureOfVendorAgreementsTextBlock>
    <KAPA:VendorAdvancesPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000439">&lt;p id="xdx_84A_ecustom--VendorAdvancesPolicyTextBlock_zOtuPccDdpK8" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_z3UKkIMW4u24"&gt;Vendor Advances&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The
Company has entered into various contracts with service providers pursuant to which the Company pays the vendor an advance at the
beginning of the contractual period. These vendor advances could be paid by the Company either in cash or in shares of common stock,
depending on the terms of the contract. The advances are reduced by the accumulated value of the services performed by the vendor or
are amortized on a straight-line basis over the service period, whichever is shorter. As of December 31, 2024, advances to vendors
totaled $&lt;span id="xdx_90C_eus-gaap--CustomerAdvancesAndDeposits_iI_pn3n3_c20241231_zugSftaZDSWc" title="Advances to vendor amount"&gt;3,115&lt;/span&gt;, with $&lt;span id="xdx_90C_ecustom--VendorAdvancesInCash_iNI_pn3n3_di_c20241231_zNSTeIrdLhXb" title="Vendor advances in cash"&gt;2,615&lt;/span&gt; being paid in cash and $&lt;span id="xdx_902_ecustom--IssuanceOfCommonSharesPaidForVendorsAdvances_pn3n3_c20240101__20241231_zswPgID777F7" title="Issuance of common shares paid for vendors advances"&gt;500&lt;/span&gt; being paid with shares of the Company&#x2019;s common stock (see Note 4).
Amortization expense relating to the vendor advances during the year ended December 31, 2024 was $&lt;span id="xdx_901_ecustom--AmortizationExpenseVendorAdvances_pn3n3_c20240101__20241231_zG0xS9taYI12" title="Amortization expense relating to vendor advances"&gt;256&lt;/span&gt;, with an unamortized balance
of $&lt;span id="xdx_900_ecustom--VendorAdvancesCurrent_iI_pn3n3_c20241231_zNdSyV9ug8A7" title="Vendor advances"&gt;2,859&lt;/span&gt; as of December 31, 2024. During the three months ended March 31, 2025, additional advances to vendors totaled $&lt;span id="xdx_905_ecustom--IssuanceOfCommonSharesPaidForVendorsAdvances_pn3n3_c20250101__20250331_zGHRqulU2S7e" title="Issuance of common shares paid for vendors advances"&gt;156&lt;/span&gt;, with
the advance being paid with shares of the Company&#x2019;s common stock (see Notes 3 and 4). Amortization expense relating to the
vendor advances was $&lt;span id="xdx_90A_ecustom--AmortizationExpenseVendorAdvances_pn3n3_c20250101__20250331_zUHuliREq3Tl" title="Amortization expense relating to vendor advances"&gt;636&lt;/span&gt;, with an unamortized balance of $&lt;span id="xdx_903_ecustom--VendorAdvancesCurrent_iI_pn3n3_c20250331_znuraBHHDmT4" title="Vendor advances"&gt;2,379&lt;/span&gt; as of March 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_ecustom--ScheduleOfVendorAdvancesTableTextBlock_zBHJpnMELoPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vendor
advances consisted of the following at March 31, 2025, and December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zPEy2vznLef8" style="display: none"&gt;SCHEDULE
OF VENDOR ADVANCES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250331_zMBMKTy3m0M7" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_zWgJyV0SPHV3" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--PrevailInfoworksIncMember_zYsH4hFTQDu" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F4F_zIlElyXVuLjf" style="width: 64%; text-align: justify; text-indent: -12pt; padding-left: 12pt"&gt;Prevail Infoworks (a)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;900&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;900&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zu0l7EtIN1j4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F42_z2mPBU0QOL15" style="text-align: justify; text-indent: -12pt; padding-left: 12pt"&gt;PreCheck Health Services (b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zEW5CuxIuXF3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F45_z27GEf7cW9mh" style="text-align: justify; text-indent: -12pt; padding-left: 12pt"&gt;CEO.CA Technologies (c)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zaYjFvFN5kvk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F48_zhHNaFSHYl53" style="text-align: justify; text-indent: -12pt; padding-left: 12pt"&gt;Belair Capital Advisors (d)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--CrossCurrentCapitalLLCMember_z9WNeQNhcHRf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F46_zp8WQRJ4lTFf" style="text-align: justify; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt"&gt;Cross Current Capital (e)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;856&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;700&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--VendorAdvancesGross_iI_maVANzSvy_zniJYtW0OSve" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vendor advances, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,271&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,115&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--VendorAdvancesAccumulatedAmortization_iNI_di_msVANzSvy_zjnKmRDVplX8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(892&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(256&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--VendorAdvancesNet_iTI_mtVANzSvy_zmvZB94q6Je4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify; text-indent: -12pt; padding-left: 12pt"&gt;Vendor advances, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,379&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,859&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;(a)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Kairos
                                            Agreement with Prevail Infoworks, Inc.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 1, 2024, the Company entered into a master service and technology agreement with Prevail Infoworks, Inc. (&#x201c;Prevail&#x201d;),
pursuant to which Prevail agreed to provide certain clinical research services to the Company. As part of the agreement, the Company
was required to make an advance payment of $&lt;span id="xdx_905_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_zprPoAiaebDh" title="Advance payment"&gt;900&lt;/span&gt; to Prevail before commencement of services and, at such time as we notify Prevail to
engage their services related to the relevant clinical trial, or six months from the date of the agreement, pay approximately $&lt;span id="xdx_90A_ecustom--MonthlyPayment_pn3n3_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_z5ccsCCqpfnh" title="Monthly payment"&gt;80&lt;/span&gt; per
month during the time Prevail performs clinical research services for the Company&#x2019;s Phase 2 ENV 105 prostate and Phase 1 ENV 105
lung clinical trials. The agreement with Prevail is subject to cancellation at any time upon 30 days&#x2019; written notice to the other
party. The Company made the advance payment to Prevail in October 2024 and it is included in vendor advances on the accompanying balance
sheet as of March 31, 2025 and December 31, 2024 (see Note 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;(b)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Kairos
                                            Agreement with PreCheck Health Services, Inc.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 20, 2024, the Company entered into a bioassay services agreement (the &#x201c;Bioassay Services Agreement&#x201d;) with PreCheck
Health Services, Inc., a Florida-based corporation (&#x201c;PreCheck&#x201d;). Pursuant to the Bioassay Services Agreement, PreCheck will
provide certain biomarker screening services for the Company&#x2019;s ongoing carotuximab (ENV105) clinical trials in order to assist
the Company in identifying lung and prostate cancer patients suitable to the Company&#x2019;s ongoing Phase 1 clinical trials for lung
cancer patients and Phase 2 clinical trials for patients with castrate resistant prostate cancer. In exchange for PreCheck&#x2019;s services,
and according to the terms of the Bioassay Services Agreement, the Company paid $&lt;span id="xdx_904_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240920__20240920__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zduXccqjwVB3" title="Payments for services"&gt;900&lt;/span&gt; to PreCheck as an advance for the future laboratory
services to be performed. The payment of $&lt;span id="xdx_90D_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zwLbkpGeqLZc" title="Payments for vendor advance"&gt;&lt;span id="xdx_90F_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zjW07xt7c818" title="Payments for vendor advance"&gt;900&lt;/span&gt;&lt;/span&gt; is included in vendor advances on the accompanying balance sheet as of March 31, 2025 and
December 31, 2024 (see Note 2). The term of the agreement is one year from the effective date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;(c)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Kairos
                                            Agreement with CEO.CA Technologies Ltd.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 23, 2024, the Company entered into an advisory and consulting services agreement (the &#x201c;CEO.CA Agreement&#x201d;) with
CEO.CA Technologies Ltd., a Canadian company (&#x201c;CEO.CA&#x201d;), pursuant to which CEO.CA will provide certain internet-based financial
information and communications services for a period of one year for a services fee of $&lt;span id="xdx_90B_eus-gaap--ManagementFeeExpense_pn3n3_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zdwOjkCdY2mk" title="Service fee"&gt;250&lt;/span&gt;. The service fee is an advance on future
services to be performed. The CEO.CA Agreement includes such services as strategic news placement, news releases, interviews, monthly
analytics and a video launch. The CEO.CA Agreement contains other customary clauses, including representations and warranties, indemnification
clauses and governing law clauses. The payment of $&lt;span id="xdx_907_eus-gaap--ManagementFeeExpense_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zCcYQ0z44iD2" title="Service fee"&gt;&lt;span id="xdx_90E_eus-gaap--ManagementFeeExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zQ4vCZ1jJsAd" title="Service fee"&gt;250&lt;/span&gt;&lt;/span&gt; is included in vendor advances on the accompanying balance sheet as of March 31,
2025, and December 31, 2024 (see Note 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;(d)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Kairos
                                            Agreement with Belair Capital Advisors Inc.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 23, 2024, the Company entered into a strategic advisory agreement (the &#x201c;Strategic Advisory Agreement&#x201d;) with Belair
Capital Advisors Inc. (&#x201c;BCA&#x201d;). BCA, a venture capital and corporate finance advisory firm, has been a long-term investor
and advisor to the Company and frequently works with early-stage pharmaceutical companies. The strategic advisory services provided by
BCA consist of corporate strategy, market positioning and long-term growth plans within the pharmaceutical sector, digital marketing
and engagement, market research analysis and business development assistance, among other things. During the one-year term of the Strategic
Advisory Agreement, in exchange for its services, the Company will pay BCA a $&lt;span id="xdx_90B_eus-gaap--ManagementFeeExpense_pn3n3_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zWK09mzIVjcf" title="Service fee"&gt;365&lt;/span&gt; fee and will issue BCA &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zH4wUeKY4gce" title="Number of shares issued"&gt;50,000&lt;/span&gt; RSUs, which will vest
at the end of six months following the date of issuance. The payment of $&lt;span id="xdx_904_eus-gaap--ManagementFeeExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_z5u2qaE8GJ13" title="Service fee"&gt;&lt;span id="xdx_90E_eus-gaap--ManagementFeeExpense_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zqWNwT1AmMp2" title="Service fee"&gt;365&lt;/span&gt;&lt;/span&gt; is included in vendor advances on the accompanying balance
sheet as of March 31, 2025, and December 31, 2024 (see Note 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;(e)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Kairos
                                            Agreement with Cross Current Capital LLC&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 1, 2024, the Company entered into a consulting agreement (the &#x201c;Consulting Agreement&#x201d;) with Cross Current Capital
LLC, a limited liability company organized under the laws of Puerto Rico (&#x201c;Cross Current&#x201d;), and Alan Masley (the &#x201c;Advisor&#x201d;),
pursuant to which Cross Current agreed to provide certain financial and business consulting services to the Company including, but not
limited, to (a) help drafting a public company competitive overview, (b) help preparing and/or reviewing a valuation analysis, (c) help
in drafting marketing materials and presentations, (d) reviewing the Company&#x2019;s business requirements and discuss financing and
businesses opportunities, (e) investor marketing, (f) investor relations introductions, (g) legal counsel introductions, (h) auditor
introductions, (i) investment banking and research introductions, (j) M&amp;amp;A canvassing and ways to grow the business organically, and
(k) stand by capital markets advisory services. For the services rendered thereunder, the Company agreed to pay Cross Current $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zs967aIjw35a" title="Number of shares issued, value"&gt;200,000&lt;/span&gt;
in cash and agreed to issue to the Advisor $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zg32SQq41PFa" title="Number of shares issued, value"&gt;500&lt;/span&gt; of restricted shares of the Company&#x2019;s common stock under the Company&#x2019;s 2023
Plan , calculated at &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zwdhN9xZw456" title="Number of shares issued"&gt;367,647&lt;/span&gt; shares (the &#x201c;Shares&#x201d;) as of the date of the agreement. The term of the Consulting Agreement
is 24 months and can be extended for another 12 months with the written consent of both parties. The Company made the $&lt;span id="xdx_900_ecustom--SettlementAgreementAmount_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z06niaGMIAY" title="Settlement agreement amount"&gt;200&lt;/span&gt; payment in
October 2024. The payment of $&lt;span id="xdx_903_ecustom--VendorPaymentAdvances_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zuE1Up2Yf3Oc" title="Vendor payment advances"&gt;200&lt;/span&gt; and the value of the shares issued of $&lt;span id="xdx_90B_eus-gaap--AdditionalCollateralAggregateFairValue_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z6yCdjjdyhR4" title="Aggregate fair value of the common stock"&gt;&lt;span id="xdx_904_eus-gaap--AdditionalCollateralAggregateFairValue_iI_pn3n3_c20250331__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zdHaZRYlUKB9" title="Aggregate fair value of the common stock"&gt;500&lt;/span&gt;&lt;/span&gt; are included in vendor advances on the accompanying balance
sheet as of March 31, 2025, and December 31, 2024 (see Note 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTfiiSp4Yj82" title="Stock issued shares"&gt;367,647&lt;/span&gt; shares issued in 2024 were subject to a &#x201c;true up&#x201d; on April 1, 2025, at which time additional shares will be issued
to the Advisor (or returned by the Advisor to the Company) in order to ensure the shares are valued at $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIZpvH8zT7f" title="Number of shares issued, value"&gt;500&lt;/span&gt; as of April 1, 2025. On April
1, 2025, the Company issued an additional&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z30ZJg7BXA84" title="Number of shares issued"&gt;166,541&lt;/span&gt; shares of its common stock to the Advisor. The fair value of the additional shares on
the date of grant was $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgBbAS3MRlag" title="Number of shares issued, value"&gt;156&lt;/span&gt;. The Company recorded the shares as common stock to be issued as of March 31, 2025, and recorded the fair
value of the shares as a vendor advance as of the same date (see Notes 2 and 4).&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A1_zKXzBpgYIBPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Agreement
with Helena Global Investment Opportunities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 12, 2024, the Company entered into an agreement with Helena Global Investment Opportunities I LTD (&#x201c;Helena&#x201d;) pursuant
to which the Company will have the right to issue and sell to Helena, from time to time, and Helena shall purchase from the Company,
up to $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20241112__20241112__us-gaap--TypeOfArrangementAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember_zX8ZODczRail" title="Number of shares issued, value"&gt;30,000&lt;/span&gt; of the Company&#x2019;s shares of common stock (the &#x201c;Equity Line of Credit&#x201d;). The Equity Line of Credit will
become available to the Company at such time as it files a registration statement on Form S-1 registering the shares issuable under the
Equity Line of Credit. In exchange for the Equity Line of Credit, the Company is obligated to issue Helena a certain number of shares
of common stock, calculated using $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20241112__20241112_zOkFyaO9FIBl" title="Number of shares issued, value"&gt;900&lt;/span&gt; divided by the lowest one-day VWAP during the five trading days prior to entry into the agreement.
As a result, the Company issued Helena &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241112__20241112__us-gaap--TypeOfArrangementAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember_zoIsXhxdEUKl" title="Number of shares issued"&gt;670,641&lt;/span&gt; shares of its common stock valued at $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueOther_pn3n3_c20241112__20241112__us-gaap--TypeOfArrangementAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember_zENKFjeTkvdl" title="Stock issued  value"&gt;1,377&lt;/span&gt; on the date of issuance. The Company accounted
for the value of the shares issued as deferred offering costs (see Note 2). The shares vested on the date of the agreement, were issued
to Helena, and are subject to a &#x201c;true up&#x201d; based upon the value of the stock at the time the company files and obtains effectiveness
of a registration statement registering the shares for resale. In addition, the Company agreed to register such shares for resale pursuant
to a registration statement on Form S-1.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 24, 2025, the Company issued another &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250424__20250424__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkWtQCztnWb7" title="Number of shares issued"&gt;384,459&lt;/span&gt; shares of its common stock to Helena. The fair value of the shares on the date of
grant was $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250424__20250424__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9lasvQbcC87" title="Number of shares issued, value"&gt;328&lt;/span&gt;. The Company recorded the shares as common stock to be issued as of March 31, 2025, and recorded the fair value of the
shares as deferred offering costs as of the same date (see Notes 2 and 4).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</KAPA:VendorAdvancesPolicyTextBlock>
    <us-gaap:CustomerAdvancesAndDeposits
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000441"
      unitRef="USD">3115000</us-gaap:CustomerAdvancesAndDeposits>
    <KAPA:VendorAdvancesInCash
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000443"
      unitRef="USD">-2615000</KAPA:VendorAdvancesInCash>
    <KAPA:IssuanceOfCommonSharesPaidForVendorsAdvances
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000445"
      unitRef="USD">500000</KAPA:IssuanceOfCommonSharesPaidForVendorsAdvances>
    <KAPA:AmortizationExpenseVendorAdvances
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000447"
      unitRef="USD">256000</KAPA:AmortizationExpenseVendorAdvances>
    <KAPA:VendorAdvancesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000449"
      unitRef="USD">2859000</KAPA:VendorAdvancesCurrent>
    <KAPA:IssuanceOfCommonSharesPaidForVendorsAdvances
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000451"
      unitRef="USD">156000</KAPA:IssuanceOfCommonSharesPaidForVendorsAdvances>
    <KAPA:AmortizationExpenseVendorAdvances
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000453"
      unitRef="USD">636000</KAPA:AmortizationExpenseVendorAdvances>
    <KAPA:VendorAdvancesCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000455"
      unitRef="USD">2379000</KAPA:VendorAdvancesCurrent>
    <KAPA:ScheduleOfVendorAdvancesTableTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000457">&lt;p id="xdx_897_ecustom--ScheduleOfVendorAdvancesTableTextBlock_zBHJpnMELoPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vendor
advances consisted of the following at March 31, 2025, and December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zPEy2vznLef8" style="display: none"&gt;SCHEDULE
OF VENDOR ADVANCES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250331_zMBMKTy3m0M7" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_zWgJyV0SPHV3" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--PrevailInfoworksIncMember_zYsH4hFTQDu" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F4F_zIlElyXVuLjf" style="width: 64%; text-align: justify; text-indent: -12pt; padding-left: 12pt"&gt;Prevail Infoworks (a)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;900&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;900&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zu0l7EtIN1j4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F42_z2mPBU0QOL15" style="text-align: justify; text-indent: -12pt; padding-left: 12pt"&gt;PreCheck Health Services (b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zEW5CuxIuXF3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F45_z27GEf7cW9mh" style="text-align: justify; text-indent: -12pt; padding-left: 12pt"&gt;CEO.CA Technologies (c)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zaYjFvFN5kvk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F48_zhHNaFSHYl53" style="text-align: justify; text-indent: -12pt; padding-left: 12pt"&gt;Belair Capital Advisors (d)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--VendorAdvancesGross_iI_hdei--LegalEntityAxis__custom--CrossCurrentCapitalLLCMember_z9WNeQNhcHRf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F46_zp8WQRJ4lTFf" style="text-align: justify; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt"&gt;Cross Current Capital (e)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;856&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;700&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--VendorAdvancesGross_iI_maVANzSvy_zniJYtW0OSve" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vendor advances, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,271&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,115&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--VendorAdvancesAccumulatedAmortization_iNI_di_msVANzSvy_zjnKmRDVplX8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(892&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(256&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--VendorAdvancesNet_iTI_mtVANzSvy_zmvZB94q6Je4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify; text-indent: -12pt; padding-left: 12pt"&gt;Vendor advances, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,379&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,859&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;(a)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Kairos
                                            Agreement with Prevail Infoworks, Inc.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 1, 2024, the Company entered into a master service and technology agreement with Prevail Infoworks, Inc. (&#x201c;Prevail&#x201d;),
pursuant to which Prevail agreed to provide certain clinical research services to the Company. As part of the agreement, the Company
was required to make an advance payment of $&lt;span id="xdx_905_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_zprPoAiaebDh" title="Advance payment"&gt;900&lt;/span&gt; to Prevail before commencement of services and, at such time as we notify Prevail to
engage their services related to the relevant clinical trial, or six months from the date of the agreement, pay approximately $&lt;span id="xdx_90A_ecustom--MonthlyPayment_pn3n3_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_z5ccsCCqpfnh" title="Monthly payment"&gt;80&lt;/span&gt; per
month during the time Prevail performs clinical research services for the Company&#x2019;s Phase 2 ENV 105 prostate and Phase 1 ENV 105
lung clinical trials. The agreement with Prevail is subject to cancellation at any time upon 30 days&#x2019; written notice to the other
party. The Company made the advance payment to Prevail in October 2024 and it is included in vendor advances on the accompanying balance
sheet as of March 31, 2025 and December 31, 2024 (see Note 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;(b)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Kairos
                                            Agreement with PreCheck Health Services, Inc.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 20, 2024, the Company entered into a bioassay services agreement (the &#x201c;Bioassay Services Agreement&#x201d;) with PreCheck
Health Services, Inc., a Florida-based corporation (&#x201c;PreCheck&#x201d;). Pursuant to the Bioassay Services Agreement, PreCheck will
provide certain biomarker screening services for the Company&#x2019;s ongoing carotuximab (ENV105) clinical trials in order to assist
the Company in identifying lung and prostate cancer patients suitable to the Company&#x2019;s ongoing Phase 1 clinical trials for lung
cancer patients and Phase 2 clinical trials for patients with castrate resistant prostate cancer. In exchange for PreCheck&#x2019;s services,
and according to the terms of the Bioassay Services Agreement, the Company paid $&lt;span id="xdx_904_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240920__20240920__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zduXccqjwVB3" title="Payments for services"&gt;900&lt;/span&gt; to PreCheck as an advance for the future laboratory
services to be performed. The payment of $&lt;span id="xdx_90D_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zwLbkpGeqLZc" title="Payments for vendor advance"&gt;&lt;span id="xdx_90F_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zjW07xt7c818" title="Payments for vendor advance"&gt;900&lt;/span&gt;&lt;/span&gt; is included in vendor advances on the accompanying balance sheet as of March 31, 2025 and
December 31, 2024 (see Note 2). The term of the agreement is one year from the effective date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;(c)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Kairos
                                            Agreement with CEO.CA Technologies Ltd.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 23, 2024, the Company entered into an advisory and consulting services agreement (the &#x201c;CEO.CA Agreement&#x201d;) with
CEO.CA Technologies Ltd., a Canadian company (&#x201c;CEO.CA&#x201d;), pursuant to which CEO.CA will provide certain internet-based financial
information and communications services for a period of one year for a services fee of $&lt;span id="xdx_90B_eus-gaap--ManagementFeeExpense_pn3n3_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zdwOjkCdY2mk" title="Service fee"&gt;250&lt;/span&gt;. The service fee is an advance on future
services to be performed. The CEO.CA Agreement includes such services as strategic news placement, news releases, interviews, monthly
analytics and a video launch. The CEO.CA Agreement contains other customary clauses, including representations and warranties, indemnification
clauses and governing law clauses. The payment of $&lt;span id="xdx_907_eus-gaap--ManagementFeeExpense_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zCcYQ0z44iD2" title="Service fee"&gt;&lt;span id="xdx_90E_eus-gaap--ManagementFeeExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zQ4vCZ1jJsAd" title="Service fee"&gt;250&lt;/span&gt;&lt;/span&gt; is included in vendor advances on the accompanying balance sheet as of March 31,
2025, and December 31, 2024 (see Note 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;(d)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Kairos
                                            Agreement with Belair Capital Advisors Inc.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 23, 2024, the Company entered into a strategic advisory agreement (the &#x201c;Strategic Advisory Agreement&#x201d;) with Belair
Capital Advisors Inc. (&#x201c;BCA&#x201d;). BCA, a venture capital and corporate finance advisory firm, has been a long-term investor
and advisor to the Company and frequently works with early-stage pharmaceutical companies. The strategic advisory services provided by
BCA consist of corporate strategy, market positioning and long-term growth plans within the pharmaceutical sector, digital marketing
and engagement, market research analysis and business development assistance, among other things. During the one-year term of the Strategic
Advisory Agreement, in exchange for its services, the Company will pay BCA a $&lt;span id="xdx_90B_eus-gaap--ManagementFeeExpense_pn3n3_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zWK09mzIVjcf" title="Service fee"&gt;365&lt;/span&gt; fee and will issue BCA &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zH4wUeKY4gce" title="Number of shares issued"&gt;50,000&lt;/span&gt; RSUs, which will vest
at the end of six months following the date of issuance. The payment of $&lt;span id="xdx_904_eus-gaap--ManagementFeeExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_z5u2qaE8GJ13" title="Service fee"&gt;&lt;span id="xdx_90E_eus-gaap--ManagementFeeExpense_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zqWNwT1AmMp2" title="Service fee"&gt;365&lt;/span&gt;&lt;/span&gt; is included in vendor advances on the accompanying balance
sheet as of March 31, 2025, and December 31, 2024 (see Note 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;(e)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Kairos
                                            Agreement with Cross Current Capital LLC&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 1, 2024, the Company entered into a consulting agreement (the &#x201c;Consulting Agreement&#x201d;) with Cross Current Capital
LLC, a limited liability company organized under the laws of Puerto Rico (&#x201c;Cross Current&#x201d;), and Alan Masley (the &#x201c;Advisor&#x201d;),
pursuant to which Cross Current agreed to provide certain financial and business consulting services to the Company including, but not
limited, to (a) help drafting a public company competitive overview, (b) help preparing and/or reviewing a valuation analysis, (c) help
in drafting marketing materials and presentations, (d) reviewing the Company&#x2019;s business requirements and discuss financing and
businesses opportunities, (e) investor marketing, (f) investor relations introductions, (g) legal counsel introductions, (h) auditor
introductions, (i) investment banking and research introductions, (j) M&amp;amp;A canvassing and ways to grow the business organically, and
(k) stand by capital markets advisory services. For the services rendered thereunder, the Company agreed to pay Cross Current $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zs967aIjw35a" title="Number of shares issued, value"&gt;200,000&lt;/span&gt;
in cash and agreed to issue to the Advisor $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zg32SQq41PFa" title="Number of shares issued, value"&gt;500&lt;/span&gt; of restricted shares of the Company&#x2019;s common stock under the Company&#x2019;s 2023
Plan , calculated at &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--CurrentCapitalLLCMember_zwdhN9xZw456" title="Number of shares issued"&gt;367,647&lt;/span&gt; shares (the &#x201c;Shares&#x201d;) as of the date of the agreement. The term of the Consulting Agreement
is 24 months and can be extended for another 12 months with the written consent of both parties. The Company made the $&lt;span id="xdx_900_ecustom--SettlementAgreementAmount_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z06niaGMIAY" title="Settlement agreement amount"&gt;200&lt;/span&gt; payment in
October 2024. The payment of $&lt;span id="xdx_903_ecustom--VendorPaymentAdvances_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zuE1Up2Yf3Oc" title="Vendor payment advances"&gt;200&lt;/span&gt; and the value of the shares issued of $&lt;span id="xdx_90B_eus-gaap--AdditionalCollateralAggregateFairValue_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z6yCdjjdyhR4" title="Aggregate fair value of the common stock"&gt;&lt;span id="xdx_904_eus-gaap--AdditionalCollateralAggregateFairValue_iI_pn3n3_c20250331__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zdHaZRYlUKB9" title="Aggregate fair value of the common stock"&gt;500&lt;/span&gt;&lt;/span&gt; are included in vendor advances on the accompanying balance
sheet as of March 31, 2025, and December 31, 2024 (see Note 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTfiiSp4Yj82" title="Stock issued shares"&gt;367,647&lt;/span&gt; shares issued in 2024 were subject to a &#x201c;true up&#x201d; on April 1, 2025, at which time additional shares will be issued
to the Advisor (or returned by the Advisor to the Company) in order to ensure the shares are valued at $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIZpvH8zT7f" title="Number of shares issued, value"&gt;500&lt;/span&gt; as of April 1, 2025. On April
1, 2025, the Company issued an additional&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z30ZJg7BXA84" title="Number of shares issued"&gt;166,541&lt;/span&gt; shares of its common stock to the Advisor. The fair value of the additional shares on
the date of grant was $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgBbAS3MRlag" title="Number of shares issued, value"&gt;156&lt;/span&gt;. The Company recorded the shares as common stock to be issued as of March 31, 2025, and recorded the fair
value of the shares as a vendor advance as of the same date (see Notes 2 and 4).&lt;/span&gt;&lt;/p&gt;

</KAPA:ScheduleOfVendorAdvancesTableTextBlock>
    <KAPA:VendorAdvancesGross
      contextRef="AsOf2025-03-31_custom_PrevailInfoworksIncMember"
      decimals="-3"
      id="Fact000459"
      unitRef="USD">900000</KAPA:VendorAdvancesGross>
    <KAPA:VendorAdvancesGross
      contextRef="AsOf2024-12-31_custom_PrevailInfoworksIncMember"
      decimals="-3"
      id="Fact000460"
      unitRef="USD">900000</KAPA:VendorAdvancesGross>
    <KAPA:VendorAdvancesGross
      contextRef="AsOf2025-03-31_custom_PreCheckHealthServicesIncMember"
      decimals="-3"
      id="Fact000462"
      unitRef="USD">900000</KAPA:VendorAdvancesGross>
    <KAPA:VendorAdvancesGross
      contextRef="AsOf2024-12-31_custom_PreCheckHealthServicesIncMember"
      decimals="-3"
      id="Fact000463"
      unitRef="USD">900000</KAPA:VendorAdvancesGross>
    <KAPA:VendorAdvancesGross
      contextRef="AsOf2025-03-31_custom_CEOCATechnologiesLtdMember"
      decimals="-3"
      id="Fact000465"
      unitRef="USD">250000</KAPA:VendorAdvancesGross>
    <KAPA:VendorAdvancesGross
      contextRef="AsOf2024-12-31_custom_CEOCATechnologiesLtdMember"
      decimals="-3"
      id="Fact000466"
      unitRef="USD">250000</KAPA:VendorAdvancesGross>
    <KAPA:VendorAdvancesGross
      contextRef="AsOf2025-03-31_custom_BelairCapitalAdvisorsIncMember"
      decimals="-3"
      id="Fact000468"
      unitRef="USD">365000</KAPA:VendorAdvancesGross>
    <KAPA:VendorAdvancesGross
      contextRef="AsOf2024-12-31_custom_BelairCapitalAdvisorsIncMember"
      decimals="-3"
      id="Fact000469"
      unitRef="USD">365000</KAPA:VendorAdvancesGross>
    <KAPA:VendorAdvancesGross
      contextRef="AsOf2025-03-31_custom_CrossCurrentCapitalLLCMember"
      decimals="-3"
      id="Fact000471"
      unitRef="USD">856000</KAPA:VendorAdvancesGross>
    <KAPA:VendorAdvancesGross
      contextRef="AsOf2024-12-31_custom_CrossCurrentCapitalLLCMember"
      decimals="-3"
      id="Fact000472"
      unitRef="USD">700000</KAPA:VendorAdvancesGross>
    <KAPA:VendorAdvancesGross
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000474"
      unitRef="USD">3271000</KAPA:VendorAdvancesGross>
    <KAPA:VendorAdvancesGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000475"
      unitRef="USD">3115000</KAPA:VendorAdvancesGross>
    <KAPA:VendorAdvancesAccumulatedAmortization
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000477"
      unitRef="USD">892000</KAPA:VendorAdvancesAccumulatedAmortization>
    <KAPA:VendorAdvancesAccumulatedAmortization
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000478"
      unitRef="USD">256000</KAPA:VendorAdvancesAccumulatedAmortization>
    <KAPA:VendorAdvancesNet
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000480"
      unitRef="USD">2379000</KAPA:VendorAdvancesNet>
    <KAPA:VendorAdvancesNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000481"
      unitRef="USD">2859000</KAPA:VendorAdvancesNet>
    <us-gaap:PaymentsForAdvanceToAffiliate
      contextRef="From2024-08-012024-08-31_custom_MasterServiceAndTechnologyAgreementMember"
      decimals="-3"
      id="Fact000483"
      unitRef="USD">900000</us-gaap:PaymentsForAdvanceToAffiliate>
    <KAPA:MonthlyPayment
      contextRef="From2024-08-012024-08-31_custom_MasterServiceAndTechnologyAgreementMember"
      decimals="-3"
      id="Fact000485"
      unitRef="USD">80000</KAPA:MonthlyPayment>
    <us-gaap:PaymentsForAdvanceToAffiliate
      contextRef="From2024-09-202024-09-20_custom_BioassayServicesAgreementMember_custom_PreCheckHealthServicesIncMember"
      decimals="-3"
      id="Fact000487"
      unitRef="USD">900000</us-gaap:PaymentsForAdvanceToAffiliate>
    <us-gaap:PaymentsForAdvanceToAffiliate
      contextRef="From2024-01-012024-12-31_custom_BioassayServicesAgreementMember_custom_PreCheckHealthServicesIncMember"
      decimals="-3"
      id="Fact000489"
      unitRef="USD">900000</us-gaap:PaymentsForAdvanceToAffiliate>
    <us-gaap:PaymentsForAdvanceToAffiliate
      contextRef="From2025-01-012025-03-31_custom_BioassayServicesAgreementMember_custom_PreCheckHealthServicesIncMember"
      decimals="-3"
      id="Fact000491"
      unitRef="USD">900000</us-gaap:PaymentsForAdvanceToAffiliate>
    <us-gaap:ManagementFeeExpense
      contextRef="From2024-09-232024-09-23_custom_AdvisoryAndConsultingServicesAgreementMember_custom_CEOCATechnologiesLtdMember"
      decimals="-3"
      id="Fact000493"
      unitRef="USD">250000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="From2025-01-012025-03-31_custom_AdvisoryAndConsultingServicesAgreementMember_custom_CEOCATechnologiesLtdMember"
      decimals="-3"
      id="Fact000495"
      unitRef="USD">250000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="From2024-01-012024-12-31_custom_AdvisoryAndConsultingServicesAgreementMember_custom_CEOCATechnologiesLtdMember"
      decimals="-3"
      id="Fact000497"
      unitRef="USD">250000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="From2024-09-232024-09-23_custom_StrategicAdvisoryAgreementMember_custom_BelairCapitalAdvisorsIncMember"
      decimals="-3"
      id="Fact000499"
      unitRef="USD">365000</us-gaap:ManagementFeeExpense>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-09-232024-09-23_custom_StrategicAdvisoryAgreementMember_custom_BelairCapitalAdvisorsIncMember"
      decimals="INF"
      id="Fact000501"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ManagementFeeExpense
      contextRef="From2024-01-012024-12-31_custom_StrategicAdvisoryAgreementMember_custom_BelairCapitalAdvisorsIncMember"
      decimals="-3"
      id="Fact000503"
      unitRef="USD">365000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="From2025-01-012025-03-31_custom_StrategicAdvisoryAgreementMember_custom_BelairCapitalAdvisorsIncMember"
      decimals="-3"
      id="Fact000505"
      unitRef="USD">365000</us-gaap:ManagementFeeExpense>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-10-012024-10-01_custom_ConsultingAgreementMember_custom_CurrentCapitalLLCMember"
      decimals="0"
      id="Fact000507"
      unitRef="USD">200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-10-012024-10-01_custom_ConsultingAgreementMember_custom_CurrentCapitalLLCMember"
      decimals="-3"
      id="Fact000509"
      unitRef="USD">500000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-10-012024-10-01_custom_ConsultingAgreementMember_custom_CurrentCapitalLLCMember"
      decimals="INF"
      id="Fact000511"
      unitRef="Shares">367647</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <KAPA:SettlementAgreementAmount
      contextRef="From2024-10-012024-10-01_custom_ConsultingAgreementMember"
      decimals="-3"
      id="Fact000513"
      unitRef="USD">200000</KAPA:SettlementAgreementAmount>
    <KAPA:VendorPaymentAdvances
      contextRef="AsOf2024-12-31_custom_ConsultingAgreementMember"
      decimals="-3"
      id="Fact000515"
      unitRef="USD">200000</KAPA:VendorPaymentAdvances>
    <us-gaap:AdditionalCollateralAggregateFairValue
      contextRef="AsOf2024-12-31_custom_ConsultingAgreementMember"
      decimals="-3"
      id="Fact000517"
      unitRef="USD">500000</us-gaap:AdditionalCollateralAggregateFairValue>
    <us-gaap:AdditionalCollateralAggregateFairValue
      contextRef="AsOf2025-03-31_custom_ConsultingAgreementMember"
      decimals="-3"
      id="Fact000519"
      unitRef="USD">500000</us-gaap:AdditionalCollateralAggregateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-04-012025-04-01_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000521"
      unitRef="Shares">367647</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-012025-04-01_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact000523"
      unitRef="USD">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-04-012025-04-01_custom_ConsultingAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000525"
      unitRef="Shares">166541</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-012025-04-01_custom_ConsultingAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact000527"
      unitRef="USD">156000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-11-122024-11-12_custom_HelenaGlobalInvestmentOpportunitiesILTDMember"
      decimals="0"
      id="Fact000529"
      unitRef="USD">30000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-11-122024-11-12"
      decimals="-3"
      id="Fact000531"
      unitRef="USD">900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-11-122024-11-12_custom_HelenaGlobalInvestmentOpportunitiesILTDMember"
      decimals="INF"
      id="Fact000533"
      unitRef="Shares">670641</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-11-122024-11-12_custom_HelenaGlobalInvestmentOpportunitiesILTDMember"
      decimals="-3"
      id="Fact000535"
      unitRef="USD">1377000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-04-242025-04-24_us-gaap_CommonStockMember_custom_HelenaGlobalInvestmentOpportunitiesILTDMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000537"
      unitRef="Shares">384459</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-242025-04-24_us-gaap_CommonStockMember_custom_HelenaGlobalInvestmentOpportunitiesILTDMember_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact000539"
      unitRef="USD">328000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000541">&lt;p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zqWGd9INJv04" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;NOTE 4 &#x2013; &lt;span id="xdx_828_zDtkd8Qtsvn8"&gt;SHAREHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Common Stock&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Authorized Shares&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;The Company&#x2019;s Certificate
of Incorporation, as filed with the State of Delaware on May 10, 2023, following the Company&#x2019;s conversion from a California corporation
into a Delaware corporation, authorizes the Company to issue up to &lt;span id="xdx_90F_ecustom--SharesAuthorized_iI_pid_c20230510_zVuRxtV3P1T5" title="Shares authorized"&gt;120,000,000&lt;/span&gt; shares, consisting of &lt;span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230510_zerZJjFwF7aj" title="Common stock, shares issued"&gt;100,000,000&lt;/span&gt; shares of common stock,
par value of $&lt;span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230510_zeJcxOJO54t4" title="Common stock, par value"&gt;0.001&lt;/span&gt; per share, and &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230510_zhx6sbUePF2g" title="Preferred stock, shares authorized"&gt;20,000,000&lt;/span&gt; shares of preferred stock, par value $&lt;span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230510_zabv1cM2QXPe" title="Preferred stock par value"&gt;0.001&lt;/span&gt; per share. Holders of shares of common stock
have full voting rights, one vote for each share held of record. Shareholders are entitled to receive dividends as may be declared by
the board of directors out of funds legally available and share pro rata in any distributions with shareholders upon liquidation. Shareholders
have no conversion, pre-emptive or subscription rights. All outstanding shares of common stock are fully paid and non-assessable. As of
March 31, 2025 and December 31, 2024 there were &lt;span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pid_c20250331_zgju3NGCas83" title="Common stock, shares issued"&gt;&lt;span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20250331_z5xf7gWD7cL7" title="Common stock, shares outstanding"&gt;15,825,118&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zmY8yK5eKIjl" title="Common stock, shares issued"&gt;&lt;span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zK0shRWPUan2" title="Common stock, shares outstanding"&gt;13,736,597&lt;/span&gt;&lt;/span&gt; shares of common stock issued and outstanding, respectively,
and &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20250331_zwac76Gpjpra" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20241231_z21CK91DRuaj" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt; shares of preferred stock outstanding, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Common Stock Issued
for Cash Upon Closing of the Company&#x2019;s Private Financing&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;On
January 14, 2025, the Company entered into a securities purchase agreement (&#x201c;SPA&#x201d;) and registration rights agreement
with an investor for the sale and issuance of &lt;span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250114__20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_z9qSKWCISLid" title="Sale of stock, number of shares issued in transaction"&gt;2,500,000&lt;/span&gt; units (the &#x201c;Pre-Funded Units&#x201d;), with each Pre-Funded Unit
consisting of a pre-funded warrant to purchase one share of common stock, exercisable for $&lt;span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_z36o49zonGr8" title="Exercisable price per share"&gt;0.001&lt;/span&gt; per share, and a common warrant to
purchase one and one half shares of common stock (an aggregate of &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pp0p0_c20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zE8QburIr3qg" title="Warrants to purchase of common stock"&gt;3,750,000&lt;/span&gt;), exercisable at $&lt;span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQ7rERlMaaEb" title="Exercisable price per share"&gt;1.399&lt;/span&gt; per share. On January 16, 2025, the
Company closed on the sale of the Pre-Funded Units for a total purchase price of $&lt;span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn3n3_c20250116__20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember_zcFWsRsjX6Xk" title="Purchase price of pre-funded unit"&gt;3,500&lt;/span&gt; (or $&lt;span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember_zzoT0Wrr1w2b" title="Shares issued, price per share"&gt;1.40&lt;/span&gt; per Pre-Funded Unit). Net proceeds
received by the Company relating to the financing, and subsequent exercise of prefunded warrants was $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3n3_c20250116__20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember_zWh4D7F7V9kk" title="Net proceeds received from financing"&gt;3,058&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;The pre-funded warrants have
an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250114__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zsS1eMWJ75nl" title="Exercise price"&gt;0.001&lt;/span&gt; per share and are immediately exercisable and will expire when exercised in full. The common warrants have
an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250114__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember_z8w3gUancoX2" title="Exercise price"&gt;1.40&lt;/span&gt; per share, &lt;span id="xdx_904_ecustom--ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_c20250114__20250114_z9WWjrlP8b9e" title="Warrants exercisable description"&gt;will be exercisable six months from issuance and will expire five and a half years from the issuance
date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;During
the three months ended March 31, 2025, the investor exercised &lt;span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z92sb2DPyc3l" title="Warrants exercised"&gt;2,010,000&lt;/span&gt;
shares of the pre-funded warrants and as of March 31, 2025, there were &lt;span id="xdx_90C_ecustom--WarrantsUnexercised_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zAca6jILQrF9" title="Warrants unexercised"&gt;490,000&lt;/span&gt;
pre-funded shares remaining unexercised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Adoption of the
2023 Equity Incentive Plan&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;In
July 2023, the Company&#x2019;s board of directors and stockholders adopted the 2023 Equity Incentive Plan (the &#x201c;2023
Plan&#x201d;). Under the 2023 Plan, the Company may grant incentive stock options to employees, including employees of any parent or
subsidiary, and nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards and
other forms of stock compensation to employees, directors and consultants, including employees and consultants of the
Company&#x2019;s affiliates. As approved, a total of &lt;span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230731__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeEquityIncentivePlanMember_zJKlaYqX7lQi" title="Common stock reserved for future issuance"&gt;1,650,000&lt;/span&gt;
shares of common stock were initially reserved for issuance under the 2023 Plan. As of March 31, 2025 and December 31, 2024, a total
of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20250331__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeEquityIncentivePlanMember_zd0lN1yAEhm9" title="Shares available for grant"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeEquityIncentivePlanMember_zDw46Pp9xELa" title="Shares available for grant"&gt;1,457,880&lt;/span&gt;&lt;/span&gt;
shares remained available for issuance under the 2023 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Grant of Restricted
Stock Units (RSUs)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_znOl1UY3MWR5" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span style="background-color: white"&gt;The following
table summarizes restricted common stock activity during the three months ended March 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span id="xdx_8B2_zro0G2YkumV7" style="display: none"&gt;SCHEDULE
OF RESTRICTED COMMON STOCK ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;b&gt;Restricted Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted Average Grant Date Fair&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: justify"&gt;Unvested, December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zo4J5tjWOVG6" style="width: 14%; text-align: right" title="Number of Restricted Shares, Unvested Beginning balance"&gt;172,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zACBeqUT19tj" style="width: 14%; text-align: right" title="Fair Value, Unvested, Beginning balance"&gt;314&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5euLO2mchWa" style="width: 14%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance"&gt;1.83&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyYJ5CNyaCOb" style="text-align: right" title="Number of Restricted shares Granted"&gt;20,120&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztjSGHgO3D82" style="text-align: right" title="Fair Value, Granted"&gt;50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGJWSKYxQbW9" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"&gt;2.49&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkN7GfUl4ntc" style="text-align: right" title="Number of Restricted shares Vested"&gt;(78,521&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_iN_pn3n3_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrxA1bTiYca6" style="text-align: right" title="Fair Value, Vested"&gt;(76&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD6xx18OPh1j" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested"&gt;0.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNz4dFXhXYUa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted shares Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0615"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z333fYfpkiI5" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0617"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEKJ7p9cuqpg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0619"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Unvested, March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFYmZdchnf48" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted Shares, Unvested Ending balance"&gt;113,599&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzKw5fFxyMs2" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value, Unvested, Ending balance"&gt;288&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpM4dMoxwrqh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance"&gt;2.54&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zJVGc2waC3yg" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;On September 23, 2024, the Company entered into a
strategic advisory agreement with Belair Capital Advisors Inc. (&#x201c;Belair&#x201d;). During the one-year term of the agreement, in exchange
for its services, the Company issued Belair &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240923__20240923__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember_zcz9Ohyp3V0h" title="Number of shares issued"&gt;50,000&lt;/span&gt; RSUs, which vest six months from the date of issuance. The fair value of the shares
on the date of grant was $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20240923__20240923_zXr8MdCRYdU4" title="Fair value of shares"&gt;100&lt;/span&gt;, which value will be amortized over the one-year service period of the agreement. &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_dn_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember_z2zxdkYdRpZi" title="Number of shares vested"&gt;None&lt;/span&gt; of these shares vested
or were issued during the year ended December 31, 2024. During the three months ended March 31, 2025, the &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember_zbJbW6AP3Ype" title="Number of shares vested"&gt;50,000&lt;/span&gt; RSUs vested and the shares
were issued to Belair.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;Upon
the closing of the Company&#x2019;s IPO, the Company entered into agreements with each of its four officers. Such agreements provided
for annual grants of RSUs in accordance with the terms of the Company&#x2019;s 2023 Equity Incentive Plan. The RSUs vest over one- or
two-year periods and are subject to full acceleration of vesting upon the sale of the Company. Upon the closing of the
Company&#x2019;s IPO in September 2024, the Company granted the officers &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240901__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--FourOfficersAgreementMember_zBNejeGo5Wh8" title="Number of shares issued"&gt;92,000&lt;/span&gt;
RSUs. The fair value of the shares on the date of grant was $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20240901__20240930__us-gaap--TypeOfArrangementAxis__custom--FourOfficersAgreementMember_zv3V5m3mMtl6" title="Fair value of shares"&gt;226&lt;/span&gt;. &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_dn_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--FourOfficersAgreementMember_z6uOZwCLZtPc" title="Number of shares vested"&gt;None&lt;/span&gt;
of these RSUs vested during the year ended December 31, 2024. During the three months ended March 31, 2025, a total of &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--FourOfficersAgreementMember_zYiqIMoyUJVi" title="Number of shares vested"&gt;28,521&lt;/span&gt;
RSUs vested and the shares were issued to the officers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;Upon the closing of the Company&#x2019;s IPO, the Company
entered into agreements with each of its three independent directors. The Company&#x2019;s policy provides that, upon initial election
or appointment to its board of directors, each new non-employee director will be granted a one-time grant, or Director Initial Grant,
with a value of $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20250101__20250331__srt--TitleOfIndividualAxis__custom--ThreeIndependentDirectorsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQPNDjBYzN0a" title="Number of shares issued, value"&gt;50&lt;/span&gt; of RSUs that will vest in substantially equal annual installments over a period of three years. The Director Initial
Grant is subject to full acceleration vesting upon the sale of the Company, in accordance with the terms of the Company&#x2019;s 2023 Plan.
In 2024, a total of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zvwlcTay1F6e" title="Number of shares granted"&gt;30,000&lt;/span&gt; RSUs were granted to the directors. The fair value of the shares on the date of grant was $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zPVmkLXW2sr" title="Fair value of shares"&gt;74&lt;/span&gt;. During the three
months ended March 31, 2025, an additional &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zlvZXs4Pkf87" title="Granted shares"&gt;20,120&lt;/span&gt; RSUs was granted to the Company&#x2019;s new director with a fair value of $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z7peKzrpAsek" title="Fair value of shares"&gt;31&lt;/span&gt;. &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_dn_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--DirectorAgreementsMember_z2iIr5bevzgi" title="Number of shares vested"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_dn_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--DirectorAgreementsMember_ztKsNAPZoN4d" title="Number of shares vested"&gt;None&lt;/span&gt;&lt;/span&gt;
of these RSUs had vested as of the three months ended March 31, 2025 or the year ended December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;During the three months ended March 31, 2025, the
Company recorded $&lt;span id="xdx_90B_ecustom--FairValueOfRestrictedStockUnits_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zr3JfvgEROWk" title="Stock compensation-related expense for fair value vesting of restricted common stock"&gt;76&lt;/span&gt; of stock compensation-related expense for the fair value vesting of restricted common stock. As of March 31, 2025,
$&lt;span id="xdx_900_ecustom--FairValueOfUnamortizedCompensation_iI_pn3n3_c20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm8PfokPuF3f" title="Fair value of unamortized compensation"&gt;280&lt;/span&gt; of unamortized compensation remained.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Stock Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zRPh3JBqEOK9" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The table below summarizes the Company&#x2019;s warrant
activities for three months ended March 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span id="xdx_8BD_zx5peycnu1Ri" style="display: none"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number of&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Warrant&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Range&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Per Share&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Balance, December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG7ExkPdZU5h" style="width: 14%; text-align: right" title="Warrants Shares, Beginning Balance"&gt;278,188&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;span id="xdx_905_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zw3RnSMwO1zf" title="Exercise Price Range Per Share, Beginning Balance"&gt;2.40&lt;/span&gt; - &lt;span id="xdx_903_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zHYp8JiW4h56" title="Exercise Price Range Per Share, Beginning Balance"&gt;4.80&lt;/span&gt; &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhTHISzzX9v9" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Warrant Warrant, Beginning Balance"&gt;4.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zx9rkEE2e1Pl" style="text-align: right" title="Warrants Shares, Granted"&gt;6,425,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zLg00osw0D24" title="Exercise Price Range Per Share, Granted"&gt;0.001&lt;/span&gt;
&#x2013; &lt;span id="xdx_905_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zYa4xrmSX0S6" title="Exercise Price Range Per Share, Granted"&gt;1.40&lt;/span&gt; &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zalttfYULl4a" style="text-align: right" title="Weighted Average Exercise Price Warrant, Granted"&gt;0.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoMomLkOoL31" style="text-align: right" title="Warrants Shares, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0679"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zz0Cgyu0ZGUj" style="text-align: right" title="Exercise Price Range Per Share, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0681"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYK9e5nbujj5" style="text-align: right" title="Weighted Average Exercise Price Warrant, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0683"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_iN_pid_di_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXSSmCr7kJPb" style="text-align: right" title="Warrants Shares, Exercised"&gt;(2,010,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRxuISik6huc" style="text-align: right" title="Exercise Price Range Per Share, Exercised"&gt;0.001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zicNkvsQa6yf" style="text-align: right" title="Weighted Average Exercise Price Warrant, Exercised"&gt;0.001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited/Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmI19NGAzaF9" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Shares, Forfeited/Expired"&gt;(150,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIiD5R6BaEva" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price Range Per Share, Forfeited/Expired"&gt;4.17&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zD9fUkg6oNae" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Warrant, Forfeited/Expired"&gt;4.17&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Balance, March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zm2nfrTaknP" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Shares, Ending Balance"&gt;4,543,188&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;span id="xdx_908_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zXAJuNDqIm6a" title="Exercise Price Range Per Share, Ending Balance"&gt;0.001&lt;/span&gt; &#x2013; &lt;span id="xdx_90B_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zOFcJpaWLmM" title="Exercise Price Range Per Share, Ending Balance"&gt;4.80&lt;/span&gt; &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcbNWOHZ8cHf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Warrant, Ending Balance"&gt;1.33&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Vested and exercisable, March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwbE3cf7Nrv8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Warrants, Vested and exercisable"&gt;793,188&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zZmT94eyvOe6" title="Exercise Price Range Per Share, Vested and exercisable"&gt;0.001&lt;/span&gt;
&#x2013; &lt;span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z3edkZ4ytpfg" title="Exercise Price Range Per Share, Vested and exercisable"&gt;4.80&lt;/span&gt; &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyWdYxVLXWb1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested and exercisable"&gt;1.03&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A8_zVylqT4mjkTg" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zljZNQpyXmFi" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The following table summarizes information concerning
outstanding and exercisable warrants as of March 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span id="xdx_8B7_zSVp0cQWvB86" style="display: none"&gt;SCHEDULE
OF OUTSTANDING AND EXERCISABLE WARRANTS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Warrants Outstanding&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Warrants Exercisable&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Range of&lt;/b&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Exercise Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;b&gt;Number Outstanding&lt;/b&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;
                                                                                                                                                                                             &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;b&gt;Remaining Contractual Life&lt;/b&gt; &lt;b&gt;(in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Average Remaining&lt;/b&gt;&lt;/p&gt;
                                                                                                                                                                                             &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Contractual Life&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zBsvWacU2RMg" title="Range of exercise prices"&gt;0.001&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_z3Rgrws4GxJl" title="Warrants Outstanding, Number Outstanding"&gt;490,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;-&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zeNTwOUURfie" style="display: none" title="Warrants Outstanding, Average Remaining Contractual Life (in years)"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zj5vfy4uPEng" title="Warrants Outstanding, Weighted Average Exercise Price"&gt;0.001&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zYPx8I5dHgi3" title="Warrants Exercisable, Number Exercisable"&gt;490,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zyHT23wh2jX4" title="Warrants Exercisable, Weighted Average Exercise Price"&gt;0.001&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zqHqZmhEYfN4" title="Range of exercise prices lower range"&gt;1.40&lt;/span&gt; - &lt;span id="xdx_909_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zBEkkdCMQREd" title="Range of exercise prices upper range"&gt;2.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zmPfOod4vwN1" title="Warrants Outstanding, Number Outstanding"&gt;3,944,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_ziS65o1YNYql" title="Warrants Outstanding, Average Remaining Contractual Life (in years)"&gt;4.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zGB04cnxTQ91" title="Warrants Outstanding, Weighted Average Exercise Price"&gt;1.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zLeh8lehsKc9" title="Warrants Exercisable, Number Exercisable"&gt;194,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zFy7qWTmkTXj" title="Warrants Exercisable, Average Remaining Contractual Life (in years)"&gt;4.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zWkh6uWUCFDi" title="Warrants Exercisable, Weighted Average Exercise Price"&gt;1.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember_zCopYuf7owIc" title="Range of exercise prices"&gt;4.80&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zITZqVCczLT6" title="Warrants Outstanding, Number Outstanding"&gt;108,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zztv0kFlmqX3" title="Warrants Outstanding, Average Remaining Contractual Life (in years)"&gt;4.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zz6dJWbG6832" title="Warrants Outstanding, Weighted Average Exercise Price"&gt;4.80&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z8AtC8v8Smag" title="Warrants Exercisable, Number Exercisable"&gt;108,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z9iVFZbxptK8" title="Warrants Exercisable, Average Remaining Contractual Life (in years)"&gt;4.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zA4BYzGpUTV3" title="Warrants Exercisable, Weighted Average Exercise Price"&gt;4.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcPQleayNeF9" title="Range of exercise prices lower range"&gt;0.001&lt;/span&gt;&#x2013; &lt;span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhYijr2DKKNa" title="Range of exercise prices upper range"&gt;4.80&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z18mFrjx5gP8" title="Warrants Outstanding, Number Outstanding"&gt;4,543,188&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmwVo1Ycqmaa" title="Warrants Outstanding, Average Remaining Contractual Life (in years)"&gt;4.22&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgKuGxXlQv4k" title="Warrants Outstanding, Weighted Average Exercise Price"&gt;1.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8ZAoGVLPSL5" title="Warrants Exercisable, Number Exercisable"&gt;793,188&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsxWURbruItf" title="Warrants Exercisable, Average Remaining Contractual Life (in years)"&gt;1.72&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zycoAar2cEA2" title="Warrants Exercisable, Weighted Average Exercise Price"&gt;1.03&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A9_zrc89PTGlkuh" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;Warrant Grants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;On
January 14, 2025, as amended on January 16, 2025, the Company entered into a securities purchase agreement (&#x201c;SPA&#x201d;) and
registration rights agreement with a select investor. In connection with the agreement, on January 16, 2025, the Company issued the
investor a pre-funded warrant to purchase up to &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_ztgVNiX7CVa8" title="Warants to purchase of common stock"&gt;2,500,000&lt;/span&gt;
shares of the Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zbLWTlofQhri" title="Exercisable price per share"&gt;0.001&lt;/span&gt;
per share. The warrant is immediately exercisable and will expire when exercised in full. The investor also received a warrant to
purchase up to &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zVTnO8Dz05yl" title="Warrants to purchase of common stock"&gt;3,750,000&lt;/span&gt;
shares of the Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zaF9XPqLZssj" title="Exercisable price per share"&gt;1.40&lt;/span&gt;
per share. &lt;span id="xdx_90B_ecustom--ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_c20250114__20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zNBsOczw7Ic8" title="Warrants exercisable description"&gt;The
warrant will be exercisable six months from the date of issuance and will expire five years from the issuance
date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;On
January 16, 2025, the Company issued a warrant to purchase common stock to the underwriters of the SPA for the purchase of &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zA8uUcE7iKkb" title="Warrant to purchase of common stock"&gt;175,000&lt;/span&gt;
shares of the Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zx1C0yWejQql" title="Exercisable price per share"&gt;1.40&lt;/span&gt;
per share. The warrant vested upon grant. The warrant was issued to the underwriters as they were the placement agents for the SPA
noted above. &lt;span id="xdx_90D_ecustom--ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_c20250114__20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_z8Aln3v8AWn7" title="Warrants exercisable description"&gt;The
warrant expires five years from the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;Warrant Exercises&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;During the three months ended
March 31, 2025, the SPA investor exercised &lt;span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zKRCDrGnU1t7" title="Warrants exercised"&gt;2,010,000&lt;/span&gt; shares of the pre-funded warrant, and as of March 31, 2025, there &lt;span id="xdx_90C_ecustom--WarrantsUnexercised_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zp3x1ohmSLoe" title="Warrants unexercised"&gt;490,000&lt;/span&gt; shares
remained unexercised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;The intrinsic value for warrant
shares outstanding as of March 31, 2025 was $&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pn3n3_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQaYqcEIcBM4" title="Warrant shares outstanding, intrinsic value"&gt;458&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Common
Stock to be Issued&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; background-color: white; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;The Company has entered into
agreements with certain vendors as describes in Note 3 that require the issuance of additional shares of common stock based upon a
defined true calculation.&#160;&#160; As of March 31, 2025, the vendors became due an aggregate of &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250331_zz5iCA03Uz5f" title="Number of shares issued"&gt;551,100&lt;/span&gt;
shares of common stock with an aggregate fair value of $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250101__20250331_zolkGKn0U2Pd" title="Number of shares issued, fair value"&gt;484&lt;/span&gt;.
The shares were issued in April 2025 and have been reflected as common stock issuable as of March 31, 2025.&#160; See further
discussion at Note 5.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <KAPA:SharesAuthorized
      contextRef="AsOf2023-05-10"
      decimals="INF"
      id="Fact000543"
      unitRef="Shares">120000000</KAPA:SharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-05-10"
      decimals="INF"
      id="Fact000545"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-05-10"
      decimals="INF"
      id="Fact000547"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-05-10"
      decimals="INF"
      id="Fact000549"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-05-10"
      decimals="INF"
      id="Fact000551"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000553"
      unitRef="Shares">15825118</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000555"
      unitRef="Shares">15825118</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000557"
      unitRef="Shares">13736597</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000559"
      unitRef="Shares">13736597</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000561"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000563"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-01-142025-01-14_custom_SecurityPurchaseAgreementMember_custom_PreFundedWarrantMember"
      decimals="INF"
      id="Fact000565"
      unitRef="Shares">2500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-01-14_custom_SecurityPurchaseAgreementMember_custom_PreFundedWarrantMember"
      decimals="INF"
      id="Fact000567"
      unitRef="USDPShares">0.001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-14_custom_SecurityPurchaseAgreementMember_custom_PreFundedWarrantMember"
      decimals="0"
      id="Fact000569"
      unitRef="Shares">3750000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-01-14_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000571"
      unitRef="USDPShares">1.399</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2025-01-162025-01-16_custom_SecurityPurchaseAgreementMember"
      decimals="-3"
      id="Fact000573"
      unitRef="USD">3500000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember"
      decimals="INF"
      id="Fact000575"
      unitRef="USDPShares">1.40</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-01-162025-01-16_custom_SecurityPurchaseAgreementMember"
      decimals="-3"
      id="Fact000577"
      unitRef="USD">3058000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-01-14_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact000579"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-01-14_custom_CommonWarrantsMember"
      decimals="INF"
      id="Fact000581"
      unitRef="USDPShares">1.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <KAPA:ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription contextRef="From2025-01-142025-01-14" id="Fact000583">will be exercisable six months from issuance and will expire five and a half years from the issuance
date.</KAPA:ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription>
    <KAPA:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants
      contextRef="From2025-01-012025-03-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact000585"
      unitRef="Shares">2010000</KAPA:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants>
    <KAPA:WarrantsUnexercised
      contextRef="AsOf2025-03-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact000587"
      unitRef="Shares">490000</KAPA:WarrantsUnexercised>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-07-31_custom_TwentyTwentyThreeEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000589"
      unitRef="Shares">1650000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-03-31_custom_TwentyTwentyThreeEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000591"
      unitRef="Shares">1457880</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-12-31_custom_TwentyTwentyThreeEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000593"
      unitRef="Shares">1457880</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000595">&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_znOl1UY3MWR5" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span style="background-color: white"&gt;The following
table summarizes restricted common stock activity during the three months ended March 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span id="xdx_8B2_zro0G2YkumV7" style="display: none"&gt;SCHEDULE
OF RESTRICTED COMMON STOCK ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;b&gt;Restricted Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted Average Grant Date Fair&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: justify"&gt;Unvested, December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zo4J5tjWOVG6" style="width: 14%; text-align: right" title="Number of Restricted Shares, Unvested Beginning balance"&gt;172,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zACBeqUT19tj" style="width: 14%; text-align: right" title="Fair Value, Unvested, Beginning balance"&gt;314&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5euLO2mchWa" style="width: 14%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance"&gt;1.83&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyYJ5CNyaCOb" style="text-align: right" title="Number of Restricted shares Granted"&gt;20,120&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztjSGHgO3D82" style="text-align: right" title="Fair Value, Granted"&gt;50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGJWSKYxQbW9" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"&gt;2.49&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkN7GfUl4ntc" style="text-align: right" title="Number of Restricted shares Vested"&gt;(78,521&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_iN_pn3n3_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrxA1bTiYca6" style="text-align: right" title="Fair Value, Vested"&gt;(76&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD6xx18OPh1j" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested"&gt;0.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNz4dFXhXYUa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted shares Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0615"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z333fYfpkiI5" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0617"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEKJ7p9cuqpg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0619"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Unvested, March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFYmZdchnf48" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted Shares, Unvested Ending balance"&gt;113,599&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzKw5fFxyMs2" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value, Unvested, Ending balance"&gt;288&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpM4dMoxwrqh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance"&gt;2.54&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000597"
      unitRef="Shares">172000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact000599"
      unitRef="USD">314000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000601"
      unitRef="USDPShares">1.83</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046"
      decimals="INF"
      id="Fact000603"
      unitRef="Shares">20120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <KAPA:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046"
      decimals="-3"
      id="Fact000605"
      unitRef="USD">50000</KAPA:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046"
      decimals="INF"
      id="Fact000607"
      unitRef="USDPShares">2.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046"
      decimals="INF"
      id="Fact000609"
      unitRef="Shares">78521</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046"
      decimals="-3"
      id="Fact000611"
      unitRef="USD">76000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046"
      decimals="INF"
      id="Fact000613"
      unitRef="USDPShares">0.97</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000621"
      unitRef="Shares">113599</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact000623"
      unitRef="USD">288000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000625"
      unitRef="USDPShares">2.54</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-09-232024-09-23_us-gaap_RestrictedStockUnitsRSUMember_custom_StrategicAdvisoryAgreementMember"
      decimals="INF"
      id="Fact000627"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-09-232024-09-23"
      decimals="-3"
      id="Fact000629"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-01-012024-12-31_custom_StrategicAdvisoryAgreementMember"
      decimals="INF"
      id="Fact000631"
      unitRef="Shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember_custom_StrategicAdvisoryAgreementMember"
      decimals="INF"
      id="Fact000633"
      unitRef="Shares">50000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-09-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember_custom_FourOfficersAgreementMember"
      decimals="INF"
      id="Fact000635"
      unitRef="Shares">92000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-09-012024-09-30_custom_FourOfficersAgreementMember"
      decimals="-3"
      id="Fact000637"
      unitRef="USD">226000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-01-012024-12-31_custom_FourOfficersAgreementMember"
      decimals="INF"
      id="Fact000639"
      unitRef="Shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2025-01-012025-03-31_custom_FourOfficersAgreementMember"
      decimals="INF"
      id="Fact000641"
      unitRef="Shares">28521</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-01-012025-03-31_custom_ThreeIndependentDirectorsMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact000643"
      unitRef="USD">50000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember"
      decimals="INF"
      id="Fact000645"
      unitRef="Shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember"
      decimals="-3"
      id="Fact000647"
      unitRef="USD">74000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember"
      decimals="INF"
      id="Fact000649"
      unitRef="Shares">20120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember"
      decimals="-3"
      id="Fact000651"
      unitRef="USD">31000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2025-01-012025-03-31_custom_DirectorAgreementsMember"
      decimals="INF"
      id="Fact000653"
      unitRef="Shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-01-012024-12-31_custom_DirectorAgreementsMember"
      decimals="INF"
      id="Fact000655"
      unitRef="Shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <KAPA:FairValueOfRestrictedStockUnits
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember59263046"
      decimals="-3"
      id="Fact000657"
      unitRef="USD">76000</KAPA:FairValueOfRestrictedStockUnits>
    <KAPA:FairValueOfUnamortizedCompensation
      contextRef="AsOf2025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact000659"
      unitRef="USD">280000</KAPA:FairValueOfUnamortizedCompensation>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000661">&lt;p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zRPh3JBqEOK9" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The table below summarizes the Company&#x2019;s warrant
activities for three months ended March 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span id="xdx_8BD_zx5peycnu1Ri" style="display: none"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number of&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Warrant&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Range&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Per Share&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Balance, December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG7ExkPdZU5h" style="width: 14%; text-align: right" title="Warrants Shares, Beginning Balance"&gt;278,188&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;span id="xdx_905_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zw3RnSMwO1zf" title="Exercise Price Range Per Share, Beginning Balance"&gt;2.40&lt;/span&gt; - &lt;span id="xdx_903_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zHYp8JiW4h56" title="Exercise Price Range Per Share, Beginning Balance"&gt;4.80&lt;/span&gt; &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhTHISzzX9v9" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Warrant Warrant, Beginning Balance"&gt;4.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zx9rkEE2e1Pl" style="text-align: right" title="Warrants Shares, Granted"&gt;6,425,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zLg00osw0D24" title="Exercise Price Range Per Share, Granted"&gt;0.001&lt;/span&gt;
&#x2013; &lt;span id="xdx_905_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zYa4xrmSX0S6" title="Exercise Price Range Per Share, Granted"&gt;1.40&lt;/span&gt; &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zalttfYULl4a" style="text-align: right" title="Weighted Average Exercise Price Warrant, Granted"&gt;0.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoMomLkOoL31" style="text-align: right" title="Warrants Shares, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0679"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zz0Cgyu0ZGUj" style="text-align: right" title="Exercise Price Range Per Share, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0681"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYK9e5nbujj5" style="text-align: right" title="Weighted Average Exercise Price Warrant, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0683"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_iN_pid_di_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXSSmCr7kJPb" style="text-align: right" title="Warrants Shares, Exercised"&gt;(2,010,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRxuISik6huc" style="text-align: right" title="Exercise Price Range Per Share, Exercised"&gt;0.001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zicNkvsQa6yf" style="text-align: right" title="Weighted Average Exercise Price Warrant, Exercised"&gt;0.001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited/Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmI19NGAzaF9" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Shares, Forfeited/Expired"&gt;(150,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIiD5R6BaEva" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price Range Per Share, Forfeited/Expired"&gt;4.17&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zD9fUkg6oNae" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Warrant, Forfeited/Expired"&gt;4.17&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Balance, March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zm2nfrTaknP" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Shares, Ending Balance"&gt;4,543,188&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;span id="xdx_908_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zXAJuNDqIm6a" title="Exercise Price Range Per Share, Ending Balance"&gt;0.001&lt;/span&gt; &#x2013; &lt;span id="xdx_90B_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zOFcJpaWLmM" title="Exercise Price Range Per Share, Ending Balance"&gt;4.80&lt;/span&gt; &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcbNWOHZ8cHf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Warrant, Ending Balance"&gt;1.33&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Vested and exercisable, March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwbE3cf7Nrv8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Warrants, Vested and exercisable"&gt;793,188&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zZmT94eyvOe6" title="Exercise Price Range Per Share, Vested and exercisable"&gt;0.001&lt;/span&gt;
&#x2013; &lt;span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z3edkZ4ytpfg" title="Exercise Price Range Per Share, Vested and exercisable"&gt;4.80&lt;/span&gt; &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyWdYxVLXWb1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested and exercisable"&gt;1.03&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000663"
      unitRef="Shares">278188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000665"
      unitRef="USDPShares">2.40</KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants>
    <KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000667"
      unitRef="USDPShares">4.80</KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000669"
      unitRef="USDPShares">4.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000671"
      unitRef="Shares">6425000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <KAPA:ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000673"
      unitRef="USDPShares">0.001</KAPA:ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted>
    <KAPA:ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000675"
      unitRef="USDPShares">1.40</KAPA:ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000677"
      unitRef="USDPShares">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000685"
      unitRef="Shares">2010000</KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <KAPA:ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000687"
      unitRef="USDPShares">0.001</KAPA:ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised>
    <KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000689"
      unitRef="USDPShares">0.001</KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000691"
      unitRef="Shares">-150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <KAPA:ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000693"
      unitRef="USDPShares">4.17</KAPA:ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000695"
      unitRef="USDPShares">4.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000697"
      unitRef="Shares">4543188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants
      contextRef="AsOf2025-03-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000699"
      unitRef="USDPShares">0.001</KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants>
    <KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants
      contextRef="AsOf2025-03-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000701"
      unitRef="USDPShares">4.80</KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000703"
      unitRef="USDPShares">1.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000705"
      unitRef="Shares">793188</KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableInPeriod>
    <KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable
      contextRef="AsOf2025-03-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000707"
      unitRef="USDPShares">0.001</KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable>
    <KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable
      contextRef="AsOf2025-03-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000709"
      unitRef="USDPShares">4.80</KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000711"
      unitRef="USDPShares">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <KAPA:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000713">&lt;p id="xdx_891_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zljZNQpyXmFi" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The following table summarizes information concerning
outstanding and exercisable warrants as of March 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span id="xdx_8B7_zSVp0cQWvB86" style="display: none"&gt;SCHEDULE
OF OUTSTANDING AND EXERCISABLE WARRANTS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Warrants Outstanding&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Warrants Exercisable&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Range of&lt;/b&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Exercise Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;b&gt;Number Outstanding&lt;/b&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;
                                                                                                                                                                                             &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;b&gt;Remaining Contractual Life&lt;/b&gt; &lt;b&gt;(in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Average Remaining&lt;/b&gt;&lt;/p&gt;
                                                                                                                                                                                             &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Contractual Life&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zBsvWacU2RMg" title="Range of exercise prices"&gt;0.001&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_z3Rgrws4GxJl" title="Warrants Outstanding, Number Outstanding"&gt;490,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;-&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zeNTwOUURfie" style="display: none" title="Warrants Outstanding, Average Remaining Contractual Life (in years)"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zj5vfy4uPEng" title="Warrants Outstanding, Weighted Average Exercise Price"&gt;0.001&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zYPx8I5dHgi3" title="Warrants Exercisable, Number Exercisable"&gt;490,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zyHT23wh2jX4" title="Warrants Exercisable, Weighted Average Exercise Price"&gt;0.001&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zqHqZmhEYfN4" title="Range of exercise prices lower range"&gt;1.40&lt;/span&gt; - &lt;span id="xdx_909_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zBEkkdCMQREd" title="Range of exercise prices upper range"&gt;2.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zmPfOod4vwN1" title="Warrants Outstanding, Number Outstanding"&gt;3,944,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_ziS65o1YNYql" title="Warrants Outstanding, Average Remaining Contractual Life (in years)"&gt;4.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zGB04cnxTQ91" title="Warrants Outstanding, Weighted Average Exercise Price"&gt;1.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zLeh8lehsKc9" title="Warrants Exercisable, Number Exercisable"&gt;194,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zFy7qWTmkTXj" title="Warrants Exercisable, Average Remaining Contractual Life (in years)"&gt;4.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zWkh6uWUCFDi" title="Warrants Exercisable, Weighted Average Exercise Price"&gt;1.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember_zCopYuf7owIc" title="Range of exercise prices"&gt;4.80&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zITZqVCczLT6" title="Warrants Outstanding, Number Outstanding"&gt;108,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zztv0kFlmqX3" title="Warrants Outstanding, Average Remaining Contractual Life (in years)"&gt;4.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zz6dJWbG6832" title="Warrants Outstanding, Weighted Average Exercise Price"&gt;4.80&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z8AtC8v8Smag" title="Warrants Exercisable, Number Exercisable"&gt;108,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z9iVFZbxptK8" title="Warrants Exercisable, Average Remaining Contractual Life (in years)"&gt;4.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zA4BYzGpUTV3" title="Warrants Exercisable, Weighted Average Exercise Price"&gt;4.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcPQleayNeF9" title="Range of exercise prices lower range"&gt;0.001&lt;/span&gt;&#x2013; &lt;span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhYijr2DKKNa" title="Range of exercise prices upper range"&gt;4.80&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z18mFrjx5gP8" title="Warrants Outstanding, Number Outstanding"&gt;4,543,188&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmwVo1Ycqmaa" title="Warrants Outstanding, Average Remaining Contractual Life (in years)"&gt;4.22&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgKuGxXlQv4k" title="Warrants Outstanding, Weighted Average Exercise Price"&gt;1.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8ZAoGVLPSL5" title="Warrants Exercisable, Number Exercisable"&gt;793,188&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsxWURbruItf" title="Warrants Exercisable, Average Remaining Contractual Life (in years)"&gt;1.72&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zycoAar2cEA2" title="Warrants Exercisable, Weighted Average Exercise Price"&gt;1.03&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</KAPA:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock>
    <KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants
      contextRef="AsOf2025-03-31_custom_ExercisePriceRangeOneMember_custom_WarrantOneMember"
      decimals="INF"
      id="Fact000715"
      unitRef="USDPShares">0.001</KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2025-03-31_custom_ExercisePriceRangeOneMember_custom_WarrantOneMember"
      decimals="INF"
      id="Fact000717"
      unitRef="Shares">490000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_custom_WarrantOneMember_custom_ExercisePriceRangeOneMember"
      id="Fact000719">P0Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-31_custom_ExercisePriceRangeOneMember_custom_WarrantOneMember"
      decimals="INF"
      id="Fact000721"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber
      contextRef="AsOf2025-03-31_custom_ExercisePriceRangeOneMember_custom_WarrantOneMember"
      decimals="INF"
      id="Fact000723"
      unitRef="Shares">490000</KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber>
    <KAPA:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_custom_ExercisePriceRangeOneMember_custom_WarrantOneMember"
      decimals="INF"
      id="Fact000725"
      unitRef="USDPShares">0.001</KAPA:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice>
    <KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit
      contextRef="From2025-01-012025-03-31_custom_ExercisePriceRangeTwoMember_custom_WarrantTwoMember"
      decimals="INF"
      id="Fact000727"
      unitRef="USDPShares">1.40</KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit>
    <KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-03-31_custom_ExercisePriceRangeTwoMember_custom_WarrantTwoMember"
      decimals="INF"
      id="Fact000729"
      unitRef="USDPShares">2.40</KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2025-03-31_custom_WarrantTwoMember_custom_ExercisePriceRangeTwoMember"
      decimals="INF"
      id="Fact000731"
      unitRef="Shares">3944688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_custom_ExercisePriceRangeTwoMember_custom_WarrantTwoMember"
      id="Fact000733">P4Y8M26D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-31_custom_WarrantTwoMember_custom_ExercisePriceRangeTwoMember"
      decimals="INF"
      id="Fact000735"
      unitRef="USDPShares">1.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber
      contextRef="AsOf2025-03-31_custom_WarrantTwoMember_custom_ExercisePriceRangeTwoMember"
      decimals="INF"
      id="Fact000737"
      unitRef="Shares">194688</KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber>
    <KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_custom_ExercisePriceRangeTwoMember_custom_WarrantTwoMember"
      id="Fact000739">P4Y6M3D</KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms>
    <KAPA:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_custom_WarrantTwoMember_custom_ExercisePriceRangeTwoMember"
      decimals="INF"
      id="Fact000741"
      unitRef="USDPShares">1.50</KAPA:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice>
    <KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants
      contextRef="AsOf2025-03-31_custom_ExercisePriceRangeThreeMember_custom_WarrantThreeMember"
      decimals="INF"
      id="Fact000743"
      unitRef="USDPShares">4.80</KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2025-03-31_custom_ExercisePriceRangeThreeMember_custom_WarrantThreeMember"
      decimals="INF"
      id="Fact000745"
      unitRef="Shares">108500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_custom_WarrantThreeMember_custom_ExercisePriceRangeThreeMember"
      id="Fact000747">P4Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-31_custom_ExercisePriceRangeThreeMember_custom_WarrantThreeMember"
      decimals="INF"
      id="Fact000749"
      unitRef="USDPShares">4.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber
      contextRef="AsOf2025-03-31_custom_ExercisePriceRangeThreeMember_custom_WarrantThreeMember"
      decimals="INF"
      id="Fact000751"
      unitRef="Shares">108500</KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber>
    <KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_custom_WarrantThreeMember_custom_ExercisePriceRangeThreeMember"
      id="Fact000753">P4Y6M</KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms>
    <KAPA:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_custom_ExercisePriceRangeThreeMember_custom_WarrantThreeMember"
      decimals="INF"
      id="Fact000755"
      unitRef="USDPShares">4.17</KAPA:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice>
    <KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000757"
      unitRef="USDPShares">0.001</KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeLowerRangeLimit>
    <KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000759"
      unitRef="USDPShares">4.80</KAPA:ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000761"
      unitRef="Shares">4543188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember"
      id="Fact000763">P4Y2M19D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000765"
      unitRef="USDPShares">1.33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber
      contextRef="AsOf2025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000767"
      unitRef="Shares">793188</KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber>
    <KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember"
      id="Fact000769">P1Y8M19D</KAPA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms>
    <KAPA:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000771"
      unitRef="USDPShares">1.03</KAPA:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember_custom_PreFundedWarrantMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact000773"
      unitRef="Shares">2500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember_custom_PreFundedWarrantMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact000775"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact000777"
      unitRef="Shares">3750000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact000779"
      unitRef="USDPShares">1.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <KAPA:ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription
      contextRef="From2025-01-142025-01-14_custom_SecurityPurchaseAgreementMember_custom_PreFundedWarrantMember"
      id="Fact000781">The
warrant will be exercisable six months from the date of issuance and will expire five years from the issuance
date.</KAPA:ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-16_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember_custom_UnderwritersMember"
      decimals="INF"
      id="Fact000783"
      unitRef="Shares">175000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-01-14_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember_custom_UnderwritersMember"
      decimals="INF"
      id="Fact000785"
      unitRef="USDPShares">1.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <KAPA:ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription
      contextRef="From2025-01-142025-01-14_custom_SecurityPurchaseAgreementMember_us-gaap_WarrantMember_custom_UnderwritersMember"
      id="Fact000787">The
warrant expires five years from the date of grant.</KAPA:ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription>
    <KAPA:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants
      contextRef="From2025-01-012025-03-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact000789"
      unitRef="Shares">2010000</KAPA:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants>
    <KAPA:WarrantsUnexercised
      contextRef="AsOf2025-03-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact000791"
      unitRef="Shares">490000</KAPA:WarrantsUnexercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2025-03-31_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000793"
      unitRef="USD">458000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact000795"
      unitRef="Shares">551100</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact000797"
      unitRef="USD">484000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000799">&lt;p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z5LoqcZiAgz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5 &#x2013; &lt;span id="xdx_827_z2spAiTwEO9h"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Kairos Exclusive License Agreements with
Cedars-Sinai Medical Center (Cedars)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The Company has entered into four Exclusive License
Agreements with Cedars, each of which grants the Company licensing rights with respect to certain patent rights owned by Cedars as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Methods of use of compounds that bind to RelA of NFkB;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Composition and methods for treating fibrosis;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Compositions and methods for treating cancer and autoimmune diseases; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Method of generating activated T cells for cancer therapy.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;For each of the exclusive license agreement in items
1, 2 and 3, the Company was required to pay an initial license fee of $&lt;span id="xdx_90C_ecustom--LicenseFee_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zq9YVMHPZyNj" title="License fee"&gt;5&lt;/span&gt;, reimburse Cedars for patent protection costs ranging from approximately
$&lt;span id="xdx_90B_ecustom--PatentProtectionCosts_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zO00ZMtnBIj7" title="Patent protection costs"&gt;9&lt;/span&gt; to $&lt;span id="xdx_90C_ecustom--PatentProtectionCosts_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zZ6XSFEu0tn4" title="Patent protection costs"&gt;61&lt;/span&gt;, pay an annual maintenance fee of $&lt;span id="xdx_90A_eus-gaap--CostMaintenance_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zHsBuWgyXUN6" title="Annual maintenance fee"&gt;10&lt;/span&gt;, and pay royalties based on &lt;span id="xdx_90A_ecustom--RoyaltyPercentage_pid_dp_uPure_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zTm78Hf66O35" title="Royalty percentage"&gt;3.75&lt;/span&gt;% of net sales and pay other non-royalty sublicense fees
ranging from &lt;span id="xdx_901_ecustom--OtherNonroyaltySublicenseFeesPercentage_pid_dp_uPure_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_ze8A7Ebqt32c" title="Other non-royalty sublicense fees percentage"&gt;5&lt;/span&gt;% to &lt;span id="xdx_905_ecustom--OtherNonroyaltySublicenseFeesPercentage_pid_dp_uPure_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zCJ3urpOvibi" title="Other non-royalty sublicense fees percentage"&gt;35&lt;/span&gt;% of sales of products. In addition, for items 1, 2 and 3, the Company is required to pay Cedars based on the following
milestones:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_906_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--PhaseOneClinicalTrialMember_z7QHM5phOP6e" title="Payment for milestone"&gt;150&lt;/span&gt; upon the successful completing of Phase I clinical trial;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_907_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemOneAndTwoMember__us-gaap--AwardTypeAxis__custom--PhaseTwoMember_zjVI82Unn4m7" title="Payment for milestone"&gt;250&lt;/span&gt; (for items 1 and 2) and $&lt;span id="xdx_907_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemThreeMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_zm7vZWoeqq6a" title="Payment for milestone"&gt;500&lt;/span&gt; (for item 3) upon the successful completing of Phase II clinical trial for a product and receipt of Food and Drug Administration (&#x201c;FDA&#x201d;) approval for a Phase III clinical trial;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_90F_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemOneAndTwoMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zvySZwFkR5ei" title="Payment for milestone"&gt;1,500&lt;/span&gt; upon receipt of FDA approval of a new drug application or equivalent foreign regulatory approval in a non-United States major commercial market; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_904_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemOneAndTwoMember_zxmGz7iKTrQf" title="Payment for milestone"&gt;250&lt;/span&gt; upon cumulative net sales exceeding $&lt;span id="xdx_906_eus-gaap--Revenues_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemOneAndTwoMember_zuBk6S1wUUk9" title="Net sales"&gt;5,000&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;For the exclusive license agreement in item 4, the
Company is required to pay an initial license fee of $&lt;span id="xdx_907_ecustom--LicenseFee_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zStwRHN7l564" title="License fee"&gt;50&lt;/span&gt; upon raising $&lt;span id="xdx_90E_ecustom--MinimumRequirermentOfCapital_iI_pn3n3_c20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zEktpNNKeepl" title="Minimum requirerment of capital"&gt;500&lt;/span&gt; in capital, pay an annual maintenance fee of $&lt;span id="xdx_90E_eus-gaap--CostMaintenance_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zt1mUwE1r7mc" title="Annual maintenance fee"&gt;10&lt;/span&gt;, pay
royalties based on &lt;span id="xdx_902_ecustom--RoyaltyPercentage_pid_dp_uPure_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zuxeb3PHTeej" title="Royalty percentage"&gt;4.25&lt;/span&gt;% of patent product sales and &lt;span id="xdx_903_ecustom--PatentProductSalesPercentage_pid_dp_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemFourMember_z4rbAzw48kCi" title="Patent product sales"&gt;0.5&lt;/span&gt;% of other sales and pay other non-royalty sublicense fees ranging from &lt;span id="xdx_902_ecustom--OtherNonroyaltySublicenseFeesPercentage_pid_dp_uPure_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zCXg6uA3KWkl" title="Other non-royalty sublicense fees percentage"&gt;5&lt;/span&gt;% to
&lt;span id="xdx_908_ecustom--OtherNonroyaltySublicenseFeesPercentage_pid_dp_uPure_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zKORXKiUKBQ6" title="Other non-royalty sublicense fees percentage"&gt;35&lt;/span&gt;%. In addition, the Company is required to pay Cedars based on the following milestones:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_901_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--PhaseOneClinicalTrialMember_z9XuO3ozOqoi" title="Payment for milestone"&gt;150&lt;/span&gt; upon the successful completing of Phase I clinical trial;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_909_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemFourMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_zMvzfWAhHkea" title="Payment for milestone"&gt;250&lt;/span&gt; upon the successful completing of Phase II clinical trial and receipt of Food and Drug Administration (&#x201c;FDA&#x201d;) or equivalent regulatory agency in another jurisdiction approval for a Phase III clinical trial;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_90C_ecustom--PaymentForMilestones_pn3n3_c20240101__20241231__srt--ProductOrServiceAxis__custom--ItemFourMember__dei--LegalEntityAxis__custom--FoodAndDrugAdministrationMember_znidBqZg6Akc" title="Payment for milestone"&gt;1,500&lt;/span&gt; upon receipt of FDA approval of a new drug application; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_905_ecustom--PaymentForMilestones_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemFourMember_zjtqcDBsC8y4" title="Payment for milestone"&gt;2,500&lt;/span&gt; upon cumulative net sales exceeding $&lt;span id="xdx_904_eus-gaap--Revenues_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemFourMember_zqZUiMfZ5r5i" title="Net sales"&gt;50,000&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Enviro Therapeutics&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;On June 2, 2021, the Company&#x2019;s wholly owned
subsidiary, Enviro,  entered into two Exclusive License Agreements with Cedars, which granted Enviro exclusive
licensing rights (which include the right to sublicense) with respect to certain patent rights owned by Cedars, as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;an Exclusive License Agreement (the &#x201c;Enviro-Cedars License Agreement (Mitochondrial DNA)&#x201d;) for Enviro to develop, manufacture, use and sell products utilized or derived from patent rights worldwide related to the &#x201c;Compositions and Methods for Treating Diseases and Conditions by Depletion of Mitochondrial DNA from Circulation and for Detection of Mitochondrial DNA&#x201d; invented by Dr. Neil Bhowmick and others; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;an Exclusive License Agreement (the &#x201c;Enviro-Cedars License Agreement (Endoglin Antagonism)&#x201d; and, collectively with the Enviro-Cedars License Agreement (Mitochondrial DNA), the &#x201c;Enviro-Cedars License Agreements&#x201d;) for Enviro to develop, manufacture, use and sell products utilized or derived from the patent rights and technical information worldwide related to the &#x201c;Sensitization of Tumors to Therapies Through Endoglin Antagonism&#x201d; invented by Dr. Neil Bhowmick and others.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;In exchange for each of the licenses, Enviro is required
to pay an upfront license fee in the mid four-figures and low-five figures, respectively. Enviro is also required to reimburse Cedars
for the costs in the mid-to-high six figures incurred in the prosecution of the patent rights subject to the Enviro-Cedars License Agreements
prior to the date of execution of such agreements, and certain costs and fees then outstanding aggregating in the low-six figures owed
by Kairos pursuant to the Kairos-Cedars License Agreements. Pursuant to the Enviro-Cedars License Agreements, Cedars shall also receive
royalty payments of a mid-single-digit percentage of net sales of products associated with the licensed patent right and less than one
percent of net sales of other products derived from Cedars&#x2019; technical information, with a minimum annual royalty fee in the low
five-digits due beginning on the third anniversary of the effective date of the Enviro-Cedars License Agreements. To the extent Enviro
derives non-royalty sublicensing revenues, a high single-digit to low double-digit percentage of such revenues would be due and payable
to Cedars, with the actual percentage of such revenues dependent on the stage of FDA authorization at the time the sublicense revenue
is generated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;Enviro is also required to pay Cedars in connection
with achieving the following Payment Milestones relating to products derived from the patent rights: successful completion of a Phase
I clinical trial; successful completion of a Phase II clinical trial, receipt of FDA approval, and approval for a Phase III clinical trial;
FDA approval of an NDA or BLA; cumulative net sales exceeding $&lt;span id="xdx_90E_eus-gaap--Revenues_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--PhaseThreeClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--EnviroCedarsLicenseAgreementsMember_zpFIc1ZuVdAa" title="Net sales"&gt;50,000&lt;/span&gt;; and cumulative net sales exceeding $&lt;span id="xdx_907_eus-gaap--Revenues_pn3n3_c20250101__20250331__srt--ProductOrServiceAxis__custom--ItemOneAndTwoMember__us-gaap--AwardTypeAxis__custom--PhaseThreeMember__us-gaap--TypeOfArrangementAxis__custom--EnviroCedarsLicenseAgreementsMember_zauTHZg3VKHk" title="Net sales"&gt;100,000&lt;/span&gt;. If all of these payment
milestones are met among both of the Enviro-Cedars License Agreements, the required milestone payments would total in the mid-to-high
seven-figures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;Pursuant to the Enviro-Cedars License Agreements,
Enviro is obligated to meet the following Commercialization Milestones. Pursuant to the Enviro-Cedars License Agreement (Endoglin Antagonism),
Enviro is obligated to &lt;span id="xdx_902_ecustom--LicenseAgreementDescription_c20250101__20250331_zOLJGelSyXYa" title="License agreement description"&gt;(1) obtain an IND for a patent product within 1 year of the effective date of the agreement, (2) commence a Phase
II trial within 2 years of the effective date of the agreement, and (3) submit an NDA or BLA to the FDA or equivalent regulatory agency
in another jurisdiction within 7 years of the effective date of the agreement. Pursuant to the Enviro-Cedars License Agreement (Mitochondrial
DNA), Enviro is obligated to (1) complete preclinical studies of a patent product within 2 years of the effective date of the agreement,
(2) complete toxicology studies within 2.5 years of the effective date of the agreement, (3) obtain IND within 3 years of the effective
date of the agreement, (4) begin a Phase I trial within 4 years of the effective date of the agreement, and (5) submit an NDA or BLA to
the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. If the Commercialization
Milestones are not met or extended, Cedars may convert the exclusive licenses into non-exclusive licenses or to a co-exclusive licenses
or terminate the licenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The Enviro-Cedars License Agreements will, unless
sooner terminated, continue in effect on a country-by-country basis until the last of the patents covering the patent rights or future
patent rights expires. Under the terms of the Enviro-Cedars License Agreements, unless waived by Cedars, the agreements would automatically
terminate: (a) if Enviro ceases, dissolves or winds up its business operations; (b) if performance by either party jeopardizes the licensure,
accreditation or tax exempt status of Cedars or the agreement is deemed illegal by a governmental body; (c) within 30 days for non-payment
of royalties or if Enviro fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (d)
within 60 days of Cedars&#x2019; failure to cure any breach or default of a material obligation under the agreements; (e) within 90 days
of Enviro&#x2019;s failure to cure any breach or default of a material obligation under the agreements; or (f) upon mutual written agreement
of the parties.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Legal
Matters&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
the Company&#x2019;s knowledge, it is not currently the subject of any material legal proceeding. In the future, the Company may be involved
in actual and/or threatened legal proceedings, claims, investigations and government inquiries arising in the ordinary course of our
business, including legal proceedings, claims, investigations and government inquiries involving intellectual property, data privacy
and security, other torts, illegal or objectionable content, consumer protection, securities, employment, contractual rights, civil rights
infringement, false or misleading advertising, or other legal claims relating to our business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <KAPA:LicenseFee
      contextRef="From2025-01-012025-03-31_custom_LicenseAgreementMember"
      decimals="-3"
      id="Fact000801"
      unitRef="USD">5000</KAPA:LicenseFee>
    <KAPA:PatentProtectionCosts
      contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MinimumMember"
      decimals="-3"
      id="Fact000803"
      unitRef="USD">9000</KAPA:PatentProtectionCosts>
    <KAPA:PatentProtectionCosts
      contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MaximumMember"
      decimals="-3"
      id="Fact000805"
      unitRef="USD">61000</KAPA:PatentProtectionCosts>
    <us-gaap:CostMaintenance
      contextRef="From2025-01-012025-03-31_custom_LicenseAgreementMember"
      decimals="-3"
      id="Fact000807"
      unitRef="USD">10000</us-gaap:CostMaintenance>
    <KAPA:RoyaltyPercentage
      contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember"
      decimals="INF"
      id="Fact000809"
      unitRef="Pure">0.0375</KAPA:RoyaltyPercentage>
    <KAPA:OtherNonroyaltySublicenseFeesPercentage
      contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000811"
      unitRef="Pure">0.05</KAPA:OtherNonroyaltySublicenseFeesPercentage>
    <KAPA:OtherNonroyaltySublicenseFeesPercentage
      contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000813"
      unitRef="Pure">0.35</KAPA:OtherNonroyaltySublicenseFeesPercentage>
    <KAPA:PaymentForMilestones
      contextRef="From2025-01-012025-03-31_custom_PhaseOneClinicalTrialMember"
      decimals="-3"
      id="Fact000815"
      unitRef="USD">150000</KAPA:PaymentForMilestones>
    <KAPA:PaymentForMilestones
      contextRef="From2025-01-012025-03-31_custom_ItemOneAndTwoMember_custom_PhaseTwoMember"
      decimals="-3"
      id="Fact000817"
      unitRef="USD">250000</KAPA:PaymentForMilestones>
    <KAPA:PaymentForMilestones
      contextRef="From2025-01-012025-03-31_custom_ItemThreeMember_custom_PhaseTwoClinicalTrialMember"
      decimals="-3"
      id="Fact000819"
      unitRef="USD">500000</KAPA:PaymentForMilestones>
    <KAPA:PaymentForMilestones
      contextRef="From2025-01-012025-03-31_custom_ItemOneAndTwoMember_us-gaap_NonUsMember"
      decimals="-3"
      id="Fact000821"
      unitRef="USD">1500000</KAPA:PaymentForMilestones>
    <KAPA:PaymentForMilestones
      contextRef="From2025-01-012025-03-31_custom_ItemOneAndTwoMember"
      decimals="-3"
      id="Fact000823"
      unitRef="USD">250000</KAPA:PaymentForMilestones>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_ItemOneAndTwoMember"
      decimals="-3"
      id="Fact000825"
      unitRef="USD">5000000</us-gaap:Revenues>
    <KAPA:LicenseFee
      contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_custom_ItemFourMember"
      decimals="-3"
      id="Fact000827"
      unitRef="USD">50000</KAPA:LicenseFee>
    <KAPA:MinimumRequirermentOfCapital
      contextRef="AsOf2025-03-31_custom_ExclusiveLicenseAgreementMember_custom_ItemFourMember"
      decimals="-3"
      id="Fact000829"
      unitRef="USD">500000</KAPA:MinimumRequirermentOfCapital>
    <us-gaap:CostMaintenance
      contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_custom_ItemFourMember"
      decimals="-3"
      id="Fact000831"
      unitRef="USD">10000</us-gaap:CostMaintenance>
    <KAPA:RoyaltyPercentage
      contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_custom_ItemFourMember"
      decimals="INF"
      id="Fact000833"
      unitRef="Pure">0.0425</KAPA:RoyaltyPercentage>
    <KAPA:PatentProductSalesPercentage
      contextRef="From2025-01-012025-03-31_custom_ItemFourMember"
      decimals="INF"
      id="Fact000835"
      unitRef="Pure">0.005</KAPA:PatentProductSalesPercentage>
    <KAPA:OtherNonroyaltySublicenseFeesPercentage
      contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MinimumMember_custom_ItemFourMember"
      decimals="INF"
      id="Fact000837"
      unitRef="Pure">0.05</KAPA:OtherNonroyaltySublicenseFeesPercentage>
    <KAPA:OtherNonroyaltySublicenseFeesPercentage
      contextRef="From2025-01-012025-03-31_custom_ExclusiveLicenseAgreementMember_srt_MaximumMember_custom_ItemFourMember"
      decimals="INF"
      id="Fact000839"
      unitRef="Pure">0.35</KAPA:OtherNonroyaltySublicenseFeesPercentage>
    <KAPA:PaymentForMilestones
      contextRef="From2025-01-012025-03-31_custom_PhaseOneClinicalTrialMember"
      decimals="-3"
      id="Fact000841"
      unitRef="USD">150000</KAPA:PaymentForMilestones>
    <KAPA:PaymentForMilestones
      contextRef="From2025-01-012025-03-31_custom_ItemFourMember_custom_PhaseTwoClinicalTrialMember"
      decimals="-3"
      id="Fact000843"
      unitRef="USD">250000</KAPA:PaymentForMilestones>
    <KAPA:PaymentForMilestones
      contextRef="From2024-01-012024-12-31_custom_ItemFourMember_custom_FoodAndDrugAdministrationMember"
      decimals="-3"
      id="Fact000845"
      unitRef="USD">1500000</KAPA:PaymentForMilestones>
    <KAPA:PaymentForMilestones
      contextRef="From2025-01-012025-03-31_custom_ItemFourMember"
      decimals="-3"
      id="Fact000847"
      unitRef="USD">2500000</KAPA:PaymentForMilestones>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_ItemFourMember"
      decimals="-3"
      id="Fact000849"
      unitRef="USD">50000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_PhaseThreeClinicalTrialMember_custom_EnviroCedarsLicenseAgreementsMember"
      decimals="-3"
      id="Fact000851"
      unitRef="USD">50000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_ItemOneAndTwoMember_custom_PhaseThreeMember_custom_EnviroCedarsLicenseAgreementsMember"
      decimals="-3"
      id="Fact000853"
      unitRef="USD">100000000</us-gaap:Revenues>
    <KAPA:LicenseAgreementDescription contextRef="From2025-01-01to2025-03-31" id="Fact000855">(1) obtain an IND for a patent product within 1 year of the effective date of the agreement, (2) commence a Phase
II trial within 2 years of the effective date of the agreement, and (3) submit an NDA or BLA to the FDA or equivalent regulatory agency
in another jurisdiction within 7 years of the effective date of the agreement. Pursuant to the Enviro-Cedars License Agreement (Mitochondrial
DNA), Enviro is obligated to (1) complete preclinical studies of a patent product within 2 years of the effective date of the agreement,
(2) complete toxicology studies within 2.5 years of the effective date of the agreement, (3) obtain IND within 3 years of the effective
date of the agreement, (4) begin a Phase I trial within 4 years of the effective date of the agreement, and (5) submit an NDA or BLA to
the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. If the Commercialization
Milestones are not met or extended, Cedars may convert the exclusive licenses into non-exclusive licenses or to a co-exclusive licenses
or terminate the licenses.</KAPA:LicenseAgreementDescription>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000857">&lt;p id="xdx_809_eus-gaap--SegmentReportingDisclosureTextBlock_z8XkEY1EvlC1" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;NOTE
6 &#x2013; &lt;span id="xdx_82A_zlsq603MtRA1"&gt;SEGMENT INFORMATION&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;The Company operates and manages its business as &lt;span id="xdx_906_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20250101__20250331_zFNtCtNOXoy5" title="Number of reportable segments"&gt;one&lt;/span&gt;
reportable segment and operates as a clinical-stage biopharmaceutical company. The Company&#x2019;s current focus is on developing immunotherapy
and cell therapies for the treatment of cancer. The Company&#x2019;s Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is the Chief Executive
Officer, who reviews financial information presented and decides how to allocate resources based on net income (loss). Net income (loss)
is used for evaluating financial performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;Significant segment expenses include research and
development, officer compensation, insurance, and stock-based compensation. Operating expenses include all the remaining costs necessary
to operate our business, which primarily include external professional services and other administrative expenses. The following table
presents the significant segment expenses and other segment items regularly reviewed by our CODM:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zwOoPqF4lB2d" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span id="xdx_8BF_zfYjnLQ59nya" style="display: none"&gt;SCHEDULE
OF SEGMENT EXPENSES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250101__20250331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zE3wkZgjfXWe" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20240331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zFLJtujBKoZ7" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Three Months Ended&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Revenues_pn3n3_zjIfQN6O33e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0863"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0864"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Less:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_zJIVhMBFVLx1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Research and development, less officer compensation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;448&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;165&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OfficersCompensation_pn3n3_zBkkTeuBOPTh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Officer compensation and wages&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0870"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--InsuranceRecoveries_pn3n3_zmOpMxR28Ti6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;105&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_z8UGnZMYgXXj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0876"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingExpenses_pn3n3_zgPWkL9ZBq17" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherOperatingIncomeExpenseNet_pn3n3_zgeUMAx9qARf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other income (expenses)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(36&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLoss_pn3n3_ziiUdJ3hBZDe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;NET LOSS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1,262&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(323&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A6_z6TV6oU9LaXd" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact000859"
      unitRef="Integer">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000861">&lt;p id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zwOoPqF4lB2d" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span id="xdx_8BF_zfYjnLQ59nya" style="display: none"&gt;SCHEDULE
OF SEGMENT EXPENSES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250101__20250331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zE3wkZgjfXWe" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20240331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zFLJtujBKoZ7" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Three Months Ended&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Revenues_pn3n3_zjIfQN6O33e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0863"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0864"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Less:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_zJIVhMBFVLx1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Research and development, less officer compensation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;448&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;165&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OfficersCompensation_pn3n3_zBkkTeuBOPTh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Officer compensation and wages&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0870"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--InsuranceRecoveries_pn3n3_zmOpMxR28Ti6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;105&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_z8UGnZMYgXXj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0876"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingExpenses_pn3n3_zgPWkL9ZBq17" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherOperatingIncomeExpenseNet_pn3n3_zgeUMAx9qARf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other income (expenses)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(36&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLoss_pn3n3_ziiUdJ3hBZDe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;NET LOSS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1,262&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(323&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-03-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact000866"
      unitRef="USD">448000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-03-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact000867"
      unitRef="USD">165000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OfficersCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact000869"
      unitRef="USD">101000</us-gaap:OfficersCompensation>
    <us-gaap:InsuranceRecoveries
      contextRef="From2025-01-012025-03-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact000872"
      unitRef="USD">105000</us-gaap:InsuranceRecoveries>
    <us-gaap:InsuranceRecoveries
      contextRef="From2024-01-012024-03-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact000873"
      unitRef="USD">8000</us-gaap:InsuranceRecoveries>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-03-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact000875"
      unitRef="USD">76000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-03-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact000878"
      unitRef="USD">536000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-03-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact000879"
      unitRef="USD">114000</us-gaap:OperatingExpenses>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2025-01-012025-03-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact000881"
      unitRef="USD">4000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2024-01-012024-03-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact000882"
      unitRef="USD">-36000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact000884"
      unitRef="USD">-1262000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact000885"
      unitRef="USD">-323000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000887">&lt;p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zzUq306wPoH1" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;NOTE 7 &#x2013; &lt;span id="xdx_825_zUsElv5Zo8xd"&gt;SUBSEQUENT EVENTS&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;On
April 1, 2025, the Company issued &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__dei--LegalEntityAxis__custom--CrossCurrentCapitalLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zF0NRtAgXVFj" title="Number of shares issued"&gt;166,541&lt;/span&gt;
shares of its common stock to Cross Current in connection with its agreement with Cross Current (see Notes 3 and 4).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;On April 24, 2025, the Company issued &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250424__20250424__dei--LegalEntityAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znBlc2wdF5hg" title="Number of shares issued"&gt;384,459&lt;/span&gt;
shares of its common stock to Helena in connection with its agreement with Helena (see Notes 3 and 4).&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-04-012025-04-01_custom_CrossCurrentCapitalLLCMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000889"
      unitRef="Shares">166541</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-04-242025-04-24_custom_HelenaGlobalInvestmentOpportunitiesILTDMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000891"
      unitRef="Shares">384459</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2025-01-01to2025-03-31" id="Fact000892">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2025-01-01to2025-03-31" id="Fact000893">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2025-01-01to2025-03-31" id="Fact000894">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2025-01-01to2025-03-31" id="Fact000895">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
